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ABSTRACT
After review of the literature, this thesis describes the extent of 
cellular responses to selective antigens in vivo, and to antigens 
and phytohaemagglutinin in vitro in immunised and transfer factor- 
treated rhesus monkeys. Preliminary in vitro and fractionation 
studies of rhesus and human transfer factor preparations are also 
presented.
In immunised animals an antigen-specific active sensitisation was 
detected by the skin delayed hypersensitivity (DH), the mixed 
leucocyte-macrophage migration (LMMI) and the lymphocyte transformation 
(LT) tests.
In animals treated with rhesus dialysable transfer factor, adoptive 
transfer of sensitisation, with a specificity related to antigen- 
sensitivity of the donor(s) (i.e. "Donor-specific") was detected only 
by the LMMI-test.
The relationship between the various tests was determined. In 
immunised monkeys, the antigen-stimulated LMMI- and LT-reactivities 
associated with each other and with the DH-reactivity. In contrast, 
in transfer factor-treated animals, these reactivities were apparently 
dissociated. Thus, in transfer factor recipients, dissociation either- 
reflected different sensitivity of the tests or indicated preferential 
lymphokine production.
Phytohaemagglutinin-stimulated transformation was depressed in 
immunised animals, whilst 1t was elevated in transfer factor-treated 
monkeys probably indicating an "adjuvant-like" activity. Thus the 
results suggest that transfer factor had specific and non-specific 
in vivo activities 1n the rhesus monkey model.
The in vitro study of human or rhesus monkey dialysable transfer 
factor In antigen-stimulated transformation tests showed augmenting 
and suppressive effects with antigen-immune or non-1mmune transfer 
factor. The degree of augmentation was related to the degree of 
antigen-sensitivity of the "recipient" (1.e. "Recipient-specific"). 
Thus, the in vitro activity of rhesus monkey or human transfer factor 
was non-specific.
Preliminary Sephadex G-25 chromatography of human and rhesus monkey 
dialysable transfer factor preparations revealed 9-11 fractlonable 
peaks with different absorption ratios, suggesting heterogeneity of 
composition.
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1. INTRODUCTION: REVIEW OF THE LITERATURE
1.1 Concept of transfer factor as a mediator of the cellular 
immune response.
1.1.1 Discovery of transfer factor (Table 1).
Landsteiner and Chase (1942) reported that skin delayed hypersensitivity 
to simple compounds could be transferred from sensitised to unsensitised 
guinea pigs with live peritoneal exudate cells, but not with heated 
cells or serum. The transferred sensitivity appeared as early as 2 days 
after the injection of the lymphoid cells, but waned within a few days. 
It was, therefore, suggested that the acquired sensitivity in the 
recipient was due to the surviving, but short-lived, donor lymphoid 
cells. This was the first demonstration that cell-mediated immunity 
could be distinguished from the humoral antibody response. Chase (1945) 
showed that delayed hypersensitivity to tuberculin could similarly be 
transferred in the guinea pig with peritoneal exudate cells and also 
with lymphocytes obtained from the spleen and lymph nodes. Such 
cellular transfer of immunity has since been repeatedly confirmed 
(Chase, 1946; Cummings et al, 1947; Klrchheimer and Welser, 1947).
Extending this study to man, Lawrence (1949, 1952) was the first to 
describe passive or adoptive cellular transfer of both local and 
systemic cutaneous delayed hypersensitivity to bacterial antigens 
(tuberculin PPD and streptococcal M antigens) using Intact viable 
blood leucocytes. In contrast to the guinea pig, where transferred 
delayed hypersensitivity could only be maintained for 3-5 days, 1t was
reported that, in man, the transferred skin reactivity persisted for 3 
months to 2 years. This observation was inconsistent with the view 
that transferred delayed hypersensitivity lasted only as long as the 
donor cells remained viable. In 1954 and 1955, Lawrence compared 
intact and disrupted blood leucocytes for their ability to transfer 
delayed skin reactivity to tuberculin and streptococcal antigens. 
Transferred skin reactions seemed to be more intense using the 
disrupted rather than the intact cells. Disruption of cells was 
achieved by lysis v/ith distilled water alone and/or freeze-thawing in 
the presence or absence of deoxyribonuclease (DNase) or ribonuclease 
(RNase). These methods of disruption did not cause loss of transfer 
activity. Since DNase and RNase do not affect transfer of delayed 
hypersensitivity in man, the mechanism of transfer did not appear to 
depend on highly polymerised DNA or RNA. Nevertheless, it was 
concluded that since only a small amount of intact or disrupted donor 
cell mass (0.1-0.4 ml of packed white blood cells) relative to a large 
recipient cell mass was required to transfer cutaneous sensitivity, 
the transfer component might be self-replicating.
Lawrence and Pappenheimer (1956) then proceeded to transfer delayed 
cutaneous hypersensitivity to diphtheria toxin and toxoid, 1n man, 
using a washed disrupted extract of white blood cells. It was shown 
that both donors and recipients possessed little diphtheria antitoxin, 
the titre being less than 0.001 un1ts/ml of serum. These findings 
suggested that the transfer extract was not Immunogenic, and that the 
transferred cutaneous delayed hypersensitivity was not a function of 
humoral antibody. A year later, Lawrence and Pappenheimer (1957), 
therefore, Introduced the term "transfer factor" (TF) to describe the
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crude water and DNase-treated human leucocyte extract, which transferred 
delayed cutaneous hypersensitivity from sensitised to unsensitised 
individuals.
Rapaport et al (1960) reported successful transfer of delayed cutaneous 
hypersensitivity to coccidioidin in man with a leucocyte extract, 
thought to contain transfer factor. This fungal antigen is limited to 
the West of the United States, but is almost absent in the East with 
an incidence of only 1.4% in New York (Lawrence, 1974). To test the 
specificity of transfer factor, the extract was therefore prepared 
from sensitive donors from California and administered to "naive" 
recipients from New York. Thirty out of 35 (86%) of the individuals 
receiving the extract from coccidioidin-positive donors acquired skin 
test-reactivity to coccidioidin. In contrast, 8 out of 9 (89%) of 
the control recipients, given extracts prepared from coccidioidin- 
negative donors, did not acquire such skin test-reactivity. Thus, 1n 
these studies coccidioidin sensitivity was transferred de novo and this 
transfer was donor-specific. The possibility of the elevation of a 
latent sensitivity to coccidioidin by means of the extract was 
excluded, since the recipients were not naturally exposed to or skin 
tested with this antigen before the injection of the extract.
In 1960, Lawrence and colleagues provided evidence that transfer factor- 
containing leucocyte extract can also specifically transfer sensitivity 
to human skin transplantation antigens as shown by the accelerated 
homograft rejection. Transfer factor was prepared from the leucocyte 
extract of an individual B after repeated exposure to skin grafts from 
another individual A. Anti-A-sensitive or "allograft-specific"
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transfer was donor-specific. The possibility of the elevation of a 
latent sensitivity to coccidioidin by means of the extract was 
excluded, since the recipients were not naturally exposed to or skin 
tested with this antigen before the Injection of the extract.
In 1960, Lawrence and colleagues provided evidence that transfer factor- 
containing leucocyte extract can also specifically transfer sensitivity 
to human skin transplantation antigens as shown by the accelerated 
homograft rejection. Transfer factor was prepared from the leucocyte 
extract of an Individual B after repeated exposure to skin grafts from 
another individual A. Anti-A-sensitive or "allograft-specific"
transfer factor was then injected into another individual C, who had 
received a skin graft from the individual A and control grafts from 
other unrelated individuals (D, E, or F). In such experiments,
Lawrence et al (1960) reported that the local injection of an 
allograft-specific transfer factor, in 4 out of 4 human recipients, 
transferred homograft-specific hypersensitivity. This was shown in 
4 to 5 days by an accelerated homograft rejection ("second-set 
reaction") of test skin grafts but not control skin grafts. In 
contrast, non-sensitive transfer factor did not transfer transplantation 
sensitivity, and could only induce the expected homograft rejection in 
10-12 days ("first-set reaction").
Maurer, in 1961, used a non-ubiquitous antigen ("neoantigen") prepared 
by the ethylene oxide-treatment of human serum, to demonstrate 
transfer of specific delayed hypersensitivity in man. Freeze-thawed 
leucocyte extracts or viable whole leucocytes, obtained from sensitive 
donors, transferred strong delayed cutaneous hypersensitivity to the 
neoantigen in 7 out of 7 recipients. The transferred skin test- 
reactivity was still present after 1 year confirming the observation 
of Rapaport et al (1960) with the coccidioidin antigen. The extracts 
of the leucocytes were as effective as the viable cells in 
transferring the antigen sensitivity. This supported the previous 
findings with the tuberculin and streptococcal antigens (Lawrence,
1954; 1955).
Adoptive transfer of cell-mediated iirmunlty 1n man was later found to 
be associated with low molecular weight substances (Lawrence et al,
28
1963). These substances could be separated, without loss of activity
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from the bulk of the disrupted leucocyte extract by exhaustive dialysis 
into distilled water and concentrated by freeze-drying. Lawrence et al 
(1963) named this material "dialysable transfer factor" (TF^). 
Traditionally this term was reserved for as yet unidentified factor 
or factors, rather than the whole crude dialysate, capable of 
specifically transferring delayed cutaneous hypersensitivity in man 
(Lawrence, 1969a, b; Lawrence and Al-Askari, 1971). Using the 
dialysable material, Zuckerman et al (1974) successfully transferred 
donor-specific delayed hyoersensitivity to another neoantigen, called 
keyhole limpet haemocyanin (KLH). They used dialysable transfer 
factor prepared from KLH-sensitive donors and, for control experiments, 
from donors not sensitive to KLH. Ten of 10 recipients of the immune 
dialysable transfer factor acquired delayed skin test hyoersensitivity 
to KLH. In contrast, none of the 11 recipients of the control 
dialysable transfer factor converted for KLH. Like the work of 
Rapaport et al (1960) with coccidioidin, these authors excluded the 
possibility that the transfer of KLH-sensitivity resulted from a 
non-specific adjuvant activity upon some precommitted lymphocytes, 
by not skin testing their recipients with KLH prior to the 
administration of transfer factor. Hence, table 1 shows some of the 
properties of dialysable transfer factor as described by Lawrence 
(1973, 1974).
It has subsequently been suggested that the term dialysable leucocyte 
extract (DLE) should be used. Instead of dialysable transfer factor, 
to encompass all the other specific and non-specific activities now 
found 1n the crude leucocyte extract (Valdlmarsson, 1975; Arala- 
Chaves et al, 1976; Mazaherl et al, 1977). (See section 1.5).
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T ab l e  1. Some properties of dialysable transfer factor
Biologi cal Biochemical Immunologi cal
Confers upon the 
recipient specific 
sensitivity of donor
Soluble, dialysable, 
lyophilisable,
M.Wt. <10,000
Not immunoglobulin
Not immunogenic
Acquired sensitivity 
is systemic
Onset early (hours) 
Duration long ( >1 year)
Not protein, albumin, 
alpha or gamma 
globulin, Orcinol 
positive.
Capacity for transfer polypoptide/poly-
function of donor 
sensitivity and TF 
dosage
Negative donors
nucleotide composition.
Inactivated at 
56°C/30 minutes
Resistant to DNase,
incapable of transfer RNase, lysosomal
hydrolases, trypsin
Leucocyte extracts 
or cell-free superna­
tants as effective 
as viable cells.
Not inactivated by 
distilled water lysis 
of cells, freeze-thawing 
(lOx), 25°C or 37°C 
for 6 hours.
Immunologically 
specific, converts 
normal lymphocytes 
in vitro and in vivo 
to antigen-responsive 
state.
Repeated test with 
antigen may increase 
intensity and duration 
of transferred sensitivity: 
not necessarily its cause
Informational molecule/ 
depressor/receptor 
site?
aAdapted from Lawrence (1973, 1974). 
bTF » transfer factor.
cDNase * Deoxyribonuclease, RNase ■ Ribonucléase.
1.1.2 Classification of mediators of cellular immunity (Table 2).
Defence against certain diseases is partly mediated by cellular 
immunity (World Health Organisation Technical Report Series, 1969).
This involves both antigen-specific and non-specific lymphoid cell 
populations (David, 1973). Antigen apparently reacts with a few 
specifically sensitised cells, presumably thymus dependent or 
T-lymphccytes, and results in the recruitment of a large number of 
non-sensitive cells and the elaboration of a number of soluble mediator 
substances or "lymphokines" (Dumonde et al, 1969; Lawrence, 1973). 
These non-antibody substances collectively mediate a variety of 
in vivo and in vitro biological phenomena, which can be studied to 
recognise and assess specific cell-mediated immunity. Altogether 
about 30 lymphokine-activities have apparently been recognised 
(Waksman and Namba, 1976).
Transfer factor was initially regarded as one such lymphokine, since 
1t was the first cell-free material to be isolated from sensitised 
cells (Lawrence, 1969a). However, it has been reported to differ from 
the lymphokines since 1t can apparently initiate, rather than simply 
mediate, cellular immunity. Transfer factor 1s dlalysable and 
therefore has a low molecular weight, (1.e. < 10,000, table 1). In 
contrast, the lymphokines are non-dialysable and have molecular 
weights of about 12,000 to 80,000 (Lawrence, 1973, 1974). Table 2, 
therefore, shows a few examples of biologically active soluble 
factors relevant to this work. It can be seen that transfer factor 
apparently requires antigen for expression of cell-mediated Immunity, 
whereas those lymphokines mentioned 1n the table do not.
Table 2. Some biologically active soluble factors elaborated by sensitised lymphocytes in the expression
of cell-mediated immunity
In vivo or in vitro 
test systems
Name given to 
soluble factor
Antigen requirement 
for expression
References
Production of delayed 
hypersensitivity skin 
reaction by antigen
Skin reactive
factor
(SRF : lymphokine)
No Section 8.1
Inhibition of leucocyte, 
macrophage or mixed 
1eucocyte-macrophage 
migration by antigen
Leucocyte and/or 
macrophage migration 
inhibition factor 
(LIF, MIF : lymphokine)
No Section 8.2
Lymphocyte trans­
formation by antigen 
or mitogen
Mitogenic or blastogénie 
factor
(MF : lymphokine)
No Section 8.3
Transfer of delayed 
hypersensitivity skin 
reaction, stimulation 
of lymphocyte trans­
formation and/or 
migration inhibition 
factor production.
Transfer factor 
(TF)
Yes Section 1
1.2 Clinical studies of human transfer factor (Tables 3-6).
The concept that transfer factor could restore defective cel 1-mediated 
immunity, as expressed by the acquisition of delayed-type skin 
reactions, resulted in its therapeutic use for the treatment of a 
wide variety of acquired and.congenital immunodeficiency states 
(Lawrence, 1974; Fudenberg et al, 1974). Therapeutic benefit from 
treatment with transfer factor has been reported for many neoplastic 
and infectious diseases (Kirkpatrick and Gallin, 1974; Zuckerman, 
1975a; Heim et al, 1976; Mazaheri et al, 1977).
1.2.1 Infectious diseases.
1.2.1.1 Fungal infections (Table 3).
A variety of fungal infections have been treated with transfer factor 
(Table 3). Coccidioidomycosis, usually self-limiting, can become 
chronic with invasion of the skin and other organs and apparently 
become resistant to treatment with antifungal agents, such as 
amphotericin B (Kirkpatrick and Gallin, 1974). One approach for 
the treatment of disseminated coccidioidomycosis has been the use of 
transfer factor. Out of 52 treated cases, 33 have been reported to 
show clinical Improvement with recovery of cellular immune reactivity 
(Graybill et al, 1973; Catanzaro and Spitler, 1976). Catanzaro and 
Spitler (1976) did not define objectively what they meant by 
"clinical improvement", but twelve of these improved conditions were 
directly associated with the beneficial effect of transfer factor, 
since antifungal agents were, 1n these cases, not used before or 
during therapy. Such an association may well be true for 2 other
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improved conditions reported by Graybill et al (1973), since these 
patients were resistant to cure with amphotericin B for up to 5 
years previous to treatment with transfer factor. These investigators 
observed clinical improvement of fungal lesions in the lung and skin 
of these patients.
Chronic disseminated amphotericin B-resistant histoplasmosis has also 
been treated with transfer factor with reported clinical improvement 
for 6 months (Graybill et al, 1976). This patient also had stage 
III Hodgkin's disease and was, at the same time as transfer factor, 
being treated with amphotericin B and steroids. The temporary 
clinical improvement could not, therefore, be attributed to transfer 
factor only.
Mucocutaneous candidiasis describes a broad variety of disease 
states and is clinically characterised by fungal lesions on the skin 
and mucous membrane (Levin et al, 1973). Several patterns of defects 
in cellular and humoral immunity have been reported among different 
populations of patients (Valdimarsson et al, 1973). The immune 
defects include absence of delayed hypersensitivity skin reaction to 
Candida, defective MIF-lymphokine production and cand1da-1nduced 
lymphocyte transformation (Valdimarsson et al, 1973). Some workers 
have treated 6 patients with candidiasis with transfer factor 
resulting 1n clinical improvement and immune conversion to Candida 
antigen (Pabst et al, 1972; Schulkind et al, 1972; Valdimarsson et al. 
1972; Moullas et al, 1973; Uttman et al, 1976, 1978). Six other 
patients with chronic mucocutaneous candidiasis were treated with 
transfer factor by Kirkpatrick et al (1972) and Griscelli (1975).
Table 3. Some clinical applications of transfer factor in fungal and bacterial diseases
Disease3 TF
source
L £
TF° Immune conversion 
preparation DH LIF/MIF LT
Clinical
improvement
References
Fungal
Coccidioidomycosis Coccidioidin+ bl,tfd 3/3 3/3 3/3 2/3 Graybill et al (1973)
Coccidioidin+ V 32/44 24/28 27/32 31/49 Catanzaro & Spitler (1976)
Histoplasmosis Histoplasmin+ tfd 0/1 1/1 0/1 1/1 Graybill et al (1976)
Candidiasis Candida-«- bl 5/6 5/6 1/5 1/6 Kirkpatrick et al (1970, 1972)
Candida-«- TFn 1/1 1/1 1/1 Pabst et al (1972)
Candida-«- TF° 1/1 1/1 1/1 Schulkind et al (1972)
Candida-«- TF? 1/1 1/1 Valdimarsson et al (1972)
Candida-«- TF° 1/1 1/1 1/1 1/1 Moulias et al' (1973)
Candida-«- TFS 1/1 Griscelli (1975)Candi da-t- TFS 2/2 2/2 1/1 2/2 Littman et al (1976, 1978)
Total: 46/60 (77%) 37/42 (88%)34/44 (77%) 42/66(64%)
Bacterial
Tuberculosis Mantoux+ tfd 1/1 1/1 1/1 1/1 Whitcomb & Rocklin (1973)
Leprosy Lepromin+ bl-tfd 6/9 0/9 ? 6/9 Bullock et al (1972)Lepromin+ TF u rD 2/5 5/5 Hastings et al (1976)
Total : 9/15 (60%) 1/1 1/10 12/15(80%)
aAll persistent and drug resistant.
■»TF. transfer factor; BL, blood leucocytes; TFp = dialysable transfer factor.
CDH, delayed cutaneous hypersensitivity; LIF/MIF, leucocyte or macrophage migration inhibition factor; LT, lymphocyte 
transformation with antigen.
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Of these, 4 patients developed positive skin hypersensitivity and 
showed conversion of MIF responsiveness, but only 1 of these 
recipients developed antigen-induced lymphocyte transformation. One 
patient, with Nezelof syndrome, did not become skin-test positive or 
develop reactivity to the in vitro tests (Kirkpatrick et al, 1972).
In none of these cases listed in table 3, clinical benefits of 
transfer factor on patients with candidiasis could totally be 
related to the beneficial effect of transfer factor, since such an 
immunotherapy was always undertaken after or during chemotherapy with 
antifungal agents. Nevertheless, it is believed that transfer factor 
played an important role, because chemotherapy alone was not adequate 
for clinical recovery. Drugs were used in an attempt to reduce the 
antigen load in order to prolong temporary remissions of 220 days 
previously reported by the use of similar immunotherapy alone 
(Kirkpatrick et al, 1970).
1.2.1.2 Bacterial infections (Table 3).
Attempts have been made to treat intracellular Mycobacterial infections 
with transfer factor (Table 3). Whitcomb and Rocklin, in 1973, 
reported beneficial effects of transfer factor 1n a case of progressive 
primary tuberculosis. The patient had failed to respond to 7J months 
of chemotherapy, even though the organisms were sensitive to the drugs 
used. This, they suggest, was due to a defect 1n the host's immune 
response and transfer factor was added to the treatment. Recovery of 
skin test reactivity, accompanied by moderate clearing of the lesions 
1n the lungs, followed the combined drug-transfer factor therapy. 
Continual chemotherapy and subsequent removal of bacterla-laden spleen
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may have sufficiently lowered the antigen load, so that transfer 
factor could induce the expression of the immunological response, which 
was absent previous to immunotherapy.
Based on the rationale that there is poor cellular defence against
Mycobacterium leprae in patients with lepromatous leprosy, Bullock
et al (1972) and Hastings et al (1976) treated 14 patients with
transfer factor. Skin test conversions occurred in 8 of these
patients. In one study (Bullock et al, 1972), 6 of 9 patients showed
slow onset of diffuse erythema and induration within the lepromatous
lesions 2 to 6 days after transfer factor-therapy. This was interpreted
by these workers as clinical improvement, but it might simply suggest
that only some immunological activity was in progress locally. The
impact of immunotherapy was, therefore, difficult to assess. Such an
assessment was especially difficult, because treatment of some patients
was frequently interrupted with chemotherapy which in 3 cases included
steroids. On the other hand, the study of Hastings et al (1976)
g
clearly revealed that, after therapy with 6.6 to 7.9 x 10 lymphocyte 
equivalent of transfer factor for a period of 12 weeks, 5 out of 5 
patients clinically improved. The beneficial effects of transfer 
factor were Indicated by the observation that the rate of bacterial 
clearing, during transfer factor therapy, was about 6 times faster 
than that seen with routine dapsone therapy. Bullock et al (1972) 
wrote that 40% of patients with arrested leprosy Infection may, even 
after chemotherapy, revert to active disease. They suggested that 
repeated administration of transfer factor to such patients could 
reconst.tute sufficient cell-mediated immune reactivity to prevent 
the high rate of relapse.
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1.2.1.3 Viral infections (Table 4).
The initial attempts at immunotherapy of viral infections employed 
viable leucocytes, presumed to contain transfer factor. Thus Kempe 
(1960) treated a young boy suffering from progressive vaccinia 
infection with peripheral blood or lymph node leucocytes, and by 
transplantation of sensitised lymph nodes from vaccinated immune 
donors. The progression of the lesions was arrested and delayed 
hypersensitivity to inactivated vaccinia virus was conferred.
Similarly O'Connell et al (1964) treated an elderly patient suffering 
from severe progressive vaccinia. Intramuscular and subcutaneous 
injections of specific immune leucocytes were given on two occasions 
about 2 months apart. Acquisition of cutaneous delayed hypersensitivity 
to vaccinia antigen and termination of the infection were reported.
These initial studies were extended to the use of dialysable transfer 
factor. Drew et al (1973) treated a patient with disseminated herpes 
zoster with dialysable transfer factor prepared from a pool of 27 
healthy donors who demonstrated immunity to varicella-zoster in vitro. 
The patient, a 44 year old man with stage IVB Hodgkin's disease and 
defective cell-mediated immunity was not treated with Immunosuppressive 
drugs or corticosteroids 1n the three months preceding therapy.
Following two subcutaneous Injections of dialysable leucocyte extract 
the vesicular lesions completely heale^. Moulias et al (1973) 
treated two children with "giant-cell" measles pneumonia with dialysable 
transfer factor from Immune donors. The patients responded with 
Improvement and regression of the pulmonary lesions. Positive in vitro 
leucocyte migration inhibition responses to measles virus were
W tÊÊHÊÈÊtÈmmtm
Table 4. Some clinical applications of transfer factor in viral diseases
Disease6 TF
source
-----TF6
preparation DH
r
Immune conversion 
---- L7F7RTF---- LT
Clinical
improvement
References
Generalised Vaccinated BL.LL 1/1 1/1 Kempe (1960)
Vaccinia Vaccinated BL 1/1 1/1 O'Connell et al (1964)
Herpes zoster Herpes + tfd 1/1 1/1 Drew et al (1973)Neonatal herpes Herpes + TFUD 1/1 Moulias et al (1973)
Measles Measles + tfd 1/1 0/1 1/1 Moulias et al (1973)pneumonia
SSPE Measles + tfd 5/7 0/2 2/7 Moulias et al (1973)
Measles +
tf“d 1/1 1/1 Vandvik et al (1973)
CMV retinitis tfd 1/1 1/1 1/1 Rytel et al (1975)
CAH Hep.B* BLJfd 2/2 Kohler et al (1974)
H e p . A W
tfd
5/5 Schulman et al (1974, 1976)
Hep.B /B+
tfd ? 4/9 Jain et aTTTl75, 1977)Hep.B+ TFU 1/1
1
1/1 0/1 Tong et al (1976)
Total: 5/5 (100%) 7/9 (78%) 2/5 (40%) 20/31 (65%)
aSSPE, subacute sclerosing panencephalitis; CMV, cytomegalovirus; CAH, chronic active hepatitis.
“tF, transfer factor; BL, blood leucocytes; LL, lymph node leucocytes; TFp, dialysable transfer factor.
CDH, delayed cutaneous hypersensitivity; LIF/MIF, leucocyte or macrophage migration inhibition factor; LT, lymphocyte 
transformation with antigen.
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reported after transfer, indicating improved cell-mediated immunity 
to the virus. Moulias et al (1973) also treated 7 children with 
sub-acute sclerosing panencephalitis, (SSPE), a degenerative disease 
associated with measles virus infection. Clinical improvement was 
seen in 2 out of the 7 children although 5 out of 7 showed 
conversion of the leucocyte migration inhibition test to measles 
antigen in vitro. Vandvik et al (1973) treated a 16 year old boy 
with SSPE with dialysable transfer factor from donors with measles 
immunity. The patient improved clinically and developed delayed 
hypersensitivity to various antigens, and a selective reduction in 
measles antibody titre in the cerebrospinal fluid and serum. Rytel 
et al (1975) treated a renal transplant patient with cytomegalovirus 
retinitis with dialysable transfer factor. Inactivation of the 
natural inflammatory lesions was seen. The patient also acquired 
delayed skin reaction and in vitro inhibition of leucocyte migration.
Attempts have been made to treat patients with chronic active 
hepatitis with transfer factor. There was no clinical improvement 
in a 29 year old patient with chronic active hepatitis who received, 
over a period of 8 weeks, 17 injections of dialysable transfer 
factor twice weekly (Tong et al, 1976). Each Injection was derived
O
from 5 x 10 leucocytes from a donor who previously had acute 
hepatitis B, and showed lymphocyte reactivity to hepatitis B surface 
antigen 1n vitro. Clinical and biochemical Improvement was not 
observed. However, the transfer of cel 1-mediated immunity was 
demonstrated by the appearance of delayed hypersensitivity to mumps and 
streptoklnase-streptodornase, and by 1n vitro lymphocyte responses to
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hepatitis B surface antigen. It was suggested that clinical Improvement
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might have been seen with increased quantity, frequency and duration 
of treatment. Kohler et al (1974) treated a healthy persistent 
carrier of hepatitis B surface antigen with lymphocytes from an 
individual who had recovered from hepatitis B 8 months previously. 
Within 24 hours of the administration of lymphocytes, there was an 
increase in the titre of the surface antigen and of serum aspartate 
transaminase levels, suggesting liver cell damage. It was presumed 
that the development of cell-mediated immunity to hepatitis B was 
reflected in the injury of the virus-laden liver cells.
Another patient, a 4 month old infant, who acquired hepatitis B 
from her mother at birth was given dialysable transfer factor 
prepared from the mother's leucocytes on two occasions. The recipient 
promptly developed an increase in the titre of hepatitis B surface 
antigen and elevation of serum transaminase activity. Subsequently, 
however, the liver function tests returned to normal and the titre 
of hepatitis B surface antigen decreased by 95%.
Jain et al (1975) treated 3 patients with dialysates prepared from 
healthy donors without any history of viral hepatitis ("normal"), 
and from donors, who had recovered from hepatitis B infection 
("specific"). One patient with hepatitis B surface antigen-positive 
chronic active hepatitis and cirrhosis did not respond to "normal" 
dialysable transfer factor, but Injection of "specific" dialysable 
transfer factor resulted 1n a two-fold Increase in T lymphocytes as 
measured by sheep red blood cell rosettlng. The second patient, 
also did not respond to "normal" dialysable transfer factor, but 
showed a transient Increase in transaminase activity. Th. *-uggested
stimulation of cel 1-mediated immunity with a resulting hepatic 
damage. The third patient suffered from antigen-positive active 
chronic hepatitis complicated by primary liver cancer. This patient 
was being treated with corticosteroids and did not respond to either 
"normal" or "specific" dialysable transfer factor. There was no 
change in the serum titre of hepatitis B surface antigen in any of 
the patients. Similarly, in another study Jain et al (1977) treated 
6 other patients with chronic active hepatitis with "specific" and 
"non-specific" dialysable transfer factor preparations. No 
beneficial clinical effects were detected histologically after any 
of these preparations, but in 3 of 6 patients, the "specific" 
transfer factor provoked a hepatitic reaction shown by transient 
elevation of serum transaminase level. In contrast, injection of 
"non-specific" transfer factor did not result in the elevation of 
this enzyme, suggesting a "donor-specific" response.
A major criticism of transfer factor therapy has been the lack of 
controlled clinical trials. Jain et al (1975) were the first to 
attempt a controlled trial of transfer factor in the treatment of 
chronic active hepatitis. Schulman et al (1976) initiated a far 
better small double-blind "controlled" trial. In this study none of 
the patients had other concomitant complications and were not on 
chemotherapy. They treated 4 patients with chronic active hepatitis 
with dialysable transfer factor from pools of donors who had recovered 
from hepatitis B and A, while 4 others received normal saline. The 
results Indicate that all 4 patients receiving dialysable transfer 
factor showed biochemical evidence of Improvement, with a fall 1n 
serum transaminase activity. In 3 of the patients 1t was considered
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that there was also histological improvement, but hepatitis B surface 
antigen remained in the serum. The patients responding to dialysable 
transfer factor have remained in remission for periods of 9 months to 
1J years. None of the 4 recipients of normal saline improved. Based 
on these observations it was considered that dialysable transfer 
factor may be useful for the management of chronic hepatitis B 
infection (Schulman et al, 1974; Schulman, 1977 personal 
communication).
In most of the above clinical studies of transfer factor in infectious 
diseases, the transfer factor was prepared from donors with strong 
delayed hypersensitivity skin reaction to the antigens of the 
infecting organism. During therapy there was, therefore, transfer 
of donor-specific skin test reactivity and in vitro responses.
However, the relationship between specific conversion of cellular 
immunity and the beneficial clinical effects of transfer factor has 
not yet been determined.
1.2.2 Neoplastic diseases (Table 5).
The mechanisms by which the host cells Inhibit the growth of cancer 
cells or destroy such cells are not completely understood (Nadler 
and Moore, 1969). However, the Importance of host resistance and 
immunological surveillance 1n influencing the growth of tumours has 
been suspected for many years (Burnet, 1967). Therefore, some 
Investigators have suggested the use of Immunocompetent cells or 
transfer factor 1n the treatment of neoplastic diseases (Thompson 
and Mathe, 1972; Ascher et al, 1976).
Table 5. Some clinical applications of transfer factor in neoplastic diseases
Disease TF
source
TFa
preparation DH
Immune conversion*5 
---- QF/HTF----  LT
Clinical
improvement
References
Alveolar soft- 
part sarcoma
Contact tfd 1/1
? LoBuglio et al (1973)
Breast cancer Normal 3/5 1/5 Oettgen et al (1974)
Hodgkin's
disease
Contacts tfd 5/8
? Khan et al (1975)
Melanoma Melanoma+
Contacts
BL
tfd+bcg
1/2 1/2
4/15 3/19
2/2
3/19
Brandes et al (1971) 
Spitler et a! (1973, 1976)
Nasopharyngeal
carcinoma
IM+
tfd 1/2 2/2 Goldenberg & Brandes (1972)
Osteogenic
sarcoma
Contact 1/1 1/1 Levin et al (1972)
Various
tunours
Contacts
tfd
13/35 Vetto et al (1976)
Total ! 11/18 (61%) 5/16 (31%) 4/21 (19%) 22/64 (34%)
aBL, blood leucocytes; TF, transfer factor; TFD dialysable transfer factor; BCG, Bacille Calmette Guerin; IM, infectious 
mononucleosis. u
DH, delayed cutaneous hypersensitivity; LIF/MIF, leucocyte or macrophage migration inhibition factor; LT, lymphocyte 
transformation.
Table 5 shows that various reports suggest a potential role for 
transfer factor for treating malignant diseases. Levin et al
(1972) have reported temporary restoration of skin test reactivity 
and arrest of growth of an osteogenic sarcoma in 1 patient. The 
patient was treated with radiation and multiple injections of 
dialysable transfer factor from a family member. After 7 months of 
therapy the patient showed signs of deterioration first shown by 
decreased skin test reactivity, and 6 weeks later, by tumour growth 
and lung metastasis. The authors suggested that the temporary 
clinical improvement may have been due to radiotherapy and/or 
transfer factor therapy. Goldenberg and Brandes (1972) used transfer 
factor from donors who had previously recovered from infectious 
mononucleosis to treat 2 patients with nasopharyngeal carcinoma. In 
both cases, temporary but definite regression of tumour growth 
occurred and in one of the patients, a delayed skin hypersensitivity 
reaction to PPD was restored. In 1973, LoBuglio et al reported that 
transfer factor prepared f»om a family contact and administered to 
a patient with alveolar soft-part sarcoma led to restoration of 
cellular immunity. The patient's lymphocytes became capable of 
producing MIF. The tumour neither regressed nor advanced during the 
6 months period of therapy. Oettgen et al (1974) treated 5 patients 
with advanced breast cancer with pooled dialysable transfer factor 
from healthy donors. Delayed hypersensitivity skin reactions to 
PPD and/or Streptokinase - Streptodornase was restored 1n 3 of the 
patients. Marked partial regression of the tumour occurred 1n 1 
patient and lasted for 6 months. After this period the tumour 
started to grow again and could no longer be controlled by transfer 
factor therapy. It cannot be, therefore, suggested that 1n this
study pooled normal transfer factor offered great promise in the 
treatment of patients with breast cancer.
Brandes et al (1971) were the first to treat 2 patients with 
disseminated melanoma with lysed buffy coat cells obtained from the 
recipients of the tumour graft. One of them developed positive 
delayed hypersensitivity and lymphocyte transformation responses to 
tumour-specific antigens. Both patients improved clinically with 
the melanoma nodules showing an overall regression over the 3 weeks 
of treatment. Spitler et al (1973) studied effect of transfer 
factor in 9 patients with such metastatic melanoma. Only 1 such 
patient, who showed significant conversion of lymphocyte transformation 
to melanoma antigens, experienced a regression of cancer during 
treatment. Also, in this patient, MIF lymphokine responses to the 
same antigen had been positive before and after immunotherapy. New 
metastases developed after 18 months when transformation and MIF 
responses were lost. In 1976, Spitler et al treated 10 other patients 
with disseminated malignant melanoma with transfer factor alone or 
combined with Bacille Calmette-Gulrin (BCG) in 7 cases. Transfer 
factor was obtained from family contacts or donors who had previously 
recovered from melanoma. After combined immunotherapy 2 patients 
improved clinically showing complete regression of all tumour nodules. 
One had recurrence of disease and died despite continued therapy, but 
the other patient remained completely free of malignant melanoma for 
over 3 years. Only 2 patients showed an Increase 1n lymphocyte 
responses to melanoma antigen, and these were the 2 patients whose 
lesions regressed after combined Immunotherapy. Three patients began 
to produce MIF after administration of transfer factor and BCG.
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Spontaneous regressions can occur in patients with malignant melanoma 
(Spitler et al, 1976). It is possible that the patients who improved 
had actually experienced such spontaneous regressions. The clinical 
benefit had, however, coincided with the administration of combined 
immunotherapy. Khan et al (1975) treated 8 patients with Hodgkin's 
disease with transfer factor. Clinical effects were not reported, 
but cellular immune responses improved in 5 of the patients with 
restoration of delayed hypersensitivity skin reactions to several 
antigens.
Vetto et al (1976) treated 35 patients with a variety of advanced 
recurrent malignant tumours with transfer factor from prolonged 
close contacts. Types of tumour included melanoma, osteogenic 
sarcoma, epidermoid carcinoma and others. Within 2 weeks of 
treatment, 13 (37%) of the patients apparently improved clinically 
for 1-12 months with over 50% regression of cancer. Eleven (31%) 
of the patients did not show a benefit from transfer factor.
However, 7 of these patients had deficient mitogen-induced in vitro 
lymphocyte responsiveness, probably due to a blocking factor 
thought to be present in their serum. The remaining 11 (31%) of 
the patients treated with transfer factor were not critically 
evaluated.
Table 5 shows that in the majority of cases, transfer factor donors 
were healthy contacts of the patients. They were selected on the 
basis that such contacts might be Immune to the aeteological 
agents of malignant diseases, especially 1f these agents were 
viruses (LoBugllo et al, 1973). It has been suggested that
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development of in vitro responses to tumour antigens may be indicative 
of clinical benefit in terms of tumour resistance (LoBuglio et al, 
1973; Spitler et al, 1976). The numbers of treated patients are 
small and, in the majority of cases, the duration of follow-up is too 
short to allow firm conclusions. Nevertheless, the above observations 
lead to the following interim conclusions: (a) cell-mediated 
responses can be restored in patients with neoplastic diseases with 
transfer factor, and (b) some of the patients can improve with 
regression of their malignant lesions. These findings do not 
establish a beneficial therapeutic role for transfer factor in 
neoplasia, but they do indicate the need for well controlled large 
scale investigations to determine the efficacy, source and optimum 
dose of transfer factor in the treatment of malignancies.
1.2.3 Immuno-regulatory diseases (Table 6).
Immuno-regulatory or immunodeficiency diseases can be either 
congenital or acquired (Roitt, 1977). Levin et al.(1973) classified 
congenital or hereditary disorders into: (a) those with defective 
humoral or B-cell system and Intact cellular immunity or T-cell 
system, (b) those with defective cellular and intact humoral immunity, 
(c) those with mixed B and T-cell deficiencies, (d) those with 
variable deficiencies and (e) those with neutrophil dysfunction 
syndrome. Table 6 shows some of the applications of transfer factor 
in the treatment of patients with some such congenital defects of 
Immunity.
Wiskott-Aldrich syndrome is an X-linked recessive disorder
Table 6. Some clinical' applications of transfer factor in immuno-regulatory diseases
Di seasea Defect Immune conversion15 Clinical References
DH LTF'/MIF---- LT improvement
Hiskott- 7/9 4/8 0/7 6/9 Levin et al (1970, 1973)
Aldrich T-cell 7/12 6/8 0/6 2/11 Spitler et al (1972)
syndrome 1/2 2/2 1/2 Ballow et al (1973)
4/4 1/4 2/4 GriscelTT(T975)
Ataxia- 4/5 ? 0/5 Griscelli (1975)
telangiec­
tasia
T-cell 3/4 3/4 0/4 1/4 Berkel et al (1977)
SCI 1/1 1/1 2/2 Levin et al (1973)
Stem 1/1 1/1 Arala-Chaves et al (1974)
cell 0/1 0/2 Griscelli (1975)
CMC B & T
cells
9/10 7/8 4/8 6/11 (See table 3)
Some B & T 3/6 2/6 Annan et al (1974)
others T-cell 1/1 Valdimarsson et al (1974)
B-cell 1/2 Griscelli (1975)
T-cell 1/1 0/1 1/1 Ballow & Good (1976)
Total: 41/56 (73%) 21/29 (72%) 7/32 (22%) 26/61 (43%)
aSCI, severe combined immunodeficiency; CMC, chronic mucocutaneous candidiasis.
bDH, delayed cutaneous hypersensitivity; LIF/MIF, leucocyte or macrophage migration inhibition factor; LT, lymphocyte
transformation with antigens.
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characterised by thrombocytopenia, eczema, recurrent infections and 
lack of cellular immunity (Levin et al, 1973). Levin and 
colleagues, who were the first investigators to use transfer factor 
therapeutically, in 1970 and 1973 reported the treatment of 9 
patients with this syndrome with dialysable transfer factor. Six 
out of nine patients improved clinically with the clearing of 
eczema and recurrent infections, some showed skin test conversion and 
4 out of 8 produced MIF, but none showed lymphocyte transformation 
responses. Spitler et al (1972) treated 12 patients with Wiskott- 
Aldrich syndrome with multiple injections of transfer factor from 
PPD skin-test positive donors. Seven out of the 12 patients 
responded with skin-test conversion. Some of these recipients 
experienced decreased incidence of infections and regression of 
splenomegaly and clearing of eczema. It was found that response 
to transfer factor in Wiskott-Aldrich syndrome appears to be 
correlated with the absence of monocyte IgG receptors. Two other 
children with this syndrome were treated by Ballow et al (1973) 
with multiple doses of dialysable leucocyte transfer factor.
Although both patients showed positive lymphocyte transformation 
responses, 1 patient developed strong skin-test reactivity to 
Candida and clinically improved with clearing of eczema and 
reduction of bleeding. The other recipient showed only delayed 
cutaneous conversion, but developed autoimmune haemolytic anaemia 
concomitantly with Coxsackle B5 pneumonitis and subsequently died 7 
months later. GriscelH (1975) treated 4 patients with Wiskott- 
Aldrich syndrome with normal transfer factor. All 4 developed skin 
test reactivity, while 2 out of 4 patients Improved clinically with 
a reduction 1n Infection and spleen size and clearing of eczema.
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Transfer factorcan, therefore, have a beneficial effect on some of 
the patients with Wiskott-Aldrich syndrome. The observed 
improvement, however, in some tranfer factjr-treated patients cannot 
necessarily be attributed to the beneficial effect of the transfer 
factor. This disease has a variable course and temporary 
spontaneous improvement can occur (Spitler et al, 1972).
Ataxia-ttlangiectasia is an autosomal recessive disease clinically 
characterised by progressive neurological symptoms and recurrent 
sinooulmonary infection. Immunologically it involves mainly 
T-cell deficiency, though some defect in humoral immunity also 
occurs (Levin et al, 1973). Altogether nine patients suffering 
from this disease have been treated with transfer factor by Griscelli 
(1975) and Berkel et al (1977). Among the 5 patients studied by 
Griscelli in 1975, four showed skin-test conversion, whilst 2 
improved clinically. Recently, Berkel et al (1977) observed that 
delayed hypersensitivity can be restored in 3 out of the 4 patients 
treated with transfer factor, but clinical improvement in appetite 
and general well being occurred in only 1 case.
X-linked dual system deficiency or severe combined immunodeficiency 
generally Involves diminished immunoglobulin levels and deficient 
cellular immune responses with absent skin-test reactivity and low 
lymphocyte transformation responsiveness to mitogen and antigens 
(Levin et al, 1973). These authors observed skin-test conversion 
and production of MIF after transfer factor-therapy of 1 oatlent 
with X-1 Inked dual-system immunodeficiency. This patient and 
another one, with autosomal recessive disease, showed clinical
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improvement and were both maintained on transfer factor injections 
and plasma transfusions. In contrast, Griscslli (1975) did not 
observe any improvement after transfer factor therapy in 2 patients 
with autosomal recessive severe combined immunodeficiency syndrome. 
These apparent inconsistencies in the therapeutic uses of transfer 
factor are, at least to some extent, due to the heterogeneity of 
the patients' immunological defects. In 1974, Arala-Chaves et al 
treated a young patient with unclassified complex immune deficiency 
disease with 2 injections of dialysable leucocyte transfer factor 
from healthy donors. Following such a therapy she showed clinical 
improvement, and developed strong delayed skin reactivity to 
Candida and streptokinase-streptodornase and a moderate and short­
lived skin test reactivity to tuberculin PPD. In addition her 
leucocytes transformed in vitro by induction with phytohaemagglutinin. 
These manifestations of cellular immunity had been absent prior to 
treatment with transfer factor.
Chronic mucocutaneous candidiasis and the effect of transfer factor 
on Immunological responses of anergic patients with this disease 
has been described above (Table 3, section 1.2.1.1).
Some patients with various other immunodef cient disorders have 
also been treated with transfer factor. Amman et al (1974) 
treated 6 patients with deficiency 1n cellular and humoral immunity 
with dialysable leucocyte transfer factor. Donors had positive 
skin reactivity to mumps, streptokinase-streptodornase, Candida and 
PPD antigens. One 10 month old patient had sex-11nked combined 
Immunodeficiency disease, while two 3} and 5 year-old patients had
thymic hypoplasia and hyperimmunoglobulinaemia. Of the 3 others,
1 patient had thymic hypoplasia and selective IgA deficiency and 
severe pulmonary insufficiency, while 1 other suffered from 
immunodeficiency with thrombocytopenia and eczema, and the last 
one had thymic hypoplasia, decreased IgG, increased IgM and absent 
IgA. Following treatment with transfer factor 3 of 6 patients 
showed improvement in phytohaemagglutinin-induced lymphocyte 
transformation and conversion of skin-test reactivity. However, 
there was not any evidence of change in antibody-mediated immunity, 
but 2 patients showed clinical improvement.
Valdimarsson et al (1974) treated a 3 year old patient with a 
defective T-lymphocyte function and had severe attacks of extensive 
skin ulceration and high fever. After injection of dialysable 
leucocyte transfer factor the patient developed improved 
phytohaemagglutinin-induced lymphocyte transformation and 
T-lymphocyte sheep red cell rosetting. The patient also clinically 
improved with regression of the lesions and remained symptom-free 
for 9 months. In addition to treatment of patients with Wiskott- 
Aldrich syndrome, Ataxia-telangiectasia and severe combined immuno­
deficiency (Table 6), Griscelli (1975) injected transfer factor 
from healthy donors into 3 normal control subjects and 2 patients 
with variable hypogammaglobulInaemia. During treatment 2 of 3 
control recipients showed skin-test conversion and all 3 responded to 
various antigens in vitro, while 1 of 2 patients improved clinically. 
Ballow and Good (1976) treated a 12 year-old patient, who was not 
capable of producing delayed hypersensitivity skin reactivity to 3 
common antigens and suffered from Intermittent bronchopulmonary
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infections, with transfer factor. After treatment with 4 injections 
of dialysable leucocyte transfer factor, conversion of skin 
reactivity occurred to 2 of the 3 antigen markers present in the 
transfer factor donor. No change occurred in lymphocyte 
transformation responses, but in the following 4 months there was 
clinical improvement without any episodes of fever or pneumonia.
From most of the above observations in the clinical application of 
transfer factor in immunodeficient disorders (table 6) the fo..owing 
conclusions can be drawn: (a) there seems to be a dissociation of 
skin test reactivity and LIF and/or MIF production from lymphocyte 
transformation, (b) there is a strong association between the skin 
test reactivity and LIF and /or MIF production, and (c) there is 
some association between skin test and cell migration (LIF/MIF) 
reactivities and clinical improvement.
The clinical use of transfer factorforthe treatment of infectious, 
neoplastic and immuno-regulatory diseases has not been free of 
investigational problems and reported side effects.
1.2.4 Investigational problems and side effects.
The above accounts of the therapeutic use of transfer factor are 
largely limited to selected clinical cases. A major criticism of 
transfer factor therapy has been the lack of properly controlled 
clinical trials. Since many diseases go through natural cycles of 
relapse and remission, and patients may be treated with other 
therapeutic agents, 1t 1s often difficult to assess the clinical 
benefit of treatment with transfer factor.
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It has been reported that transfer factor is a safe therapeutic 
agent. However, reactivation associated with reconstitution of 
cellular immunity may in itself produce deleterious side-effects.
For example Moulias et al (1973) reported that regression of the 
pulmonary lesions in the children with measles pneumonia was 
associated with an initial inflammatory response. Drew et al (1973) 
reported that their patient with Hodgkin's disease and disseminated 
herpes zoster developed fever and intense erythema around the 
vesicles following injections of dialysable leucocyte transfer 
factor. It has also been suggested that the increases in serum 
transaminase levels in chronic active hepatitis after the 
administration of dialysable leucocyte transfer factor may reflect 
liver damage due to cellular immune reactions against the virus-laden 
liver cells (Kohler et al, 1974).
A further complication was reported by Sallow et al (1973). They 
reported autoimmune haemolytic anaemia following transfer factor- 
therapy in patients with Wiskott-Aldrich syndrome. However, they 
had already observed that there was an unusually high Incidence of 
autoimmune haemolytic anaemia in patients who suffered from Wiskott- 
Aldrich syndrome and were not treated with transfer factor. This 
complication may have not, therefore, been due to transfer factor.
Side effects Including headache, nausea, arthralgia, malaise and 
pain at the site of disease lesions have all been observed.
(O'Connell et al. 1964; Brandes et al, 1971; Bullock et al, 1972;
Graybill et al, 1973).
In contrast to these deleterious effects, Hastings et al (1976) in 
180 subcutaneous and intradermal injections of transfer factor did 
not detect any side effect in his patients. Nor did Oettgen et al
(1974) in their patients with breast cancer, or Khan et al (1975) 
in their's with Hodgkin's disease even when a high dose of transfer
g
factor equivalent to 4.9 x 10 leucocytes was used.
Against such background of mainly uncontrolled clinical applications 
of transfer factor and only a few reports of possible adverse 
consequences, it seems prudent to use transfer factor for the therapy 
of diseases primarily when conventional therapeutic measures are 
inadequate.
In order to use transfer factor more effectively in the future 
treatment of various diseases, its in vitro and in vivo biological 
activities and the specificities of these activities must be 
determined. The possible relationship between such activities and 
the therapeutic benefits of transfer factor must be investigated.
1.3 Biological activity of transfer factor preparations 
in vitro (Tables 7-8).
It 1s postulated that leucocyte dlalysates thought to contain transfer 
factor can convert non-immune lymphocytes to Immune lymphocytes. Thus,
1t should be possible to culture non-1mmune lymphocytes with transfer 
factor and look for the acquisition of the ability to respond to 
specific antigen. Such specific effects have been reported and were 
detected by lymphocyte transformation, migration inhibition.
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lymphocytotoxicity or other in vitro tests. Transfer factor also 
contains substances which can non-specifically alter in vitro lymphocyte 
responses. Only some of these in vitro responses, if any, may be 
immunologically relevant and reflect non-specific in vivo effects.
1.3.1 Lymphocyte transformation (Table 7).
Table 7 shows that, Adler et al (1970) and Palmer and Smith (1974) 
reported that tuberculin-immune human dialysable leucocyte transfer 
factor could, in transformation cultures, transfer the ability to 
respond to tuberculin PPD. The "recipient" lymphocytes were from 
non-immune mice. In contrast, transfer factor obtained from donors 
not immune to PPD was not effective. Similarly, more recently 
such in vitro transfer of transformation reactivity to leishmania 
major antigen by leishmania-positive, and not leishmania-negative, 
transfer factor was reported by Sharma et al (1977) using human 
lymphocyte "recipients" in culture.
Lawrence in 1969 initially added water-dialysed human transfer 
factor to human lymphocytes in vitro 1n the presence of specific 
antigen. It was suggested that transfer factor could confer on the 
"recipient" the antigen sensitivity of the donor, but such activity 
was Irregular. Ascher et al (1974) presented evidence that this 
Irregular activity could be overcome by dialysis Into tissue culture 
medium. Such tissue culture medium-dialysed transfer factor (TFj^) 
was prepared from a donor, who had marked delayed hypersensitivity 
skin reaction to an antigen and had already transferred this 
reactivity Invlvo. On addition of this transfer factor to lymphocyte
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Table 7. In vitro properties of transfer factor.
I. lymphocyte transformation.
Biological effect Donor
specificity
References
Augmentation of + 
transformation + 
to antigens. +
1
•
Adler et al (1970)
Ascher et al (1974)
Palmer and Smith (1974) 
Sharma et al (1977) 
Arala-Chaves et al (1976) 
Burger et al (1976 a, b) 
Hamblin et al (1976 a) 
Ascher and Andron (1976) 
Salaman (1976)
Littman et al (1977)
This study (Section 6)
Augmentation of 
transformation 
to mitogens.
Burger et al (1976 b) 
Hamblin-ef al (1976 b)
cultures from a poor responder transformation occurred only in the 
presence of that antigen. When only such medium-dialysed transfer 
factor was added to non-immune lymphocytes, significant stimulation 
or transformation was not observed. Medium-dialysed transfer 
factor, prepared from skin test-negative individuals, did not cause 
such antigen-dependent transformation. The stimulation in culture 
of non-immune lymphocytes occurred only in the presence of those 
antigens to which the transfer factor donor was sensitive. This 
reactivity was, therefore, related to the state of the donor’s 
sensitivity (i.e. "donor-specific").
In contrast, there are now reports that similar lymphocyte- 
stimulation effects have occurred to antigens to which the transfer 
factor-donor was not sensitive (Hamblin, 1975; Hamblin et al,
1976a; Ascher and Andron, 1976; Salaman, 1976; Littman et al,
1977). This finding led to the concept that such in vitro activity 
of transfer factor results from the non-specific augmentation of 
pre-committed cells, rather than the initiation of previously 
uncommitted lymphocytes (? "recipient-specific"). Similar non-specific 
activity has been observed 1n mitogen-induced lymphocyte transformât!on 
cultures (Burger et al, 1976 b; Hamblin et al, 1976 b).
A complex set of factors, therefore, govern the in vitro effects 
of transfer factor on lymphocyte transformation. Sensitivity states 
of the donor and recipient cells are suggested to be two such 
contributory factors (Arala-Chaves et al, 1976).
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1.3.2 Cell migration inhibition (Table 8).
Table 8 shows that dialysable transfer factor affects migration of 
guinea pig peritoneal exudate cells and peripheral blood leucocytes 
alone or mixed with macrophages in the presence of specific antigen.
Salaman (1974) demonstrated that direct migration of normal guinea 
pig peritoneal exudate cells was inhibiced, in the presence of low 
concentrations of PPD, if dialysable transfer factor from strongly 
sensitive PPD donors were used. Usually there was not any 
inhibition in the presence of PPD negative dialysable transfer 
factor. At higher concentrations of PPD the results were not so 
consistent. Sephadex column fractions of non-dialysable transfer 
factor from guinea pigs immunised with ovalbumin or bovine gamma 
globulin have also been used. Dunnick and Bach (1975) used such 
fractions and reported a 24 - 28 per cent migration inhibition of 
guinea pig cells in the presence of specific antigen. In the presence 
of non-specific antigen migration inhibition was only 5 - 1 5  per cent.
Read and Zabriskie (1972) employed a direct peripheral blood 
leucocyte migration test to demonstrate the in vitro effect of 
transfer factor. Dialysable transfer factor from tuberculin 
sensitive donors was Incubated with non-immune leucocytes. Migration 
of these cells was Inhibited 1n the presence of PPD. These 
observations were extended to studies of measles virus-immune 
dialysable transfer factor 1n patients with multiple sclerosis, and 
Epste1n-Barr virus-sensitive material 1n patients with nasopharyngeal 
carcinoma (Goldenberg and Brandes, 1972; Utermohlen and Zabriskie, 1973).
61
Table 8. In vitro properties of transfer factor.
II. cell migration inhibition and others.
Biological effect Donor References
specificity
Macrophage migration + Paque et al (1973)
inhibition + Sal aman (1974)
+ Dunnick and Bach (1975)
Leucocyte migration + Goldenberg and Brandes (1972)
inhibition + Read and Zabriskie (1972)
+ Utermohlen and Zabriskie (1973)
Mixed leucocyte-macrophage 
migration inhibition
? Dabrowska et al (1976)
Cytotoxicity + Levin (1974)
Chemotaxis - Gall in and Kirkpatrick (1974)
T-lymphocyte Mendes et al (1975)
maturation - Valdlmarsson (19/5)
- Holzman et al (1976)
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In similar studies Paque et al (1973) used the indirect migration 
inhibition test. Leucocytes from skin-test negative individuals 
were incubated with whole cell lysate or non-dialysable transfer 
factor and specific antigen. Transfer factor donors were strongly 
positive to histoplasmin and/or coccidioidin. In the presence of 
any one of these antigens MIF was released and inhibited the migration 
of guinea pig macrophages. Dialysable transfer factor and the cell 
lysate or non-dialysable transfer factor, in the absence of antigen 
or in the presence of non-specific antigen, were ineffective.
The in vitro activity of transfer factor has also been investigated 
by using a mixed leucocyte-macrophage migration system (Dabrowska 
et al, 1976). It was indicated that some human dialysable transfer 
factor preparations, from tuberculin-positive donors, apparently 
conferred a positive mixed cell migration reactivity to tuberculin 
PPD upon mixed populations of Mantoux-negative lymphocytes and 
guinea pig macrophages. However, antigen specificity and 
reproducibility of this effect were not confirmed.
All these reports suggest that it may be possible to adoptively 
sensitise previously unsensitised lymphocytes by transfer factor, 
so that MIF and/or LIF lymphokines are generated to a specific antigen.
1,3.3 Lymphocytotoxlcity (Table 8).
Levin (1974) has described an assay system for transfer factor by 
employing dialysable transfer factor from family contacts of 
patients with osteogenic sarcoma. Dialysable transfer factor, from
such family contacts, induced increased lymphocytotoxicity to 
cultured osteogenic sarcoma cells. Transfer factor, prepared from 
donors whose lymphocytes were not cytotoxic for sarcoma cells or 
for hypernephroma cells, was not effective.
1.3.4 Leucocyte chemotaxis (Table 8).
Gall in and Kirkpatrick (1974) have found that human dialysable 
transfer factor was strongly chemotactic for granulocytes, and 
weakly chemotactic for monocytes in vitro and in vivo in the monkey 
skin. Sephadex G-25 fractionation studies revealed that those 
fractions capable of transferring in vivo delayed hypersensitivity 
skin reactions were also chemotactic both in vivo and in vitro.
1.3.5 Maturation of lymphocytes (Table 8).
Wybran et al (1973) observed that injections of dialysable transfer 
factor improved cellular immunity 1n patients with T-lymphocyte 
deficiency. Such an Improvement was measured by a marked increase 
1n circulating T-lymphocytes. This led to the concept that transfer 
factor contains a component capable of promoting T-cell maturation 
or mobilisation 1n the circulation. It 1s not yet clear whether 
the number of T-lymphocytes Increase following Incubation of 
peripheral blood lymphocytes with transfer factor. Despite this,
1t has been reported that trypslnlsed or heat-treated lymphocytes 
regain their capacity to form rosettes with sheep red blood cells 
much earlier, 1f they are Incubated with dialysable transfer factor 
rather than in tissue-culture medium (Mendes et al, 1975;
$¿Mfck
Valdimarsson, 1975). Therefore, these studies suggested that transfer 
factor contains T-cell receptors or markers. In contrast, the 
observation that puromycin-treated trypsinised lymphocytes no longer 
had the ability to reform rosettes with sheep red blood cells, 
suggested that transfer factor does not contain the receptors 
(Holzman et al, 1976). The demonstration that dialysable transfer 
factor preparations stimulate the synthesis of a T-lymphocyte 
marker, may well account for the beneficial effect of transfer 
factor observed in patients with T-cell immunodeficiency (Section 
1.2.3, table 6).
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1.4 Animal models for transfer factor (Tables 9-10).
1.4.1 Previous study of transfer factor in the rhesus monkey 
(Table 9).
In 1972, Maddison et al demonstrated that both dialysable and non- 
dialysable transfer factor preparations, from rhesus monkeys 
infected with Schistosoma mansonl or mycobacteria, or from PPD 
sensitive humans, were capable of transferring histologically positive 
delayed hypersensitivity skin reactions to recipient rhesus monkeys. 
Some specificity was suggested by the fact that monkeys receiving 
human or monkey tuberculin sensitive transfer factor did not respond 
to S. mansonl. However, some monkeys receiving transfer factor from 
"non-sens1t1sed" animals showed positive delayed hypersensitivity to 
PPD. In some recipients, skin test conversion was associated with 1n 
vitro transformation. Maddison (1974) suggested that transfer 
factor may also be of therapeutic value 1n Infectious diseases 1n
the rhesus monkey. She observed that immune transfer factor 
administered together with hyperimmune serum was effective in reducing 
the worm burden of monkeys infected with Schistosoma mansoni . This 
implied transfer of immunity to this infection in this animal.
Gallin and Kirkpatrick (1974) demonstrated that human dialysable 
transfer factor, prepared from donors responsive to mumps, 
streptokinase-streptodornase and Candida antigens, transferred 
delayed skin reactivity to recipient rhesus monkeys. Reactions 
were histologically confirmed and reflected the antigen sensitivity 
of the donors, both in intensity and specificity.
Zanelli and Adler (1975) transferred cutaneous sensitivity from 
BCG-sensitised rhesus monkeys to rhesus and cynomolgus monkeys.
They used viable cells, cell lysates or non-lyophylised dialysable 
transfer factor. The recipient monkeys converted to skin test 
positive on histological examination, but their lymphocyte 
transformation responses to PPD remained negative.
Recently, Dumonde et al (1976) reported transfer of skin test 
reactivity to keyhole limpet haemocyanln and tuberculin PPD in 1 
rhesus monkey given multiple injections of immune transfer factor.
These Investigators and Scallse et al (1976) have also reported 
marked transfer of mixed leucocyte-macrophage migration reactivity 
to keyhole limpet haemocyanln, tuberculin PPD and/or hepatitis B 
surface antigen by means of immune dialysable rhesus transfer factor.
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Table 9. In vivo properties of transfer factor in the rhesus monkey
Reference TF preparation Assessment of immune 
transfer
Maddison et al 
(1972) t f d/t f nd (rhesus)- rhesus
+ve skin biopsies, +ve 
LT to Schistosoma man- 
sonii and mycobacteria.
Gallin and
Kirkpatrick
(1974)
t f d/t f nd (human)
—  rhesus
+ve skip biopsies to PPD 
or to mumps, SKSD, PPD 
& Candida.
Zanel1i and 
Adler (1975)
Viable cells/cel 1 
lysate/TFp (rhesus)
—  rhesus & cynomolgus
+ve skin biopsies to PPD, 
-ve LT to PPD.
Dumonde et al 
(1976)
TFp (rhesus) 
—  rhesus
+ve skin biopsies to 
KLH, PPD, +ve LMMI to 
PPD, KLH, -ve LT.
Scalise et al 
(1976)
TFq (rhesus) 
— rhesus
-ve skin biopsies to PPD, 
KLH, +ve LMMI to 
PPD, KLH, and HBsAg.
This study 
(Sections 3-5)
TFd (rhesus) 
— rhesus
+ve skin biopsies and 
LMMI to PPD, KLH & HBsAg, 
but -ve LT.
TF = transfer factor, TFD/TFND = dialysable/non-dialysable transfer 
factor preparations, PPO = purified protein derivative of tuberculin, 
SKSD = streptokinase-streptodornase, HSV-1 = herpes simplex virus 
type 1, DNCB => dinltrochlorobenzene, HBsAg = purified hepatitis B 
surface antigen, KLH = keyhole limpet haemocyanin, LT = lymphocyte 
transformation, LMMI = mixed leucocyte-macrophage migration test.
1.4.2 Transfer factor study in other animals (Table 10).
In the guinea pig system, Bloom and Chase (1967) attempted exhaustive 
studies to transfer delayed hypersensitivity with transfer factor. 
Guthrie et al (1967) reported the transfer of sensitivity to 
dinitrofluorobenzene using supernatants, derived from the incubation 
of sensitised cells with this chemical antigen. These observations 
were extended by others, some with highly controversial outcome, to 
a study of transfer of specific delayed hypersensitivity by 
guinea pig dialysable transfer factor (Burger and Jeter, 1971; 
Rosenfeld and Dressier, 1974). These findings have proved difficult 
to repeat in many laboratories.
More recently Clinton and Magoc (1976) have reported that dialysable 
transfer factor, from animals infected with Leishmania enriettii or 
actively immunised with Freund's complete adjuvant, transferred 
specific delayed skin reaction, macrophage migration Inhibition 
and lymphocyte transformation to recipient animals.
Welch et al (1976a, b) reported that guinea pigs, primed with 
tuberculin PPD or streptokinase-streptodornase, can acquire antigen- 
specific skin test reactivity. These observations were extended 
to look for donor and recipient specificity, and the biochemical 
fractionation of the transfer activity (Vandenbark et al, 1976;
Wilson et al, 1976, 1977). Whilst the results are not yet complete, 
1t was suggested that donor specificity may be essential for 
transfer since transfer factor from antigen-negative or unsensitised 
donors have proved ineffective.
Table 10. In vivo properties of transfer factor in other animals
Reference TF preparation Assessment of immune 
transfer
Guthrie et al 
(1967) TFND (9uinea pig) +ve skin test to DNFB
-* guinea pig
Burger & Jeter 
(1971), Rosenfeld 
& Dressier (1974)
TFq (guinea pig) 
—  guinea pig
+ve skin test to DNCB
Clinton and 
Magoc (1976)
TFQ (guinea pig) 
-• guinea pig
+ve skin test and MMI 
to PPD and Leishmania.
Welch et al 
(1976 ä r r y
TFd (human) -► guinea 
pig (primed)
+ve skin tests to PPD 
and SKSD.
Trepo and Prince 
(1976)
TFq (human)
-* chimp's
TF^/viable leucocytes 
(chimp's) — chimp's
+ve skin biopsies & LMT 
to PPD, HBsAg.
+ve skin biopsy to HBsAg.
Steele et al 
(1976)
Cell lysates (baboon) 
—  baboon, cebus, 
marmoset
+ve skin tests (17%) and 
LT (33%) to monilia, 
tetanus , mumps, HSV-1, 
DNCB, PPD.
Shifrine et al 
(1976)
Cell lysate (dogs) 
— dogs
+ve LT to Coccidioides 
immitis, increased LT to 
PHA', -ve LT to PPD.
Rifkind et al 
(1976)
TFp (human) -• Mice +ve skin test, foot pad 
swelling test to 
coccidioidin.
TF = transfer factor, TFp - dialysable transfer factor, TFNQ * non- 
dialysable transfer factor, DNFB = dlnltro-fluorobenzene, DNCB = 
dinitrochlorobenzene, PPD = purified protein derivative of tuberculin, 
SKSD = streptokinase-streptodornase, HBsAg ■ purified hepatitis B 
surface antigen, MMI - macrophage migration Inhibition test,
LMT - leucocyte migration test, LT - lymphocyte transformation test, 
PHA « phytohaemagglutinin.
In other animals, Trepo and Prince (1976) observed that transfer 
factor, from human or chimpanzee donors sensitised to hepatitis B 
virus and/or PPD, transferred sensitivity to hepatitis B surface 
antigen (HBsAg) and/or PPD in recipient chimpanzees, which were 
chronic asymptomatic carriers of HBsAg for over 2 years. Transfer 
factor used was in the form of dialysable human or chimpanzee 
transfer factor or viable chimpanzee blood leucocytes. Adoptively 
transferred delayed hypersensitivity to sensitising antigens was, 
in the recipient animals, detected by the acquisition of delayed 
skin test reactivity and inhibition of leucocyte migration test. 
Specificity of transfer factor was implied by the fact that, when 
its source was from a person with positive delayed hypersensitivity 
skin reaction to PPD, the recipient chimpanzee became skin test 
positive to this antigen. Transfer factor from donors not sensitive 
to PPD were not effective.
Recently, Steele et al (1976) injected three species of nonhuman 
primates; baboons, cebus monkeys and marmosets, with dialysable 
transfer factor from a human donor and non-dialysable transfer 
factor from baboons. Transfer of sensitivity was evaluated by gross 
skin testing and lymphocyte transformation. 45% of skin tests and 65% 
of the lymphocyte transformation tests became positive in recipients 
Injected with human transfer factor. In recipients of baboon 
transfer factor 17% of skin tests and 33% of transformation tests 
converted to positive. Using many antigens to which donors were 
sensitised and not sensitised (monlUa, tetanus, herpes simplex 
type 1, dinitrochlorobenzene and PPD), 1t was possible to show that 
recipients never converted to antigens to which transfer factor 
donors were negative or not sensitised.
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In dogs, Shifrine et al (1976) transferred sensitivity to Coccidioides 
immitis using canine transfer factor in the form of blood leucocyte 
lysate. This was detected by lymphocyte transformation to antigen. 
Phytohaemagglutinin stimulation in transfer factor recipients also 
increased, probably implying transfer of non-specific sensitivity or 
a host response to injection of transfer factor.
In mice, Rifkind et al (1976) observed that dialysable transfer 
factor, from skin test and lymphocyte transformation positive human 
donors, transferred delayed hypersensitivity to coccidioidin antigen 
in mice. Sensitivity was detected by the skin and foot pad swelling 
tests. In contrast, transfer factor from non-reactive normal donors 
was ineffective.
1.5 The problem of specificity.
Immunological specificity of transfer factor has always been a 
controversial issue (Bloom, 1973; Arala-Chaves and Fudenberg,
1976; Salaman and Valdimarsson, 1976; Mazaheri et al, 1977).
Thus, the following sections discuss the various clinical or in vivo 
and in vitro observations on the specificity of transfer factor.
1.5.1 • Clinical observations.
Clinical and Immunological observations on the acquisition of delayed 
type hypersensitivity following the administration of transfer factor 
have led to the concept, that transfer factor converts non-immune
à  •
to immune lymphocytes in vivo. Thus, it has been repeatedly reported
that previously unresponsive recipients acquire delayed type skin 
reactions to antigens to which the donor was positive (Lawrence 
et al, 1960; Rapaport et al, 1960; Maurer, 1961; Zuckerman et al, 
1974; Kirkpatrick and Smith, 1976). (See section 1.1.1). However, 
there are reports that recipients may acquire skin test reactivities 
which were not demonstrable in the donor (Levin et al, 1971;
Spitler et al, 1972; G.-iscelli, 1975). It has also been shown 
that not all positive skin reactions demonstrable in the donor may 
be transferred to the recipient (Kirkpatrick and Smith, 1976).
Other alterations in the cellular-immune responsiveness, which do 
not apparently relate to donor specificity, have been reported in 
recipients. These include altered mixed lymphocyte culture 
responsiveness (Dupont et al, 1974), increased responsiveness to 
phytohaemagglutinin in vitro (Arala-Chaves et al, 1974;
Valdimarsson et al, 1974), and increases in the numbers of 
circulating T-cells as shown by Increased sheep red blood cell 
rosetting (Wybran et al, 1973). These observations, 1n man, have 
led to the concept that dialysable leucocyte transfer factor, in 
addition to conferring antigen responsiveness, may also possess non­
specific adjuvant like properties. Further support for this 
hypothesis has been gained from laboratory studies designed to test 
dialysable leucocyte transfer factor activity tn vivo 1n animals 
and 1n vitro.
1.5.2 In vivo and 1n vitro observations.
Much of the scepticism which surrounded the early work on transfer
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factor resulted from the inability to demonstrate the transfer 
phenomenon in animals. Recently, however, studies in nonhuman 
primates, guinea pigs and other animals (Tables 9-10) have 
demonstrated that some of the immunological properties of leucocyte 
extracts, or transfer factor, described in man (Tables 3-6) may be 
reproduced in animals.
In nonhuman primates successful transfer of delayed hypersensitivity 
using viable leucocytes, leucocyte extracts, and dialysable transfer 
factor, has been reported from monkey to monkey and from man to 
monkey (Table 9: Zanelli and Adler, 1975; table 10: Steele et al, 
1976a). Immunological specificity was shown by the observation 
that recipients never converted to antigens to which the donor did 
not react in vivo.
In guinea pigs transfer of delayed hypersensitivity has proved 
extremely difficult (Bloom and Chase, 1967). However, recent 
studies have shown that guinea pigs, primed with antigen, gave 
delayed skin reaction following injection of dialysable leucocyte 
transfer factor (Table 10: Welch et al, 1976a, b). Whilst 
exposure to antigen is a pre-requisite for the demonstration of 
subsequent delayed hypersensitivity skin reactions, the role of donor 
specificity 1n eliciting such responses has yet to be fully 
determined.
In vitro tests for transfer factor have also provided evidence for 
both specific and non-specific activities 1n dialysable transfer factor 
preparations (Tables 7-8). Thus, 1n vivo and 1n vitro test systems
/
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for transfer factor lend support to the clinical observations that 
dialysable leucocyte transfer factor contains both specific and 
non-specific activities. The relative importance of the specific 
and non-specific activities of transfer factor for the treatment of 
disease have yet to be delineated. The biochemical properties of 
dialysable leucocyte transfer factor have been investigated in an 
attempt to determine which components are responsible for the 
alterations in cellular immune function in vivo and in vitro.
1.6 Biochemical properties and fractionation of transfer
factor.
Using the transfer of delayed hypersensitivity as the criteria for 
assessing activity, the properties described in table 1 were 
reported by Lawrence (1973, 1974).
Fractionation of crude dialysable leucocyte transfer factor has 
been attempted in order to locate its specific and non-specific 
components. Sephadex column chromatography has shown the material 
to be of heterogenous composition, and that it can be separated into 
a number of fractions (Baram et al, 1966; Arala-Chaves et al, 1967; 
Gottlieb et al, 1973; Zuckerman et al, 1974; Burger et al, 1976a; 
Vandenbark et al, 1977). Several publications report that one of 
the fractions, rich 1n hypoxanthine, 1s associated with the ability 
to transfer delayed skin reactions (0'Dor1s1o et al» 1976;
Kirkpatrick et al, 1976; Tomar et al. 1976). Others have produced 
evidence for fractions, which stimulate non-spec1fIcally weak 
immune reactivity 1n vivo (Krohn et al, 1976a, b; 1977) and augment
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lymphocyte transformation in vitro (Burger et al, 1976a, b; Littman 
et al, 1977). More biochemical studies are required to relate these 
activities to each other and to the therapeutic efficacy of transfer 
factor.
1.7 Mode of action of transfer factor.
Various theories have been postulated to explain how transfer factor 
may initiate and/or promote cell-mediated hypersensitivity.
1.7.1 Informational derepressor theory.
Lawrence (1969a) suggested that transfer factor may be an informational 
polynucleotide, possibly a short double stranded RNA or a specific 
gene derepressor. Apparently, previously uncommitted naive lymphocytes 
are instructed to produce antigen-specific receptors and become 
specifically sensitised. These lymphocytes subsequently undergo clonal 
proliferation and donor specific delayed hypersensitivity is thereby 
induced. In fact, Dumonde and Maini (1971) speculated that, in the 
presence of a specific antigen, leucocyte dialysates containing 
transfer factor may induce non-sensitised lymphocytes to produce 
lymphokines to mediate cell-mediated immunity (Dumonde et al, 1969).
In the rhesus monkey model, there is evidence that transfer factor 
may initiate such adoptive sensitisation for selective lymphokine 
production (Dumonde et al, 1976).
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1.7.2 Receptor theory.
The easiest explanation would be that dialysable transfer factor 
carries the donor-specific receptor, but this is thought to be 
unlikely (Valdimarsson, 1975). Transfer factor may act by 
stimulating recipient lymphocytes to produce more transfer factor, 
which then recognises and stimulates a select group of non­
immunoglobulin cell surface receptors, called mini receptors. 
Dialysable transfer factor may react with these receptors thereby 
initiating an appropriate signal calling for the transfer of cell- 
mediated immunity (Burnet, 1974).
1.7.3 Superantigen theory.
Another suggestion is that transfer factor may be a macrophage 
processed highly immunogenic "superantigen". This seems 
incompatible with the finding that on injection into individuals, 
it does not apparently lead to antibody synthesis (Lawrence, 1969a). 
Furthermore, serial transfer of delayed hypersensitivity from 
individuals A to B to C has been reported and does not support this 
postulate (Lawrence, 1974; Kirkpatrick and Smith, 1976).
1.7.4 Adjuvant theory.
It has been observed that in vivo and in vitro recipients of transfer 
factor are capable of responding to antigens to which donors were 
skin-test negative (Levin et al, 1970, 1971 ; Spitler et al, 1972 ;
Griscelli, 1975; Khan et al, 1975; Hamblin et al, 1976b; Krohn
et al, 1976b; Khan, 1977; Littman et al, 1977). Therefore, an
alternative view to the transfer of specific sensitivity is that 
transfer factor, in some situations, acts as an immunologically 
non-specific adjuvant and promotes the activity of precommitted 
lymphocytes. According to this theory the effectiveness of transfer 
factor depends upon the immune status of the recipient rather than 
that of the donor.
1.8 Conclusions
1.8.1 The rhesus monkey as a useful experimental model for the 
study of transfer factor (Table 9).
Some of the investigators mentioned above have reported evidence 
that, the rhesus monkey (Macaca mulatta) can provide a useful 
experimental model for the in vivo study of transfer factor 
(Table 9). Others have reported that immune rhesus transfer factor, 
in vitro, transferred cellular Immune responses to rhesus monkey 
and human lymphocytes (Baram and Condoulis, 1970). These 
investigators also later showed that even fractions of antigen- 
specific rhesus monkey dialysable leucocyte transfer factor, can be 
assayed by MIF production in vitro (Baram and Condoulis, 1976).
In contrast to man, the rhesus monkey permits relatively free 
choice of immunogen and a ready monitoring of the cellular Immune 
status of transfer factor donors and recipients. Healthy anergic 
human volunteers, unlike the rhesus monkey, present ethical, 
immunological and organisational problems.
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Compared with the other nonhuman primates, this species was more 
readily available during these experiments and was generally more 
economically purchased and maintained. Unlike the smaller animals, 
the rhesus monkey, besides providing a larger and more convenient 
source of transfer factor, provides a larger surface area for a 
range of skin tests.
In comparison to mice, rats, guinea pigs and rabbits, rhesus monkeys 
also have the convenience of a much larger volume of blood required 
for a range of in vitro tests.
1.8.2 Background to design of the present experimental work.
In view of the use of dialysable transfer factor for the treatment 
of various diseases in man (Section 1.2, tables 3-6), and the 
controversy surrounding its specificity in vivo and in vitro and mode 
of action (Sections 1.3-1.5, Section 1.7) the present study was set 
up. The main aims of this study were (a) to test the rhesus monkey 
as a useful experimental model for the study of dialysable transfer 
factor, (b) to extend the limited evidence for the specificity of 
dialysable transfer factor activity in vivo and in vitro, (c) to 
develop satisfactory method or methods of monitoring the in vivo 
activity of transfer factor 1n the rhesus monkey model, and (d) to 
make preliminary observations on the fractionation properties of 
dialysable transfer factor prepared from man or monkey.
Background to the design of parts of the present experimental work 
has already been described above (Section 1.8.1) and reported by
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Dumonde et al (1976) and Scalise et al (1976). Therefore, the present
Thesis reports detailed study of the following:
(a) The extent of delayed skin test hypersensitivity (DH) acquired 
by both actively immunised donor and dialysable transfer factor- 
treated recipient rhesus monkeys and its specificity;
(b) the extent of cellular hypersensitivity, as measured by the 
direct mixed leucocyte-macrophage migration test (LMMI), 
acquired by both actively immunised and dialysable transfer 
factor-treated rhesus monkeys and its specificity;
(c) the extent of cellular hypersensitivity, as measured by the 
whole blood lymphocyte transformation test (LT), acquired by 
both actively immunised and dialysable transfer factor-treated 
rhesus monkeys and its specificity;
(d) the in vitro activity of dialysable transfer factor preparations, 
from monkey or man, upon antigen-stimulated human lymphocytes and 
its specificity, and
(e) the preliminary fractionation properties of rhesus monkey and 
human dialysable transfer factor preparations, as indicated by 
their elution through Sephadex G-25 columns.
2. EXPERIMENTAL DESIGN AND METHODS.
In this work the following experiments were carried out:
In vivo study: the experiments consisted of studying the acquisition 
and specificity of delayed hypersensitivity (DH), mixed leucocyte 
macrophage migration (LMMI) reactivity and lymphocyte transformation 
(LT) responses to selective antigens. These tests were done in 
rhesus monkeys actively immunised with Freund's complete adjuvant 
(FCA) only, and keyhole limpet haemocyanin or hepatitis B surface 
antigen in Freund's complete adjuvant (KLH/FCA, HBsAg/FCA). Such 
tests were also carried out in rhesus monkeys injected with water- 
or vacuum-dialysed homologous leucocyte transfer factor (Rh-TFWg, 
Rh-TFV[)).
In vitro study: the experiments consisted of studying the activity 
of both monkey and human dialysable leucocyte transfer factor.
Both preparations were made by dialysis into tissue culture medium 
(monkey: Rh-TFDM, human: H-TFDM). Human leucocyte or purified 
lymphocyte cultures (LC, PL) were used to detect augmentation of 
lymphocyte transformation by antigens with dialysable leucocyte 
transfer factor of monkey and man.
Fractionation of both monkey and human leucocyte dialysates was 
carried out. Dialysable leucocyte transfer factor was prepared by 
vacuum-dialysis (monkey: R h - T F y 0 ,  Human: H - T F y p ) .  Fractionation 
was by column chromatography using Sephadex G-25.
■
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2.1 Protocols for active sensitisation of rhesus monkeys
(Figs. la-d).
Figure la shows that 2 monkeys (H25, H26) were actively immunised 
with 100 ug KLH in FCA. At the same time two others (H23, H24) 
were immunised with 1 mg KLH in FCA. The mixed leucocyte- 
macrophage migration test was carried out, about 2 and 5 weeks 
after immunisation, with 3-100 ug/ml of sensitising antigens. These 
antigens were keyhole limpet haemocyanin (KLH), purified protein 
derivative of tuberculin (PPD) and particulate tubercle bacilli 
(TB). Skin tests were carried out with 10 ug KLH or PPD about 3 
and 6 weeks after active sensitisation. On about the 6th week, 
after the completion of the second skin test, these animals were 
killed for the preparation of KLH-immune and FCA-immune Rh-TFp.
Figure lb shows immunisation of another 7 animals with FCA with or 
without KLH. The LMMI and LT tests were carried out 2-3 times 
before active immunisation. These tests were also done 5 to 42 
days after immunisation. The LMMI test was carried out with 
3-200 ug/ml antigens and the LT test with 5-100 wg/ml antigens and 
phytohaemagglutinln. Skin tests were done on two occasions 12-14 
and 26-28 days after active sensitisation. These animals' own red 
blood cells were transfused back. For transfusion, packed red 
blood cells were made up to the original volume of blood drawn with 
non-pyrogenic sterile normal saline. These animals were killed 
40-42 days after immunisation for preparation of KLH-immune and 
FCA-immune dialysable rhesus transfer factor.
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Fig. la. First protocol for active sensitisation of
rhesus monkeys with keyhole limpet haemocyanin 
in Freund's complete adjuvant (KLH/FCA)
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Fig. lb. Second protocol for active sensitisation of rhesus monkeys 
with keyhole limpet haemocyanin in Freund's complete 
adjuvant or only this adjuvant (FCA ± KLH).
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Figure lc shows that one monkey (HI5) was actively immunised with 
1 mg purified hepatitis B surface antigen in FCA (HBsAg/FCA). The 
LMMI test was carried out about 3 and 7 weeks after active 
sensitisation. Only 1/10 and 1/25 dilutions of a stock solution 
of purified hepatitis B surface antigen were used in this test.
Skin testing was done with 50 yg HBsAg. This was carried out about 
4 weeks after active sensitisation. On about the 13th week this 
animal was exsanguinated and the lymph nodes and spleen were removed 
for the preparation of HBsAg-immune and FCA-immune Rh-TFp.
Figure Id shows immunisation of another 5 rhesus monkeys with 
HBsAg/FCA. The LMMI and LT tests were carried out 2-3 times before 
and at various intervals, after immunisation. For the migration 
test 3-100 wg/ml antigen (KLH, PPD or HBsAg), and for the 
transformation test 5-100 pg/ml antigen (PPD or HBsAg) were used.
All rhesus monkeys were killed 42-51 days after immunisation for 
preparation of HBsAg-immune and FCA-immune transfer factor. Their 
mean total weight loss by the end of immunisation experiments in 
figures lb and Id was about 10%.
2.1.1 Selection of rhesus monkey donors of dialysable transfer 
factor for the in vivo study (Table 11).
Table 11 shows that normal unsensitised and actively Immunised rhesus 
monkeys served as donors of dialysable leucocyte transfer factor for 
the in vivo study. Such dialysates were designated normal and immune 
Rh-TFjj respectively.
Fig. 1c. First protocol for active sensitisation of a
rhesus monkey with hepatitis B surface antigen in 
Freund's complete adjuvant (HBsAg/FCA).
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FCA-immune dialysable leucocyte transfer factor (Rh-TFp).
Fig. Id. Second protocol for active sensitisation of rhesus monkeys 
with hepatitis B surface antigen in Freund's complete 
adjuvant (HBsAg/FCA).
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contained lmg HBsAg in FCA.
mixed leucocyte-macrophage migration test: KLH, PPD, HBsAg at 3-100 yg/ml.
lymphocyte transformation test: PPD, HBsAg at 5-100 ug/ml.
weight in kg, SK = skin test: PPD, HBsAg at 10 & 30 ug.
killed and collected blood and lymph nodes/spleen for preparation of
HBsAg- and FCA-immune dialysable leucocyte transfer factor (Rh-TFp).
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86
Table 11. Rhesus monkey donors and recipients of dialysable 
rhesus transfer factor used for the in vivo study.
Rh-TFp donor® Rh-TrD recipient15
tRhesus Immunity Rhesus Dose
(1) Pool SM Normal H35 2 (2.4 x 109 )
(2) H45 Normal H49 1 (4.5 x 109 )
(3) H32 FCA H48 1 (5.3 x 109 )
(4) H43 HBsAg/FCA H37 1 (4.5 x 109 )
(5) H43 HBsAg/FCA H38 1 (4.5 x 109 )
(6) Pool C KLH/FCA H46 1 (4.5 x 109)
(7) Pool C KLH/FCA H47 1 (4.5 x 109)
(8) Pool C KLH/FCA H36 3 (4.5 x 109)
(9) HI 5 HBsAg/FCA H33 1 (4.2 x 109 )
(10) HI-4* KLH/FCA H19 1 (8.0 x 109)
O D HI-4* KLH/FCA HI 8a 1 (4.0 x 109)
(12) H23-24* KLH/FCA H27 1 (4.0 x 109)
aPool SM, rhesus monkey cells kindly provided by Dr. Shirley Maddison; 
Pool C, obtained from monkeys H16, 17, 20 and 34a.
transfer factor 1n experiments 1 to 8 were "vacuum-dialysed" and 1n 
9 to 12 were "water-dialysed".
Transfer factor prepared by Professor 6. Scalise (Department of 
Medical Microbiology, London School of Hygiene and Tropical Medicine).
Other details: see section 2.1 to 2.2.1.
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Normal Rh-TFp preparations were obtained from lymphoid cells of 
2 healthy rhesus monkeys. Cells for one such preparation were 
provided by Dr. Shirley Maddison (Division of Parasitology, Centre 
for Disease Control, Atlanta, Georgia, USA). The other donor was 
considered normal on the basis that naive monkeys did not generally 
react to sensitising antigens in vitro.
Immune Rh-TFp was obtained from actively immunised or sensitised 
rhesus monkeys. 17 male and female monkeys were immunised (3.5 - 
8 kg weight) by one set of intramuscular and intradermal injections 
of Freund’s complete adjuvant (FCA) alone or two antigens 
individually emulsified in FCA. The sensitising antigens used 
were keyhole limpet haemocyanin (KLH: 100 yg - 1 mg) and hepatitis B 
surface antigen (HBsAg: 1 mg). FCA always contained 3 mg heat 
killed tubercle bacilli (TB).
2.2 Protocols for adoptive sensitisation of rhesus monkeys 
(Figs. 2a-e).
The protocols for adoptive sensitisation of naive rhesus monkeys 
with water- and vacuum-dialysed rhesus transfer factor were as 
follows:
Figures 2a-c show that four naive rhesus monkeys received one 
injection of immune water-dialysed Rh-TF^. Two others were given
Recipients
Monkey HI 8: 
(control: NaCl)
Monkey HI9: 
(Immune Rh-TF^)
Fig. 2a. First protocol for adoptive sensitisation of a 
rhesus monkey following an injection of homologous 
dialysable leucocyte transfer factor immune to keyhole 
limpet haemocyanin and Freund's complete adjuvant.
Rh-TFWD or NaCl
-11 to -5D
Before 
3 x LMMI
i
Day
" 0" +2D +7D +14D +70D
LMMI LMMI
SK
LMMI
SK
LMMI
NaCl
Rh-TF,
LMMI
SK
WD
= sterile normal saline : 20 mis.
= water-dialysed rhesus monkey leucocyte transfer factor, 
g
Dose : 8 x 10 lymphocytes.
= mixed leucocyte-macrophage migration test: KLH, PPD, TB, at 3-100 yg/ml. 
= skin test: KLH, PPD at 30 yg.
Fig. 2b. Second protocol for adoptive sensitisation of rhesus
monkeys following an injection of homologous dialysable 
leucocyte transfer factor immune to keyhole limpet 
nramocyanin and Freund's complete adjuvant.
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Monkey H27: 
(Inmune Rh-TFyjj) -4/-3D
I
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1
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1
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I
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______I_
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1
Before
1
LMMI
1
SK
1
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1
LMMI
(Inmune Rh-TF^) LMMI
Rh-TFyo * water-dialysed rhesus monkey leucocyte transfer factor.
Dose: 4 x 109 lymphocytes.
UWI = mixed leucocyte -macrophage migration test: KLH, PPD, TB at 3-100 yg/ml. 
SK = skin test: KLH, PPD at 30 yg.
Fig. 2c. First protocol for adoptive sensitisation of a rhesus 
monkey following an injection of homologous dialysable 
leucocyte transfer factor immune to hepatitis B surface 
antigen and Freund's complete adjuvant.
Recipients
Monkey H33:
(Iirmune Rh-TFMD)
Monkey H34:
(Control: NaCl)
NaCl = sterile normal saline: 30 mis.
Rh-TFwo = water-dialysed rhesus monkey leucocyte transfer factor.
Dose: 4.2 x 109 lymphocyte equivalent.
LMMI = mixed leucocyte-macrophage migration test: HBsAy at 1/10, 1/25 dilution.
SK = skin test: HBsAg at 50 ug.
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only sterile normal saline. These animals were examined only by in 
vitro LMMI test 3-11 days before and 2-70 days after Rh-TF^p 
injection. Skin tests were carried out 7-14 days after the injection.
Figure 2d shows that multiple injections of vacuum-dialysed 
homologous Rh-TFy0 was also used in adoptive sensitisation. Both 
mixed leucocyte-macrophage migration and lymphocyte transformation 
tests were carried out some days before and 3-34 days after the 
first injection of normal and immune Rh-TFyD. Skin tests were 
carried out 13-34 days after this injection. Packed red blood cells 
from the previous week were suspended in sterile normal saline, 
stored at 4°C, and transfused back into the same animal the following 
week. The final volume of transfusion was the same as the original 
volume of blood withdrawn the previous occasion.
Figure 2e shows that 6 other naive monkey recipients were given one 
injection of vacuum-dialysed Rh-TFyp on day zero. Both normal and 
immune leucocyte dialysates were used. All these animals were 
examined twice by cell migration and transformation tests 7-28 days 
before Rh-TFyD injection. After this injection migration tests were 
carried out between days 2-21, transformation tests between days 
2-17, and skin tests on days 14 and 21. Blood transfusion was given 
on 4 occasions on days 7-21.
2.2.1 Selection of rhesus monkey recipients of homologous 
dlalysable leucocyte transfer factor (Table 11).
Figures 2a-e show that "naive" recipient monkeys were first examined 
by mixed leucocyte-macrophage migration test and/or lymphocyte
V
Fig. 2d. The only protocol for adoptive sensitisation of a
rhesus monkey with multiple injections of homologous 
dialysable leucocyte transfer factor.
Rh-TFVD
Recipients |
Monkey H35: Day Day
’(Normal Rh-TFyD) -57 to -50 "0" +3D
I---------- 0 ■ o
Monkey H36: Before
2(Immune Rh-TFyjj)
3 x LMMI Rh-TF,
3 x LT
* Rh-TFV[)
+6D
I
+13D
1
+20D
1
+27D
_____I____
+34D 
_____ I—1
LMMI
1 1
LMMI
1
LMMI
LT LT LT
LMMI BT LMMI SK
LT LT
BT
SK SK
BT BT
Rh-TFyo * vacuum-dialysed rhesus monkey leucocyte transfer factor.
^Injected on days 0, 3 (2.4 x 10^ lymphocyte equivalent/dose). *At day 20 NaCl was injected instead 
of normal Rh-TFyjj. 2Injected on days 0, 3, 20. (4.5 x 10^  lymphocyte equivalent/dose).
Util = mixed leucocyte-macrophage migration test: KLH, PPD, TB at 3-200 jjg/ml.
LT » lymphocyte transformation test: KLH, PPD, TB, PHA at 5-100 yg/ml.
SK « skin test: KLH, PPD at 50 yg.
BT * blood transfusion.
Fig. 2e. Last protocol for adoptive sensitisation of rhesus monkeys with 
one injection of homologous dialysable leucocyte transfer factor.
Recipient Monkeys
] H 3 7
2 H38
^ 4 6
4 H 4 7
5H48
6H49
R h - T F VD
Day
■28 to -7
DayN Q I . +2D +7D
Before
2 x LMMI 
2 x LT
LMMI
LT
LMMI
BT
+14D
I
+17D
I
+21D 
_____ L_1
LMMI
1
LMMI
LT BT
BT LMMI SK
SK LT
BT
igen and Freund's complete i
Rh-TFvn = vacuum-dialysed rhesus monkey leucocyte transfer factor.
’ These animals received R h - T F y D immune to hepatitis B surface a 
Dose: 4.5 x 109 lymphocyte equivalent.
3,4 Received Rh-TFun immune to keyhole limpet haemocyanin and FCA. Dose: 4.5 x 109 lymphocyte equivalent.
VD
Received R h - T F y p  immune to only F C A . Dose: 5.3 x 10y lymphocyte equivalent. 
„9Received normal R h - T F y p . Dose: 4.5 x 10 lymphocyte equivalent.
UWI = mixed leucocyte-macrophage migration test: KLH, PPD, TB, HBsAg at 3-200 yg/ml.
LT = lymphocyte transformation test: KLH, PPD, TB, HBsAg, PHA at 5-100 yg/ml.
B T * blood transfusion, SK * skin test: KLH, PPD, HBsAg at 50 yg.
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transformation test. This was to demonstrate absence of cellular
hypersensitivity towards KLH, PPD, T3 and HBsAg, and to establish
baselines. Each dose of lyophilised homologous dialysable leucocyte
g
transfer factor (Rh-TF^) was made from 4-8 x 10 donor lymphocytes.
This was dissolved in 20-30 ml volumes of sterile normal saline. It 
was injected intramuscularly in all four limbs and subcutaneously 
over the back of individual recipient monkeys. Rh-TFp was prepared 
either by dialysis into water (Rh-TFWp) or by ultrafiltration into 
vacuum (Rh-TFVD).
Table 11 shows that altogether 10 rhesus monkeys received immune- 
Rh-TFp, while 2 received normal-Rh-TF^. Of the former group four 
were recipients of the water-dialysed material, whilst all other 
recipient animals were injected with the vacuum-dialysed material.
2.3 Selection of human donors of dialysable leucocyte transfer
factor for in vitro and fractionation studies.
Lymphoid cells for the preparation of dialysable transfer factor 
were supplied by Dr. Anne S. Hamblin (Kennedy Institute of Rheumatology, 
London). Healthy persons served as donors of normal dialysable 
leucocyte transfer factor or H-TFp. Skin testing was carried out by 
Intradermal Injection of 100 TU of old tuberculin (Evans Medial Ltd., 
London), or Its equivalent of 2 ug tuberculin PPD. For Injection, 
antigen was dissolved 1n 0.1 ml of pyrogen-free sterile saline.
Normal donors were not skin tested with KLH. Normal human dialysable 
leucocyte transfer factor was used for both in vitro and fractionation
studies. The material used for in vitro purposes was dialysed into
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tissue culture medium (H-TF^), while that fractionated was vacuum- 
dialysed (h-tfvd).
2.4 Selection of human leucocyte or purified lymphocyte culture 
"recipients" of monkey or human dialysable leucocyte transfer 
factor.
Leucocytes and purified lymphocytes were obtained from human venous 
blood. 30-60 mis heparinised blood (25-30 U/ml) were taken from 
laboratory workers. Majority of the donors had been previously 
Mantoux tested and were reported to be positive. None of the donors, 
with the exception of one, were actively sensitised with keyhole 
limpet haemocyanin. The immunised subject was actively sensitised 
with 500 yg KLH by one intradermal injection (Dr. R.N. Maini,
Kennedy Institute of Rheumatology, London). A positive intradermal 
skin test with 50 yg KLH was taken as an indication for successful 
sensitisation.
2.5 Preparation of dialysable leucocyte transfer factor from 
monkey or man for in vivo, in vitro and fractionation 
studies (Fig. 3).
Figure 3 shows that dialysable leucocyte transfer factor for use in 
vivo was prepared only from rhesus monkeys, while that for in vitro 
and fractionation purposes was obtained from both monkey and man.
Pooled rhesus monkey lymph node and spleen leucocytes were used for 
the preparation of leucocyte dialysates for the in vivo study.
Dialysable leucocyte transfer factor for the in vitro study was
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Fig. 3. I. Various Methods of Preparing Dialysable Leucocyte
Transfer Factor
RHESUS MONKEY HUMAN
Exsanguinated by 
cardiac puncture 
(plate 1)
Heparinised blood 
(10 vols)
6% Dextran 
(1 vol)
Red cells removed 
by sedimentation/37°C. 
Plasma-leucocyte 
layer collected
Removed lymph 
nodes & spleen 
(plate 2)
Pooled sectioned 
tissue 
+
50 mis Eagle's MEM
Crushed at room 
temperature. 
Leucocyte pool 
made up to 100 mis. 
with Eagle's MEM.
Venous blood in 
blood packs with 
ci trate-phosphate 
dextrose or CPD.
1
Differential 
centrifugation 
at 25°C
I
Leucocytes 
resuspended 
in 10 mis. 
heparinised 
saline
Lymphocytes and polymorphs in the leucocyte suspension 
were counted. Centrifuged at 200 g for 10-15 minutes 
at 22-25°C. Leucocyte rich pellet was frozen and 
stored at -20°C.
I
D
1 ml. sterile water and 100 pg DNAse per 10 lymphocytes 
added. Pellet frozen and thawed lOx (-70°C to +37°C) to 
produce leucocyte lysate. Dialysable leucocyte transfer 
factor extracted by dialysis for in vivo, in vitro and 
fractionation studies.
(see Part II).
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Fig. 3. II. Various Methods of Preparing Dialysable Leucocyte
Transfer Factor
Leucocyte lysate
I
Medium or Water dialysis 
for 24 hours at 4°C
Ultrafiltration or vacuum- 
dialysis for 36-48 hours at 4°C.
Dialysis tubing 
Leucocyte lysate
ssue culture medium 
D istilled water
Stirrer
Evacuated 
Buchner 
Flask
Dialysis 
tubing 
Leucocyte 
Lysate + 
water
In vitro In vivo Fractionation
Medium dialysed 
rhesus monkey 
or human transfer 
factor:
(1.e. Rh-TFDM or
h-t fdm) .
Water or vacuum dialysed 
rhesus monkey leucocyte 
transfer factor:
(1.e. Rh-TFWD or 
Rh-TFyp).
Vacuum dialysed 
rhesus monkey or 
human leucocyte 
transfer factor: 
(1.e. Rh-TFyp or 
H-TFvd).
For more details see sections 2.5.1 to 2.5.7.
prepared from blood leucocytes of monkey and man. Leucocyte 
dialysates used for fractionation purposes were from blood leucocytes 
of man or monkey and from lymph node and spleen leucocytes of rhesus 
monkey.
2.5.1 Isolation of leucocytes from rhesus monkey blood (Plate 1).
The rhesus monkey donor was anaesthesised by an intramuscular 
injection of "Ketalar" (stock solution: 50 mg/ml) and the mean 
concentration of anaesthetic used was 12.5 mg per kilogram weight 
of the animal. 150-390 mis of blood (mean volume: 45 mls/kg weight) 
were obtained by cardiac puncture of normal and actively sensitised 
rhesus monkeys (Plate 1), and mixed with 50 units/ml of preservative- 
free heparin and 6% dextran (M. wt. 200,000-275,000: final 
concentration 0.5%). This mixture was taken up into 50 ml sterile 
plastic syringes and placed vertically into an incubator at 37°C to 
sediment the red blood cells within the mean time of 40-55 minutes. 
Wide gauge needles (Yale: 19G 1$: 40/11) were attached to these 
syringes and the leucocyte-plasma layer was harvested by applying 
steady, but gentle, pressure on the vertically held syringe plunger. 
The recovered leucocytes, whose average volume was about 55% of the 
original volume of blood, were counted for lymphocytes and polymorphs 
and generally contained > 50% lymphocytes. After counting,the 
leucocyte layer was divided up Into appropriate volumes containing 
multiples of 108 lymphocytes, placed Into sterile plastic universals 
and centrifuged at 22°C for 15 minutes at 200 g (centrifuge: MSE 
Mistral 2L). Supernatants were decanted and the cell pellets were 
quickly frozen 1n a mixture of dry 1ce and methanol (-70°C) before 
being stored at -20°C until required.
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2.5.2 Isolation of leucocytes from rhesus monkey lymph-nodes 
and spleen (Plate 2).
After exsanguination of rhesus monkeys their major lymph nodes and 
spleen were removed aseptically. Lymoh nodes were obtained from 
the cervical, thoracic and inguinal regions of normal and actively 
sensitised donor monkey (Plate 2). These were immediately chopped 
up into small pieces at room temperature. Lymph-node and spleen 
pieces were transferred into a sterile bottle containing about 
50 ml Eagles minimum essential medium without serum (1 x Eagles MEM). 
This mixture of lymphoid tissue was crushed through a sterile 
nickel sieve into a nickel crucible (3.5 cms diameter x 3.5 cms height) 
under a safety cabinet. The leucocyte pool from the crucible was 
periodically transferred into another sterile bottle and subsequently 
volume made up to about 100 ml with Eagles MEM. The lymphoid cell 
suspension was mixed gently by hand and counted for lymphocytes and 
polymorphs and found to contain 97% lymphocytes. As in blood, this 
leucocyte pool was ali quoted into appropriate volumes containing
O
multiples of 10 lymphocytes. Aliquots were centrifuged, supernatants 
decanted, Individual cell pellets quickly frozen and stored at -20°C 
until required.
2.5.3 Isolation of leucocytes from human blood.
Normal venous blood from healthy human donors was collected into 
Fenwall double transfer packs (South West Blood Transfusion Centre,
St. George's Hospital, Tooting, London). The first one of these 
bags contained Citrate-Phosphate-Dextrose (CPD). The ratio of
blood to CPD was 7:1 (450 mis: 63 mis). Red and white cells were 
separated from plasma by differential centrifugation. Red cells 
were first separated by centrifugation at 3000-4000 g for 20 seconds.
The supernatant leucocyte/plasma layer was transferred into the 
second bag and centrifuged again. This was spun at 2500 g for 15 
minutes. Most of the plasma was removed from the leucocyte pellet.
These cells were resuspended in the remaining plasma and placed in 
Sterilin universal containers. This pack was washed out with 
physiological saline containing 25-30 units/ml heparin. This was 
also added to the leucocytes in the Sterilin containers. Universals 
containing cells were centrifuged at 200 g for 10 minutes at 25°C. 
Supernatant was removed from each leucocyte pellet. The cells from 
each Universal were pooled and resuspended in 10 mis of physiological 
saline. A sample was counted for lymphocytes and polymorphs. The 
leucocyte suspension was divided into appropriate aliquots with known 
numbers of lymphocytes and polymorphs. Each volume was centrifuged 
at 200 g for 10 minutes at 25°C. Supernatants were removed from 
the cell pellets, which were stored at -20°C. The total lymphocyte 
and polymorph content per 450 mis blood, from different donors,
O
varied considerably. The total lymphocytes varied from 1.5 x 10 
to 7 x 10®, while polymorphs ranged from 0.13 x 10® to 2.5 x 10® 
per unit of blood.
2.5.4 Treatment of human and monkey leucocyte pellets to produce 
lysates. .
Each lymphoid cell pellet was thawed at 37°C. It was treated with 
1 ml non-pyrogen1c sterile distilled water and 100 ug deoxyribonuclease
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or DNAse for 10 lymphocytes. The DNAse used for the preparation of 
dialysable leucocyte transfer factor for the in vivo study was crude, 
while that for in vitro and fractionation studies was pure. The 
treated cell pellet was freeze-thawed 10 times within 6-8 hours aL 
-70°C to +37°C. After such processing a manageable lysed extract of 
lymphoid cells or a leucocyte lysate was obtained ready for dialysis. 
All leucocyte lysates were stored at -20°C until required for 
dialysis.
2.5.5 Water-dialysis of monkey leucocyte lysate for in vivo use 
(Fig. 3).
Figure 3 above shows that the leucocyte lysate used for the in vivo
study was derived from pooled rhesus monkey lymph-node and spleen
cells. The method of Lawrence and Al-Askari (1971) was followed
with minor modifications. An appropriate length of 8 mm Visking
dialysis tube was soaked in sterile distilled water without boiling.
The cell lysate was dialysed against sterile distilled water at 4°C
g
for 24 hours (50 ml/10 lymphocytes). The dialysate or water- 
dialysed rhesus monkey leucocyte transfer factor (Rh-TFWD) was 
sterilised by filtration through 0.22 MllUpore filter. This was 
Immediately freeze dried and stored at 4°C until used.
2.5.6 Medium-dialysis of human and monkey leucocyte lysates 
for in vitro use (F1g. 3).
Figure 3 above shows that for the in vitro study human and rhesur 
leucocyte lysates were both obtained from blood. The method of
Hamblin (1975), a modified method of Ascher et al, (1974) was used. 
The cell lysate from man or monkey was pipetted into 8 mm Visking 
tube. The dialysis tube had been twice boiled in distilled water 
to remove heavy metal ions and to sterilise it. This was dialysed 
against glutamine containing Minimal Essential Medium for suspension
Q
culture (1% glutamine in MEMS: 16 ml/10 lymphocytes) for 24 hours 
at 4°C with constant stirring. Thus 1 ml medium contained the 
dialysate from 6 x 10® lymphocytes. The leucocyte dialysate was 
sterilised by filtration through 0.22m Millipore filter and was 
stored at 4°C until use. Such "medium-dialysed1' leucocyte transfer 
factor from man was designated H-TFDM and that from monkey Rh-TF^.
2.5.7 Vacuum-dialysis of human and monkey leucocyte lysates for 
in vivo and fractionation studies (Fig. 3).
The method of Burger et al, (1974) with minor modifications was 
used. A semi-permeable 8 mm Visking tube which was twice boiled in 
distilled water was connected to a glass funnel (~4.5 cms diameter). 
After making 3 knots to the bottom of the tube, it was passed 
through a hole in a silica rubber bung (size: 3.3 cms diameter).
This was firmly attached to a 500 ml Buchner type flask. The flask 
was evacuated until the dialysis tube tautly expended. The leucocyte
g
lysate was transferred Into the dialysis tube (approximately 5 x 10 
lymphocytes/apparatus) and washed with 5 ml non-pyrogen1c sterile 
distilled water. Vacuum-dialysis or ultrafiltration continued 
for 36-48 hours at 4°C. More water was periodically added. By the
g
end of the dialysis added water amounted to 4 mls/10 lymphocytes. 
When dialysis was completed the tube was usually dry. The vacuum
704
was subsequently released, dialysate collected and sterilised by 
filtration through a 0.22 y Millipore filter. Such dialysates of 
man and monkey were designated H-TFVD and Rh-TFyp respectively.
Each dose of sterile dialysate used for in vivo or fractionation 
purposes was freeze-dried twice. Once, because of its large volume, 
it was freeze-dried in 1 litre round bottomed flasks. For the 
second time this was taken up into 10 ml non-pyrogenic sterile 
distilled water, transferred into an ampoule and again freeze-dried. 
All such preparations were stored at 4°C until required.
2.6 Skin tests (Plate 3, table 12).
Skin tests were carried out in normal saline-injected actively 
sensitised and dialysable leucocyte transfer factor-treated rhesus 
monkeys. This was to establish presence or absence of delayed 
hypersensitivity response (DH), an in vivo manifestation of cell- 
mediated immunity (Maddison, 1973).
Normal rhesus monkeys were skin tested with 0.1 ml saline containing 
30 yg PPD or KLH or 50 yg HBsAg (Figs. 2a-b, section 2.3). Actively 
sensitised animals were skin tested with 10 and/or 30 or 50 yg of 
the sensitising antigens (Figs, la-d, section 2.1). However, to 
test the in vivo specificity of homologous dialysable transfer 
factor, recipients of transfer factor were tested with 30 and/or 50 yg 
of all the antigens (KLH, HBsAg, PPD: figures 2a-e, section 2.3).
The conventional Intrapalpebral skin test used 1n the monkey limits 
the number of tests in any one animal. Thus, plate 3 shows that skin


Table 12. Evaluation of histologically active delayed 
hypersensitivity in rhesus monkeys.
Reactivity® 
of donor 
or recipient 
monkeys
Degree of mononuclear 
cell exudate
sub-epidermal deep-dermal
Large
mononuclear
cells
Maximum*5
total
score
Active Drt 0, 1+, 2+ 0, 1+, 2+ 0, 1+ 1+ to 5+
Baseline 0 0 0 0
aDH, delayed cutaneous hypersensitivity.
'’OH 1+ * very weak, 2+ = weak, 3+ = moderate, 4+ = strong, 5+ = very strong. 
For details see section 2.6.
tests were carried out by intradermal injections into the chest area. 
After gross clinical measurement of the diameter of induration and/or 
erythema at 4, 24 and 48 hours, the skin test sites were biopsied at 
48 hours for the study of lymphocyte infiltration. Skin reactions 
were considered clinically positive when the diameter of induration 
and/or erythema was more than 3 mms. This cut-off point was 
considered reasonable, because none of the skin tests, carried out 
with salir.e with or without an antigen in the 2 normal monkeys 
used, or with saline alone in all the monkeys used, produced a 
reactivity greater than 3 mms 1n diameter. Histological examinations 
were also carried out because of the well recognised lack of 
consistent appearance of gross delayed hypersensitivity skin 
reactions in this species (Baram et al, 1971; Maddison et al, 1972). 
Gross skin reactions with erythema have, however, been described 
in rhesus monkeys (Mackler et al, 1971).
Table 12 above shows how delayed hypersensitivity reaction was 
histologically evaluated by the degree of monocytic infiltration.
Both sub-epidermal and deep-dermal areas were examined and the degree 
of exudatlng monocytes in each area was scored zero to 2+. Thus, 
so far, total score range was zero to 4+. To this was added a 
score of zero to 1+ 1f large monocytes were respectively not 
prominent or prominent. Thus, a total score of zero to 5+ could 
be finally obtained. Saline Injected sites 1n all monkeys and all 
sites in normal monkeys served as the baseline (DH * o).
2.7 In vitro cellular hypersensitivity tests.
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2.7.1 Mixed leucocyte-macrophage migration or LMMI test 
(Plates 4-5).
A modified method of mixed cell migration shown previously to be 
suitable for cellular hypersensitivity testing in man was followed 
(Rajapakse and Glynn, 1970). Monkey blood leucocytes were mixed 
with normal guinea-pig macrophages in a ratio of 1:2 respectively 
before capillary migration. To obtain the macrophages, 1-3 cross­
bred albino guinea-pigs of the Hartley strain were injected intra- 
peritoneally with about 25 mis of sterile warm liquid paraffin.
The mean weight of each guinea-pig was about 800 grams. Peritoneal 
exudate cells were harvested 72-120 hours later with 200 mis of 
Hank's balanced salt solution. The cell suspension was spun at 
175 g for 10 minutes at 4°C and the cell pellet was resuspended in 
7-10 mis of 10-20% horse serum in Eagle's MEM and washed 3 times. 
Subsequently it was resuspended in 2-3 mis of the same medium and 
counted. Peritoneal exudate cells were suspended at 3.0 x 107 
cells/ml and on average consisted of 81% macrophages, 11% lymphocytes 
and 8% polymorphs. They were kept on melting 1ce until required.
To obtain normal or immune rhesus leucocytes 10-14 mis of heparinlsed 
(50 U/ml) monkey blood were drawn from the femoral vein (Plate 4). 
Whole blood was mixed with half volumes of 1.5% dextran made up 1n 
Hank's solution (final concentration 0.5%). Red cells were largely 
removed by sedimentation for 30-60 minutes at 37°C. Leucocytes were 
centrifuged at 145 g at room temperature and washed three times with 
10-20% horse serum 1n Eagle's MEM. They were suspended at 1.5 x 107 
cells/ml 1n this medium at room temperature (average > 50% 
lymphocytes). An equal volume of washed oil-induced guinea-pig
■ ■ ■
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peritoneal exudate cells at 3 x 10^ cells/ml was then added. The 
cell mixtures were kept on ice, taken up into microcapillary tubes, 
plugged with wax, centrifuged at 145 g in a bench centrifuge for 5 
minutes and cut at cell-fluid interphase. The packed cell ends were 
quickly migrated from microhaematocrit capillary tubes. These were 
placed in individual wells of a 12-well sterile migrating chamber 
unit and 3-6 capillaries were used per antigen dilution (Plate 5). 
Wells were filled with 10-20% horse serum in Eagle's MEM containing 
3-200 pg/ml antigen. Antigens were keyhole limpet haemocyanin, 
purified protein derivative of tuberculin, particulate tubercle 
bacilli and purified hepatitis B-surface antigen (i.e. KLH, PPD, TB, 
HBsAg). Migration areas were measured by Planimetry and migration 
ratios or indices (MI), related to medium alone, were evaluated 
after 18-20 hours at 37°C in a 5% COg: air incubator.
MI = Migration with antigen (test)___________A migration index of
Migration with only medium (control)
less than 0.8 was considered significant (MI < 0.8) (Section 8.2.1). 
The direct, rather than Indirect, method of cell migration was used 
because of its rapidity in setting up a large number of tests.
The LMMI test, rather than other cell migration tests, was used in 
order to develop a new method to assay cellular hypersensitivity in 
the actively Immunised and tranfer factor-treated rhesus monkeys.
2.7.2 Whole blood lymphocyte transformation or LT tests.
(Plate 4).
Lymphocyte transformation was measured by using a modification of a 
whole blood culture technique (Junge et al, 1970; Main! et al, 1974).
0.1 ml quantities of heparlnlsed monkey whole blood was added to 
0.9 ml of Eagle's MEM containing an antigen or a mitogen. Venous
blood was obtained as before (Plate 4). The antigens were KLH, PPD, 
TB, HBsAg; while the mitogen was reagent grade phytohaemagglutinin 
(PHA). The concentration range was 5-100 ug/ml. Cultures were 
set up in triplicate for each concentration. Tubes were maintained 
for 6 days at 37°C in 5% COg: air. On the 5th day they were 
pulsed with 1uCi ^H-thymidine in 0.1 ml Eagle's MEM (specific 
activity 15-19 Ci/mM). All cultures were harvested 18 hours later 
for B-scintillation counting. In harvesting of cultures red cells 
were lysed with 3% acetic acid, once washed with phosphate buffered 
saline and protein precipitated with cold 5% trichloro-acetic acid. 
After 1-2 hours of storage at 4°C, each culture precipitate was 
filtered through a 2.5 cm fibreglass filter. Tubes were once 
again washed with cold 5% trichloro-acetic acid and precipitates 
dried with a Methanol wash. Filters were dried at 60°C "hot oven" 
for 30-60 minutes. Each one was transferred into a clean dry 
disposable glass or plastic vial containing 5 mis scintillation 
fluid. Vials were counted for B-particles 1n a Tracerlab Spectro 
Matic Scintillation counter.
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LT results were expressed as stimulation ratios or Indices (SI) 
in the presence of antigen or PHA 1n relation to medium 1n the 
absence of stimulant. These were corrected for background: 
counts per minute with stimulant (test)
SI A stimulation
counts per minute in medium alone (control)
Index of greater than 2.0 (SI > 2) was considered positive (Section 8.3.1), 
The In vitro lymphocyte transformation test has been suggested to
be more sensitive than skin tests for detecting tuberculin
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hypersensitivity in the rhesus monkey (Baram et al, 1971). Mackler 
et al (1971, 1972) have demonstrated transformation responses to 
ascaris, trinitrophenyl-keyhole limpet haemocyanin and 
phytohaemagglutinin in rhesus monkeys. Thus, to extend the studies 
above, a simple in vitro lymphocyte transformation test was used 
here to: (a) monitor cellular hypersensitivity in the rhesus 
monkey, and (b) to determine its relationship to skin tests in the 
actively immunised or transfer factor-treated animals.
2.8 Lymphocyte transformation tests used to detect the in
vitro activity of dialysable leucocyte transfer factor 
from monkey or man.
2.8.1 Leucocyte culture "recipients" (LC) of dialysable leucocyte 
transfer factor.
Leucocytes were separated, from human venous blood mixed with 
25-30 units/ml heparin and 0.5% dextran, by sedimentation at 37°C 
(mean lymphocyte content 33%). The leucocyte-plasma layer was 
centrifuged at 25°C for 10 minutes at 200 g. The supernatant plasma 
was clarified of platelets by centrifugation for 15-30 minutes 
again at 25°C at 200 g. The leucocyte pellet was suspended in 
tissue culture medium (minimum essential medium for suspension 
cultures: MEM-S). This contained 30% homologous platelet-free 
plasma at a concentration of 1 x 10® lymphocytes/ml. Test cultures 
contained 1 ml (1 x 10® lymphocytes) of leucocyte suspension made 
up to 2 ml with MEMS alone or MEMS containing medium-dialysed 
leucocyte transfer factor (0.25, 0.5, 1.0 ml). The final plasma
concentration was 15%. Both human and monkey leucocyte dialysates 
were used (H-TFDM and Rh-TFDM). Augmentation activity of both 
H-TFdm and Rh-TFDM was tested on transformation by purified protein 
derivative of tuberculin and keyhole limpet haemocyanin. Tuberculin 
was added at 2 yg/tube and haemocyanin at 10-100 yg/tube. Each 
concentration was made up in 0.1 ml MEMS. Culture tubes, at least 
in triplicate tests, were incubated at 37°C in an atmosphere of 
5% CO2 in air. On the 6th day 0.1 ml (i.e. lyCi) 3H-thymid1ne with 
a specific activity of 5 Ci/mM was added to each tube. Leucocytes 
were harvested for B-counting after 24 hours by the method of 
Wolstencroft and Dumonde, (1970).
2.8.2 Purified lymphocyte "recipients" (PL) of dialysable 
leucocyte transfer factor.
Lymphocytes were isolated in 2 steps (73-95% pure). In the first 
step leucocytes, from 500 mis blood, were separated by sedimentation 
with 50 mis dextran (10:1). The leucocyte/plasma supernatant was 
centrifuged as before and the leucocyte pellet resuspended in 16 mis 
homologous plasma. In the second step, the leucocyte suspension was 
carefully layered onto 8 mis of freshly made mixture of Flcoll/ 
Trlosil (I.e. 2 vols. leucocytes: 1 vol. F1coll/Tr1osi1). The 
gradient was centrifuged at 25°C for 30 minutes at about 260 g.
The white purified lymphocyte layer was transferred to a fresh tube 
and washed 3 times with 20 mis MEMS. Purified lymphocytes were 
counted and made up to a concentration of 1 x 106 lymphocytes/ml 
as above for 1n vitro experiments.
2.9 Fractionation of monkey and human dialysable leucocyte
transfer factor preparations.
Only vacuum-dialysed leucocyte transfer factor was fractionated.
O
Leucocyte dialysate was prepared from 5-6 x 10 lymphocytes of 
normal monkey or man. Fractionation was by Sephadex 6-25 column 
chromatography.
2.9.1 Sephadex G-25 column chromatography.
Freeze-dried dialysable leucocyte transfer factor was taken up 
into above 0.5 - 2 mis of distilled deionised water. This was 
filtered through a 0.22m Millipore. 50 ul was removed and stored 
at -20°C, so that extinction readings of the crude or unfractionated 
material could later be determined at 260 nm and 280 nm wavelengths 
(E260 and E2gQ). The remainder was loaded onto a Sephadex G-25 
column. One-two columns were used (1.6 cms x 90 cms each). When 
two columns were used, they were joined in series. The columns 
were eluted with a volatile buffer of 0.02M ammonium bicarbonate/acetic 
acid, pH 7.4. Flow rate was adjusted to deliver 10 mis eluent per 
hour using a peristaltic pump. About five to fifteen minutes 
aliquots were collected by the automatic fraction collector at 
4°C (<v 0.9 to 2.7 mis). Extinction readings of each aliquot were 
taken at 260 nm and 280 nm and the fractionation profile or graph 
of extinction against aliquot number was plotted. The appropriate 
aliquots, making up each peak, were pooled to give each fraction of 
dialysable leucocyte transfer factor. The extinction of each 
fraction at 260 nm and 280 nm was now determined and each freeze-
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dried in round bottomed flasks. Each new dialysable leucocyte 
transfer factor fraction was then taken up into 5 ml of volatile 
buffer at room temperature and sterilised by filtration through 
0.22 p Millipore filter. This was divided into five 1 ml aliquots 
and again freeze-dried in ampoules and stored at -20°C.
2.10 Properties of test antigens and phytohaemagglutinin
(Plate 6).
2.10.1 Keyhole limpet haemocyanin (KLH).
This is a strong, non-ubiquitous ("neoantigen"), protein antigen 
isolated from the haemolymph of giant keyhole limpets (Megathura 
crenulata) found in the Pacific Ocean (Weigle, 1964). KLH molecules 
can readily associate in acid pH (6.5, tris) and dissociate in 
alkali pH (> 7.5, tris: Fay, 1975: Personal communications). It 
has been used as a sensitising antigen in immunisation studies of 
man or monkey (Curtis et al, 1970; Mackler et al, 1971). It has 
also been employed for the in vivo and in vitro studies of transfer 
factor (Baram and Condoulis, 1970; Zuckerman et al, 1974; Burger 
et al, 1976a).
Thus, KLH was used in this work to test the specificity of the 
acquired responses in actively Immunised and transfer factor-treated 
rhesus monkeys, and 1n the in vitro study of transfer factor 
because of (a) Its rarity 1n nature, and (b) past use 1n the study 
of transfer factor (see appendix for the preparation of the stock 
solution).
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2.10.2 Purified protein derivative of tuberculin (PPD).
This is a common soluble protein antigen isolated from cultures of 
human tubercle bacilli. It was obtained in neutralised freeze- 
dried form (PPD 292). This was used in the in vivo and in vitro 
studies of transfer factor. Its effects were compared with those 
of particulate tubercle bacilli in the mixed-cell migration and 
transformation tests in the in vivo study (see appendix for the 
preparation of the stock solution).
2.10.3 Tubercle bacilli (TB).
This antigen consisted of particulate, heat-killed, freeze-dried 
human mycobacteria (TB 292). It was used in parallel with PPD 
to determine if it had a different effect in the mixed-cell 
migration and lymphocyte transformation tests used in the in vivo 
study (see appendix for the preparation of the stock solution).
2.10.4 Hepatitis B surface antigen (HBsAg: Plate 6).
Infection with hepatitis B virus is intimately associated with the 
appearance 1n the human serum of the Dane particle containing a 
42 nm particle, called hepatitis B core antigen. The surface of 
the core antigen 1s covered by the hepatitis B surface antigen 
displaying complex reactivities (HBsAg: plate 6). The group-specific 
antigen has been named "a" and there are at least four phenotypes: 
adw, adr, and ayr. There may be other determinants. The surface
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antigen reactivity is shared by small spherical 18-22 nm particles, 
the tubular forms and the outer shell of the 42 nm Dane particles 
(Zuckerman, 1975b). In this study HBsAg/ad was used because of 
its clinical importance in man. Cellular immune responses to HBsAg 
were followed in actively sensitised and transfer factor-treated 
rhesus monkeys (see appendix for the preparation of the purified 
stock solution of HBsAg).
2.10.5 Phytohaemagglutinin (PHA).
Ling, in 1968, described PHA as a plant agglutinin or lectin, 
prepared from a bean called Phaseolus vulgaris. It contains both 
protein and carbohydrate, is water-soluble and has a molecular 
weight of about 118,000. It agglutinates red cells of many species, 
and is mitogenic and can, therefore, stimulate lymphocytes to enter 
blastogenisis in vitro. Thus, PHA was used in the present study 
to determine (a) the normal lymphocyte transformation response to 
PHA in virgin rhesus monkeys, and (b) the effects of active 
Immunisation or transfer factor upon the PHA-response in this 
species (see appendix for the preparation of the stock solution).
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3. RESULTS OF THE DELAYED HYPERSENSITIVITY (DH) SKIN TESTS
Skin tests in normal, actively sensitised and transfer factor-treated 
monkeys were examined clinically and histologically as described 
above (Section 2.6).
3.1 Normal and actively sensitised monkeys (Figs. 4-6, 
plates 7-10, tables 13-14).
3.1.1 Clinical DH-responses to KLH, PPD, or HBsAg (Figs. 4a-c, 
plate 7).
Two normal control monkeys, injected with 20-30 mis normal saline, 
were skin tested twice with 30-50 yg KLH, PPD or HBsAg (Section 2.2: 
Figs. 2a, 2c, monkeys H18, H34). The first skin test was carried 
out on day 7 and the second on day 14. None of the animals showed 
clinically positive DH-responses to any of the antigens, since 
induration and/or erythema were not detected at 24-48 hours in any 
of the 12 tests carried out (Diameter < 3mms).
In contrast, when monkeys were actively immunised with FCA, with or 
without KLH or HBsAg (Section 2.1: figs, la-d), clinically positive 
skin-test reactivity to 10-30 yg KLH, PPD or HBsAg was detected.
These responses were measured 1n some representative animals for 10 yg 
antigen 1n 37 out of 40 tests (93%) (Figs. 4a-c). Maximum reactivity, 
after the first or the second skin test, developed at 24 or 48 hours. 
There was also evidence of immediate hypersensitivity response, since 
1n those animals examined some had developed measurable Induration 
and/or skin colour change at 4 hours (Erythematous or yellow). This 
was detected in 13 out of 15 tests (89%) after the first and the
INTRADERMAL SK IN  TEST RESPONSES
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1st skin test 2nd skin test 
( 2 weeks) ( 4 weeks )
Fig. 4. Induration diameters in skin test reactivity at 4 to 43 
TSSurs-against (a) KLH, (b) PPD, (c) HBsAg 1n representative 
rhesus monkeys actively sensitised with (a) 100 ug KLH 1n FCA, 
(b) FCA + KLH or HBsAg, and (c) 1 mg HBsAg 1n FCA.
Saline control sites and normal animals were negative, 1.«. 
Induration diameter < 3mms. For protocols see section 2.1, 
figures lb, d. Monkeys are coded from H16-H43.


second skin test. The general pattern of the clinically positive 
DH-responses to all the sensitising antigens was similar (Figs.
4a cf 4b cf 4c). Such 4-hour observations were not carried out 
after the first skin test in animals actively sensitised with KLH 
in FCA (Fig. 4a). One animal, immunised with HBsAg in FCA, showed 
an exceptionally large induration diameter at 24 or 48 hours after 
the second skin test with 10 yg HBsAg (Fig. 4c: monkey H43).
An example of an immunised monkey with clinically positive DH- 
responses to 10-30 yg PPD and HBsAg is shown in plate 7. Higher 
skin test concentration of these antigens produced larger induration 
and erythema than the lower concentration.
3.1.2 Histological DH-responses to KLH, PPD or HBsAg (Figs. 5-6, 
plates 8-10).
Figure 5a demonstrates that a normal monkey, injected with only 
saline,was skin tested with 10-30 ug KLH and PPD, and another one 
skin tested with 50 yg HBsAg. They showed no histological evidence 
of DH-response. The 48 hour histological examination of such 
baseline DH-responses to an antigen or only saline always revealed 
little infiltration of dermal layers with cells (Plates 8-9).
Compared with the normal monkeys above, all the 17 rhesus monkeys 
actively Immunised with FCA, with or without KLH or HBsAg, showed 
histologically positive DH-responses. Such responses to KLH, PPD 
and HBsAg antigens were all well marked after the first skin test 
by 1 to 4 weeks, and were still present after the second skin test
(a ) N o rm a l m onkeys
(b) Actively sensitised monkeys
i+ve DH 8/8 ¡17/17J6/6 ¡0/14 8/8 ¡16/lôj 5/5 ¡0/11
n 8 | 7 J 6 ! 14 8 j 16 | 5 ! 11
"B> 5t- mm 1 oooo 1 a  1 • 1 ooo î AAA 1
SL 1 1 1 1 1 1
8  4+ • 1 OOOO 1 AA | • j <5»  j |
S>2 3+ ¡ooco [ A |
1 1 1 •»I GO £A |
3  s 2+ M M  |OODOO | AA | «MMtoâcol 11 I .IE o>
'•= 1 + 1 1 1£ o 1 1 1 1 1 1Q w
0 i i i 1 1 ! »
1st skin test 2nd skin test
(weeks 1-4) (weeks 2-6)
Fig. S. Histological results of maximum DH-responses to 10-50 pg 
antigen 1n (a) normal saline-treated, and (b) actively sensitised 
rhesus monkeys (FCA ± KLH or HBsAg).
n, number of monkeys; (•) KLH; (o) PPD; (A) HBsAg; (•) Saline.
JÉ
Mates 9a-b. Histologically negative baseline skin 
delayed hypersensitivity response to saline alone in 
a representative rhesus monkey (DH » 0)
(a) Low power : 72x, (b) high power : 288x
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by 2 to 6 weeks (Fig. 5: DH = 2+ to 5+). Positive DH-responses 
were histologically characterised by widespread infiltration of all 
dermal layers with lymphocytes, macrophages and polymorphs. The 
latter were mainly prominent in the more intense reactions (Plates 
lOa-b: DH > 3+).
In the actively immunised animals, skin tests carried out with 
30 yg PPD or HBsAg produced a more marked mean histological 
reactivity than those with 10 yg PPD or HBsAg (Fig. 6). Therefore, 
as for the clinical observations (Plate 7), the intensity of the 
acquired DH-responses depended upon the dose of PPD or HBsAg used 
for the skin test.
3.1.3 Comparison of DH-conversion rates to KLH, PPD or HBsAg 
1n normal and actively sensitised monkeys (Table 13).
Table 13 shows that, none of the tests in the normal control animals 
became histologically positive for KLH, PPD or HBsAg, whilst all the 
tests in the actively immunised animals became positive. When sum 
of all the tests with these antigens were taken together, the acquired 
DH-reactivity was highly significant 1n the immunised animals 
(P < 0.001).
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1st skin test
(a) PPD (b) HBsAg
10
5
I
30 (pg antigen)
2nd skin test
Fig. 6. Mean Intensity of histologically positive DH-responses to 
different doses (10-30 ug) of PPD or HBsAg 1n actively sensitised 
rhesus monkeys (FCA i HBsAg).
n, number of monkeys; 1 mean i SEM.
ITable 13. Comparison of DH-conversion rates to KLH, PPD and HBsAg 
in normal and actively immunised rhesus monkeys.3
J \
Irnnunisation*5 Total no. of monkeys with +ve DH (48 hr histology)0 Total
with SKI (10-50 yg)
SK2 (10-30 yg) SKI + SK2
KLH PPD HBsAg Sum KLH PPD HBsAg Sum All antigens
Nothing/NaCl 
(Control)
0/1 0/1 0/1 0/3 0/1 0/1 ND 0/2 0/5
FCA t 
antigen
8/8 17/17 6/6 31/31 8/8 16/16 5/5 29/29 60/60
P for x* - - - < 0.001 • - - - < 0.001 < 0.001
aFrom figures 5a-b (Section 3.1.2).
bNaCl, normal saline; FCA, Freund's complete adjuvant.
CSK1, first skin tests; SK2, second skin tests; KLH, keyhole limpet haemocyanin; PPD, purified protein derivative 
of tuberculin; HBsAg, hepatitis B surface antigen; ND, not done.
I
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Transfer factor-treated monkeys (Figs. 7-8, plates 11-13, 
tables 14-16).
3.2.1 Clinical DH-responses to KLH, PPD or HBsAg (Plate 11, 
tables 14-15).
Four control animals were treated with a single injection of dialysable
rhesus transfer factor (Table 14). None of the recipients showed
clinical DH-responses to 50 pg KLH, PPD or HBsAg after the first skin
test (Induration diameter < 3 mms). However, after the second
skin-test 1 animal became positive to 50 pg KLH (Monkey H38;
induration diameter 5.5 mms). Similarly, 9 virgin rhesus monkeys
treated with a single injection of immune dialysable rhesus transfer
g
factor, equivalent to 4 to 8 x 10 lymphocytes, did not demonstrate 
skin test-reactivity to 30 or 50 pg KLH, PPD or HBsAg up to 21 days 
after the injection in any of the 44 tests carried out.
Table 15 shows that, in another control animal treated with 2 
injections of normal dialysable transfer factor, there was no clinical 
DH-response to KLH, or PPD (Monkey H35). In contrast, in one animal 
(Monkey H36), given 3 injections of KLH- and FCA-immune transfer
Q
factor, each equivalent to 4.5 x 10 lymphocytes, skin test reactivity 
was detected after the second and third skin test on days 27 and 34 
respectively. Such reactivity to PPD or HBsAg, was not detected 
after the first Injection of transfer factor.
Thus, altogether clinically positive DH-responses were seen 1n only 1 
out of 23 (4*) skin tests 1n 5 animals treated with control dialysable 
transfer factor (1e. normal or unrelated to test antigen), and 1n 4 
out of 53 tests (8X) 1n 10 test animals treated with Immune dialysable 
transfer factor. Clinically negative results In transfer factor- 
treated animals were characterised by the absence of any Induration or
Table 14. The extent of clinical DH-responses in 4 monkeys following one
injection of control vacuum-dialysed rhesus transfer factor (Rh-TFVD).
14 days ♦SKIN TEST 21 days
Recipient monkey Induration diameter (mms) Induration diameter (mms)
and KLH PPD HBsAg NaCl KLH PPD HBsAg NaCl
dose of Rh-TFyD 50 pg 50 pg 50 pg 0.1 ml 50 pg 50 pg 50 pg 0.1 ml
H37: HBsAg/FCA 0 0 0 0
1(4.5 x 109)
H38: HBsAg/FCA 0 < 3 5.5 0
1(4.5 x 109)
H48: FCA 0 0 0 0 0 0
1(5.3 x 109)
H49: Normal 0 0 0 0 0 0 0 0
1(4.5 x 109)
*
Average diameter of 24 hour induration: > 3 mms, positive (Section 2.6).
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Table 15. Acquisition of delayed hypersensitivity following 
multiple injections of vacuum-dialysed rhesus 
monkey dialysable leucocyte transfer factor (Rh-TFVD).
Skin test +Mean 
antigen
diameter of 24 
times after
hr-induration 
first Rh-TFyp
(mm) at different 
injection.
and dose 13 days 27 days 34 days
Monkey H35
(Normal Rh-TFyp)
KLH 0 0 0
PPD 50 yg 0 0 0
HBsAg ND ND ND
NaCl (0.1 ml) 0 0 0
Monkey H36
(KLH/FCA Rh-TFV[))
KLH 0 7 10
PPD 50 yg 0 12 13
HBsAg ND ND ND
NaCl (0.1 ml) 0 0 0
Monkeys skin tested about 2, 4 and 5 weeks after first Injection of 
Rh-TFyQ* Normal Rh-TFVD {total = 2 (2.4 x 109) lymphocytes}
Injected at days 0 and 3 followed with saline on day 20. Immune 
Rh-TFVD injected on day 0, 3 and 20 {total = 3(4.5 x 109 ) lymphocytes}.
+D1ameter > 3 mms considered positive (Section 2.6); NO, not done.
Also see appropriate protocol (Section 2.2.1, fig. 2d).
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Plate 11. Clinically negative 48 hour 
delayed hypersensitivity responses to 
antigens in a representative rhesus monkey 
given one injection of homologous 
dialysable transfer factor.
H * 50ng HBsAg, K = 50wg KLH,
P = 50pg PPD, S = saline control.
Plate 11. Clinically negative 48 hour 
delayed hypersensitivity responses to 
antigens in a representative rhesus monkey 
given one injection of homologous 
dialysable transfer factor.
H = 50gg HBsAg, K = 50pg KLH,
P = 50ug PPD, S = saline control.
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erythema (Plate 11). This was similar to the appearance of the skin 
on the chest of a normal monkey, but was in direct contrast to the 
highly reactive DH-response seen in the actively immunised animals 
(Plate 7). The clinically positive DH-response seen in 1 recipient 
animal was not unfortunately Dhotographed (Table 15: monkey H36).
3.2.2 Histological DH-responses to KLH, PPD or HBsAg (Fig. 7, 
plates 12-13).
Figure 7a shows that 2 to 5 animals, depending on the antigen, were
9treated with 4.2 to 5.3 x 10 lymphocyte-equivalent of control 
dialysable rhesus transfer factor. After the first skin test, none 
reacted to KLH, or HBsAg (DH = 0 ), but 1 showed reactivity to 
PPD (DH = 2+). After the second skin test, 2 animals acquired 
positive DH-responses to KLH and 1 to HBsAg. The animal which showed 
no DH-reactivity to PPD after the first skin test, also remained 
non-reactive to PPD after the second skin test. The one animal with 
positive DH-response to PPD after the first skin test, was not 
unfortunately biopsied after the second skin test for histological 
examination.
Figure 7b shows that 3 to 9 animals injected with immune dialysable 
rhesus transfer factor were skin tested with various antigens.
Animals received a single injection of transfer factor, equivalent 
to 4-8 x 10® lymphocytes, or 3 Injections on days 1, 3 and 20, each 
equivalent to 4.5 x 10® lymphocytes (See section 2.2.1: table 11). 
After the first skin test, 1 animal became positive for KLH 
(DH « 2+), 5 animals for PPD (DH - 2+ to 3+) and 1 for HBsAg (DH - 2+).
(a ) M o n k e y s  t re a te d  w ith  c o n tro l R h -T F ^
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1st skin tests 
(weeks 1-2)
2nd skin tests 
(weeks 2-4)
F1g. 7. Histological results of maximum DH-responses to 30-50 ug 
antigen 1n rhesus monkeys treated with (a) control or (b) immune 
homologous dialysable transfer factor (Rh-TFp).
n, number of monkeys; (•) KLH; (o) PPD; (a) HBsAg; (e) saline 
control Rh-TFjj * normal or unrelated to test antigen; Immune 
Rh-TFD *= immune to test antigen.
After the second skin test, 2 animals had converted for KLH, 7 for 
PPD and 2 for HBsAg (DH = 1+ to 4+).
Negative histology in transfer factor-treated monkeys was 
characterised by the infiltration of dermal layers with minimum 
number of cells (Plates 12a-b). This was similar to the histology 
of the baseline skin test-reactivity (Plates 8-9). On the other 
hand, positive histology in transfer factor-treated animals showed 
various perivascular foci of cellular infiltration in one or more 
dermal layers (Plates 13a-b). In the actively immunised animals, 
all the dermal layers were relatively densely infiltrated with cells 
(Plates lOa-b).
3.2.3 Comparison of DH-conversion rates to KLH, PPD or HBsAg 
1n monkeys treated with control and immune transfer 
factor (Table 16).
From table 16 the results of the skin tests showed the following:
In animals treated with control transfer factor (normal or unrelated 
to test antigen) 1 out of 2 animals acquired DH-react1v1ty to PPD 
after the first skin test. However, after the second skin test, 2 
out of 4 and 1 out of 3 animals acquired DH-react1v1ty to KLH and 
HBsAg respectively. In animals treated with the Immune transfer 
factor (related to test antigen), after the first skin test 1 out 
of 6 animals acquired DH-react1v1ty to KLH, 5 out of 9 to PPD and 
1 out of 3 to HBsAg. After the second skin test, 2 out of 4 animals 
showed DH-react1v1ty to KLH, 6 out of 7 to PPD and 2 out of 3 to
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Plates 12a-b. Histologically negative skin delayed 
hypersensitivity response to an antigen in a 
representative rhesus monkey injected with homologous 
dlalysable transfer factor (DH = 0).
(a) Low power : 7?x (b) high power : 288x
Plates 13a-b. Histologically P°siÌ )£ns^ nad y 
hypersensitivity response to an antigen In 
representative rhesus monkey injected with 
homologous dlalysable transfer factor (DH 3+j.
(a) Low power : 72x, (b) high power : 288x
Table 16. Comparison of DH-conversion rates to KLH, PPD and HBsAg in monkeys 
treated with control and immune dialysable rhesus transfer factor.3
Rh-TFDb
Status
Total no. of monkeys with +ve DH (48 hr histology)0 
SKI (30-50 uq) SK2 (10-30 vq)
Total 
SKI + SK2
KLH PPD HBsAg Sum KLH PPD HBsAg Sum All antigens
Control 0/5 1/2 0/3 1/10 2/4 0/1* 1/3 3/8 4/18
(lot) (38%) (22%)
Inmune 1/6 5/9 1/3 7/18 2/4 6/7 2/3 10/14 17/32
[39%) (71%) (53%)
P for x - - - > 0.05 - - - > 0.05 > 0.05
3 From figures 7a-b (Section 3.2.2). 
b Rh-TFD, dialysable rhesus transfer factor.
c SKI, first skin tests; SK2, second skin tests; KLH, keyhole limpet haemocyanin; PPD, purified protein 
derivative of tuberculin; HBsAg, hepatitis B surface antigen.
*
Histology of the recipient with positive DH-response in the first skin test was not available at the time 
of the second skin test.
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The sum of the first and/or the second skin tests, with all the antigens 
taken together, revealed that the number of skin tests showing DH- 
reactivity increased after the second skin test. This occurred in 
animals treated with control or immune transfer factor. Comparison 
of the cumulative results showed no significant difference between 
the control and immune transfer factor preparations in their 
histological conversion of skin test reactivity to the antigens used 
(P > 0.05).
3.2.4 Relationship of the dose and/or methods of dialysis of
transfer factor to the acquired DH-reactivity to KLH, PPD 
or HBsAg (Fig. 8).
Figure 8 shows the mean DH-responses acquired after the first skin
test carried out 1-2 weeks after injection(s) of vacuum-dialysed or
water-dialysed KLH-1mmune, FCA-immune or HBsAg-immune rhesus transfer
factor. The total doses of KLH-1mmune or FCA-immune transfer factor,
g
given before 20 days, was equivalent to 4 to 9 x 10 lymphocytes 
(Section 2.2.1: table 11).
Figure 8a shows the mean histological DH-responses 1n animals treated 
with the vacuum-dialysed KLH-1mmune transfer factor. The 2 monkeys 
treated with the low dose (= 4.5 x 10® lymphocytes) did not acquire 
any DH-react1v1ty to 50 ug KLH. In contrast, when a higher dose 
(= 9 x 10® lymphocytes) was given to another animal some DH-response 
was detected (Mean DH = 2+). Unlike the vacuum-dialysed KLH-1mmune 
transfer factor, none of the animals treated with the water-dialysed
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Fig. 8. Effect of the dose and/or different methods of dialysis 
of immune transfer factor upon the mean DH-responses to (a) KLH, 
(b) PPD, and (c) HBsAg 1n recipient monkeys.
Rh-TFn , rhesus dlalysable transfer factor; Rh-TFvD. Vacuum- 
dialysed rhesus transfer factor; Rh-TFwo, Water-dialysed rhesus 
transfer factor; n, number of monkeys; J, mean response i SEM.
The absence of such reactivity to KLH was not dose-dependent, since
DH-reactivity was not detected in the animals given either the lower
o
or the higher dose of transfer factor (= 4 to 8 x 10 lymphocytes).
Figure 8b shows the mean histological DH-responses in animals 
injected with FCA-immune transfer factor. Those animals given the
g
lower dose of the vacuum-dialysed transfer factor (= 4.5 to 5.3 x 10 
lymphocytes), acquired a less reactive mean DH-response of 2+ to 
50 pg PPD, whilst those given the higher dose (=9 x 10 lymphocytes), 
acquired a more reactive mean DH-response of 3+. Again, unlike the 
6 recipients of the vacuum-dialysed FCA-immune transfer factor, the 
3 recipients of the water-dialysed FCA-immune transfer factor did 
not respond to 30 pg PPD (DH = 0). The absence of such reactivity to 
PPD, as for KLH above, was not dependent on the dose of the water- 
dialysed transfer factor.
Similarly figure 8c shows the animals treated with HBsAg-immune
g
transfer factor. Only a low dose was used (= 4.2 to 4.5 x 10 
lymphocytes). When 2 animals were treated with the vacuum-dialysed 
transfer factor, a very weak mean DH-react1v1ty of 1+ to 50 pg HBsAg 
was obtained. However, when one animal was given a comparable dose 
of water-dialysed transfer factor, 1t did not react to 50 pg HBsAg 
(DH » 0).
Thus, from figure 8 the following were concluded: (a) that the 
acquisition of DH-react1v1ty to KLH, PPD or HBsAg resulted from the 
injection of only the vacuum-dialysed and not the water-dialysed
transfer factor developed any DH-reactivity to 30 pg KLH (Mean DH = 0).
transfer factor, and (b) that the degree of such acquired DH- 
responses to KLH and PPD was dependent on the dose of transfer 
factor.
4. RESULTS OF THE MIXED LEUCOCYTE-MACROPHAGE MIGRATION
(LMMI) TESTS.
LMMI tests were carried out in normal, actively sensitised and 
transfer factor-treated rhesus monkeys. The migration indices were 
calculated as described previously (Section 2.7.1), and a migration 
index (MI) of less than 0.8 was arbitrarily considered positive 
(Plates 14a-b). The reason for this cut-off point will be discussed 
later (Section 8.2.1).
4.1 Normal and actively sensitised monkeys (Figs. 9-16, 
plates 14a-b, tables 17-18).
4.1.1 Maximum LMMI-responses to KLH, PPD, TB and HBsAg (Figs. 
9-10).
The LMMI test was carried out in naive rhesus monkeys in order to 
determine the normal baseline responses to 3-200 ug/ml KLH, PPD, TB 
and HBsAg (Figs. 9a-d). The mean migration Indices in these 
monkeys were above 0.8 (MI > 0.8) for all the concentrations of all 
the antigens, though some Individual animals showed non-specific 
reactivity to KLH, PPD, TB and HBsAg at one or more concentration. 
Such reactivity was most prevalent for KLH (Fig. 9a).
In comparison with the virgin monkeys above, when animals were 
actively Immunised with FCA, with or without KLH or HBsAg, the 
results shown 1n figures lOa-d were obtained. FCA always contained 
3 mgs particulate tubercle bacilli. Depending on the concentration
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Plates 14a-b. Mixed leucocyte-macrophage migration from 
capillary tubes 1n an actively or adoptively sensitised 
rhesus monkey (MI < 0.8)
(a) Area of fan 1n the presence of antigen (test).
(b) Area of fan 1n the absence of antigen (control).
MI, migration index ■» (a) ♦ (b).
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Fig. 9. Maximum baseline LMMI dose-response to (a) KLH or (b) PPD in normal rhesus 
monkeys.
n, number of monkeys; ^ mean MI t SEM.
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Fig. 9. Maximum baseline LMMI dose-response to (c) TB or (d) HBsAg in normal rhesus 
monkeys.
n, number of monkeys; ) J, mean MI t SEM; * ©  1/25, + ©  1/10 dilutions of HBsAg.
« 3  '  33 1 100 '  200 1
Concentration of KLH (pg/ml) Concentration of PPD (pg/ml)
Fig. 10. Maximum LMMI dose-response to (a) KLH or (b) PPD in rhesus monkeys 
actively sensitised with FCA with or without KLH or HBsAg.
n, number of monkeys; $ $ mean MI t SEM.
Concentration of TB (pg/ml) Concentration of HBsAg (pg/ml)
Fig. 10. Maximum LMMI dose-response to (c) TB or (d) HBsAg in rhesus monkeys 
actively sensitised with FCA with or without KLH or HBsAg.
n, number of monkeys; \ J mean MI t SEM; ND, not done; * © 1/25 dilution 
of HBsAg.
of each antigen, LMMI-reactivity (MI < 0.8) to KLH was detected in 2 
to 6 animals (Fig. 10a), to PPD in 3 to 7 animals (Fig. 10b), to TB 
in 4 to 5 animals (Fig. 10c) and to HBsAg in 2 to 3 animals (Fig. lOd). 
Mean migration indices were always equal to or below 0.8 for 
3-200 yg/ml KLH, PPD and TB (Figs. lOa-c), but for HBsAg this was so 
for 33-100 ug/ml and not for 3 ug/ml (Fig. lOd). There was a dose- 
dependent response for 3-100 yg/ml KLH or HBsAg and for 3-200 yg/ml TB, 
but not for PPD.
4.1.2 Time-dependent acquisition of LMMI-reactivity to KLH, PPD 
TB or HBsAg (Figs. 11-14).
A naive control monkey, injected with 20 mis normal saline, did not 
acquire LMMI-reactivity to 100 yg/ml KLH or TB up to 10 weeks after 
the injection (Figs. 11a, 13a). This monkey did, however, acquire 
reactivity to the same concentration of PPD 2 weeks after the saline 
injection (Fig. 12a: MI = 0.74). Another control monkey, injected 
with 30 mis normal saline, did not show a positive response to 
100 yg/ml HBsAg before or up to 3 weeks after the Injection (F1g. 14a).
Skin tests with 30 yg or 50 yg HBsAg were not followed with a 
positive LMMI-response to KLH or HBsAg in the saline-injected control 
monkeys (Figs. 11a, 14a). However, a skin test with 30 yg PPD, 
carried out 1 week after the saline injection, was followed by 
LMMI-reactivity to PPD, but not to TB (Figs. 12a, 13a).
Unlike the saline-injected virgin monkeys, animals Immunised with 
FCA, with or without an antigen (KLH or HBsAg), acquired LMMI- 
reactivity towards KLH, TB or HBsAg 2 to 5 weeks after the Immunisation
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Fig. 11. Time course of LMMI-responses to 100 wg/ml KLH before and 
after (a) Injection of a control monkey with saline, and (b-d) 
immunisation of 4 monkeys with KLH in FCA.
NaCI, sterile normal saline; + skin test with KLH; shaded area, 
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Fig. 12. Time course of LMMI-responses to 100 yg/ml PPD before and 
after (a) injection of a control monkey with saline, and (b-e) 
Immunisation of 7 monkeys with FCA with or without KLH or HBsAg.
NaCI, sterile normal saline; + skin test with PPD; sheded *rea, 
any time before saline Injection or Immunisation; Immunised H33a 
with FCA containing 3 mg tubercle, H16, H17, H26 with 100 wg KLH 1n 
FCA, H23 with 1 mg KLH, and H43, H44 with 1 mg HBsAg 1n FCA;
(o) 100 vg/ml PPD.
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Fig. 13. Time course of LMMI-responses to 100 pg/ml TB before and after 
(a) injection of a control monkey with saline, and (b-d) immunisation of 
5 monkeys with FCA with or without KLH.
NaCI, sterile normal saline; * skin test with PPD; shaded area, 
any time before saline Injection or immunisation; Immunised H33a with 
FCA containing 3 mg tubercle; H16, H17, H26 with 100 pg KLH in FCA;
H23 with 1 mg KLH in FCA; (a ) 100 pg/ml TB.
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(a) M o n k e y  H 3 4 (b) M o n k e y  H I 5
(c) Monkey H43 (d) Monkey H44
HBsAg/FCA HBsAg/FCA
Fig. 14. Time course of LMMI-responses to 100 yg/ml or 1/25 dilution 
of HBsAg before and after (a) injection of a control monkey with 
saline, and (b-d) Immunisation of 3 monkeys with HBsAg in FCA.
NaCl, sterile normal saline; + skin test with HBsAg; shaded area, 
any time before saline injection or immunisation; immunised H15,
H43, H44 with 1 mg HBsAg in FCA; (®) 1/25 dilution HBsAg; (&) 100 yg/ml 
HBsAg.
(Figs, llb-d, 13b-d, 14b-d). Such reactivity also developed towards 
PPD 2 to 5 weeks after the immunisation, but this was not unlike the 
saline-injected monkey (Figs. 12a cf 12b-e).
4.1.3 Comparison of LMMI-conversion rates to KLH, PPD, TB or 
HBsAg in normal and actively sensitised monkeys (Table 17).
Table 17 shows conversion rates for LMMI-reactivity to 3-200 yg/ml 
antigen in normal and immunised animals. The table demonstrates 
that, in the normal control animals injected with nothing or saline,
5% to 11% of the tests, depending on the antigen, became positive.
Thus, some non-specific reactivity to the antigens used was detected. 
Between 9 and 22 animals were monitored depending on the antigen and 
its concentration (Figs. 9a-d).
Table 17 also shows that 50% to 79% of the tests converted in the 
immunised monkeys, depending on the antigen. Three to 12 actively 
immunised animals were monitored with different concentrations of 
KLH, PPD, TB or HBsAg (Figs. lOa-d).
Comparison of the above results revealed that the likelihood for the 
acquisition of LMMI-react1v1ty by the immunised monkey was highly 
significant for all these antigens, but more so for KLH, PPD and TB 
(P < 0.001), than for HBsAg (P < 0.005).
4.1.4 Relationship of the Immunising dose of KLH and the acquired 
LMMI-react1v1ty (F1g. 15).
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Table 17. Comparison of LMMI-conversion rates to KLH, PPD, TB 
or HBsAg in normal and actively immunised monkeys. 9
Immunisationb Total no. of +ve LMMI (MI < 0 .8) testsc
with KLH PPD
3-200 wg/ml 
TB HBsAg Sum
Nothing/NaCl 9/80 4/80 5/71 2/38 20/269
(control) (11%) (5%) (7%) (5%) (7%)
FCA + KLH 19/24 21/41 19/32 5/10 64/107
or HBsAg (79%) (51%) (59%) (50%) (60%)
P for x2 < 0.001 < 0.001 < 0.001 < 0.005 < 0.001
aFrom figures 9-10 (Section 4.1.1).
bNaCl, normal saline; FCA, Freund's complete adjuvant.
CLMMI, mixed leucocyte-macrophage migration test done at any time 1n 
normal controls and at 2 to 7 weeks after active immunisation.
KLH, keyhole limpet haemocyanln; PPD, purified protein derivative 
of tuberculin; TB, particulate tubercle baclll1; HBsAg, purified 
hepatitis B surface antigen; MI, migration index.
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Concentration of KLH in 
immunogen KLH/FCA
Fig. 15. The effect of different concentrations of KLH 1n FCA 
upon the LMMI-responses 1n actively sensitised monkeys.
n, number of monkeys; J, SEM.
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Figure 15 shows that the amount of KLH in FCA affected the intensity 
of the acquired reactivity to 100 yg/ml KLH in the immunised monkeys. 
The 2 animals immunised with 100 yg KLH in FCA acquired a stronger 
mean LMMI-reactivity (Mean MI = 0.57), than the 4 animals immunised 
with 1 mg KLH 1n FCA (Mean MI = 0.67).
4.1.5 Relationship between the maximum LMMI- and DH-responses 
to KLH, PPD, TB or HBsAg (Fig. 16, table 18).
From figure 16 and table 18, it is evident that none of the saline- 
injected control monkeys showed both positive LMMI- and DH-responses 
to KLH, PPD, TB or HBsAg. Only 1 control animal was used for KLH,
PPD and TB and 1 for HBsAg.
In contrast to the controls, 2 to 7 immunised animals, depending on 
the antigen, acquired both positive LMMI- and DH-responses to KLH, 
PPD, TB or HBsAg. Three to 12 immunised animals were monitored with 
the LMMI and skin tests at the same time. Thus, the table shows that 
in the actively immunised animals, when all antigens were considered, 
there was 66% and 65% association between the positive LMMI-tests and 
the positive DH-responses after the first or the second skin tests 
respectively. Such an association was significantly different from 
the controls after the first skin test (P < 0.05), but not after the 
second skin test (P > 0.1).
4.2 Transfer factor-treated monkeys (Figs. 17-28, tables
19-20).
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LMMI vs D H 
(a) C O N T R O L  M O N K E Y S
(b) IMMUNISED M O N K E Y S
SKI: (1-4 weeks) SK2 •. (2-6 weeks)
D H  : histology (10-50 jig antigen)
Fig. 16. Relationship between the maximum LMMI- and DM-responses to 
kLH, PPD, TB and HBsAg 1n (a) normal control, and (b) actively 
Immunised monkeys.
SKI, first skin test; SK2, second skin test; (•) KLH; (o) PPD; (a ) TB; 
*(HBsAg : a 100 yg/ml , O  1/25 dilution); EZ3 positive LMMI and DH.
Table 18. Relationship between the acquisition of maximum LMMI- and DH-responses 
to KLH, PPD, TB and HBsAg in actively iimiunised rhesus monkeys.3
Immunisation*3
with
Animal conversions (MI < 
LMMI & SKI
0.8, DH l+)/animals
LMMI
usedc 
& SK2
KLH PPD TB HBsAg Sum KLH PPD TB HBsAg Sum
Nothing 0/1 0/1 0/1 0/1 0/4 0/1 0/1 0/1 ND 0/3
(control)
FCA + KLH 6/7 7/12 5/9 3/4 21/32 6/7 7/12 5/9 2/3 20/31
or HBsAg (66?) (65?)
P for x2 - - - - < 0.05 - - - - > 0.1
3 From figure 16.
b FCA, Freund's complete adjuvant.
c LMMI, mixed leucocyte-macrophage migration test done before and 2 to 7 weeks after immunisation; SKI, first skin 
test done before and after immunisation; SK2, second skin test done before and after immunisation; KLH, keyhole 
linpet haemocyanin; PPD, purified protein derivative of tuberculin; TB, particulate tubercle bacilli; HBsAg, 
hepatitis B surface antigen; ND, not done; MI, migration index; DH, delayed hypersensitivity.
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4.2.1 Maximum LMMI-responses to KLH, PPD, TB and HBsAg (Figs.
17-18).
Figures 17a-d demonstrate that 2 to 4 naive monkeys depending on 
the antigen, received control dialysable transfer factor. None 
developed LMMI-reactivity to 3 to 33 pg/ml KLH, or to 3 to 200 pg/ml 
PPD or TB, or to 3 to 100 pg/ml HBsAg. However, reactivity was
acquired by 1 to 3 animals for 100-200 pg/ml KLH and by 2 animals
for 200 pg/ml HBsAg (Figs. 17a, d). Therefore, some non-specific 
reactivity was detected to KLH and HBsAg, but not to PPD or TB. Mean 
migration indices revealed absence of reactivity (MI > 0.8) towards 
3-100 pg/ml KLH, PPD, TB and HBsAg, but they showed a dose response 
for KLH or HBsAg. However, dose-response for PPD or TB was irregular.
In contrast to the results of the controls above, figures 18a-d show 
the results of the animals treated with the immune dialysable 
rhesus transfer factor. Depending on the concentration of the test 
antigen, 2 to 6 recipients of KLH-immune transfer factor converted 
when tested with 3-200 pg/ml KLH (Fig. 18a: MI < 0.8). Similarly,
3 to 5 converted for PPD, 4 for TB and 1 to 3 for HBsAg (Figs. 18b-d).
Mean migration indices showed irregular dose-response for KLH, PPD 
or TB, but a good dose-response for HBsAg. Unlike most of the 
controls (Figs. 17a-d), here mean Indices revealed reactivity 
(MI < 0.8) for 3-200 pg/ml KLH (F1g. 18a), for 3, 100 and 200 pg/ml 
PPD (Fig. 18b), for 33-100 pg/ml TB (F1g. 18c), and for 33-200 pg/ml 
HBsAg (F1g. 18d). These reactivities were stronger for KLH or 
HBsAg, than for PPD or TB.
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Fig. 17. Maximum LMMI dose-response to (a) KLH, or (b) PPD in rhesus monkeys treated
with control dialysable rhesus transfer factor.
n, number of monkeys; $ $, mean MI t SEM.
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Fig« 17. Maximum LMMI dose-response to (c) TB, or (d) HBsAg in rhesus monkeys treated
with control d ia ly sab le  rhesus tra n sfe r  factor.
n, number of monkeys; { mean MI i SEM.
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Fig. 18. Maximum LMMI dose-response to (c) TB or (d) HBsAg in rhesus monkeys treated 
with immune dialysable rhesus transfer factor.
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4.2.2 Time-dependent acquisition of LMMI-reactivity to KLH, PPD, 
TB and HBsAg (Figs. 19-26).
From figures 19 to 22 it can be seen that none of the control 
recipients showed LMMI-reactivity to 100 ug/ml antigen before the 
administration of transfer factor. Similarly, up to 21 to 34 days 
after the first or only injection of a "vacuum-dialysed" preparation 
of transfer factor, none of the animals developed reactivity to 
100 yg/ml PPD (Fig. 20), or to the same concentration of TB or 
HBsAg (Figs. 21-22). However, 1 control recipient unexpectedly 
acquired non-specific reactivity to 100 ug/ml KLH 6 days after the 
first injection of control transfer factor (Fig. 19a).
The recipients of the immune transfer factor preparations, unlike 
most of the controls above, acquired LMMI-reactivity towards 
selective antigens 2-14 days after the first or only injection of 
transfer factor (Figs. 23-26). Among the animals which converted, 
the onset of reactivity to 100 ug/ml KLH or TB appeared as"early" 
as 2 to 6 days, or as "late" as 7-14 days after the 1njection(s) of 
transfer factor (Figs. 23, 25). For 100 ug/ml or 1/25 dilution of 
HBsAg, such reactivity first appeared "early" by 2 to 6 days, but 
never "late" (Figs. 24, 26).
Skin tests 1n animals treated with the control or the Immune transfer 
factor did not Influence the acquisition of reactivity (Figs. 19-26). 
This was because the acquired reactions towards all the antigens 
always appeared before the first skin test.
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F1g. 19. Time course of LMMI-responses to 100 ug/ml KLH before and 
after treatment of 5 monkeys with control dialysable rhesus transfer 
factor.
t Rh-TFD, normal or unrelated dialysable rhesus transfer factor;
* * dose of Rh-TFn in lymphocytes (Also see section 2.2.1: table 11) 
+ skin test with KLH; —  Rh-TFVD, vacuum-dialysed rhesus transfer 
factor; shaded area, any time before Rh-TFp.
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C O N T R O L  Rh - TFn & PPD
(a) Man key H35 : 2 (2 .4  x 109 )*
1
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Fig. 20. Time course of LMMI-responses to 100 pg/ml PPD before and 
after treatment of 2 monkeys with control dialysable rhesus transfer 
factor.
1 Rh-TFn, normal dialysable rhesus transfer factor; *dose of Rh-TFp 
1n lymphocytes (Also see section 2.2.1; table 11); f skin test 
with PPD; —  Rh-TFwp, vacuum-dialysed transfer factor; shaded area, 
any time before Rh-TFp.
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CONTROL Rh -  TFp & TB
(a) Monkey H 35: 2 ( 2 .4  x 109 )*
(b) Monkey H 49: 1 ( 4. 5 x 109 )*
Fig. 21. Time course of LMMI-responses to 100 pg/ml TB before and 
after treatment of 2 monkeys with control dialysable rhesus transfer 
factor.
I Rh-TFo, normal dialysable rhesus transfer factor; * dose of RIi-TFq 
1n lymphocytes (Also see section 2.2.1: table 11); * skin test 
with PPD; —  Rh-TFyD , vacuum-dialysed transfer factor; shaded area, 
any time before Rh-TFp.
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Fig. 22. Time course of LMMI-responses to 100 ug/ml HBsAg before and 
after treatment of 4 monkeys with control dlalysable rhesus transfer 
factor.
iRh-TFn, normal or unrelated dlalysable rhesus transfer factor; * dose 
of Rh-TFn in lymphocytes (Also see section 2.2.1: table 11); ♦ skin 
test with HBsAg; —  Rh-TF„D , vacuum dialysed transfer factor; shaded 
area, any time before Rh-TF«.
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F1g. 23. Time course of LMMI-responses to 100 vg/ml KLH before and 
after treatment of 6 monkeys with KLH-1mmune dlalysable rhesus 
transfer factor.
t Rh-TFn, dlalysable rhesus tranfer factor; * dose of Rh-TFn 1n 
lymphocytes (Also see section 2.2.1: table 11); f skin test
with KLH; —  Rh-TFyD» vacuum-dialysed transfer factor; - --Çi’-IÊWD*
water-dialysed transfer factor; shaded area, any time before Rh-TFp.
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i. 24. Time course of LMMI-responses to 100 wg/ml PPD before and 
er treatment of 9 monkeys with FCA-1mmune dlalysable rhesus transfer
factor.
t  Rh-TFn, dlalysable rhesus transfer factor; *dose of Rh-TFn 1n 
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Fig. 25. Time course of LMMI-responses to 100 pg/ml TB before and 
after treatment of 9 monkeys with FCA-immune dlalysable rhesus transfer 
factor.
1 Rh-TFp, dialysable rhesus transfer factor; * dose of Rh-TFp in 
lymphocytes (Also see section 2.2.1: table 11); * skin test with
PPD; —  Rh-TFyp, vacuum-dialysed transfer factor; ---  Rh-TF^p,
water-dialysed transfer factor.
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Fig. 26. Time course of LMMI-response to 100 ng/ml or 1/25 dilution 
of HBsAg before and after treatment of 3 monkeys with HBsAg-immune 
dialysable rhesus transfer factor.
1 Rh-TFn, dialysable rhesus transfer factor; * dose of Rh-TFp 1n 
lymphocytes (Also see section 2.2.1: table 11); ♦ skin test with
HBsAg; —  Rh-TFvn, vacuum-dialysed transfer factor; --- Rh-TFWn,
water dialysed transfer factor; shaded area, any time before Rh-TFp; 
©, 1/25 dilution HBsAg; A, 100 yg/ml HBsAg.
1In various recipients of the immune transfer factor, some of the 
acquired reactions to various antigens were detected either on one 
occasion ("Transient") or repeatedly on several occasions ("Lasting"). 
The transient reactivities lasted for only 1 day, but the lasting 
ones lasted for 2 to 68 days (Figs. 23-26). The length of this 
period of reactivity seemed to depend on the test antigen, the method 
of dialysis or the dose of transfer factor. For example, after the
g
injection of 4 x 10 lymphocyte-equivalent of water-dialysed transfer 
factor, the acquired LMMI-reactivity to 100 yg/ml KLH appeared by day 
3 and persisted through to day 14 (Fig. 23a: monkey H18a). When 
another animal was given twice this dose of water-dialysed transfer 
factor, the LMMI-reactivity to KLH first appeared by day 2 and was 
still present by day 70 (Fig. 23a: monkey H19). In comparison to 
such water-dialysed transfer factor, the injection of a total dose 
of 4.5 x 109 or 9 x 109 lymphocyte-equivalent of vacuum-dialysed 
transfer factor was only followed by the appearance of a transient 
reactivity to KLH on day 6, 7 or 14 (Figs. 23b-c).
4.2.3 Comparison of LMMI-convers1on rates to KLH, PPD, TB or
HBsAg in monkeys treated with control and immune transfer 
factor (Table 19).
The data 1n table 19 show the acquired maximum LMMI-reactivity to 
3-200 wg/ml antigen 1n animals treated with control (normal or 
unrelated to test antigen) or Immune transfer factor (related to 
test antigen).
The table reveals that 1n animals treated with control transfer 
factor, 13« or 20* of the tests became positive for HBsAg or KLH
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Table 19. Comparison of LMMI-conversion rates to KLH, PPD, TB 
and HBsAg in monkeys treated with control and immune 
dialysable homologous transfer factor. 3
Rh-TFDb Total no. of +ve LMMI (MI < 0 .8) testsc
Status KLH PPD
3-200 vg/ml 
TB HBsAg Sum
Control 4/20 0/8 0/8 2/16 6/52
(20%) (13%) (12%)
Immune 16/21 17/33 16/33 9/10 58/97
(76%) (52%) (49%) (90%) (60%)
P for x2 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
aFrom figures 17-18 (Section 4.2.1). 
bRh-TFD , dialysable rhesus transfer factor.
CLMMI, mixed leucocyte-macrophage migration test done at any time 
before or after the first or only Injection of Rh-TFp. KLH, 
keyhole limpet haemocyanln; PPD, purified protein derivative of 
tuberculin; TB, particulate tubercle bacilli; HBsAg, hepatitis 
B surface antigen; MI, migration Index.
9  ¿ J  ''T -  ’ - —  — — - - - - - - -- - - - :- - - - - - -
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respectively, but none became positive for PPD or TB. Thus, non­
specific reactivity was only detected for HBsAg or KLH. A total of 
2 to 5 control animals were monitored, depending on the antigen 
(Figs. 17a-d).
In contrast to the controls, 49% to 90% of the tests, depending on 
the antigen, converted when monkeys were treated with the immune 
transfer factor preparations. Between 2 and 9 recipients were 
monitored with different concentrations of the various antigens 
(Figs. 18a-d).
A comparison of these results showed that, the difference between the 
acquisition of LMMI-reactivity, in control and immune transfer factor- 
treated animals was highly significant for KLH, PPD, TB and HBsAg, 
when antigens were taken individually or altogether (Table 19:
P < 0.001).
4.2.4 Relationship between the different doses and/or methods of 
dialysis of transfer factor and the intensity of maximum 
LMMI-responses to KLH, PPD and TB (Fig. 27).
From Fig. 27 it can be seen that dose per dose, monkeys treated with 
the water-dialysed transfer factor, rather than the vacuum-dialysed 
transfer factor, produced a stronger mean LMMI-response to KLH or 
TB (Figs. 27a, c). However, for PPD, this was so only for the 
higher dose of transfer factor, and not the lower dose (Fig. 27).
4.2.5 Relationship between the maximum LMMI- and DH-responses to 
KLH, PPD, TB or HBsAg (F1g. 28, table 20).
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(a) KLH -  immune Rh-TFn
2o>
5
(c) FCA -  immune Rh -  TFn
Rh-TR,
TB (lOOpg/ml)
(b) FCA - immune Rh zJL d_
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Fig. 27. Relationship between the different doses and/or methods 
of dialysis of immune transfer factor and the intensity of maximum 
LMMI-responses to (a) KLH, (b) PPD, and (c) TB.
n, number of monkeys; J , mean t SEM; Rh-TF0, dialysable rhesus 
transfer factor; Rh-TFyQ, vacuum dialysed transfer factor; Rh-TFyQ, 
water-dialysed transfer factor.
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From figure 28 and table 20 it is evident that none of the monkeys 
injected with the control transfer factor showed both positive 
LMMI- and DH-responses to KLH, PPD, TB or HBsAg. This was so after 
the first or the second skin test. Therefore, in these animals 
there was a negative correlation between the maximum LMMI reactivity 
and the first or the second skin test responses.
In contrast, in animals treated with the immune transfer factor, 
some animals converted for both the LMMI test and the first or the 
second skin test. Therefore, there was some positive correlation 
between the acquired maximum LMMI- and DH-responses to the various 
antigens. When all the antigens were taken together, after the 
first skin test there was 26% correlation, which increased to 43% 
after the second skin test, but such correlations were not significantly 
different from the controls (Table 20: P > 0..1 and > 0.05 respectively).
L M M I  vs DH
(a) CONTROL Rh -  TFD
SKI : (7 -  14 days) SK2 : (14 - 2 7  days)
DH : histology (30 -  50 pg antigen)
Fig. 28. Relationship between the maximum LMMI- and DH-responses to 
KLH, PPD, TB and HBsAg 1n monkeys treated with (a) control or (b) 
immune rhesus dialysable transfer factor.
SKI, first skin test; SK2, second skin test; • KLH; o PPD; A TB; 
* (A 100 yg/ml HBsAg; @  1/25 dilution of HBsAg); eza positive LMMI 
and DH; Rh-TFp, rhesus dialysable transfer factor.
Table 20. Relationship between the acquisition of maximum LMMI- and DH-responses 
to KLH, PPD, TB and HBsAg in transfer factor-treated rhesus monkeys. 3
Rh-TFo“
Status
Animal conversions (MI < 
LMMI & SKI
0.8, DH >y l+)/animals 
LMMI
used0 
& SK2
KLH PPD TB HBsAg Sum KLH PPD TB HBsAg Sum
Control 0/5 0/2 0/2 0/3 0/12 0/4 0/1 0/1 0/3 0/9
Immune 1/6 3/9 2/9 1/3 7/27 2/4 3/7 i n 2/3 9/21
(26*) (43*)
P for x2 > 0.1 m > 0.05
a From figures 28a-b.
I
b Rh-TFjj, dialysable rhesus transfer factor.
c LMMI, mixed leucocyte-macrophage migration test done after Rh-TFp injection(s); SKI, first skin test; SK2, 
second skin test; KLH, keyhole limpet haemocyanin; PPD, purified protein derivative of tuberculin; TB, 
particulate tubercle bacilli; HBsAg, hepatitis B surface antigen; MI, migration index; DH, delayed 
hypersensitivity.
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5. RESULTS OF THE LYMPHOCYTE TRANSFORMATION (LT) TESTS
LT tests were carried out in normal, actively sensitised and transfer 
factor-treated rhesus monkeys and the stimulation indices were 
calculated as described before (Section 2.7.2). A stimulation index 
(SI) of more than 2.0 was arbitrarily considered positive. Reasons 
for this cut-off point will be discussed later (Section 8.3.1).
5.1. Normal and actively sensitised monkeys (Figs. 29-39,
Tables 21-23).
5.1.1 Maximum LT-responses to KLH, PPD, TB and HBsAg (Figs.
29-30).
To determine the normal range of baseline responses to 1-100 yg/ml 
KLH, PPD, TB and HBsAg. LT tests were carried out in virgin 
rhesus monkeys (Figs. 29a-d). Non-specific reactivity was not 
detected for TB at any concentration (Fig. 29c: SI < 2), but some 
such reactivity was detected for the other antigens (SI > 2). Two 
to 5 virgin animals converted for 5-100 yg/ml KLH (Fig. 29a), 1 
animal for 1-5 yg/ml PPD (Fig. 29b), and 1 to 2 for 50-100 yg/ml 
HBsAg (Fig. 29d). Despite these non-specific reactivities In Individual 
monkeys, mean values of the stimulation indices revealed absence of 
LT-react1v1ty to all the antigens at 1-100 yg/ml concentration range 
(Figs. 29a-d: mean SI < 2).
In comparison with the virgin monkeys above, the actively Immunised 
animals showed positive LT-responses. Figure 30 demonstrates that
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Fig. 29. Maximum baseline LT dose-response to (a) KLH or (b) PPD in normal rhesus monkeys,
n, number of monkeys; $ J, mean SI t SEM.
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(a) KLH
Fig. 30. Maximum LT dose-response to (a) KLH in rhesus monkeys 
actively immunised with KLH 1n FCA.
n, number of monkeys; mean SI i SEM.
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(b) PPD
Concentration of antigen (|ig/ml)
Fig. 30. Maximum LT dose-response to (b) PPD, (c) TB or (d) HBsAg 
in rhesus monkeys actively immunised with FCA with or without HBsAg.
n, number of monkeys; $ | mean SI i SEM.
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1 to 7 animals converted, depending on the antigen and its 
concentration. Mean stimulation indices for 5-50 yg/ml antigen 
revealed reactivity to KLH, PPD, TB and HBsAg (Mean SI > 2), and 
the intensity of this reactivity was highly marked for KLH (Mean 
SI > 30).
5.1.2 Time-dependent LT-responses to KLH, PPD, TB and HBsAg 
(Figs. 31-34).
From figures 31a, b, d and 32-34, it can be seen that animals 
immunised with FCA, with or without KLH or HBsAg, began to acquire 
LT-reactivity towards 10 yg/ml KLH, PPD, TB or HBsAg 1 to 4 weeks 
after the immunisation. In 1 animal, immunised with KLH in FCA, 
reactivity to KLH was detected before and 2 to 5 weeks after the 
immunisation (Fig. 31c). However, the intensity of maximum 
reactivity to this antigen was much greater 4 weeks after the 
immunisation (SI =15), than any time before (SI = 3).
The intensity of the acquired maximum reactivity towards 10 yg/ml 
test antigens varied, depending on the antigen and the particular 
Immunised monkey. Such maximum reactivity ranged from a stimulation 
Index of just over 2 for PPD or TB to 92 for KLH (Fig. 32d: monkey 
H36a; F1g. 33a: monkey HI7j F1g. 31a: monkey H16).
5.1.3 Comparison of LT-convers1on rates to KLH, PPD, TB or 
HBsAg 1n normal and actively sensitised monkeys (Table 21).
The data 1n table 21 shows conversion rates for LT-react1v1ty to 
5-50 yg/ml antigen in normal and actively immunised monkeys.
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LT WITH KLH
KLH/FCA (w“ ks)
(b) Monkey H l7
KLH /FCA  (we8ks)
+
it
(c) Monkey H34a (d) Monkey H20
F1g. 31. Time course of LT-responses to 10 wg/ml 
after (a-d) Immunisation of 4 monkeys with 100 yg
KLH before and 
KLH 1n FCA.
♦ skin test with KLH; shaded area, any time before Immunisation; 
(•) 10 yg/ml KLH.
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LT WITH PPD
(a) Monkeys H16, H17 (b) Monkeys H32, H33a
At
(c) Monkey H34a (d) Monkeys H 35a, H36a
Fig. 32. Time course of LT-responses to 10 yg/ml PPD before and after 
(a-d)' immunisation of 7 monkeys with FCA with or without KLH or HBsAg.
+, Skin test with PPD; shaded area, any time before Immunisation; 
immunised H16, H17 and H34a with 100 yg KLH 1n FCA; H32 and H33a with 
FCA containing 3 mg tubercle; H35a and H36a with 1 mg HBsAg 1n FCA; 
(o) 10 yg/ml PPD.
LT WITH TB
7 90
'6
(a) Monkeys HI6 HI7
KLH/FCA (weeks)
(b) Monkey H32
Fig. 33. Time course of LT-responses to 10 yg/ml TB before and after 
(a-b) immunisation of 3 monkeys with FCA with or without 100 yg KLH.
Skin test with PPD; shaded area, any time before immunisation; 
immunised H16 and H17 with 100 yg KLH in FCA; H36 with only FCA 
containing 3 mg tubercle; (a ) 10 yg/ml TB.
LT WITH HBsAg
(a) Monkey H35a
H B ^ / F C A  (w~ k*)
(b) Monkey H36a
HBtAfl/FCA
Fig. 34. Time course of LT-responses to 10 yg/ml HBsAg before and 
after (a-b) immunisation of 2 monkeys with 1 mg HBsAg in FCA.
♦, Skin test with HBsAg; shaded area, any time before Immunisation; 
(a ) 10 yg/ml HBsAg.
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Table 21. Comparison of LT-conversion rates to KLH, PPD, TB or 
HBsAg in normal and actively immunised monkeys.3
Immunisation13 Total no. of +ve LT (SI >2) tests0
5-50 pg/ml
with KLH PPD TB HBsAg Sum
Nothing/NaCl 8/51 1/51 0/30 1/30 10/162
(control) (16%) (2%) (0%) (0%) (6%)
FCA + KLH 12/12 21/24 12/18 5/6 50/60
or HBsAg (100%) (88%) (67%) (83%) (83%)
P for x2 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
aFrom figures 29-30 (Section 5.1.1).
bNaCl, normal saline; FCA, Freund's complete adjuvant.
CLT, lymphocyte transformation test done at any time before (normal 
controls) or after the active immunisation. KLH, keyhole limpet 
haemocyanin; PPD, purified protein derivative of tuberculin;
TB, particulate tubercle bacilli; HBsAg, purified hepatitis B 
surface antigen; SI, stimulation index.
792 6
Depending on the antigen, none to 16% of the tests became reactive in 
the normal control monkeys, compared with 67% to 100% conversion for 
tests in the immunised animals. Therefore, although some non-specific 
reactivity appeared for KLH and PPD, the difference in the acquisition 
of reactivity to antigen between the normal and immunised animals was 
highly significant when all the antigens were taken separately or 
altogether (P < 0.01).
5.1.4 Relationship between the maximum LT- and DH-responses to 
KLH, PPD, TB or HBsAg (Fig. 35, table 22).
After the first or the second skin test, depending on the antigen,
2 to 7 actively immunised animals acquired both positive LT- and 
DH-responses (Fig. 35, table 22). When all the antigens were taken 
together, the rate of such double-conversion was 85%, regardless of 
the number of skin tests. Therefore, there was an association between 
the lymphocyte transformation and the delayed hypersensitivity tests 
in the actively Immunised animals. Such data were not available for 
naive animals.
5.1.5 Relationship between the maximum LT- and LMMI-responses to 
KLH, PPD or TB (F1g. 36, table 23).
From the figure and the table 1t can be seen that 2 to 3 out of 3 
to 4 Immunised animals converted when both LT and LMMI tests were 
carried out with KLH, PPD or TB. In the few animals, where these 
tests were performed at the same time and when all the test antigens 
were considered altogether, the double-conversion rate was 73%.
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LT vs DH
IMMUNISED MONKEYS
0 ------1------1------1------1------1------1 ------ j------ 1------1------1------ 1------ 1
0 1+ 2+ 4+ 5t- 0  1+ 2+ 4+  5+-
SKI : -  (1-4 weeks) SK2 ; -  ( 2 - 6  weeks)
DH : histology ( 10 -  50 pg antigen)
Fig. 35. Relationship between the maximum LT- and DH-responses to 
KLH, PPD, TB and HBsAg 1n actively immunised monkeys.
SKI, first skin test; SK2, second skin test; • KLH; o PPD; A TB; 
A HBsAg; Gza positive LT and DH.
Table 22. Relationship between the acquisition of maximum LT and DH-responses 
to KLH, PPD, TB and HBsAg in actively immunised rhesus monkeys.3
Immunisationb 
with
Animal conversions (SI > 
LT & SKI
2, DH » l+)/animals used0 
LT & SK 2
KLH PPD TB HBsAg Sum KLH PPD TB HBsAg Sum
Nothing ND ND ND ND - ND ND ND ND -
FCA + KLH 4/4 7/8 4/6 2/2 17/20 4/4 7/8 4/6 2/2 17/20
or HBsAg (85%) (85%)
a From figure 35.
b FCA, Freund's complete adjuvant; KLH, keyhole limpet haemocyanin; HBsAg, hepatitis B surface antigen.
c SI, stimulation index; DH, delayed hypersensitivity; LT, lymphocyte transformation test; SKI, first skin 
test; SK2, second skin test; TB, particulate tubercle bacilli; PPD, purified protein derivative of 
tuberculin; HD, not done.
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LT vs LMM1
Immunised monkeys
LMM1 : (100 pg/ml antigen)
Fig. 36. Relationship between the maximum LT- and LMMI-responses 
to KLH, PPD and TB in actively immunised monkeys.
xr7-A positive LT and LMMI; • KLH; o PPD; k TB.
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Table 23. Relationship between the acquisition of maximum 
LT and LMMI-responses to KLH, PPD and TB in 
actively immunised rhesus monkeys.8
Immunisation^
with
Animal conversions (SI > 2, MI < 0.8)/animals usedc
KLH PPD
LT & LMMI 
TB HBsAg Sum
Nothing ND ND ND ND -
FCA i KLH 3/3 2/4 3/4 ND 8/11
or HBsAg (73%)
a From figure 36.
b FCA, Freund's complete adjuvant; KLH, keyhole limpet haemocyanin; 
HBsAg, hepatitis B surface antigen.
c SI, stimulation index; MI, migration Index; LT, lymphocyte 
transformation test; LMMI, mixed leucocyte-macrophage migration 
test; PPD, purified protein derivative of tuberculin; TB, particulate 
tubercle bad 111; ND, not done.
Thus, an association existed between the transformation and the 
migration tests in the actively immunised monkeys. Again such data 
were not available for naive monkeys.
5.1.6 Baseline LT dose-response to PHA in normal rhesus monkeys 
(Fig. 37).
When 6 to 15 normal monkeys were monitored by the LT test using 
5-300 yg PHA, the dose-response shown in figure 37 was obtained.
Except for 5 yg/ml PHA, all the monkeys showed reactivity to 
10-300 yg/ml PHA, with the maximum mean reactivity detected for 
100 yg/ml PHA (Mean SI = 428). The normal baseline response in these 
animals for 100 yg/ml PHA ranged from a stimulation index of about 
70 to 4250.
5.1.7 Maximum LT dose-response to PHA in actively immunised 
rhesus monkeys (Fig. 38).
The figure demonstrates that, in monkeys actively immunised with FCA, 
with or without KLH or HBsAg, there was a good PHA dose-response.
Like the normal animals above, positive reactivity was not detected 
for all the monkeys when LT-tests were carried out with 5 yg/ml PHA, 
but was detected for all when a concentration of 25 or 100 yg/ml 
PHA was used. For 100 yg/ml PHA, maximum mean stimulation Index was 
about 93 and, therefore, fell within the normal range of reactivity 
found 1n the unsensitised monkeys (Section 5.1.6: mean SI = 70 to 
4250).
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Concentration of PHA (jig/ml)
F1g. 37. Maximum baseline LT dose-response to 5-300 yg/ml PHA In 15 
normal rhesus monkeys.
n, number of monkeys; vertical bars represent mean SI t SEM;
(x) stimulation Index of Individual animals to 5-300 yg/ml PHA.
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F1g. 38. Maximum LT dose-response to 5-100 pg/ml PHA 1n 8 rhesus 
monkeys actively Immunised with FCA with or without KLH or HBsAg.
n, number of monkeys; vertical bars represent mean SI ± SEM;
(x) stimulation Index of Individual animals to 5-100 ug/ml PHA.
5.1.8 Depression of LT-response to PHA after active immunisation 
(Fig. 39).
When the LT test was carried out in 7 unsensitised monkeys with 
100 ug/ml PHA, the mean reactivity was normal (Mean SI = 173).
After the immunisation, however, the LT-response to the same 
concentration of PHA was significantly depressed in 5 to 8 animals.
One week after the immunisation the mean reactivity was greatly 
depressed (Mean SI = 83), but it was still within the normal range 
(Section 5.1.6: mean SI = 70 to 4250). However, by 2 to 5 weeks 
after the immunisation, the mean reactivity was reduced even more to 
below the lower limit of the normal response (Mean SI = 70). The 
depression of LT response to PHA was regular for 1 to 3 weeks after 
the immunisation, but for unknown reasons, it became irregular after 
this time.
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5.2 Transfer factor-treated monkeys (Figs. 40-45, tables
24-26).
5.2.1 Maximum LT-responses to KLH, PPD and HBsAg (Figs. 40-41).
When 2 to 5 virgin rhesus monkeys were treated with control transfer 
factor, only 2 animals showed positive LT-react1v1ty to 10 ug/nil 
KLH, but none showed reactivity to 5 or 50 ug/ml KLH or to 5-50 ug/ml 
PPD or HBsAg. Such tests were not carried out with TB (F1g. 40).
In contrast, when 2 to 6 virgin monkeys were given immune transfer 
factor, depending on the concentration of the test antigen, 1 to 2
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u Weeks after Immunization
FCA ± antigen
Fla, 39. LT-response to 100 pg/ml PHA 1n 8 rhesus monkeys before and 
after active immunisation with FCA with or without KLH or HBsAg.
n, number of monkeys; vertical bars represent mean SI i SEM; SKI, SK2 
first and second skin tests with an antigen; shaded area, any time 
before immunisation; (*) stimulation Index of Individual animals to 
100 yg/ml PHA.
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Fig. 40. Maximum LT dose-response to (a) KLH, (b) PPD, or (c) HBsAg 
•In rhesus monkeys treated with control dialysable rhesus transfer
factor.
n, number of monkeys; { 5 5» mean SI t SEM; Rh-TFp, rhesus 
dialysable transfer factor.
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IMMUNE Rh - TFd 
(a) KLH
*
iI
It
+A
4
Concentration of antigen (pg/ml)
F1g. 41. Maximum LT dose-response to (a) KLH, (b) PPD, or (c) HBsAg 
in rhesus monkeys treated with Immune dlalysable rhesus transfer factor.
n, number of monkeys; | mean SI t SEM; Rh-TFp, rhesus dlalysable 
transfer factor.
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animals converted for KLH, 1 for PPD and none for HBsAg (Fig. 41). 
There was an increasing dose-response for KLH, but not for PPD or 
HBsAg. Again, like the control animals above, tests were not 
carried out with TB.
5.2.2 Time-dependent acquisition of LT-reactivity to KLH or 
PPD.
In one of the control animals above, the acquisition of non-specific
LT-reactivity to 10 yg/ml KLH was very weak (Section 5.2.1, fig. 40:
g
SI = 2.2). This appeared 2 days after the injection of 4.5 x 10 
lymphocyte-equivalent of normal transfer factor (Section 2.2.1, 
table 11: monkey H49). In another control, such acquired reactivity 
to KLH was also weak (Section 5.2.1, fig. 40: SI = 2.1), but 1t 
appeared 34 days after the first of the two injections together
Q
obtained from 4.2 x 10 normal lymphocytes (Section 2.2.1, table 11: 
monkey H35).
The 1 animal above (Section 5.2.1: fig. 41), which showed positive 
LT-response to 10 ug/ml KLH after treatment with immune transfer 
factor, reactivity was present before (SI * 2.6) and 2 days (SI ■ 2.4) 
or 14 days after the treatment (SI = 2.8). Therefore, true 
conversion for this antigen did not occur 1n this monkey recipient
Q
of 4.5 x 10 lymphocyte-equivalent of KLH-immune transfer factor 
(Section 2.2.1, table 11: monkey H47). Where PPD was concerned, 
however, true conversion occurred. The acquired LT-react1v1ty to 
10 pg/ml PPD, though very weak (Section 5.2.1, fig. 41: SI »* 2.1), 
appeared 27 days after the first of the 3 injections of immune
Q
transfer factor, each prepared from 4.5 x 10 lymphocytes, (Section
2.2.1, table 11: monkey H36).
5.2.3 Comparison of LT-conversion rates to KLH, PPD or HBsAg in
monkeys treated with control and immune transfer factor 
(Table 24).
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The table shows that when all the tests for 5-50 pg/ml were considered, 
in 5 animals treated with control (normal or unrelated to test antigen) 
transfer factor, 2 out of 15 tests converted to KLH, but none to PPD 
or HBsAg. In 6 animals treated with immune transfer factor (related 
to test antigen), 4 out of 9 tests converted to KLH and 1 out of 18 to 
PPD, but none to HBsAg. When sum of all the tests with each or all 
the antigens were considered, the difference between the cumulative 
rates of conversion in the animals treated with control and immune 
transfer factor preparations was not significant (P > 0.2 < 0.6).
5.2.4 Relationship between the maximum LT- and DH-responses to
The figure and the table demonstrate that, after the first skin test, 
none of the recipients of the control or immune transfer factor 
showed double conversion of LT- and DH-responses to KLH, PPD or HBsAg. 
After the second skin test, only 1 animal showed such double 
conversion for KLH, but none for PPD or HBsAg. Therefore, unlike the 
actively immunised monkeys (Section 5.1.4, fig. 35, table 22), there
was no positive correlation between the lymphocyte transformation and
KLH, PPD or HBsAg (Fig. 42, table 25).
delayed hypersensitivity skin tests in transfer factor-treated r~J—
Table 24. Comparison of LT-conversion rates to KLH, PPD 
and HBsAg in monkeys treated with control and 
dialysable homologous transfer factor.3
Rh-TFDb
Status
Total no. of +ve LT (SI > 2) testsc
KLH PPD
5-50 ug/ml 
TB HBsAg Sum
Control 2/15 0/6 ND 0/12 2/37
(13%) (5%)
Immune 4/9 1/18 ND 0/6 5/33
(44%) (6%) (15%)
> 0.2 > 0.5 > 0.3
P for x < 0.3 < 0.6 < 0.4
aFrom figures 40-41 (Section 5.2.1). 
bRh-TFD , dialysable rhesus transfer factor.
CLT, lymphocyte transformation test done any time before or 2 to 34 
days after transfer factor.
KLH, keyhole limpet haemocyanin; PPD, purified protein derivative 
of tuberculin; TB, particulate tubercle bacilli; HBsAg, hepatitis 
B surface antigen; SI, stimulation index; ND, not done.
5LT vs DH
(a) CONTROL Rh -  TFQ
' •
.2» « o -------1-------1-------1-------1-------1-------1 -------1-------1-------1-------1-------1------- I
§ J j  0 1+ 2+ 3+ 4+  5t- 0 1+ 2+ 3+ 4+ 5+
o  _E
(b) IMMUNE Rh -  TF^
0 1 + 2 + 3 + 4 + 5 1 -  0 1+ 2+ 3+ 4+ 5+
SKI : ( 7 - 1 4  days) SK2 ; (14 -  27 days)
DH : histology ( 30 -  50 pg antigen)
Fig- 42. Relationship between the maximum LT- and DH-responses to 
k l h , ppd or HBsAg 1n (a) control and (b) immune transfer factor- 
treated monkeys.
LT, lymphocyte transformation test; DH, delayed hypersensitivity; 
Rh-TFo, dialysable rhesus transfer factor; SKI, first skin test; 
SK2, second skin test; e KLH: o PPD: A HBsAg; g7a positive LT 
and DH.
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Table 25. Relationship between the maximum LT and DH-responses to
KLH, PPD and HBsAg in transfer factor-treated monkeys.3
Kti-TFDb Animal conversions (SI > 2, DH >, l+)/animals usedc
Status LT & SKI LT & SK2
KLH PPD TB HBsAg Sum KLH PPD TB HBsAg Sum
Control 0/5 0/2 ND 0/4 0/11 1/4 0/1 ND 0/4 1/9
Immune 0/3 0/6 ND 0/2 0/11 0/3 0/6 ND 0/2 0/11
a From figures 42a-b.
b Rh-TFp, dialysable rhesus transfer factor.
c LT, lymphocyte transformation test done after Rh-TFQ injection(s); SKI, first skin test; SK2, second skin 
test; KLH, keyhole limpet haemocyanin; PPD, purified protein derivative of tuberculin; TB, particulate 
tubercle bacilli; HBsAg, hepatitis B surface antigen; SI, stimulation index; DH, delayed hypersensitivity; 
ND, not done.
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5.2.5 Relationship between the maximum LT and LMMI-responses 
to KLH, PPD or HBsAg (Fig. 43, table 26).
It is evident from figure 43 and table 26 that, none of the animals 
treated with control transfer factor converted for KLH, PPD or 
HBsAg when monitored with the lymphocyte transformation and the 
migration tests. When recipients of the immune transfer factor 
preparations were monitored, only 1 animal showed the double 
conversion of response to KLH, but none to PPD or HBsAg. Therefore, 
in contrast to the immunised monkeys (Section 5.1.5, fig. 36, 
table 23), there was a negative correlation between the transformation 
and migration tests in the transfer factor-treated monkeys.
5.2.6 Maximum LT dose-response to PHA (Fig. 44).
The figure reveals that, in 6 transfer factor-treated rhesus monkeys, 
there was a good dose-response to 5-100 ug/ml PHA, and the positive 
reactivity to each concentration was detected in all the recipient 
monkeys. The pattern of the dose-response for these animals was 
similar to that of the actively immunised animals, but the mean 
reactivity per concentration of PHA was greater 1n the transfer 
factor-treated animals than in the actively immunised ones (Figs.
44 cf. 38).
5.2.7 Elevation of LT-response to PHA (Fig. 45).
When the LT-tests were carried out with 100 pg/ml PHA, any time
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LT vs LMM1
■ ■ i
0 L 1 I I I I I | { I | | |
0 .4  0 .8  1 .2
Migration Index (Ml)
LMM1 : ( 100 j ig /m l antigen)
^9- 43. Relationship between the maximum LT- and LMMI- responses 
to KLH, PPD or HBsAg 1n (a) control and (b) Immune transfer factor- 
treated monkeys.
LT, lymphocyte transformation; LMMI, mixed leucocyte-macrophage 
migration; Rh-TFo, dlalysable rhesus transfer factor; • KLH: 
o PPD: A HBsAg;EZ3 positive LT and LMMI.
Table 26. Relationship betv/een the maximum LT and LMMI-responses
to KLH, PPD and HBsAg in transfer factor-treated monkeys.3
Rh-TFDb Animal conversions (SI > 2, MI < 0.8)/animals usedc
Status
KLH PPD
LT & LMMI 
TB HBsAg Sum
Control 0/4 0/2 ND 0/4 0/10
Immune 1/3 0/6 ND 0/2 1/11
3 From figures 43a-b.
b Rh-TFD , dialysable rhesus transfer factor.
Q
SI, stimulation Index; MI, migration index; LT, lymphocyte 
transformation; LMMI, mixed leucocyte-macrophage migration;
KLH, keyhole limpet haemocyanin; PPD, purified protein derivative 
of tuberculin; TB, particulate tubercle bacilli; HBsAg, hepatitis 
B surface antigen; ND, not done.
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Concentration of PHA (pg /  ml)
Fig. 44. Maximum LT dose-response to 5-100 pg/ml PHA 1n 6 rhesus 
monkeys treated with dlalysable rhesus transfer factor.
n, number of monkeys; vertical bars represent mean SI t SEM;
(*) stimulation Index of individual animals to 5-100 wg/ml PHA.
+
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e
|  Days offer
(Rh-TFp =  4 .5  -  5 .3  x 10^ lymphocytes)
- LT-response to 100 pg/ml PHA 1n 6 rhesus monkeys before 
and after one Injection of dlalysable rhesus transfer factor.
n, number of monkeys; vertical bars represent mean SI * SEM;
5kl» T*2, first and second skin tests done with KLH, PPD or HBsAg; 
shaded area, any time before rhesus dlalysable transfer factor 
¿ ^ _tfd ); (*) stimulation Index of Individual animals to 100 yg/ml
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before and 2 to 21 days after the administration of a single injection 
of transfer factor, the results in figure 45 were obtained. Before 
transfer factor, the mean reactivity was within the normal range 
(SI = 230), but 2 to 17 days after the transfer factor, though still 
within the normal range (Section 5.1.6: SI > 70 < 4250), there was 
uniform elevation of the mean reactivity to PHA (Mean SI > 370). 
However, by days 20 to 21, the LT-response had almost returned to 
that detected before the injection of transfer factor (Mean SI = 240).
r
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6. RESULTS OF THE IN VITRO STUDY OF DIALYSABLE LEUCOCYTE
TRANSFER FACTOR FROM MONKEY OR MAN.
An attempt has been made to determine whether transfer factor in vitro 
can confer and/or augment lymphocyte transformation responses to the 
antigens KLH and PPD in recipient cultures.
A "neoantigen" KLH (Section 2.10.1) was included in the study, since 
it is unlikely that the human donors of the "recipient" lymphocytes 
in vitro would have come into contact with this antigen. Thus, in 
experiments where an attempt was made to transfer KLH-sensitivity 
in vitro with dialysable transfer factor, such "unsensitised" cells 
were considered ideal "recipients". In contrast, tuberculin PPD 
was used, because donors of the "recipient" cells would most likely 
be Mantoux-positive due to the United Kingdom's vaccination 
programme with BCG. Therefore, to demonstrate the augmenting activity 
of dialysable transfer factor in vitro, such "sensitised" cells were 
used as the recipients of transfer factor 1n culture.
The effects of "medium-dialysed" transfer factor (TF^), prepared 
from man or rhesus monkey as described before (H-TFDM or Rh-TF^: 
section 2.5.6 & fig. 3), were studied on cultured human leucocytes 
or purified lymphocytes (LC or PL: section 2.8). These "recipient" 
cells were obtained from Individuals who had been immunised or not 
immunised with KLH and were mainly Mantoux-positive (Section 2.4).
The concentrations of the antigens used to monitor the in vitro 
activity of transfer factor were 10, 33 or 100 wg KLH and 2 wg PPD
per culture. The augmenting effect of transfer factor on lymphocyte 
transformation, demonstrated by increased incorporation of tritiated 
thymidine by the "recipient" human lymphocytes in vitro, was 
calculated according to the method of Hamblin (1975: Fig. 46).
6.1 Augmentation of lymphocyte transformation to KLH with
rhesus or human transfer factor (Figs. 46-48, table 27).
Figures 47-48 show that, in 4 experiments, KLH-positive or KLH- 
negative rhesus transfer factor (obtained from monkeys immunised 
with KLH in FCA or only FCA respectively) was added to leucocyte 
cultures in the presence of 10 pg KLH. The "recipient" leucocytes 
in culture were obtained from individuals who were actively immunised 
or not immunised with KLH.
Figure 47 shows that there was no evidence for transfer of KLH- 
sensitivity by KLH-positive rhesus transfer factor, to unsensitised 
"recipient" human leucocytes in vitro. There was no significant 
difference in the mean disintegrations per minute for cultures 
incubated with 0.25 to 1.0 ml of KLH-pos1t1ve or KLH-negat1ve rhesus 
transfer factor alone or 1n the presence of 10 pg KLH.
In contrast, figure 48 shows the same KLH-positive or KLH-negat1ve 
rhesus transfer factor added to cultured "recipient" leucocytes, 
obtained from an Individual Immunised with KLH. Both KLH-positive 
and KLH-negative preparations of transfer factor caused augmentation 
of lymphocyte transformation to 10 pg KLH. Thus, such augmenting 
activity was not related to the sensitivity of the transfer factor
CALCULATION OF IN VITRO 
AUGMENTATION
Medium TF Antigen TF 
control alone alone + Ag
^9; 46- Calculation of the augmenting effect of a single volume of medium-dialysed 
in lymphocyte transformation (Hamblin, 1975).
Mean DPM of at least triplicate cultures is represented by the bars. Augmentation t< 
Aug. TFa„ = a (TF + Ag) minus A TF +AAg . TF = transfer factor, Ag = antigen, DPM = 
per minute.
transfer factor
i an antigen or 
disintegration
f^9- 47• Absence of in vitro transfer of KLH-sensitivity by (a) KLH-positive, or (b) KLH-negative 
rnesus transfer factor to unsensitised "recipient" human leucocytes.
RH-TFdh, rhesus monkey medium-dialysed transfer factor; DPM, disintegration per minute.
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^ : Æ r r h e1 u r S s % ? ? a r t o r ,"P'’<’C,te transfonMtio" t0 *  <•> «.H-posfti»e, and
rhesus monkey medium-dialysed transfer factor; 
on the bars represent augmentation in DPM x 10’3.
DPM, disintegration per minute; numbers
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Table 27. In vitro augmentation by rhesus or human transfer factor of tritiated
thymidine uptake by human lymphocyte stimulation with KLH.a
b ^DM <lonor
c Recipient culture dAug.: DPMX10"■3 KLH
(KLH type (KLH T/C ffdm cone.
sensitivity) sensitivity) 0.25 O cn 1 . 0 (ug/ml)
Ì .  R h - T F ^ g (+) PL (-) 2.2 3.3 7.4 -0.7 10
2. H-TFjj^ (-) PL (-) 1 . 0 -0.8 -0.4 2.9 10
3* Rh~TFDM/l6 (+) PL (-) 1.7 8.1 2.4 1 . 0 33
4 .  R h - T F DM/32 (-) PL (-) 1.7 6.3 7.9 -5.1 33
5. H-TFdm/1 (-) PL (-) 1.7 4.4 5.4 -3.8 33
6 .  R h - T F p ^ ^ (+) LC (+) 13.1 26.7 29.2 10.9 100
7. R h - T F DM^ 1 7 (+) LC (-) 4.3 4.6 2.5 2.9 10 0
8- Rh-TFDM/33a (-) LC (-) 4.3 2.7 7.2 -6.7 100
9. Rh-TFM / 33a (-) LC (+) 13.1 18.5 29.0 0.1 100
a KLH, keyhole limpet haemocyanin.
b TFDM’ mediun-dialysed transfer factor; Rh-TF^, medium-dialysed rhesus transfer factor; H-TFDM, medium- 
dialysed human transfer factor.
c T/C = counts per minute with antigen (test) i  counts per minute without antigen (control); PL, purified 
lymphocyte culture; LC, leucocyte culture.
d Augmentation in disintegrations per minute calculated as in figure 46.
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donor to KLH. The optimum augmentation was observed with 0.5 ml of 
either preparation of transfer factor.
Table 27 shows the results of 9 other experiments with 3 batches 
of rhesus transfer factor (Rh-TFDM/16, Rh-TFDM/32, Rh-TFDM/17) and 
2 batches of human transfer factor (H-TFDM^2 , ) used at
0.25, 0.5 and 1 ml volumes. As in figure 48, augmentation of 
lymphocyte transformation to 10-100 pg KLH was caused by all batches 
of the rhesus or human transfer factor with at least one of the 
volumes of transfer factor used. However, depending on the KLH- 
sensitivity of the donor or the in vitro "recipient" of transfer 
factor, all batches of rhesus or human transfer factor also caused 
suppression of lymphocyte transformation to 10, 33 or 100 pg KLH. 
Such suppressive activity was caused by 0.25, 0.5 or 1.0 ml of the 
human transfer factor, but only by 1.0 ml of the rhesus transfer 
factor (Table 27: experiments 1, 2, 4, 5, 8 ).
The augmenting or suppressive effects were not donor-specific, 
since KLH-positive or KLH-negative rhesus transfer factor and KLH- 
negative human transfer factor preparations augmented or suppressed 
tritiated thymidine uptake by KLH-stlmulated lymphocytes in vitro.
6.2 Augmentation of lymphocyte transformation to PPD with
rhesus or human transfer factor (F1g. 49, table 28).
Figure 49 shows the results of 3 experiments with 2 batches of rhesus 
transfer factor and 1 batch of human transfer factor. Each transfer 
factor preparation was added, at different volumes (0.25 to 1.0 ml),
Recipient" SENSITISED to tuberculin PPD
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Fi2^ 49. Comparative augmentation of in vitro responses of sensitised human lymphocytes by (a-b) PPD- 
positive rhesus, and (c) PPD-negativeliormal human transfer factor preparations. '
" ^ iuir dia1ysed transfer factor; h-tfDM* human medium-dialysed transfer factor; 
DPM, disintegration per minute; numbers on bars represent augmentation in DPM x 10 "3.
to purified "recipient" human lymphocytes in vitro in the presence 
or absence of 2 ug PPD. The 2 rhesus donors of transfer factor 
were actively immunised with Freund's complete adjuvant with or 
without an antigen (Rh-TF^ : PPD +ve), whilst the human donor was 
Mantoux-negative (H-TF^ : PPD -ve). Both preparations of PPD- 
positive rhesus transfer factor and the one preparation of PPD- 
negative human transfer factor, like the KLH-system above (Section 
6.1), augmented lymphocyte transformation to 2 jig PPD in vitro.
In 1 experiment with rhesus transfer factor, the volume producing 
maximum augmentation was 0.25 ml (Fig. 49a), whilst in the other 2 
experiments with rhesus or human transfer factor the optimum volume 
was 1.0 ml (Figs. 49b-c).
Table 28 shows the results of 5 other experiments with 2 batches of 
PPD-positive rhesus transfer factor (Rh-TF0M/16’ R h - T F ^ ^ )  and 2 
batches of PPD-negative human transfer factor (H-TFDM/^, H"TFDM/,3) 
used at 0.25, 0.5 and 1.0 ml volumes.
All batches of rhesus or human transfer factor showed only an 
augmenting activity at all the volumes used, except for one batch 
of human transfer factor, which also showed a suppressive effect at 
0.25 ml volume (Table 28: experiment 5). The optimum volume 
producing maximum augmentation varied with the various batches of 
rhesus or human transfer factor.
The augmenting and/or suppressive effects caused by the human transfer 
factor were not donor-specific, since PPD-negat1ve transfer factor 
augmented and/or suppressed trltlated thymidine uptake by PPD-
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Table 28. In vitro augmentation by rhesus or human transfer factor of tritiated
thymidine uptake by human lymphocyte stimulation with PPD.a
E
TFpM donor
c
Recipient culture
■a------------ IJ
Aug.: DPMX10 J PPD
(PPD
sensitivity)
type (Mantoux) T/C
0.25
tfdm (mls) 
0.5 1 . 0
cone.
(ug/mls)
Rh-TF^g (♦) PL ? 21.6 97.9 88.7 87.8 2
2. Rh-TF0M/34 (+) LC + 59.8 98.1 135.2 95.8 2
3. H-TFdm/1 (-) LC + 59.8 9.9 10.4 12.8 2
4* H_TFDM/1 (-) PL ? 7.6 33.9 62.9 86.0 2
5* H-TFDM/3 (-) LC + 35.1
00CO1 29.6 17.3 2
a PPD, purified protein derivative of tuberculin.
TFj^, medium-dialysed transfer factor; R^TF^, medium-dialysed rhesus transfer factor; H-TF^, medium- 
dialysed human transfer factor.
c T/C * counts per minute with antigen (test) * counts per minute without antigen (control); PL, purified 
lymphocyte culture; LC, leucocyte culture.
d Augmentation in disintegrations per minute calculated as in figure 46.
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stimulated lymphocytes in vitro. It was not possible to determine 
the donor-specificity of the augmenting activity of the rhesus 
transfer factor, because PPD-negative transfer factor was not used 
in any experiment.
6.3 Correlation of in vitro augmentation by rhesus or human
transfer factor and antigen sensitivity of the recipients 
(Figs. 50a-d).
Figure 50 shows correlation of the extent of in vitro augmentation 
by 0.25 to 1.0 ml transfer factor and the extent of sensitivity of 
the "recipient" human lymphocyte or leucocyte cultures to 10-100 jig 
KLH or 2 ug PPD.
Figures 50a and 50c show that, when the rhesus transfer factor was 
used, there was a linear relationship between the increasing degree 
of in vitro augmentation and the Increasing degree of the "recipient" 
culture-sensitivity to KLH or PPD. This correlation was higher and 
more significant for KLH (Fig. 50a: r ■ +0.7 P < 0.001) than for 
PPD (Fig. 50c: r * +0.6 P < 0.05). Similarly, figure 50b shows that, 
when the human transfer factor was used, the degree of augmentation 
also seemed to Increase with the Increasing degree of the "recipient" 
culture-sensitivity to KLH, but the number of tests was too few for 
this relationship to be statistically significant (n ■ 3, r ■ +0.6 
P > 0.1). In contrast, figure 50d shows that, the degree of 
augmentation by the human transfer factor decreased significantly as 
the degree of the "recipient" culture-sensitivity to PPD Increased 
(r = -0.7, P < 0.05).
RECIPIENT SPECIFICITY
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(a) Rh-TFDM : KLH-ve (b) H-TFn ju  : KLH-ve
or M (normal)
KLH+ve
o
-S' (c) Rh-TFDM : PPD+ve (d) H-TFDM : PPD-ve
g (normal)
Log DPM : "reclplan t" culture response to KLH or PPD
Fig. 50. Correlation of 1n vitro augmentation by human or rhesus 
transfer factor and recipient sensitivity to (a-b) KLH, or 
(c-d) PPD.
From figures 48-49 and tables 27-28. Rh-TFoM or H-TFd m , medium- 
dialysed rhesus or human transfer factor; DPM, disintegration per 
minute; n, number of tests with different volumes of transfer factor; 
r, sample correlation coefficient; P, level of significance.
Therefore, the in vitro augmenting activity of rhesus or human 
transfer factor was "recipient-specific", because there was a 
significant linear relationship between the degree of augmenting 
activity by rhesus or human transfer factor and the degree of 
"recipient" cell-sensitivity to KLH and/or PPD (Figs. 50a, c, d).
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7. RESULTS OF THE PRELIMINARY BIOCHEMICAL ANALYSIS OF
DIALYSABLE LEUCOCYTE TRANSFER FACTOR FROM MAN OR MONKEY
7.1 Fractionation of transfer factor on Sephadex G-25.
Crude transfer factor was prepared by "vacuum-dialysis" of human 
peripheral blood leucocytes (H-TFyp), rhesus monkey peripheral blood 
leucocytes (Rh-TFy^gj) or pooled lymph-node and spleen cells 
(Rh-TFyjyLBj) (See section 2.5.7, fig. 3). Each preparation was 
fractionated on column(s) of Sephadex G-25 as described before 
(Section 2.9), and an attempt was made to compare some of the 
fractionation properties of the above transfer factor preparations.
The extinction of each fraction was measured at 260 nm, predominantly 
to detect derivatives of nucleic acids, and at 280 nm, chiefly to 
detect derivatives of proteins (E260, ^280^' *n add^ti°n » the elution 
volume (Vg) of each fraction 1n the gel was measured and the ratio 
of the elution volume to total bed volume (Vt) was determined (Vg/Vt). 
To characterise the behaviour of each fraction, without reference to 
the size of the column, the partition coefficient (Kav) between the 
liquid phase and the gel phase was calculated. This was calculated 
according to the method of Krohn et al (1976b, 1977), by the 
formula Kay - (Vg - VQ) ♦ (Vt - VQ ) or (Vg - VQ) ♦ Vj. where VQ 
represented the void or dead volume, Vt the total volume of the gel 
bed, Vi the Inner volume. Thus, compounds adsorbing to the gel have 
Kflv values of greater than 1.0, whilst non-adsorbing substances 
have K values of less than 1.0.
7.1.1 Normal transfer factor from human or rhesus monkey blood 
or rhesus lymph-nodes and spleen (Figs. 53-56, table 29).
Crude dialysable transfer factor, prepared from normal human blood
8leucocytes, containing 6 x 10 lymphocytes, was dissolved in 0.5 ml 
volatile buffer and fractionated on one column of 1.6 x 90 cms of 
Sephadex G-25 (Kindly carried out by Mr. Brian Ellis, Immunology 
Division, Kennedy Institute of Rheumatology, Hammersmith, London)
(Section 2.9.1). These leucocytes were contaminated with red blood 
cells and, on average, contained about 17% polymorphs (Section 2.5.3).
O
Similarly, transfer factor, prepared from 5 x 10 lymphocytes of 
normal rhesus monkey blood or pooled lymph-node and spleen leucocytes, 
was dissolved in 2 mis volatile buffer and fractionated on 2 serially 
connected columns of 1.6 x 90 cms each (Section 2.9.1). The rhesus 
leucocytes were contaminated with red blood cells and, on average, 
contained less than 50% or 3% polymorphs respectively (Sections 2.5.1 & 
2.5.2). Such fractionation of human and rhesus monkey transfer 
factor preparations led to the following results.
Figures 51-53 show that, depending on the species and lymphocyte 
source of transfer factor, fractionation resulted in 9 to 11 
distinguishable elution peaks. The appropriate tubes were recombined 
to give 9 to 11 fractions, with various elution volumes. Figure 51 
shows that, for the human transfer factor (H-TFyD), there were 9 
fractions, coded A - H, with fraction B being divided Into B1 and B2. 
Similarly, figure 52 demonstrates that, for the rhesus transfer 
factor prepared from blood (Rh-TFVD^BI), there were 10 fractions, 
designated BI-BX. Figure 53 shows that fractionation of the rhesus
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H U M A N  TRANSFER FACTOR
(H - V
— 3.‘- ^ • Sephadex G-25 fractionation of dialysable transfer factor from normal human blood (H-TFyp).
A singie cdain of 1.6 x 90 cms was used and 0.9 ml aliquots collected (Section 2.9.1). Vn = void
volume (35 mis); Vt * total bed volume (95 mis); “ - --------------  **' 0Ve = elution volume (41 - 162 mlsj.
RHESUS TRANSFER FACTOR 
( Rh "TFvd/b| ^
b m —  E 260 nm
Two serially connected columns of 1.6 x 90 cms each were used and 2.7 mis aliquots collected,
volume (190 mis); Vt = total bed volume (390 mis); Ve = elution volume (211-729 mis).
Vn = void
RHESUS TRANSFER FACTOR 
< Rh- TFVDA S I )
l!? Seri?ily ?°?necied columns of 1.6 x 90 cms each were used and 2.7 mis aliquots collected,
volume (190 mis); Vt = total bed volume (390 mis), Ve = elution volume (192-729 mis).
void
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transfer factor, derived from pooled lymph-nodes and spleen 
(Rh-TFVD/LSI), resulted in 11 fractions, coded LI - LX, with 
fraction LIV being divided into LIVa and LIVb.
Table 29 shows the preliminary fractionation properties of all the 
3 transfer factor preparations. The absorption ratios E26c/E280 
of fractions A - C and H of the human transfer factor and 
fractions BI - BVI and BVIII - BX and LI - LX of the 2 rhesus 
transfer factor preparations were less than 2, suggesting presence 
of protein components. In contrast, all the other fractions, be 
it human or rhesus in origin, had absorption ratios of more than 2, 
suggesting presence of nucleic acid components. Fractions F and G 
of the human transfer factor and fraction BVII of one rhesus 
transfer factor (Rh-TFyD^Bj) had high ratios of 4.14, 6.54 and 
4.39 respectively.
The table also shows the partition coefficient (K 1 values of theGV
different fractions. Depending on the lymphocyte source, the first 
5 to 6 fractions of each transfer factor preparation had values of 
1.0 or less, suggesting the presence of non-adsorbing substances.
In contrast, all the other fractions had coefficient values of 
more than 1.0, suggesting the presence of substances which adsorbed 
to the gel column.
Elution ratios Ve/Vt shown 1n the table Indicated that, depending 
on the lymphocyte source, the first 5 to 6 fractions eluted within 
the total bed volume since ratios were either equal to or less than 
1.0. This was not so for the rest of the fractions (V0/Vt >1).
Table 29. Summary of data for Sephadex G-25 fractionation of dialysable 
leucocyte transfer factor preparations from man and monkey.
Fr
ac
ti
on
V tfvd
Fr
ac
ti
on
★
*h"TFVD/BI
★
Rh'TFVD/LSI
E260/E280 > V Vt
■
E260/E280 Kav V Vt
Fr
ac
ti
oi
E260/E280 Kav ve/vt
A 0.88 0.10 0.46 BI 1.47 0 . 1 1 0.54 LI 1.29 0 . 0 1 0.49
B1 1.09 0.28 0.58 BII 1.40 0.27 0.62 : LI1 1.48 0.19 0.58
B2 1.20 0.40 0.66 biii 1.27 0.28 0.69 ' L111 1.40 0.38 0 . 6 8
C 1.19 0.53 0.74 - - - - } LIVa 1.33 0.56 0.77
D 2.08 0.75 0.89 BIV 1.17 0.70 0.84 ' LIVb 1.24 0.70 0.84
E 2.00 0.92 1.00 BV 1.42 0.89 0.94 ! LV 1.60 0 . 8 8 0.94
F 4.14 1.15 1.16 BVI 1.64 1.28 1.14 J LVI 1.75 1.28 1.14
G 6.54 1.45 1.28 BVII 4.39 1.55 1.28 ' LVII 1.58 1.50 1.25
- - - - BV III TTTT 2 . 0 0 1.51 '  LVIII 1.13 2 . 0 0 1.51
- - - - BIX 0.82 2.36 1.70 J LIX 0.78 2.36 1.70
H 0.60 2.12 1.80 BX 0.90 2.70 1.87 ! LX 0.85 2.70 1.87
*
Dialysable leucocyte transfer factor preparations were obtained by vacuum-dialysis from normal donors:
human blood « H-TFyg, rhesus blood * Rh-TFVD^BI, pooled rhesus lymph-node and spleen cells = Rh-TFyD^LSj. 
Absorption ratio: ^60^280 = Extinction at 260 nm i Extinction at 280 nm.
Partition coefficient: Kay = (Vg - VQ) * (Vt - VQ). Elution ratio = Vg * Vt.
Abbreviations: Vg = elution volume (ml), V0 * void volume (ml), V^. = total bed volume (ml).
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Thus, this may suggest the presence of substances with different 
molecular weights.
Figures 54a-b show absorption spectra of the crude rhesus monkey 
transfer factor, prepared either from blood or mixed lymph-node 
and spleen cells. Both preparations revealed peak absorption at 
250-260 nm, suggesting presence of substances derived from nucleic 
acids. Concentration of these components was more marked in the 
transfer factor preparations from the rhesus blood, than that from 
the rhesus lymph-node-spleen cells. Such an analysis was not 
carried out for the human transfer factor preparation.
The above results of preliminary biochemical analysis of normal 
dialysable transfer factor preparations from man and monkey, as 
indicated by Sephadex G-25 gel filtration, therefore, revealed 
some species similarity of their elution properties.
RHESUS TRANSFER FACTOR
Optical density scanning of crude preparation of dialysable transfer factor derived 
t P) normal rhesus monkey blood (Rh-TFVD/BI) or (b) pooled lymph node-spleen, (Rh-TFVD/LSI).
O.D., optical density.
if
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8. DISCUSSION
8.1 Delayed hypersensitivity and the skin reactive factor 
(SRF): the DH-skin test as the in vivo indicator of 
cel 1-mediated immunity.
Delayed hypersensitivity is defined here as that in vivo
sensitivity characterised by the 24 to 48 hour clinical and
the 48 nour histological features already described (Section 2.6).
Transfer of delayed hypersensitivity from sensitised to non-sensitised 
guinea pigs and humans by means of lymphoid cells established 
delayed hypersensitivity as an in vivo manifestion of cel 1-mediated 
immunity (CMI) (Section 1.1.1: Landsteiner and Chase, 1942;
Chase, 1945, 1946; Cummings et al, 1947; Kirshheimer and Weiser, 1947; 
Lawrence, 1949, 1952). It has been suggested that soluble substances 
produced by activated lymphocytes mediate delayed hypersensitivity 
skin reactions to an antigen (Bennett and Bloom, 1968). They showed 
that PPD stimulated cultures of lymphocytes, from guinea pigs with 
delayed hypersensitivity to tuberculin, produce a soluble substance 
MIF into the supernatant. This MIF-conta1n1ng supernatant could 
inhibit the migration of normal guinea pig peritoneal exudate cells. 
Sephadex G-100 chromatography of the supernatant produced a fraction 
containing MIF, which was proteinaceous with an estimated average 
molecular weight of 67,000. Following an Intradermal injection into 
normal guinea pigs, the same fraction produced skin reactions which 
were clinically characterised at 4 hours by erythema and Induration, 
and histologically at 24 hours by monocytic Infiltration. Ant1gen-cell 
interaction, therefore, produces SRF as well as MIF (Dumonde et al,
1969; Pick et al, 1969). This SRF lymphoklne may mediate delayed 
cutaneous hypersensitivity (Dumonde, 1970; Dumonde and Ma1n1, 1971).
Based on the clinical and histological criteria of delayed hypersensitivity
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(Section 2.6), this thesis reports on the extent of such a reaction 
in the actively immunised and dialysable transfer factor-treated 
monkeys (Section 3). The conversion rates of the clinically and/or 
histologically acquired delayed hypersensitivity to KLH, PPD or 
HBsAg, the suitability of the chest as the skin test area, and the 
specificity of the reactions in the immunised and transfer factor- 
treated monkeys are discussed below.
8.1.1 Acquisition and antigen-specificity of DH-skin test
reactivity in immunised monkeys: active sensitisation.
Clinically and/or histologically positive 24-48 hour delayed hyper­
sensitivity to various antigens have previously been described in immune 
rhesus monkeys (Phillips et al, 1970; Baram et al, 1971; Mackler et al, 
1971; Maddison et al, 1972; Zanelli and Adler, 1975; Dumonde et al, 
1976). In the representative immunised animals here, clinically 
positive 24-48 hour delayed hypersensitivity was seen In the majority 
of skin tests. The conversion rates for delayed hypersensitivity were 
14 out of 16 tests (88%) with 10 yg PPD in 4 animals, 11 out of 12 
tests (92%) with 10 yg HBsAg in 3 animals and 12 out of 12 tests (100%) 
with 10 yg KLH 1n 3 animals (Section 3.1.1: figs. 4a-c). The mean 
clinical conversion rate with all these antigens was 93%, a rate 
comparable to that of 82% observed for PPD by Baram et al (1971) 1n 22 
BCG-immunised animals. However, these conversion rates are 1n contrast 
to that (0%) observed by others who were not able to clinically 
demonstrate delayed hypersensitivity to Schistosoma antigen or PPD 1n 
any of the 8-29 monkeys either Infected with the parasite or various 
mycobacteria or immunised with adult Schistosoma worm extract 1n
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FCA (Maddison et al, 1971, 1972). It therefore seems that 
clinical evaluation of skin tests for delayed hypersensitivity, 
in this species, can produce inconsistent results. As a result, 
like others, (Zanelli and Adler, 1975) clinical observations 
for delayed hypersensitivity were routinely followed with 
48 hour histological examination of biopsies (Section 2.6).
Histologically positive 48 hour delayed hypersensitivity 
skin test reactions to KLH, PPD or HBsAg were observed. The 
reactions occurred after the first or the second skin test at 
1 to 4 and 2 to 6 weeks respectively in all the 60 tests carried 
out in 17 actively immunised monkeys (Section 3.1.2: fig. 5b; 
section 3.1.3: table 13). Similar conversion rates were 
observed by others for sensitising antigens in the few rhesus 
monkeys immunised with FCA containing trinitrophenyl-KLH (Mackler 
et al, 1971) and immunised with BCG (Zanelli and Adler, 1975).
The difficulties in interpreting the appearance of clinically 
positive skin test reactions at 48 hours, 1n some animals with 
PPD or HBsAg (Section 3, fig. 4b: monkeys H34a, H42 after second 
skin test with PPD; fig. 4c: monkey H42 after the first skin 
test with HBsAg) were overcome by histological examination of the 
skin biopsy. The lack of clinically positive reactions 1n some 
tests was probably related to the low levels of histologically 
positive reactions detected (DH : 1+ to 3+). This view 1s 
consistent with a report by Baram et al (1971), who have also 
described difficulties 1n skin testing and the lack of consistent 
appearances of clinically positive delayed hypersensitivity skin 
test reactions for low levels of delayed hypersensitivity 1n 
sensitised rhesus monkeys. These difficulties may have been 
associated with the site of the skin test (Chase, 1976).
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Intradermal skin tests in the rhesus monkey have been carried out 
on the eyelid (Baram et al, 1971; Maddison et al, 1971) and on the 
chest or the back (Maddison et al, 1972). In these experiments, 
intradermal skin tests were carried out on the chest area 
(Section 2.6, plate 3). Chase (1976) has said that, in screening 
African-imported monkeys the chest is not proven to be a good 
test area for delayed hypersensitivity. In this study, the 
majority of the tests in the immunised animals showed reactivity. 
Clinically the cumulative 24 to 48 delayed hypersensitivity reaction 
was detected in 38 out of 40 tests (95%) (Section 3.1.1: figs. 4a-c), 
whilst histologically the cumulative 48 hour biopsies revealed 
active delayed hypersensitivity in 60 out of 60 tests (100%)
(Section 3.1.2 : fig. 5b). Such high clinical and histological 
reactions indicate that the chest area is a suitable area for skin 
testing the immunised animals according to the protocols used 
(Section 2.1: figs. la-d). This was supported by the evidence for 
good dose-responses to 2 of 3 skin test antigens. Histologically,
30pg PPD or HBsAg produced a more marked mean delayed hypersensitivity 
response than 10pg PPD or HBsAg (Section 3.1.2: fig. 6). Unlike 
the intrapalpebral skin tests, recommended by Chase (1976) and 
carried out by some workers in this species (Baram et al, 1971; 
Maddison et al, 1971), the chest area has some advantages not shared 
by the eyelids.The chest does not limit the number of skin tests 
to one or two antigens, or to a few dilutions, or only to clinical 
examinations. It provides a relatively large area which can be 
used for many skin tests and can easily be blopsled for 
histological studies.
Two comparisons may be considered for assessing the antigen- 
specificity of delayed hypersensitivity reactions in the immunised 
animals. The reactions can either be compared with those produced 
by the same antigens in other naive control animals (Baratri et al,
1971) or with those produced with unrelated antigens in the same 
animals (Maddison et al, 1972). To determine antigen-specificity 
of the acquired delayed hypersensitivity to KLH.PPD and HBsAg in 
the immunised animals reported here, skin tests with the same 
antigens were carried out in 2 saline-injected normal rhesus 
monkeys as controls. Comparison of the results showed a highly 
significant difference between the control (naive) and immunised 
animals in their conversion of the skin test from negative to 
positive delayed hypersensitivity after the first or the second skin 
test taken either separately or together (Section 3.1.3: table 13, 
PcO.OOl). In agreement with this report, similar antigen-specific 
acquisition of delayed hypersensitivity responses have been reported 
by Baram et al (1971) in rhesus monkeys immunised with BCG or 
infected with mycobacterium tuberculosis, and by Maddison et al
(1972) in animals infected v/ith Schistosoma mansoni or mycobacteria. 
However, as in this study, Baram et al, did not carry out skin tests 
in the immunised animals with an unrelated (non-specific antigen), 
but compared their results with skin tests done 1n naive control 
animals.
Thus, immunisation of rhesus monkeys with FCA, with or without 
KLH or HBsAg, seemed to Induce specifically active sensitisation 
For delayed hypersensitivity skin test to an antigen. Such 
sensitisation could qualitatively and quantitatively be monitored 
with intradermal skin tests on the chest area. These findings led
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to the use of such skin tests to monitor delayed hypersensitivity 
in rhesus monkeys treated with homologous dialysable transfer factor.
8.1.2 Acquisition and specificity of DH-skin test reactivity 
in transfer factor-treated monkeys.
Transfer factor often fails to transfer delayed hypersensitivity 
responses clinically in rhesus monkeys (Maddison et al, 1972;
Zanelli and Adler, 1975). In support of this observation, there 
were low cumulative conversion rates for clinical observation 
of skin tests. Only 1 out of 23 (4%) skin tests converted in 
animals treated with control dialysable transfer factor, ie. 
transfer factor normal or unrelated to test antigen (Section 3.2.1: 
table 14, monkey H38; KLH: induration diameter = 5.5mms), and 4 
out of 53 (8%) skin tests converted in recipients treated with 
immune dialysable transfer factor i.e. transfer factor immune to 
test antigen (Section 3.2.1: table 15, monkey H36, KLH: induration 
diameter = 7-10mms, PPD; induration diameter = 12-13mms). In contrast 
to these conversion rates, those rates reported by Steele et al
(1976) for clinically positive delayed hypersensitivity skin tests 
were lower for control dialysable transfer factor (unrelated to 
test antigen) and higher for immune dialysable transfer factor. In 
3 other nonhuman primate species as recipients, these investigators 
observed cumulative conversion rates of zero out of 17 (0%) and 19 
out of 42 (45%) with control (unrelated to test antigen) and 
immune human dialysable transfer factor preparations respectively.
A higher cumulative clinical conversion rate of 32 out of 42 
tests (80%), for delayed hypersensitivity to E1mer1a 
bovis and PPD has recently been reported by Klesius
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and Fudenberg (1977) in 17 cattle recipients of unfractionated 
and alcohol-precipitated immune homologous dialysable transfer 
factor. Thus, the source of lymphocytes and the procedure for 
preparation of the transfer factor and the species sensitivity of 
the recipients are possible factors influencing the differences 
in the clinical conversion rates after administration of 
dialysable transfer factor. In addition, skin testing of 
recipients before treatment with dialysable transfer factor 
(Steele et al, 1976; Klesius and Fudenberg, 1977) may have played 
a role in the higher clinical rates of conversion of negative 
to positive delayed hypersensitivity.
Histologically some transfer of delayed cutaneous hypersensitivity 
responses occurred in the course of the study in the recipients 
of dialysable transfer factor (Section 3.2.3: table 16). In 
all the 12 recipients, the cumulative histological conversion 
rate of 4 out of 18 (22%) skin tests occurred with the control 
transfer factor (normal or unrelated to test antigen). In contrast, 
a higher cumulative conversion rate of 17 out of 32 (53%) skin 
tests occurred with the Immune transfer factor. These cumulative 
rates are comparable to those found by others with 4 out of 23 test 
conversions (17%) with control homologous dialysable transfer factor 
and with 8 out of 12 test conversions (67%) with immune dialysable 
rhesus transfer factor 1n 3 rhesus recipients (Maddison et al, 1972).
However, these results are contrary to those for three rhesus 
monkeys used by ZanelH and Adler (1975). These workers reported 
no conversion 1n 8 tests with control (unrelated to test antigen) 
dialysable rhesus transfer factor, but obtained a higher conversion
I
rate of 13 out of 15 tests (87%) with the immune dialysable 
transfer factor. Similarly, Gall in and Kirkpatrick (1974), 
after administration of dialysable human transfer factor 
into 3 rhesus monkey recipients, observed no conversion in 8 
tests after the control unrelated dialysable transfer factor, 
but 5 out of 7 test conversions (71%) after the immune dialysable 
transfer factor. Therefore, higher rates of conversion were 
indicated histologically rather than clinically (see above).
The delayed hypersensitivity results obtained here by 
histological examination of skin biopsies were considered more 
reliable and used to question the possible effect of skin testing 
the recipients before the administration of dialysable transfer 
factor.
It has been reported that, guinea pigs treated with dialysable 
human transfer factor, only acquire delayed hypersensitivity 
skir test reactivity when they have been pre-exposed or 'primed' 
to subsensitising doses of antigen (Welch et al, 1976a,b).
In the experiments reported here none of the recipient rhesus 
monkeys were previously skin tested with HBsAg. One recipient 
was skin tested with KLH, but it did not convert to this antigen.
In contrast, all the recipients were previously Mantoux tested by the 
suppliers. Thus, the majority of the recipients were not primed 
with HBsAg or KLH, but all were with tuberculin. After Immune 
transfer factor administration, 2 out of 9 first skin tests 
converted to KLH and HBsAg, and 5 out of 9 to PPD (Section 3.2.3: 
table 16). Thus, there seems to be some Indication that priming 
might increase the rate of the first skin test conversion after 
the administration of rhesus dialysable transfer factor.
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This is perhaps supported by the observation that the 
cumulative rate of conversion to antigen increased after 
control or immune transfer factor at the time of the second 
skin test (Section 3.2.3: table 16). The use of delayed 
hypersensitivity skin test, in either primed or unprimed 
recipients, has not unequivocally established the biological 
specificity of the in vivo activity of transfer factor (Section 1.5). 
Despite this, however, the skin test was used here to investigate 
the problem of specificity. The in vivo specificity of the 
rhesus dialysable transfer factor throughout this thesis is 
discussed in terms of antigen-sensitivity of the donor ("Donor- 
specific"). Donor-specific acquisition of reactivity is defined 
as that sensitivity transferred to an antigen to which the 
donor is sensitised. On the basis of this definition, a 
comparison of the cumulative results of control and test 
recipients indicated that, the acquisition of delayed hypersensitivity 
after the first and the second skin test together, in transfer 
factor-treated monkeys, seemed to be non-specific, i.e. not related 
to antigen-sensitivity of the donor(s) (Section 3.2.3, table 16: 
P>0.05). This non-specificity is supported by similar findings 
of others in man (Section 1.5.1 : Levin et al, 1971; Spitler et al, 
1972; GriscelH, 1975) (Khan et al, 1975; Krohn et al, 1976a;
Khan, 1977) and the rhesus monkey (Section 1.4.1: Maddison et al, 
1972). Rhesus dialysable transfer factor, like the human material, 
may therefore contain components which augment non-spec1f1cally 
delayed hypersensitivity skin tests. The apparent non-spec1f1c1ty 
of rhesus dialysable transfer factor seen here can be interpreted 
in two ways. Firstly, that repeated skin testing alone may result 
in the conversion of the skin test from negative to positive
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(Baram et al, 1966; Maini et al , 1976). Secondly, that repeated 
skin testing may bring out the dormant nonspecific reactivity 
induced by dialysable transfer factor (Khan, 1977). The nonspecific 
activity was found here to PPD after the first skin test, whilst 
against KLH and HBsAg only after the second skin test (Section 3.2.3: 
table 16). This difference between PPD and the other antigens may 
be explained as follows. Firstly, the normal control dialysable 
transfer factor was prepared from cell pellets made from a monkey 
recently imported and skin tested three times with old tuberculin 
and was therefore primed with this antigen. Secondly all recipient 
animals were also probably primed with tuberculin, since they are 
routinely screened for tuberculosis by a Mantoux test prior to 
laboratory use. Thus, in this work, the delayed skin test reactivity 
to PPD in the recipients does not seem to be an appropriate test 
for the determination of the specificity of the in vivo activity 
of the rhesus dialysable transfer factor. For the other antigens 
(KLH, HBsAg), the nonspecific effects were not detected after the 
first skin test, but were after the second. This may be because 
repeated skin testing may have resulted 1n the induction of 
delayed hypersensitivity and/or dialysable transfer factor had 
nonspecific in vivo activity. The former was unlikely in this 
study because the two normal saline-injected monkeys were skin tested 
twice with KLH or HBsAg and showed no histological evidence of 
delayed hypersensitivity (Section 3.1.3: table 13). Thus the rhesus 
dialysable transfer factor may have had nonspecific activity towards 
these antigens. However, the number of DH-skln tests with control 
transfer factor are too few for meaningful detailed study of the 
in vivo specificity of the thesus dialysable transfer factor with 
such selective antigens.
Therefore, DH-skin test on the chest of the rhesus monkeys 
seemed to be an appropriate in vivo test of CMI for detecting 
antigen-specific active sensitisation of animals with FCA, with 
or without an antigen. It does not appear to be an appropriate 
test for monitoring CMI in transfer factor-treated monkeys, or 
for determining the in vivo specificity of transfer factor in 
this species.
8.2. Cellular hypersensitivity and the macrophage or leucocyte 
inhibition factor (MIF, LIF): the LMMI-test as an in vitro 
indicator of cell-mediated immunity.
Cellular hypersensitivity is indicated here by significant 
migration inhibition of indicator cells in vitro. Several 
in vitro cell migration tests have been de:;ribed to measure 
cellular hypersensitivity to antigens in man and animals.
These are the direct and indirect macrophage or leucocyte 
migration tests and the mixed cell migration test (LMMI).
In 1932, Rich and Lewis reported that tuberculin PPD specifically 
inhibited the in vitro migration of macrophages from explants 
of spleen and lymph nodes taken from guinea pigs with delayed 
hypersensitivity skin reaction to PPD, but PPD had no effect on 
explants from normal animals. Thus, they lay the foundation for 
the development of the in vitro cell migration assay system of 
cellular hypersensitivity as a parameter of delayed hypersensitivity 
reaction in vivo. In 1962, George and Vaughan Introduced the 
technique of Inhibition of migration of guinea pig peritoneal
exudate cells ( > 70% macrophages) from capillary tubes. This 
correlated with delayed hypersensitivity to PPD and egg albumin 
in guinea-pigs immunised with BCG or egg albumin in FCA. These 
studies were soon confirmed and extended by others in the 
guinea-pig system (David et al, 1964a, b; Bloom and Bennett,
1966, 1968; David, 1966, 1968). It was found that only as few 
as 10 - 20% of the peritoneal exudate cells need be specifically 
sensitive to inhibit the migration of the whole population of 
peritoneal exudate cells (David et al , 1964b). Bloom and Bennett 
(1966) and David (1966) found that the macrophages, and not the 
lymphocytes, constitute the migrating indicator cells of the 
peritoneal exudate cells, but the sensitive lymphocytes were 
necessary for inhibition to occur. The sensitive lymphocytes, 
during incubation with specific antigen, elaborated a soluble, 
non-dialysable and heat-stable substance which specifically inhibited 
the in vitro migration of normal guinea-pig peritoneal exudate cells, 
presumably the macrophages, and reflected the state of delayed 
hypersensitivity in vivo (Bloom and Bennett, 1966; David, 1966,
1968). This mediator was given the name migration inhibition factor 
i.e. MIF (Bloom and Bennett, 1966). MIF mediates the inhibition of 
migration of the indicator cells either alone or by Interaction 
with antigen (Bennett and Bloom, 1967), and 1s synthesised by the 
sensitive lymphocytes upon contact with the specific antigen 
(Bloom and Bennett, 1968; Dumonde et al, 1969).
Thor and Dray (1968) used the direct capillary macrophage 
migration test for studies in man and found that the specific
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inhibition of macrophages, obtained from lymph nodes of 
sensitised human subjects, correlated with delayed 
hypersensitivity reaction to PPD or histoplasmin. However, 
the relative inaccessibility of human macrophages made it 
difficult to apply such direct macrophage capillary tube 
technique to man. Thus, in an attempt to develop a more 
useful clinical test, Thor et al, (1968) developed an indirect 
cell migration system and first showed MIF in man, as opposed 
to guinea pig. Human peripheral blood lymphocytes, obtained 
from sensitised subject and incubated for 72 hours with PPD 
or histoplasmin or coccidioiodin, produced MIF in the 
supernatant. This specifically inhibited the migration of 
normal guinea pig macrophages. They suggested that this 
factor in man was analagous to that in the guinea pig, and 
since the human MIF inhibited guinea pig macrophages, it lacked 
species specificity. Such an in vitro detection of cellular 
hypersensitivity has been confirmed by others 1n man with PPD, 
streptokinase-streptodornase and Candida antigens (Rocklin et al, 
1970a, b). This Indirect MIF assay has proved to be slow for 
clinical tests and led to the development of a direct 1n vitro 
assay system.
Some Investigators have shown that human buffy coat cells can 
also serve as Indicator cells. In 1968, Soborg demonstrated 
that the 24-hour migration of human peripheral leucocytes, 
obtained from a human subject after primary Immunisation with 
killed Brucella bacteria, was Inhibited 1n the presence of the
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specific antigen. He suggested this direct and rapid test 
as a useful in vitro test of specific de'ayed hypersensitivity 
in man. These findings were later confirmed and extended by 
Bendixen and Soborg (1969) with PPD, Brucella or "organ-specific" 
antigens, by Curtis and Hersh (1973) with KLH, by Maini et al
(1973) with particulate TB, and by others with HBsAg (Yeung- 
Laiwah et al, 1973; Reed et al, 1974: Lee et al, 1975).
Clausen (1971) developed a leucocyte migration test in agarose 
and demonstrated a correlation between inhibition of migration 
and delayed hypersensitivity skin reaction to PPD. He showed 
such agarose plate cultures to be more sensitive than the 
capillary tube technique for the PPD system, and to have the 
advantage of using less human leucocytes and less antigen than 
the capillary leucocyte migration method. The migration 
indicator cells in the leucocyte capillary technique have been 
identified as both mononuclear and polymorphonuclear leucocytes 
(Bendixen and Soborg, 1969; Rosenberg and David, 1970; Clausen,
1971; Read and Zabriskie, 1972).
Like the capillary macrophage migration test, 1t was suggested 
that a mediator, similar to or the same as MIF, may also cause 
the in vitro inhibition of the leucocyte migration (Bendixen and 
Soborg, 1969). Recently, Rocklin (1974) purified the products 
of activated human lymphocytes by column chromatography. He 
showed that both the in vitro macrophage and leucocyte migration 
inhibition systems correlate with the in vivo delayed hypersensitivity 
to tuberculin PPD, streptoklnase-streptodomase and Candida, but 
are assay systems for two functionally and physically different 
lymphokines. One is MIF (M. wt. 23,000) and inhibits the
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migration of guinea pig macrophages or human monocytes, but 
not the human polymorphs. The other is the leucocyte 
inhibition factor or LIF (M. wt. 63,000), which inhibits 
the migration of human polymorphs, but not that of guinea pig 
macrophages or human monocytes.
There have been reports of difficulties in relating 
inhibition of leucocyte migration from capillaries or in 
agarose to delayed hypersensitivity in vivo (Kaltreider et al,
1969). In some cases, inhibition of leucocyte migration 
may be adversely affected by abnormalities of the indicator 
cells, which may even be absent or insufficiently sensitive 
(Marsman et al, 1972). Thus, another cell migration technique 
has been developed in an attempt to overcome some of these 
problems.
In 1970, Rajapakse and Glynn introduced an in vitro method 
as an assay of cellular hypersensitivity to PPD in man. They 
migrated, from capillaries, normal guinea pig peritoneal exudate 
cells (macrophages) mixed with purified human peripheral blood 
lymphocytes obtained from sensitive or normal subjects. They 
suggested that the guinea pig macrophages were the Indicator 
cells and found, that only as few as 3-15% of sensitive human 
lymphocytes were required to cause significant Inhibition of 
migration of the Indicator cells. A close correlation was 
reported between the mixed cell migration Inhibition and delayed 
hypersensitivity skin test reaction to PPD. Lack of inhibition
J»' * *
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of migration of normal peritoneal exudate cells alone or 
mixed with 3-15% normal or sensitive human lymphocytes, in 
the absence of PPD (controls), showed that mixing of such 
cells from two different species did not spontaneously cause 
inhibition of migration. The usefulness of such mixed lymphocyte- 
macrophage migration inhibition test, as an index of antigen- 
specific cellular hypersensitivity and, as an in vitro correlate 
of antigen-specific delayed hypersensitivity skin test, was 
later confirmed and extended by others in man with tuberculin 
PPD, Candida and streptokinase-streptodornase antigens (Marsman, 
et al, 1972; Marsman and Van der Hart, 1974).
A mixed leucocyte-macrophage migration test (LMMI) was used 
for this study, which was adapted to the rhesus monkey leucocytes 
(not pure lymphocytes), and extended to four antigens, KLH,
PPD, TB and HBsAg. Such a test was considered to have the following 
advantages over other migration tests.
Sabioncello et al, (1976) compared the direct and indirect 
macrophage migration inhibition with direct and Indirect leucocyte 
migration Inhibition 1n guinea pigs. It was found that in animals 
with delayed hypersensitivity skin test positive reactions to 
tuberculin PPD, all such systems behave alike and reflected the 
delayed hypersensitivity status of the test animals. Thus, they 
suggested that both macrophages and peripheral leucocytes seemed 
to be equally valuable for such in vitro cell migration tests of 
cellular hypersensitivity. It therefore seems advantageous to
combine both the macrophage migration and leucocyte migration 
tests, in the form of mixed leucocyte-macrophage migration 
test, to detect cellular hypersensitivity in vitro as an index 
of delayed hypersensitivity in vivo. The inhibition of the 
mixed leucocyte-macrophage migration probably indicates 
production of MIF and LIF. Thus, such a mixed cell migration 
test may be a more effective indicator of cellular hypersensitivity 
than either macrophage migration or leucocyte migration test 
alone. The other advantages of the LMMI test are as follows.
Compared with the direct macrophage migration test, the LMMI 
test does not use monkey peritoneal exudate cells (macrophages).
This could only be obtained by killing an expensive animal and 
would limit the number of tests to one. Compared with the direct 
capillary leucocyte migration test, the LMMI test does not need 
a large volume of blood to carry out many tests with multiple 
dilutions of different antigens. Compared with indirect MIF or 
LIF assay, the LMMI test is quick and relatively simple to set 
up.
In these experiments the LWII test was sequentially carried out 
in normal, actively immunised and transfer factor-treated rhesus 
monkeys (Sections 2.1 and 2.2), and used to monitor cellular 
hypersensitivity. The LMMI results obtained are shown above 
(Section 4), and the conversion rates for acquisition of 
Inhibition of migration and Its specificity to KLH, PPD, TB 
and HBsAg are discussed below on the basis of the criteria used 
to Indicate significant cellular hypersensitivity LMMI-reactivity 
(Sections 8.2.1-8.2.3).
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combine both the macrophage migration and leucocyte migration 
tests, in the form of mixed leucocyte-macrophage migration 
test, to detect cellular hypersensitivity in vitro as an index 
of delayed hypersensitivity in vivo. The inhibition of the 
mixed leucocyte-macrophage migration probably indicates 
production of MIF and LIF. Thus, such a mixed cell migration 
test may be a more effective indicator of cellular hypersensitivity 
than either macrophage migration or leucocyte migration test 
alone. The other advantages of the LMMI test are as follows. 
Compared with the direct macrophage migration test, the LMMI 
test does not use monkey peritoneal exudate cells (macrophages). 
This could only be obtained by killing an expensive animal and 
would limit the number of tests to one. Compared with the direct 
capillary leucocyte migration test, the LMMI test does not need 
a large volume of blood to carry out many tests with multiple 
dilutions of different antigens. Compared with indirect MIF or 
LIF assay, the LMMI test is quick and relatively simple to set 
up.
In these experiments the Lftll test was sequentially carried out 
1n normal, actively immunised and transfer factor-treated rhesus 
monkeys (Sections 2.1 and 2.2), and used to monitor cellular 
hypersensitivity. The LMMI results obtained are shown above 
(Section 4), and the conversion rates for acquisition of 
inhibition of migration and Its specificity to KLH, PPD, TB 
and HBsAg are discussed below on the basis of the criteria used 
to Indicate significant cellular hypersensitivity LMMI-react1v1ty 
(Sections 8.2.1-8.2.3).
8 . 2.1 Criteria for LMMI-reactivity to antigen (Tables 30-31).
In experiments carried out for this work a migration index of 
less than 0.8 (MI < 0.8: section 2.7.1) was used throughout as a 
criteria for positive LMMI-response or presence of cellular 
hypersensitivity. This index as a point of significance was 
selected for two main reasons. Firstly, a line drawn at 80% 
migration (MI = 0.8) clearly separated the majority of the actively 
sensitised monkeys from the normal control animals for all 
dilutions of KLH, PPD, TB and HBsAg (3-200 pg/ml: section 4.1.1: 
figs. 9 cf 10). Secondly, using similar or other cell migration 
techniques in man or guinea pigs, other investigators have also 
considered a Ml < 0.8 as indicative of acquisition of cellular 
hypersensitivity to various antigens (George and Vaughan, 1962; 
David et al, 1964a, b; Soborg, 1968; Rocklin et al, 1970a;
Marsman et al, 1972; Marsman and Van der Hart, 1974; Ramsey 
et al, 1976). Using this cut-off point the potentially toxic 
effects of the antigens on the migration test was excluded in 
order to validate the acquisition of cellular hypersensitivity 
LMMI-reactivity.
It has been reported that 1n similar tests with mixed human 
lymphocyte and normal guinea pig peritoneal exudate cells, the 
latter are the migrating indicator cells (Rajapakse and Glynn,
1970). In order to exclude the possible non-specific influence 
of direct antigen toxicity on the migration of these cells, normal 
guinea pig peritoneal exudate cells (e Average > 80% macrophages)
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were migrated from capillaries in the presence or absence of 
3-200pg/ml KLH, PPD, TB or HBsAg. Table 30 clearly shows almost 
total absence of non-specific toxic reactivity to the antigens 
used. Only 2 out of 64 tests (3%) showed toxic effects (200yg/ml 
KLH and HBsAg: MI<0.8). In the mixed leucocyte-macrophage 
migration tests carried out here, peripheral rhesus polymorphs 
and/or monocytes as well as the guinea pig macrophages could have 
been the indicator cells. To exclude the possible non-specific 
influence of direct toxicity of the antigens on the migration of 
the mixed indicator cells, normal rhesus leucocytes mixed with 
normal guinea pig peritoneal exudate cells were migrated from 
capillaries in the proportions and numbers described previously 
(Section 2.7.1). Table 31 shows that, 1n a total of 269 tests 
carried out with all the antigens at all dilutions, only 20 tests 
(7%) converted indicating minimal direct antigen toxicity on the 
mixed cells. Furthermore it indicated that significant inhibition 
(MI<0.8) was not due to the mixing of the normal cells from the two 
species. Thus, in the LMMI tests carried out in the actively 
immunised rhesus monkeys (Section 4.1.1: fig. lOa-d), the acquisition 
of apparent cellular hypersensitivity migration responses to various 
concentrations of the different antigens used was not due to the 
direct toxicity of the antigens on the normal guinea pig peritoneal 
exudate cells alone (Table 30), or mixed with the rhesus leucocytes 
(Table 31).
8.2.2 Acquisition and antigen-spec1f1city of LMMI-reactivity 
1n Immunised monkeys: active sensitisation (Table 32).
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Table 30 Migration indices (MI) of 18-20 hour capillary migration 
of normal guinea-pig peritoneal exudate cells (PEC) alone 
in the presence of antigens KLH, PPD, TB and HBsAg.3
Test antigens 
(ug/ml)
MI : 4x10^ macrophages/ml^ 
0) (2) (3) (4)
Mean MIC 
t SEM
KLH: 3 0.96 1.25 1.10 1.23 1.14 ! 0.01
33 1.12 1.19 1.01 0.99 1.08 t 0.01
100 1.03 0.96 0.80 0.95 0.94 Ì 0.00
200 0.97 0.92 0.64 0.83 0.84 t 0.01
PPD: 3 1.17 1.19 1.23 1.18 1.19 t 0.00
33 1.15 1.14 1.03 1.22 1.14 t 0.00
100 1.09 1.09 1.10 1.30 1.11 i 0.01
200 0.99 0.87 1.10 1.14 1.03 t 0.01
TB: 3 1.21 1.17 1.20 0.95 1.13 t 0.01
33 1.07 1.18 1.14 1.13 1.13 t 0.01
100 1.07 1.21 1.20 1.24 1.18 t 0.00
200 1.03 0.97 1.08 1.23 1.08 t 0.01
HBsAg: 3 1.16 1.24 1.19 1.12 1.18 t 0.00
33 1.14 1.18 1.19 1.20 1.18 t 0.00
100 0.86 0.99 0.96 0.97 0.95 t 0.00
200 0.75 0.87 0.86 0.91 0.85 t 0.00
aPEC on average contained > 80% macrophages.
Ml < 0.8 represents significant inhibition (underlined). 
SEM, standard error of the mean.
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Table 31 Total number of LMMI-tests with normal rhesus leucocytes 
mixed with normal guinea-pig peritoneal exudate cells 
(PEC) in the presence of antigens KLH, PPD, TB and HBsAg.a
Test antigens Total no. of +ve LMMI (MI < 0.8) testsb
3 33
(ug/ml)
100 200 E 3-200
KLH 3/22 1/22 4/21 1/15 9/80
(11%)
PPD 0/22 1/22 1/21 2/15 4/80
(5%)
TB 0/19 1/19 2/18 2/15 5/71
(7%)
HBsAg 0/9 0/2 0/10 2/10 2/38
(5%)
All 3/72 3/65 7/70 7/55 20/269
antigens (4%) (5%) (10%) (13%) (7%)
aLeucocytes and macrophages from both species were mixed as described 
before (Section 2.7.1).
bFrom figures 9a-d (Section 4.1.1).
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In immunised monkeys the conversion rates of the mixed 
cell migration tests varied from one antigen to another.
These rates were 50%, 51%, 59% and 79% for 3-200ug/ml 
HBsAg, PPD, TB and KLH respectively, making a cumulative 
mean rate of 60% (Section 4.1.3: table 17). Compared 
with the control unsensitised monkeys such conversion 
rates were highly significant (P<0.005 or <0.001).
Therefore, in the studies reported here, the mixed cell 
migration test, originally described by Rajapakse and Glynn
(1970) for detection of human hypersensitivity, was 
successfully adapted to detect the sensitivity of the rhesus 
monkey leucocytes.
It has been suggested that sequential, rather than a single, 
determination in the leucocyte migration test might provide 
a more significant index of cellular hypersensitivity against 
PPD in man (Ramsey et al, 1976). Here, sequential mixed cell 
migration tests in the immunised monkeys, showed that there was 
some variation in the onset and duration of the acquired 
LMMI-reactivity to an antigen. After immunisation the onset of 
reactivity varied from 2 to 5 weeks in different animals.
The reactivity was picked up on 1 occasion ("transient"), or 
repeatedly for 2, 3, or 4 weeks ("lasting") (Section 4.1.2, 
figs. 11-14). Thus, this transient or lasting reactivity 
might mean that carrying out only one migration test after 
immunisation is of little value, since 1t may not detect positive 
responses. In contrast, carrying out the test at weekly Intervals 
between 2 to 5 weeks of immunisation, probably will detect the
reactivity making the LMMI test more meaningful. However, such 
different patterns of responses might also indicate that different 
immunised animals respond differently to the sensitising antigens.
To determine whether repeated skin tests with an antigen induce 
inhibition of mixed cell migration, LMMI-tests were carried out 
in naive saline-treated rhesus monkeys, skin tested twice with 
KLH, PPD or HBsAg. Such an influence was considered unlikely 
in these experiments, since 30ug KLH and 50ng HBsAg did not 
significantly inhibit migration of the mixed cells in the LMMI-tests 
carried out with these antigens in these rhesus monkeys (Section 
4.1.2: figs. 11a, 14a). In contrast, when 30yg PPD was used for 
the skin test in such a naive monkey the migration of cells seemed 
to be significantly inhibited by PPD, but not by TB (Section 4.1.2: 
figs. 12a, 13a). The 100ug/ml concentration of PPD used for the 
LMMI test was non-toxic (Section 8.2.1: tables 30-31), and TB was 
a more effective antigen for inhibition of migration (Section 
4.1.1: figs. 10b cf 10c). It might be deduced from this that 
TB, rather than PPD, should have significantly inhibited migration 
of the mixed cells, if the skin test with PPD had induced true 
cellular hypersensitivity. However, this was not so and it may 
be concluded that skin tests do not seem to influence inhibition of 
mixed cell migration in these experiments.
The acquired cellular hypersensitivity, as indicated by LMMI-reactivity 
(MI<0.8) in the immunised rhesus monkey was antigen-specific 
(Section 4.1.3: table 17). The total number of positive LMMI tests 
carried out with 3-200ug/ml antigen 1n normal controls animals was
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compared with those in the immunised monkeys. There was a 
highly significant difference between the individual rates of 
conversion for KLH P<0.001) for PPD (P<0.001) for TB (P<0.001) 
and for HBsAg (P<0.005), and the cumulative rate of conversion 
for all these antigens (P<0.001). Thus, the acquired cellular 
hypersensitivity can be said to be antigen-specific. It has 
already been demonstrated that the direct toxicity of antigens 
on the migration cells was minimal (Section 8.2.1). It 1s also 
known that the immunised animals were naive before immunisation 
(MI>0.8) (Section 4.1.2: figs, llb-d, 12b-e, 13b-d, 14c-d). Thus, 
the antigen-specific cellular hypersensitivity must have resulted 
from active sensitisation of the immunised animals with FCA, with 
or without KLH or HBsAg.
To determine the true antigen-specificity of the LMMI-test 1n 
the immunised monkeys, tests may also be carried out with unrelated 
antigens. Such tests were only carried out in a few monkeys, but 
it was found that the LMMI-test was totally specific for tuberculin 
PPD or TB and HBsAg. In 3 monkeys immunised with FCA, with or 
without HBsAg, none of the tests non-specifically converted to an 
unrelated antigen (KLH) at any concentration used (Table 32). In 
contrast, some of the tests showed conversion to one or more 
sensitising antigens, at one or more concentration (Table 32). Thus 
like the direct or indirect macrophage migration test and leucocyte 
migration tests (David et al, 1964a; Rocklin, 1974), the direct LMMI 
test used here can assay for antigen-specific cellular hypersensitivity 
in this species.
Table 32 Antigen-specificity of LMTII-responses any time after 
immunisation of representative rhesus monkeys with 
FCA with or without HBsAg.3
Cone, of test Migration indices (MI) in monkeys immunised with*5
antigen FCA FCA/HBsAg FCA/HBsAg
(yg/ml) *(H33a) *(H42) *(H43)
KLH: 3 0.98 Ì .15 0.90
33 0.80 1.10 0.91
100 0.98 1.10 0.89
200 1.15 ND NO
PPD: 3 0.89 0.91 0.68
33 0.88 0.86 0.55
100 0.77 1.13 0.60
200 0.79 ND . ND
TB: 3 0.78 ND ND
33 0.84 ND ND
100 0.63 ND ND
200 0.71 ND ND
HBsAg: 3 ND 0.79 0.83
33 ND 0.75 0.73
100 ND 0.81 0.58
200 ND ND ND
aLMMI-tests read after 20 hours of Incubation (Section 2.7.1) 
^MI < 0.8 underlined and significant (Section 2.7.1).
NO, not done; * Code of monkeys.
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It was established that the LMMI-test under the conditions 
of these experiments was qualitatively a reliable in vitro 
technique of detecting antigen-specific cellular hypersensitivity 
in the actively sensitised monkeys. The acquired cellular 
hypersensitivity (LMMI:MI<0.8) did not seem to be significantly 
influenced by direct toxicity of an antigen in the LMMI-test 
or by repeated skin testing of monkeys. These findings, and 
the observation that the LMMI-test may also quantitively measure 
responses in the actively sensitised animals (Section 4.1.4: 
fig. 15), resulted in the application of this in vitro mixed cell 
migration test to monitor responses in rhesus monkeys injected 
with homologous dialysable transfer factor.
8.2.3 Acquisition and donor-specificity of LMMI-reactivity in 
transfer factor-treated monkeys: adoptive sensitisation 
(Tables 33-34).
Leucocyte or macrophage migration tests have successfully been 
used to detect conversion of cellular hypersensitivity to an 
antigen in patients treated with transfer factor (Section 1.2.1: 
table 3-6). Similarly a leucocyte migration test has been employed 
to monitor transfer of cellular hypersensitivity to PPD and HBsAg 
in chimpanzees treated with immune human dialysable transfer factor 
(Section 1.4.1: table 10; Trepo and Prince, 1976). Acquisition 
of reactivity to PPD and Le1shman1a has also been detected in guinea 
pigs treated with homologous dialysable transfer factor by a 
macrophage migration test (Section 1.4.1: table 10; Clinton and Magoc, 
1976). In contrast, the mixed cell migration test has only once been
used in monitoring cellular hypersensitivity in one human 
treated with transfer factor (Arala-Chaves et al, 1977).
In this study, ten naive rhesus monkeys were treated with 
immune transfer factor. A total of 58 out of 97 (60%) of 
all LMMI tests, carried out with all antigens at all 
concentrations, showed reactivity (Section 4.2.1: figs. 18a- 
d; Section 4.2.3; table 19). Such cumulative rate of 
conversion was not significantly different from a total of 
70 out of 105 (67%) in vitro leucocyte or macrophage migration 
tests, which converted to various microbial and tissue antigens 
in patients treated with human transfer factor by many 
investigators (Section 1.2.1: tables 3-6). The LMMI-test in 
the rhesus monkey, therefore, was apparently as good as the 
in vitro leucocyte and macrophage migration tests in man in 
detecting transfer of cellular hypersensitivity by the Immune 
rhesus dialysable transfer factor. The individual cumulative 
rates of conversion were 49%, 52%, 76% and 90% for 3-200vig/ml 
TB, PPD, KLH and HBsAg respectively in rhesus monkeys treated 
with immune homologous dialysable transfer factor (Section 4.2.3: 
table 19). A comparable mixed leucocyte-macrophage migration 
test has most recently been used to detect transfer of cellular 
hypersensitivity to Candidin, PPD, and streptokinase-streptodornase 
in one transfer factor-treated patient with disseminated 
candiloma acuminatus (Arala-Chaves et al, 1977). This observation, 
therefore, lends preliminary support to the view that the LMMI- 
test developed 1n the rhesus monkey can probably be reliably 
adapted to monitor cellular hypersensitivity 1n transfer factor-
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treated human subjects.
The onset of LMMI-reactivity in the recipient animals showed 
2 different patterns. It occurred "early" (2-6 days) or 
"late" (7-14 days) (Section 4.2.2: figs. 22-26). These 
patterns seemed to be related to 3 factors. Table 33 shows 
that both the early and the late onset of reactivity to KLH 
PPD or TB occurred in monkeys converting after treatment with 
KLH-immune or FCA-immune transfer factor. Only an early onset 
of reactivity to HBsAg occurred in animals, which converted 
after treatment with HBsAg-immune transfer factor. Thus, the 
different patterns of onset of cellular hypersensitivity may 
be related to the type of test antigen or the antigen- 
sensitivity of the injected transfer factor. This table also 
shows that, among all the animals converting after treatment 
with comparably low (=4.0 to 5.3 x 109 lymphocytes) or high 
doses of transfer factor (=8.0 to 9.0 x 109 lymphocytes), the 
majority of the LMMI-tests converted late after treatment with 
the lower dose, but converted early after the higher dose.
Thus, this indicated that the different patterns of the onset 
of cellular hypersensitivity might also be related to the 
dosage of the injected transfer factor. The table also shows 
that, regardless of the dose of dialysable transfer factor, 
among the early responders, the majority of the LMMI-tests (67%) 
converted after injection of monkeys with the water-dialysed 
and not the vacuum-dialysed (50%) transfer factor In contrast, 
amongst the late responders, the majority of the LMMI-tests 
converted after the vacuum-dialysed (50%) and not the water-dialysed
Table 33. The different patterns of the onset of LMMI-reactivity 
in rhesus monkeys converting after administration of 
immune dialysable homologous transfer factor.3
Test antigens 
(100 yg/ml)*
Onset of LMMI-reactivity (MI < 0.8)b 
"Early" ( 2 - 6  days) "Late" (7 - 14 days)
Rh-TFWQ Rh-TFyp Rh-TFWD Rh-TFVD
Injected dose of Rh-TFD
Q
= 4-5.3x10 lymphocytes
KLH 1
1 2 )
PPD 1 1{ 4/10 1 1 I 6/10
TB 1 (i (40%) 1 ( (60%)
HBsAg 1 )
Injected dose of Rh-TFp
q
= 8-9x10 lymphocytes
KLH
1 1 )|
PPD 1 6/7 1 1/7
TB > (86%) ( (14%)
HBsAg 2 )1 1 I
Total : 6/9 4/8 3/9 4/8
(67%) (50%) (33%) (50%)
aFron section 4.2.2: figures 23-26.
bRh-TF^p, water-dialysed rhesus transfer factor; Rh-TFVp, vacuum- 
dialysed rhesus transfer factor; Rh-TFp, dialysable rhesus transfer 
factor.
*LMMI test for 1 monkey treated with HBsAg-immune Rh-TF^p (Fig. 26a) 
was carried out with 1/25 dilution of HBsAg.
transfer factor. Thus, it was indicated that the different 
patterns of the onset of cellular hypersensitivity, in 
transfer-treated monkeys, might be related not only to the 
type of test antigen, but also to the dose and the method 
of dialysis of rhesus transfer factor.
The duration of the acquired LMMI-reactivity to KLH, PPO,
TB and to HBsAg also varied in these experiments from one 
transfer factor to recipient monkey to another. The 
acquired reactivity was seen on one occasion ("transient") 
or repeatedly for 2 to 68 days after the onset of 
reactivity ("lasting") (Section 4.2.2). These patterns 
were influenced by 3 factors. Firstly, table 34 shows that 
both transient and lasting reactivities were seen for KLH,
PPD, and TB in monkeys converting after administration of 
KLH-immune or FCA-immune transfer factor. Only a lasting 
reactivity occurred for HBsAg in animals treated with HBsAg- 
immune transfer factor. Thus, the duration of the acquired 
reactivity, like the time of onset of reactivity (Table 33), 
may be related to the type of test antigen or the antigen- 
sensitivity of the injected transfer factor. Secondly, among 
all the animals converting after administration of comparably 
low dose of transfer factor (=4.0 to 5.3 x 109 lymphocytes), 
the majority of the tests showed lasting reactivity (56%), 
and not transient reactivity (46%). Among those receiving 
comparably high doses of transfer factor (=8-9 x 10e lymphocytes), 
one half of all tests (50%) showed either transient or lasting 
reactivity to all antigens used. Thus, the high dose of the
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Table 34. Duration of the acquired LMMI-reactivity in rhesus monkeys 
converting after administration of immune dialysable 
homologous transfer factor.9
Test antigens 
(100 yg/ml)*
Duration of LMMI-reactivity (HI < 0.8)b
"Transient'* (1 day) "Lasting" (2 ■- 63 days)
Rh-TFW0 Rh-TF VD Rh-TFWQ Rh-TFVD
Injected dose of Rh-TFQ
9
= 4-5.3x10 lymphocytes
KLH 1 2 | 1 V
PPD 1 ( 5/II 1 / 6/11
TB 1 f (46%) 1 ( (56%)
HBsAg ) 1 2 1
Injected dose of Rh-TF^ = 8-9x109 lymphocytes
KLH 1 1 1
PPD 1 ( 3/6 1 ( 3/6
TB 1 ((50%) 1 ( (50%)
HBsAg ND
'
NO )
Total : 1/7 7/10 6/7 3/10
(14%) (70%) (85%) (30%)
aFrom section 4.2.2: figs. 23-26.
Rh-TFW D , water-dialysed rhesus transfer factor; Rh-TFVD, vacuum 
dialysed rhesus transfer factor; Rh-TF^, dialysable rhesus transfer 
factor.
*LMMI-test for 1 monkey treated with HBsAg-immune Rh-TFWQ (Fig. 26a) 
was carried out with 1/25 dilution of HBsAg.
NO, not done.
injected transfer factor, unlike the low dose, did not seem to 
favour either the transient or the lasting pattern of the 
duration of the acquired cellular hypersensitivity in the 
recipient monkeys. Thirdly, amongst the responders with 
"transient" reactivity, the majority of the tests (70%) 
converted after injection of the vacuum-dialysed and not 
the water-dialysed transfer factor (14%). Conversely, 
among the responders with lasting reactivity, the majority 
of the tests (86%) converted after the water-dialysed, and 
not the vacuum-dialysed, transfer factor (30%). Therefore, 
the different patterns of duration of the acquired cellular 
hypersensitivity in transfer factor-treated animals seemed 
to be influenced not only by the test antigen, but also by 
the dose and type of dialysis of rhesus transfer factor.
The acquired cellular hypersensitivity in the recipient 
monkeys seemed to be due to adoptive sensitisation by 
dialysable transfer factor. LMMI tests carried out before 
the administration of control or immune transfer factor 
revealed significant non-reactivity to KLH, PPD, TB or 
HBsAg (Section 4.2.2: figs. 19-26). This demonstrated that 
all the recipient monkeys were previously naive for the 
antigens used. Skin tests did not seem to significantly 
influence inhibition of the mixed cell migration because:
(1) in all the animals which converted after treatment with 
the immune transfer factor preparations, the acquired LMMI- 
reactivity appeared before the first skin test with 30-50pg 
KLH, PPD or HBsAg, and (2) none of the recipients of the 
control transfer factor preparations showed LMMI-reactivity after
the first or subsequent skin tests. Even in the one animal, 
which converted after treatment with control transfer factor, 
the acquired LMMI-reactivity to KLH appeared 8 days before the 
first skin test (Section 4.2.2: fig. 19a). Therefore, 
dialysable rhesus transfer factor probably adoptively 
sensitised the recipient animals conferring cellular 
hypersensitivity LMMI-reactivity to an antigen.
The specificity of the in vivo activity of transfer factor 
towards some antigens has for long been a controversial issue 
in man and animals (Section 1.5). Based on the definitions of 
donor-specificity and nonspecificity (Section 8.1.2), in the 
experiments reported here the in vivo activity of rhesus transfer 
factor was donor-specific for KLH, PPD, TB and HBsAg. This 
was unequivocally indicated by the significant acquisition of 
LMMI-reactivity to specific antigens in animals treated with 
the immune and not the control normal or unrelated dialysable 
transfer factor (Section 4.2.3: table 19). In support of this 
work, Trepo and Prince (1976) suggested donor-specific transfer 
of leucocyte migration inhibition for PPD or HBsAg by dialysable 
transfer factor in the human to chimpanzee system (Section 1.4.2: 
table 10). Others have reported donor-specific transfer of MIF 
activity, indicated by direct or indirect inhibition of guinea 
pig macrophage migration by Leishmania enrietti in the guinea 
pig to guinea pig system (Clinton and Magoc, 1976), or by Candida 
and streptokinase-streptodornase in the man to man system 
(Kirkpatrick and Smith, 1976). Hence, if dialysable rhesus
transfer factor acts without further antigen upon naive animals, 
it may do so by specifically "sensitising" a cell population 
concerned with initiation and/or production of MIF/LIF 
lymphokines.
Therefore, the LMMI test served as an appropriate in vitro 
technique for qualitatively following specific cellular 
hypersensitivity, not only in the actively immunised, but 
also in transfer factor-treated monkeys. In addition, there 
were indications that this test could also quantitatively 
measure responses in this species (Section 4.1.4: fig 15; 
section 4.2.4: fig 27).
8.3 Cellular hypersensitivity and the mitogenic or
blastogenic factor (MF): the LT test as an in vitro 
indicator of cell-mediated immunity.
Several in vitro lymphocyte transformation tests, using 
peripheral blood or tissue lymphocytes, have been described 
in man and animals to assay cellular responsiveness 
specifically to an antigen or non-specifically to a mitogen 
like phytohaemagglutinin (Ling, 1968). Lymphocyte transformation 
is indicated in this study by significant in vitro incorporation 
of tritiated thymidine by lymphocytes stimulated by antigens 
(KLH, PPD, TB, HBsAg) or a mitogen (PHA).
Here, cellular hypersensitivity is defined as the in vitro 
reactivity induced by antigen in the lymphocyte transformation
test, an in vitro correlate of CMI. Experiments in
guinea pigs and man showed that lymphocyte transformation 
can be induced by an antigen and it was suggested that this 
phenomenon depended upon the presence of delayed hypersensitivity 
specific for the immunising antigen (Mills, 1966; Oppenheim, 
1968). Some investigators have even reported that the 
in vitro lymphocyte transformation may be a more sensitive 
technique for the detection of the in vivo delayed 
hypersensitivity than the skin test (Oppenheim, 1968).
Stimulation of lymphocyte transformation in vitro by PHA 
probably reflects the immunocompetence of T-cells in vivo 
(Reisenbuk and Ioks, 1974). In 1964, Robbins reported 
transformation of peripheral blood lymphocytes by PHA in 
man, and subsequently this was extended to laboratory animals 
like, monkeys, rabbits, guinea pigs, hamsters, rats and mice 
(Knight et al, 1965). Thus, in vitro transformation tests 
have traditionally been used to monitor, not only the specific 
cellular hypersensitivity or CMI to an antigen, but also the 
non-specific general cellular responsiveness to PHA. Both 
antigen-induced and PHA-induced transformation responses are 
thought to be mediated by soluble substances or lymphokines 
called the mitogenic or blastogenic factor(s).
In 1969, Dumonde et al showed that, sensitised lymph node 
cells from immunised guinea pigs, could be stimulated to 
produce lymphokine in vitro by incubation with a specific
antigen, and not with an unrelated antigen. This lymphokine
was called mitogenic factor (MF) and it was suggested as a 
mediator of the in vitro transformation of unsensitised 
lymphocytes. In 1971, Wolstencroft reported that normal 
lymphocytes can also be activated with PHA to elaborate a 
mitogenic factor. It is unlikely that the cell-free 
activities, attributed to MF, MIF and skin reactive factors 
are attributable to the same molecule (Bray et al, 1976).
It has been suggested that the mitogenic and other 
lymphokines may be involved in the expression and regulation 
of cell-mediated immunity. (Wolstencroft and Dumonde,
1970). Furthermore, it is likely that antigen and mitogen- 
induced in vitro lymphocyte transformation may be mediated by 
a mitogenic factor.
Lymphocytes from the rhesus monkey can also be stimulated 
by PHA or an antigen to undergo transformation in vitro 
(Ling, 1968). In 1970, Phillips et al showed that rhesus 
lymph node or spleen cells, separately or mixed, can specifically 
respond to the sensitising antigens in rhesus monkeys sensitised 
with FCA containing malaria parasite-antigens or sheep red blood 
cells. They reported that this transformation correlated with 
the delayed hypersensitivity. In 1971 and 1972, Mackler et al 
found antigen-induced transformation in delayed hypersensitivity 
in a monkey immunised with trinitrophenyl-KLH suspended in FCA 
and PHA-1nduced transformation in normal monkeys. Thus previous 
studies have shown that, 1n the rhesus monkey, lymphocytes can 
also transform in vitro by antigen or PHA to reflect specific
delayed hypersensitivity or non-specific cellular responsiveness
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respectively.
Against the above background, in these experiments a whole blood 
lymphocyte transformation technique (Section 2.7.2) was used to 
monitor cellular hypersensitivity to antigens KLH, PPD, TB 
or HBsAg or responsiveness to a mitogen PHA in normal, immunised 
and transfer factor-treated rhesus monkeys. A whole blood 
technique rather than a purified lymphocyte technique, was used 
because the assay procedure is simpler, less expensive, more 
rapid and uses very little blood. Transformation was quantified 
by liquid scintillation counting of tritiated thymidine uptake. 
Such radioactive quantification, rather than the other methods 
like morphological or autoradiographic evaluation, was used 
because it has been reported that, in man or rhesus monkey, 
tritiated thymidine uptake is more reproducible, simpler and 
quicker than the others (Ling, 1968; Schellekens and Eijsvoogel, 
1968; Mackler et al, 1972). The LT-results obtained are shown 
above (Section 5) and the conversion rates for the acquisition 
of lymphocyte transformation and its specificity to KLH, PPD 
and/or TB and HBsAg together with its nonspecific stimulation 
by PHA are discussed below on the basis of the criteria used to 
indicate significant LT-reactiv1ty (Sections 8.3.1 - 8.3.5).
8.3.1 Criteria for LT-reactivity to antigen or mitogen.
In these experiments a stimulation Index of above 2.0 (Section 
2.7.2) was used throughout as a significant indication of LT-
reactivity to antigen or PHA. This index was justified for the 
following reasons. Firstly, at this cut-off point the majority 
of the normal unsensit’c'ed rhesus monkeys showed no response to 
1 to 100 vg/ml KLH, PPD, TB or HBsAg (Section 5.1.1, figs. 29a-d:
SI<2.0), whilst majority of the actively immunised animals 
responded to 5-50 ug/ml of these antigens (Section 5.1.1, figs.
30a-d: SI>2.0). Secondly, an index of more than around 2.0 
has been used by others, in man and non-human primates, to 
indicate presence of cellular hypersensitivity towards number 
of antigens (Junge et al, 1970; Baram et al, 1971; Maini et al, 
1974; Steele et al, 1976 ). On the basis of this cut-off point, 
to validate the acquisition of cellular hypersensitivity to an 
antigen, the possible interference with LT-reactivity of previous 
sensitisation with an antigen, cross-reactivity of stimulants 
and/or potential mitogenicity of some antigens had to be considered.
It has been reported that LT-reactivity can occur to KLH in normal 
control human subjects (Curtis et al, 1970), or to PPD in normal 
control rhesus monkeys (Baram et al, 1971). Similarly, in the 
experiments reported here, some normal control rhesus monkeys showed 
positive LT-responses to KLH, PPD and HBsAg, but not to TB, at 2 
or more concentrations (Section 5.1.1: figs. 29a-d). Such responses 
can be indicative of previous sensitisation of the animals with 
KLH, PPD or HBsAg, and/or of cross reactivity of these antigens 
with others, and/or potential mitogenicity of these antigens.
KLH is isolated from a crustacean (Section 2.10.1) and it is 
unlikely that rhesus monkeys would have previously been sensitised.
In man KLH may be mitogenic because pre-immunisation studies 
in LT-tests have revealed dose-dependent in vitro response to 
this antigen (Curtis et al, 1970). KLH might also cross-react 
with some cell products in this test. Thus, since an increasing 
number of normal monkeys convert with the increasing in vitro 
concentration of KLH (Section 5.1.1: fig. 29a) it is likely that 
the LT-reactivity to this antigen in the normal animals, as in 
man (Curtis et al, 1970), resulted from the mitogenic activity 
of KLH.
In contrast to KLH, tuberculin PPD (Section 2.10.2) is a 
ubiquitous antigen and, therefore, normal monkeys could have 
easily experienced natural sensitisation with this antigen.
In any event, sensitisation may have occurred because all the 
rhesus monkeys used had previously been screened for tuberculosis 
by skin tests with PPD by the importers. These considerations 
may explain the PPD-stimulated LT response seen in normal animals 
(Section 5.1.1: fig. 29b).
HBsAg is associated with the hepatitis B virus (Section 2.10.4) 
and can infect man and monkey (Zuckerman, 1975b; Zuckerman et al,
1975). Whether HBsAg cross reacts with other antigens or not is 
not clear, but this is a possibility because of its complex 
composition of lipids, polypeptides and some carbohydrates 
(Howard, 1975). Since there seemed to be a slight indication of 
a dose-response pattern in the normal animals (Section 5.1.1:
■fig. 29d), HBsAg may have been mitogenic, but to a lesser extent
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than KLH (Section 5.1.1: figs. 29a cf 29d). Thus, the LT-test 
reactivity in normal animals was probably due to non-specific cross­
reactivity and/or mitogenicity of KLH or HBsAg, and not due to true 
acquisition of cellular hypersensitivity to these antigens 
(Section 5.1.1: figs. 29a, d). In contrast, the responses to PPD 
probably resulted from previous sensitisation (Section 5.1.1: 
fig. 29b). When all antigens were taken together only 18 out of 
243 tests (7%) were positive. As a result of such minimal non­
specific reactivity in normal monkeys, the acquisition of LT- 
reactivity to an antigen in the actively immunised monkeys was 
considered significant.
8.3.2 Acquisition and antigen-specificity of LT-reactivity in 
immunised monkeys: active sensitisation (Table 35).
Adopting the above criteria for in vitro LT-reactivity (Section 
8.3.1), in the immunised animals the conversion rates of lymphocyte 
transformation tests were 67%, 83%, 88% and 100% for 5-50 yg/ml TB, 
HBsAg, PPD and KLH respectively making a cumulative mean conversion 
rate of 83% (Section 5.1.3: table 21). Compared with the control 
normal animals, such conversion rates were highly significant 
(P < 0.01). A conversion rate of 22 out of 39 positive tests (57%) 
was observed by Baram et al (1971) for PPD-induced transformation in 
22 BCG-immunised rhesus monkeys. A conversion rate of 19 out of 23 
tests (83%) occurred in KLH-induced transformation seen by Curtis 
et al (1970) in 14 normal human subjects Immunised with KLH. Thus, 
as in man, in this species the lymphocyte transformation test used, 
was a reliable index of cellular hypersensitivity to KLH, PPD, TB
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and HBsAg. The soluble tuberculin PPD antigen seemed to be a more 
effective stimulant than the particulate TB antigen, since the 
former had a higher conversion rate (88%) than the latter (67%).
The acquisition of cellular hypersensitivity to KLH, PPD, TB and 
HBsAg was time-dependent. Sequential in vitro transformation tests 
were carried out before and after immunisation (Section 2.1: 
figs, lb, d). Results showed that, in all but one animal tested 
with KLH (Section 5.1.2: fig. 31c), LT-reactivity to 10 ug/ml KLH, 
PPD, TB or HBsAg was absent before immunisation. However, after 
immunisation it appeared in the majority of cases 1 to 4 weeks later 
and lasted for 1 to 5 weeks (Section 5.1.2: figs. 31a, b, d, 32-34). 
Such time-dependent acquisition of cellular hypersensitivity, as 
indicated by LT-reactivity agree with similar observations of 
Baram et al (1971) for PPD in actively sensitised rhesus monkeys, 
and with those of Curtis et al (1970) for KLH in actively sensitised 
normal humans.
Skin tests with an antigen did not seem to produce positive in vitro 
transformation. In the majority of animals immunised with FCA with 
or without KLH, lymphocyte transformation tests converted to 10 ug/ml 
KLH, PPD or TB before the first skin test carried out with 30 ug KLH 
or 10-30 ug PPD (Section 5.1.2: figs. 31-33). However, the effect 
of the skin test on lymphocyte transformation with HBsAg, in animals 
immunised with FCA containing HBsAg, remained unknown, since 
significant transformation was not seen before the first skin test 
with 10-30 ug HBsAg (Section 5.1.2: fig. 34).
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and with those of Curtis et al (1970) for KLH in actively sensitised 
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Skin tests with an antigen did not seem to produce positive in vitro 
transformation. In the majority of animals immunised with FCA with 
or without KLH, lymphocyte transformation tests converted to 10 ug/ml 
KLH, PPD or TB before the first skin test carried out with 30 ug KLH 
or 10-30 pg PPD (Section 5.1.2: figs. 31-33). However, the effect 
of the skin test on lymphocyte transformation with HBsAg, in animals 
immunised with FCA containing HBsAg, remained unknown, since 
significant transformation was not seen before the first skin test 
with 10-30 ug HBsAg (Section 5.1.2: fig. 34).
In the actively sensitised animals, the mean intensity of the acquired 
maximum LT-reactivity varied from one antigen to another, and from 
one concentration to another (Section 5.1.1: figs. 30a-d). The 
acquired transformation response was always highest for KLH with 
mean stimulation indices of 38, 31 and 43 for 5, 10, 50 pg/ml KLH 
respectively (Section 5.1.1: fig. 30a). Baram et al (1971) showed 
that the mean transformation response to 80 yg/ml PPD, in all the 
tests carried out in their actively sensitised monkeys, was higher 
(Mean SI = 22) than that observed in these experiments (Section 5.1.1: 
fig. 30b, mean SI = 7.0, 8.0 and 7.0 for 5, 10 and 50 yg/ml PPD 
respectively). This lower degree of in vitro transformation response 
may be derived from the use of lower concentrations of PPD from a 
different source, and of a different transformation test system. A 
whole blood technique (Section 2.7.2) was used here, whilst Baram 
et al (1971) used cotton wool-filtered enriched lymphocyte cultures. 
The higher red blood cell and other cell contaminants in the whole 
blood transformation cultures used here may have been responsible 
for the lower PPD-stimulated response. It is unlikely that the 
presence of only red blood cells can affect the in vitro response of 
lymphocytes to a stimulant (Junge et al, 1970). Factors probably 
contributing more effectively to such reduced in vitro responses, to 
such PPD-st1mulated whole blood cultures, are the larger proportions 
of granulocytes, monocytes and platelets present in a whole blood 
lymphocyte culture.
The cellular hypersensitivity induced by active Immunisation of 
rhesus monkeys and Indicated by LT-react1v1ty (SI > 2.0) was antigen- 
specific (Section 5.1.3: table 21). When the total number of
positive LT-tests carried out with 5-50 yg/ml antigen in normal 
control animals were compared with those in the immunised monkeys, 
there was a highly significant difference between the rates of 
conversion for KLH, PPD, TB and HBsAg taken separately or altogether 
( P  < 0.001). Thus, the induced cellular hypersensitivity was 
considered to be antigen-specific. This was supported by tests 
carried out in the immunised animals using antigens unrelated to 
the sensitising antigens (Table 35). These tests were only carried 
out in a few representative monkeys, and indicated that the whole 
blood in vitro lymphocyte transformation used in these experiments 
seemed to be specific for PPD, TB and HBsAg (Table 35). In the 3 
monkeys shown in this table, only 1 out of 10 tests non-specifically 
converted to an unrelated antigen KLH at 50 vg/ml, whilst 16 out of 
24 (67%) tests converted to one or more sensitising antigens at 
various concentrations. Thus, rhesus monkeys can be actively 
sensitised with FCA, with or without KLH or HBsAg. Their lymphocytes 
can, under the conditions of these experiments, specifically respond 
to the sensitising antigen(s) by the in vitro whole blood 
transformation technique.
8.3.3 PHA-induced in vitro lymphocyte transformation 1n normal 
monkeys.
Lymphocyte transformation to PHA has been regarded as a measure of 
cellular responsiveness reflecting the integrity and immuno­
compétence of T-lymphocytes (Reisenbuk and Ioks, 1974). In these 
experiments 71 out of 75 of all tests (95%) carried out in normal 
monkeys showed significant responsiveness to 5-300 vg/ml PHA with
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Table 35. Antigen-specificity of LT-responses three weeks after 
immunisation of representative rhesus monkeys with 
FCA with or without HBsAg.a
Cone, of test 
antigen 
(ug/ml)
Stimulation indices (SI) in monkeys immunised withb
FCA
*(H32)
FCA
*(H33a)
FCA/HBsAg
*(H42)
KLH: 5 1.2 1.5 1.4
10 1.8 1.6 ND
50 1.8 2.1 ND
100 2.0 1.7 0.9
PPD: 5 2.3 2.1 1.7
10 3.8 2.4 2.0
50 3.5 2.3 1.1
100 3.4 1.7 1.2
TB: 5 2.4 1.0 ND
10 2.6 1.2 ND
50 5.2 2.1 ND
100 5.5 2.7 ND
HBsAg: 5 ND ND 2,8
10 ND ND 3.0
50 ND ND 2.2
100 ND ND 0.6
aLT-tests carried out as described before (Section 2.7.2), except for 
monkey H42 where 0.03 ml blood, rather than 0.1 ml, was used per 
culture.
bSI > 2.0 underlined and significant (Section 2.7.2).
ND, not done; *Code of monkeys.
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a good dose-response (Section 5.1.6: fig. 37). Such reactivity 
established the whole blood transformation test in these experiments 
as a reliable measure of in vitro cellular reactivity. This 
confirmed the findings of others (Mackler et alt 1972), who showed 
PHA-induced blastogenesis using purified rhesus peripheral 
lymphocytes in culture. However, Mackler et al (1972) could only 
demonstrate a significant dose-response in "roller" cultures and 
not stationary cultures, whereas here a dose-response was seen using 
stationary cultures. When the in vitro concentrations of PHA used 
were above the optimum, the degree of the mean response fell 
(Section 5.1.6: fig. 37). This probably indicated accumulation of 
potentially toxic metabolic products affecting the cells undergoing 
blastogenesis (Mackler et al , 1972), induction of suppressor factors 
and/or toxicity of PHA.
The wide range of reactivity to PHA at all concentrations in individual 
animals (Section 5.1.6: fig. 37) may result from the following. 
Different proportions of different contaminants like red blood cells 
and non-transforming leucocytes and/or the different immuno­
compétence of lymphocytes. These hypotheses can only be proved by 
the use of purified T- and B-lymphocytes 1n the test in much the same 
way as that used by Clot et al (1975). They reported that, in man, 
in vitro lymphocyte transformation by PHA can occur with only "\0% 
T-cells added to B-cells, but not with B-cells alone. Thus, the 
experiments reported here show that, PHA-stimulated stationary whole 
blood cultures can be used to examine non-specific responsiveness of 
normal lymphocytes, presumed to be T-lymphocytes. As a result, such 
lymphocyte transformation tests with PHA were used to determine the
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general state of cellular responsiveness in actively immunised 
monkeys.
8.3.4 Depression of PHA-induced lymphocyte transformation in 
immunised monkeys.
Using the optimum concentration of PHA, in vitro lymphocyte trans­
formation tests were carried out with immune rhesus lymphocytes 
(Section 5.1.7: fig. 38). There was evidence for depression of mean 
reactivity 1 to 5 weeks after immunisation compared with the mean 
maximum reactivity before immunisation (Section 5.1.8: fig. 39).
Such observations are, in contrast to the findings of others, who did 
not observe depression of lymphocyte transformation to PHA in KLH- 
sensitised normal human subjects (Curtis et al, 1970). Antibodies to 
PHA can inhibit the in vitro blastogenic activity of PHA (Ling, 1968). 
Thus, it is likely that in the immunised monkeys, the depression of 
the in vitro transformation to PHA might have been due to inhibition 
of blastogenesis by cross-reacting antibodies reacting with PHA 
in vitro and thereby possibly preventing good contact with cells.
The depression effect could also have been due to a reduced efficiency 
in the production of mitogenic factor(s), probably mediating the 
PHA-induced in vitro lymphocyte transformation (Section 8.3). The 
last and simplest possibility is that the main population of the 
responsive cells are not in circulation.
The whole blood lymphocyte transformation test can be used to monitor 
cellular hypersensitivity to an antigen 1n actively sensitised 
monkeys (Section 8.3.2). It can also be used to detect general
cellular responsiveness to PHA in normal and immunised monkeys 
(Sections 8.3.3 and 8.3.4). As a result, this test was used to 
monitor antigen- and PHA-induced responses in transfer factor- 
treated monkeys.
8.3.5 Acquisition and non-specificity of LT-reactivity to 
antigen in transfer factor-treated monkeys.
The in vitro lymphocyte transformation test with KLH, PPD and 
HBsAg showed cumulative conversion rates of 5 out of 33 tests (15%)
2 to 27 days after treatment of recipients with immune dialysable 
transfer factor (Section 5.2.3: table 24). In contrast, Steele 
et al (1976) found a cumulative rate of conversion of 26 out of 
40 tests (65%) to a battery of antigens for the lymphocyte 
transformation test after treatment of 9 animals of 3 species of 
other non-human primates with immune human dialysable transfer 
factor. Klesius and Fudenberg (1977) have reported a cumulative 
conversion rate of 28 out of 34 (80%) of lymphocyte transformation 
tests to PPD and Eimoria bovis in 17 recipient cattle treated with 
immune homologous transfer factor. Comparably high cumulative LT- 
conversion rates have been reported to some fungal antigens in 
transfer factor-treated patients (Section 1.2.1.1: table 3, 
cumulative conversion rate * 77%). However, 1n 1975, Zanelli and 
Adler (Section 1.4.1: table 9) reported no LT-conversion to PPD 
in 5 rhesus monkeys treated with immune rhesus transfer factor, 
whilst others reported conversion rates of only 10% to 40% for 
bacterial, viral, neoplastic tissue and other antigens 1n transfer 
factor-treated patients (Sections 1.2.1.2 - 1.2.1.3: tables 3-4; 
sections 1.2.2 - 1.2.3: tables 5-6). Thus, the species of the donor
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and the recipient, the method of preparation of transfer factor, and 
the state of health of the recipients probably affect the conversion 
rate of the lymphocyte transformation test. The low rate of LT- 
conversion in transfer factor-treated monkeys reported here may have 
arisen from inhibition of blastogenesis by blocking factor(s). For 
example auto-antibodies or some antigen-antibody complexes could 
have covered potentially reactive lymphocytes, thereby preventing 
either antigen recognition and/or production of blastogenic factor. 
Alternatively, the LT-test was simply not adequate in detecting 
adoptive sensitisation of this species with dialysable transfer factor 
(Zanelli and Adler, 1975).
Despite the low cumulative rates of conversion, a higher individual 
LT-rate of conversion of 4 out of 9 tests (44%) was recorded for 
KLH in animals treated with immune transfer factor (Section 5.2.3: 
table 24). This response to KLH with the immune transfer factor 
did not seem to be related to the specificity of the donor(s), since 
a conversion rate to KLH of 2 out of 15 tests (13%) was also found 
with the control transfer factor (Section 5.2.3: table 24, KLH:
P > 0.2). Therefore, some LT-tests converted to KLH after injection 
of rhesus monkeys with dialysable transfer factor, but the conversions 
were apparently non-specific. The potential mitogenicity of KLH 
probably influenced the LT-conversions 1n the recipient animals, 
since the rate of LT-reactivity to KLH 1n normal rhesus monkeys 
(Section 5.1.3: table 21) was high (16%) compared with the other 
antigens ( < 2%). Thus the acquisition of transformation reactivity 
to KLH (Section 5.2.3: table 24) may not have been due to adoptive 
sensitisation with transfer factor, but due to the potential
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mitogenicity of KLH. Thus, the LT-test here does not seem to be an 
adequate in vitro test for following the cellular hypersensitivity 
responses to KLH in transfer factor-treated rhesus monkeys.
8.3.6 Elevation of PHA-induced in vitro lymphocyte transformation 
responses in transfer factor-treated monkeys.
The optimum dose of PHA in lymphocyte transformation tests in transfer 
factor-treated rhesus monkeys was the same as that for normal or 
immunised monkeys (100 yg/ml) (Section 5.1.6: fig. 37; section 
5.2.7: fig. 38; section 5.2.6: fig. 44). Using this concentration 
of PHA an elevation of the mean in vitro transformation reactivity 
was found 2-17 days after injecting rhesus monkeys with dialysable 
homologous transfer factor (Section 3.2.7: fig. 45). Increased 
lymphocyte transformation responses to this mitogen have been 
observed by others in transfer factor-treated patients with an immuno­
deficiency disorder (Amman et al, 1974; Valdimarsson et al , 1974), 
or in dogs injected with canine transfer factor (Shifrine et al,
1976). Such results in rhesus monkeys may reflect a non-specific 
"adjuvant-like" activity present in dialysable transfer factor 
(Valdimarsson et al, 1974). Assuming that a mitogenic factor 
mediates the PHA-stimulated in vitro response, then the transfer 
factor may have stimulated a population of cells to elaborate more 
of this lymphokine. Alternatively more T-cells may have been 
recruited into the pool (Wybran et al, 1973), thereby increasing 
the in vitro reactivity to PHA. It is likely that T-cells rather 
than B-cells were the ones influenced by transfer factor, since in 
man it has been shown that PHA-st1mulated in vitro transformation 
requires T-cells (Clot et al, 1975).
In the experiments here the LT-test did not emerge as a sensitive 
in vitro technique for monitoring cellular hypersensitivity to 
antigens in rhesus monkeys treated with transfer factor (Section 
8.3.5). It could, however, detect the apparent non-specific 
"adjuvant-like" activity of transfer factor in vivo, indicated by 
the elevation of PHA-induced lymphocyte transformation (See above).
8.4. Association or dissociation of the different CMI-tests
in immunised or transfer factor-treated monkeys (Table 36).
It has been reported that cell migration inhibition tests or 
lymphocyte transformation tests are in vitro correlates of the in vivo 
delayed hypersensitivity skin test to an antigen in sensitised man 
or animals (David et al, 1964b; Ling, 1968; Thor et al, 1968; 
Rajapakse and Glynn, 1970; Baram et al, 1971; Marsman et al, 1972). 
In support of these observations, table 36 shows that when all the 
LMMI- and DH-skin tests, LT- and DH-skin tests or LT- and LMMI-tests 
were taken together, with all the antigens, most of the paire< asts 
(LMMI/DH, LT/DH, LT/LMMI) converted in the immunised monkeys 
(66% - 85%), but not in transfer factor-treated animals (0% - 33%). 
Comparison of such double-conversion of tests in immunised animals, 
with that in animals treated with the immune transfer factor, 
showed that the likelihood of these conversions was significantly 
greater 1n the former than in the latter (Table 36: P < 0.005). 
Therefore, it can be said that in the immunised monkeys the in vitro 
cellular hypersensitivity tests "associated" with each other (l.e. 
LT/LMMI) and with the in vivo delayed hypersensitivity (1.e.
LMMI/DH, LT/DH).
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Table 36. Relationship between the different tests (OH, LMMI, LT) 
of cell-mediated immunity in immunised and transfer 
factor-treated monkeys.
Rhesus Cumulative no. of double-conversion of tests/all tests
injection
with
LMHI& DHa LT & DHb LT a LMMIC
FCA + KLH 
or HBsAg
41/63 (66%) 34/40 (85%) 8/11 (73%)
Immune
Rh-TFp
16/48 (33%) 0/22 1/11 ( 9%)
P for x2 < 0.005 < 0.005 < 0.005
aFrom sections 4.1.5, table 18 and 4.2.5, table 20.
bFrom sections 5.1.4, table 22 and 5.2.4, table 25.
cFrom sections 5.1.5, table 23 and 5.2.5, table 26.
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In contrast, in transfer factor-treated monkeys double conversions 
mainly occurred in the LMMI/DH pair of tests. Compared to the 
immunised animals these conversions were not significant. Thus, 
the in vitro cellular hypersensitivity LMMI-test and the in vivo 
delayed hypersensitivity skin test (LMMI/DH) can be said to be 
"dissociated" from each other. This observation is in contrast 
to other reports suggesting an association of DH-skin test with a 
cell migration inhibition test in diseased patients injected with 
transfer factor (Section 1.2: tables 3 and 6) (Spitler et al,
1975; Arala-Chaves et al , 1977). Thus, such differences in the 
relationship of these tests might be indicative of species 
differences in adoptive sensitisation of transfer factor recipients 
for preferential lymphokine production, or different sensitivity 
of these tests in man and monkey.
In the immunised monkeys here, the association of the various test 
reactivities may indicate that the DH-skin test, probably Indicative 
of the skin reactive factor(s) (Section 8.1); the in vitro LT-test, 
probably indicative of blastogénie factor(s) (Section 8.3) and the 
in vitro LMMI-test probably indicative of the MIF/LIF (Section 8.2) 
are comparably sensitive as assay systems for such lymphokines.
It is also possible that these tests are Indicative of different 
manifestations of the same lymphokine molecule. However, in the 
guinea pig, parallel bioassays using the three of these lymphokines 
against a standard preparation have indicated that they are 
heterogeneous (Bray et al, 1976). It is, therefore, likely that the 
so called skin reactive, blastogénie and MIF/LIF lymphokines are 
also heterogeneous in the rhesus monkey. By inference, therefore.
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the dissociation of the LMMI- and DH-skin test reactivities in 
transfer factor-treated monkeys might be indicative of preferential 
lymphokine production.
Hence, table 36 indicates that in the immunised monkeys, the LMMI- 
and LT-conversion of tests associated with each other and with 
the DH-skin test conversion. In contrast, in transfer factor- 
treated monkeys, only the LMMI- and DH-skin tests, and not the 
others (LT/LMMI, LT/DH), seemed to convert together, but the LMMI- 
conversion apparently dissociated from the DH-skin test conversions.
8.5 Effects of different methods of preparation of rhesus 
dialysable transfer factor upon its in vivo activity.
For the in vivo study, dialysable human transfer factor has 
traditionally been prepared from heparinised peripheral blood 
leucocytes. Such cells are treated with deoxyribonuclease and 
magnesium sulphate, freeze-thawed seven to ten times and the extract 
of completely disrupted leucocytes is exhaustively dialysed into 
equal or 50 times greater volume of water (Lawrence and Al-Askari,
1971). Another method of preparation of human transfer factor, 
originally described by Arala-Chaves et al (1967) and later modified 
by Burger et al (1974), Involves dialysis of blood leucocyte 
extracts Into a vacuum ("ultrafiltration"). In all these methods 
the leucocyte dlalysates containing transfer factor are subsequently 
freeze-dried, reconstituted 1n saline or water, and their biological 
activity tested by their ability to convert delayed hypersensitivity 
skin tests with different antigens. In the experiments presented
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here, the dialysable rhesus transfer factor for the in vivo study 
was prepared by water-dialysis and vacuum-dialysis of leucocyte 
lysates, obtained from treated pooled lymph node and spleen cells 
(Sections 2.5.2, 2.5.4, 2.5.5, 2.5.7). The in vivo biological 
effect(s) of these preparations were monitored not only by the 
in vivo delayed hypersensitivity skin tests (Section 2.6), but also 
by the in vitro mixed leucocyte-macrophage migration and lymphocyte 
transformation tests (Section 2.7).
When comparable doses of dialysable rhesus transfer factor were 
administered into naive rhesus recipients, the water-dialysed 
transfer factor, prepared from actively immunised donor(s) (Section 
3.1.2: figs. 5b, 6 , plates lOa-b), did not transfer delayed 
hypersensitivity skin test reactions to KLH, PPD or HBsAg (Section 
3.2.4: fig. 8). Similar observations in this species were 
reported by Zanelli and Adler (1975). However, in most instances 
reported by others in the human to human, human to rhesus, or rhesus 
to rhesus system, the water-dialysed transfer factor did transfer 
skin test reactivity to an antigen (Lawrence et al, 1963;
Maddison et al, 1972; Gall in and Kirkpatrick, 1974; Littman et al, 
1978). In this work, the absence of systemic transfer of skin test 
reactivity to an antigen with water-dialysed transfer factor may 
be because lower doses of KLH and PPD were used for skin testing 
recipients of the water-dialysed transfer factor, rather than the 
recipients of the vacuum-dialysed transfer factor. Assuming this 
was not the case, then other factors may have played a role. The 
preparations may have not contained component(s) responsible for 
transferring delayed hypersensitivity skin test reactivity. These
component(s) were somehow inactivated either during the long and 
laborious preparation procedures or after injection by the 
recipients. The skin test conversion activity may have been present, 
but it was so weak that the recipient animals did not respond 
strongly enough for the skin tests to pick up the delayed 
hypersensitivity responses. Finally the skin tests may have been 
carried out at times when transferred delayed hypersensitivity had 
not yet developed or had already disappeared. Zanelli and Adler
(1975) did not, at first, succeed in systemically transferring 
skin test reactivity to PPD, from rhesus to rhesus or rhesus to 
cynomolgus monkeys, with water-dialysed transfer factor prepared by 
the standard method of Lawrence and Al-Askari (1971). However, they 
succeeded after slightly modifying the preparative method to 
include gentle rupturing of rhesus blood leucocytes with mechanical 
shearing and subsequent dialysis into tissue culture medium. On 
the other hand, Gallin and Kirkpatrick (1974) modified the standard 
technique of dialysable transfer factor preparation by separating 
the human blood leucocytes by leukophoresis to prepare a water- 
dialysed transfer factor for the transfer of delayed hypersensitivity 
skin test reactions to mumps and other antigens 1n the rhesus monkey 
system. It is possible that similar or other small modifications 
in the preparation of water-dialysed transfer factor could have 
helped to obtain skin test-active dialysable rhesus transfer factor 
1n these experiments.
The majority of the transfer factor was prepared by vacuum-dialysis 
(Section 2.5.7). Such vacuum-dialysed rhesus transfer factor, at 
one or more doses, did transfer delayed hypersensitivity skin test
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reactions to KLH, PPD or HBsAg in some rhesus monkey recipients 
(Section 3.2.2: fig. 7, plates 13a-b; section 3.2.4: figs. 8a-b). 
Such positive results agreed with those of others, who also used 
vacuum-dialysed transfer factor, prepared from human blood leucocytes, 
to transfer delayed hypersensitivity skin tests to various antigens 
in man (Arala-Chaves et al, 1967; Burger et al, 1974). It is 
possible that vacuum-dialysis, rather than water-dialysis, of 
lysed rhesus leucocytes from pooled lymph node-spleen cells was 
capable of dialysing out transfer factor component(s) responsible 
for the transfer of skin test-reactivity to the antigens used under 
the conditions of these experiments.
In these experiments, both water-dialysed and vacuum-dialysed immune 
rhesus transfer factor transferred mixed cell migration reactivity 
to KLH, PPD, TB and HBsAg in some recipient animals (Section 4.2.2: 
figs. 23-26). However, the mean intensity of LMMI-responses in 
animals treated with immune transfer factor was stronger with the 
water-dialysed than with the vacuum-dialysed material (Section 4.2.4: 
fig. 27). Thus, in these recipients the LMMI-responses also seemed 
to be influenced by the method of dialysis of transfer factor.
Unlike some investigators (Section 1.4.1: table 9; Zanelli and 
Adler, 1975), others (Section 1.4.1: table 9; Maddison et al, 1972) 
have reported conversion of lymphocyte transformation 1n tests to 
antigens in rhesus monkeys treated with water-dialysed rhesus transfer 
factor. In this work, lymphocyte transformation tests were carried 
out only 1n the recipients of vacuum-dialysed, and not water-dialysed 
transfer factor. The conversion of tests seemed to be mainly
limited to the potential mitogenicity of KLH (Section 5.2.1: fig.
41a; section 8.3.5). Therefore, although here the influence of 
the method of dialysis of transfer factor could not be determined 
upon the lymphocyte transformation tests, it did seem to affect the 
delayed hypersensitivity skin tests and the mixed cell migration 
tests.
8.6 Non-specific in vitro activity of human or rhesus dialysable 
transfer factor.
It has been reported that dialysable human transfer factor can 
specifically sensitise non-immune lymphocytes, or non-specifically 
augment transformation of previously sensitised cells to an antigen 
in vitro (Section 1.3: table 7). To test these findings and extend 
them to the rhesus monkey, both rhesus and human dialysable transfer 
factor preparations were employed with "recipient" human lymphocyte 
or leucocyte cultures and KLH or PPD as described before (Section 2.8).
In contrast to previous reports (Section 1.3.1: Adler et al, 1970; 
Ascher et al, 1974; Palmer and Smith, 1974; Sharma et al, 1977) 
there was no indication that positive transfer factor could transfer 
antigen sensitivity to unsensitised "recipient" human leucocytes 
in vitro (Section 6.1: figs. 47-48). It is possible that the 
rhesus transfer factor could not cross the species barrier to transfer 
antigen-responsiveness to naive human lymphocytes in vitro.
However, Baram and Condoulls (1970) could not transfer KLH-sens1t1v1ty 
to naive rhesus lymphocytes in vitro with rhesus dialysable transfer
factor, although they successfully transferred such sensitivity with
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non-dialysable transfer factor. This suggested that the latter may 
be more effective in vitro. Preliminary experiments carried out 
during this work revealed no such transfer of KLH-sensitivity to 
unsensitised human lymphocytes by non-dialysable rhesus transfer 
factor (Personal observations).
It was demonstrated that both rhesus and human dialysable transfer 
factor preparations can, non-specifically augment, or suppress KLH- 
and/or PPD-stimulated lymphocyte transformation in vitro (Section 
6.1: fig. 48, table 27; section 6.2: fig. 49, table 28). These 
results confirmed and extended those of others, who have reported 
that dialysable human transfer factor, or fractions of it, can 
augment antigen-stimulated lymphocyte transformation, as indicated 
by increased incorporation of tritiated thymidine in vitro 
(Hamblin, 1975) (Section 1.3.1, table 7: Ascher and Andron, 1976; 
Burger et al, 1976a, b; Hamblin et al, 1976a; Sal aman, 1976;
Littman et al, 1977). Some of these investigators have also observed 
suppression of in vitro transformation in cultures containing antigen 
and whole or fractions of human dialysable tranfer factor (Burger 
et al, 1976a; Hamblin et al, 1976a).
Specificity of the in vitro activity, as Indicated by lymphocyte 
transformation tests, has always been a controversial Issue. It has 
been found that the human transfer factor may or may not be donor- 
specific in vitro (Section 1.3.1: table 7) (Mazaheri et al, 1977). 
Some have even suggested that the non-specific effect(s) may be 
masking the specific activity (Arala-Chaves et al, 1976). These
experiments showed that the rhesus dialysable transfer factor, prepared
from donors sensitised or not sensitised to KLH, were similarly 
effective in augmenting cultured "recipient" human lymphocyte 
transformation responses to KLH (Section 6.1: fig. 48, table 27).
The human dialysable transfer factor, prepared from Mantoux negative 
donors, augmented PPD-induced transformation of human lymphocytes 
in vitro (Section 6.2: fig. 49, table 28). Thus, in agreement 
with the observations of many with the human dialysable transfer 
factor, it was shown that the augmentation of antigen-induced 
lymphocyte transformation was not related either to the KLH-sensitivity 
or PPD-sensitivity of the rhesus or human transfer factor donors 
respectively (Hamblin, 1975) (Section 1.3.1: Ascher and Andron,
1976; Burger et al, 1976a, b; Hamblin et al , 1976a; Sal aman, 1976; 
Littman et al, 1977).
It has been found that the degree of the in vitro augmentation by 
human dialysable transfer factor is related to antigen sensitivity 
of the "recipient" cells in vitro (Hamblin, 1975). This has been 
repeatedly confirmed with the human dialysable transfer factor 
(Burger et al, 1976b; Hamblin et al, 1976a), but never with the 
rhesus monkey dialysable transfer factor. The findings of this work 
supports this view 1n the rhesus monkey. It was found that the 
degree of augmentation of KLH- and/or PPD-1nduced lymphocyte 
transformation by rhesus or human dialysable transfer factor was 
significantly related to the antigen-sensitivity of the "recipient" 
lymphocytes in vitro (Section 6.3: fig. 50a, r = +0.7 P < 0.001; 
fig. 50c, r - +0.6 P < 0.05, fig. 50d, r =■ 0.7 P < 0.05). Thus, such 
augmenting effects of rhesus and human dialysable transfer factor 
preparations can be said to be "recipient-specific" (Arala-Chaves
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and Fudenberg, 1976). In this thesis, in agreement with the 
observations of others (Hamblin, 1975; Burger et al, 1976b; Hamblin 
et al, 1976a, c), the degree of augmentation of KLH- and/or PPD- 
induced lymphocyte transformation by rhesus dialysable transfer 
factor increased with the increasing antigen-sensitivity of the 
"recipient" cells in vitro (Section 6.3; figs. 50a, c). However, 
in contrast to these findings and those of Hamblin (1975) and Hamblin 
et al (1976a, c), the degree of the augmenting activity to PPD by 
the human dialysable transfer factor decreased, with the increasing 
degree of "recipient" sensitivity to this antigen (Section 6.3: 
fig. 50d).
Within the current framework of the theories of transfer factor 
activity (Section 1.7), the absence of transfer of KLH-sensitivity 
to naive lymphocytes in vitro by rhesus transfer factor (i.e. 
absence of adoptive sensitisation in vitro)does not support the 
view that transfer factor is an "informational derepressor", a 
"minireceptor" or a metabolised but highly immunogenic "superantigen" 
(Sections 1.7.1 - 1.7.3). However, 1t 1s possible that the recipient- 
specific augmenting effect by rhesus or human dialysable transfer 
reflects the immunologically non-specific adjuvants promoting the 
activity of specifically sensitised lymphocyte populations to antigen 
(Bloom, 1973) (Section 1.7.4).
Such evidence of an "adjuvant-11ke" activity has been said to be 
reinforced (Hamblin et al, 1976c) by the demonstration that transfer 
factor can augment lymphocyte transformation responses to 
phytohaemagglut1n1n and/or pokeweed mitogen in vitro (Burger et al,
297
1976b; Hamblin et al, 1976b). This may be related to the in vivo 
augmenting activity of transfer factor, indicated by the elevation 
of PHA-induced LT-responses detected here in monkeys (Section 8.3.6) 
or by others in humans and dogs (Amman et al, 1974; Valdimarsson 
et al, 1974; Shifrine et al, 1976). In this work, however, the 
direct relationship between the in vitro and the in vivo activities 
of transfer factor could not be determined, since the same transfer 
factor was not used throughout these experiments. Others have 
presented evidence that the in vitro augmenting effect of human 
dialysable transfer factor cannot be correlated to its apparent 
donor-specific in vivo activity in man. Littman et al (1977) 
reported that a fraction of human transfer factor with the in vitro 
augmenting activity did not transfer skin test reactivity in vivo 
and, that the fraction with this in vivo activity was inactive 
in vitro. Furthermore, whilst the in vivo activity of transfer 
factor is traditionally thought to be derived from lymphocytes, the 
in vitro augmenting activity has been derived from pure polymorphs 
(Littman et al, 1977) and other cells, like L-cells and BHK-cells 
(Hamblin et al, 1976c). In order to determine the nature and 
biological specificity of dialysable transfer factor, and to relate 
the various in vivo and in vitro activities to one another, and to 
its clinical effects, purified fractions of dialysable transfer 
factor should in the future be used 1n all experiments.
8-7 Sephadex G-25 fractionation properties of rhesus or human 
dialysable transfer factor.
It has been reported that dialysable transfer factor contains various
in vivo and in vitro biological activities whose relationship to 
one another and to the apparent beneficial clinical effects of 
administration of transfer factor, is not yet understood (Sections
1.2 - 1.4). The components responsible for these effects have 
never been unequivocally located or isolated in a pure form, and 
their biological specificities have always been controversial 
(Sections 1.5 - 1.6). It has been reported that the human dialysable 
leucocyte transfer factor contains polypeptides and polynucleotides, 
hypoxanthine, uracil, adenine, guanine, cytosine, and many others as 
yet unidentified substances (Baram et al, 1966; Lawrence, 1974; 
Burger et al, 1976a; Kirkpatrick et al, 1976; Krohn et al, 1976a, b 
O ’Dori sio et al, 1976; Tomar et al, 1976; Krohn et al, 1977;
Littman et al, 1977; Wilson et al, 1977b).
In this study, crude concentrated dialysable leucocyte transfer 
factor from man or monkey were fractionated on columns of Sephadex 
G-25 (Section 2.9). A preliminary attempt was made to compare some 
of their fractionation properties. These were indicated by: (1) 
the absorption spectra of the crude rhesus preparations (Section 7: 
fig. 54), (2) the elution profiles of the human and rhesus 
preparations (Section 7: figs. 51-53), (3) the E26(/E280 absorPt'*on 
ratios, (4) the Vg/Vt elution ratios, and (5) the partition 
coefficient values of each separated fraction (Section 7: table 29). 
No attempt was made here to test the various fractions in vivo or 
in vitro or to chemically characterise them, but experiments can be 
designed in the future for such determinations.
Different number of elution peaks (2 to 14) have been separated by
other workers when human or rhesus monkey dialysable transfer factor 
was fractionated on Sephadex G 10, G 25, G 200 or DEAE-cellulose 
(Baram and Mosko, 1962; Lawrence et al, 1963; Baram et al, 1966; 
Arala-Chaves et al, 1967; Gottlieb et al, 1973; Neidhart et al ,
1973; Zuckerman et al, 1974; Reymond and Grob, 1975; Baram and 
Condoulis, 1976; Burger et al, 1976a; Kirkpatrick et al, 1976;
Krohn et al, 1976a, b, 1977; Wilson et al, 1977a, b). In the 
experiments reported here, Sephadex G-25 fractionation of dialysable 
transfer factor, prepared from normal human or rhesus blood leucocytes 
or from pooled rhesus lymph node and spleen leucocytes, revealed 9,
10 and 11 elution peaks respectively (Section 7: figs. 51-53). The 
type of chromatography columns, the size of the columns, the elution 
buffer and the method of preparation and dialysis of transfer factor 
are amongst the many factors which influence the number of elution 
peaks. In this work, one factor influencing the difference in the 
number of peaks between the human (Section 7.1.1: fig. 51) and the 
rhesus preparations (Section 7.1.1: figs. 52-53) was probably the 
longer length of column(s) used for the latter {2 (1.6 x 90 cms)}, 
compared with the former {1 (1.6 x 90 cms)}. This is supported by 
similar observations of Baram et al (1966). They found that when 
human cell-free extract, containing dialysable transfer factor with 
skin test converting activity, was fractionated on Sephadex G-25, 
the number of elution peaks Increased from about 4 to 10 by increasing 
the column length from 2 x 45 cms to 2 x 95 cms.
The E26Q/E28g ratios for the different fractions of the dialysable 
transfer factor preparations varied with the Individual peaks 
(Section 7: table 29). It has been suggested that this indicates
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different compositions (Baram and Mosko, 1965). The relatively high 
and low ratios are indicative of derivatives of nucleic acids and 
protein respectively (Mr. Brian Ellis, 1978, personal communications). 
Here, the most revealing findings are that 2 of the peaks from the 
human material making up the fractions F and G, and 1 peak from the 
rhesus blood material, making up fraction B VII, had very high 
ratios (Section 7, table 29: E26(/E280 > * < 7). In contrast,
none of the peaks from rhesus lymph node-spleen cells showed such a 
high ratio (Section 7, table 29: E260^E280 < High ratios, not
necessarily in the same magnitude, have been associated with a 
nucleotide material, notably hypoxanthine (Neidhart et al, 1973; 
Kirkpatrick et al, 1976; O ’Dorisio et al, 1976; Tomar et al, 1976). 
Thus, in this work, the human and rhesus blood material, but not the 
rhesus lymph node and spleen material, probably contained nucleotide- 
rich fraction(s).
It has been reported that, the hypoxanthine-rich fractions of the 
human dialysable transfer factor, on Sephadex G-25, can elute after 
the total bed volume at about 1.25 Vt (Neidhart et al, 1973;
Zuckerman et al, 1974; Kirkpatrick et al, 1976; Wilson et al,
1977b). In view of this, it 1s likely that amongst the high ratio 
fractions from the human and rhesus preparations, the human fraction 
G (Section 7, table 29: H-TFyD , E26(/E280 ®*®*) eluting at 1*28 V^ 
and the rhesus fraction B VII (Section 7, table 29: Rh-TFyjygj, Eggg/ 
E280 4 *3®) eluting at 1.28 Vt were also hypoxanth1ne-r1ch fractions. 
This was later found to be consistent with the observation that a 
commercially prepared hypoxanthine also eluted in the same region 
of these columns (Hamblin, 1978: personal communications). The
hypoxanthine-rich fraction of human dialysable transfer factor is 
said to contain the skin converting capacity (Neidhart et al, 1973; 
Zuckerman et al, 1974; Kirkpatrick et al, 1976; Wilson et al, 
1977b), but hypoxanthine alone does not seem to be responsible for 
it (Kirkpatrick et al, 1976; Wilson et al, 1977b). If the 
hypoxanthine-rich fractions were to contain the skin converting 
activity, this should reside in the human fraction G (Section 7, 
table 29: H-TFVD) or in the rhesus fraction B VII (Section 7, 
table 29: Rh-TFVD/BI).
The molecular weight of the human dialysable transfer factor 
component(s), with the capacity to convert skin tests from negative 
to positive, has been estimated to be less than 10,000 on the basis 
of both dialysis (Lawrence, 1974) and column chromatography (Arala- 
Chaves et al, 1967; Gottlieb et al, 1973). Here, in agreement 
with the evidence from other laboratories (Neidhart et al, 1973; 
Reymond and Grob, 1975; Krohn et al, 1976a, b, 1977), the partition 
coefficient and elution ratios indicated that all the preparations 
contained gel adsorbing (Section 7, table 29: Kay > 1, Vg/Vt > 1) 
and non-adsorbing substances (Section 7, table 29: KflV < 1, Vg/Vt 
< 1). Thus, the molecular weight of the various fractions, including 
the hypoxanthine-rich ones, could not have been determined by the 
region of elution of the various fractions.
Ultraviolet absorption spectra of preparations of crude concentrated 
human dialysable transfer factor has been reported to have a peak 
absorption at 255nm wavelength, Indicating the presence of components 
derived from nucleic acids (Kirkpatrick and Gall in, 1974).
Ultraviolet absorption spectra were determined for the two crude 
monkey preparations (Section 7: fig. 54) and both preparations 
revealed peak absorption between 250-260nm, probably indicating 
presence of substances derived from nucleic acids. This absorption 
was stronger in the rhesus material from blood (Section 7: fig. 54a) 
than that from lymph node and spleen cells (Section 7: fig. 54b), 
suggesting that the concentration of substances derived from nucleic 
acids was greater in the former than in the latter. This might be a 
reflection of the different number of lymphocytes and polymorphs 
found in the rhesus blood and lymph node-spleen leucocytes, from 
which the transfer factor preparations were made (Section 7.1.1).
Therefore, Sephadex G-25 column chromatography indicated that normal 
human and the rhesus dialysable transfer factor preparations were 
of heterogeneous composition and separable into 9 to 11 fractions. 
Only the human or the rhesus preparation from the blood leucocytes, 
apparently contained a hypoxanthine-rich fraction eluting at 1.28 Vt , 
whilst these preparations and that from the rhesus lymph node and 
spleen cells contained gel adsorbing and non-adsorbing substances.
No attempt was made to determine the molecular weight of the 
different fractions or their biological activities, but experiments 
may be designed to find out the possible in vivo and in vitro effects 
of these fractions. However, dialysable transfer factor contains a 
wide range of small molecular weight substances, like histamine, 
prostaglandin, serotlnln, all of which may be pharmacologically 
active (Hamblin, 1978). Thus, 1n studying the various in vitro and 
in vivo biological phenomena, Interferences from artefacts and 
relevance of these to the various activities of dialysable transfer 
factor must be considered.
Ultraviolet absorption spectra were determined for the two crude 
monkey preparations (Section 7: fig. 54) and both preparations 
revealed peak absorption between 250-260nm, probably indicating 
presence of substances derived from nucleic acids. This absorption 
was stronger in the rhesus material from blood (Section 7: fig. 54a) 
than that from lymph node and spleen cells (Section 7: fig. 54b), 
suggesting that the concentration of substances derived from nucleic 
acids was greater in the former than in the latter. This might be a 
reflection of the different number of lymphocytes and polymorphs 
found in the rhesus blood and lymph node-spleen leucocytes, from 
which the transfer factor preparations were made (Section 7.1.1).
Therefore, Sephadex G-25 column chromatography indicated that normal 
human and the rhesus dialysable transfer factor preparations were 
of heterogeneous composition and separable into 9 to 11 fractions. 
Only the human or the rhesus preparation from the blood leucocytes, 
apparently contained a hypoxanthine-rich fraction eluting at 1.28 Vt , 
whilst these preparations and that from the rhesus lymph node and 
spleen cells contained gel adsorbing and non-adsorbing substances.
No attempt was made to determine the molecular weight of the 
different fractions or their biological activities, but experiments 
may be designed to find out the possible in vivo and in vitro effects 
of these fractions. However, dialysable transfer factor contains a 
wide range of small molecular weight substances, like histamine, 
prostaglandin, serotlnln, all of which may be pharmacologically 
active (Hamblin, 1978). Thus, 1n studying the various 1n vitro and 
1n vivo biological phenomena. Interferences from artefacts and 
relevance of these to the various activities of dialysable transfer 
factor must be considered.
9. CONCLUSIONS
Studies of cell-mediated immune responses in rhesus monkeys, 
either actively immunised with FCA, with or without KLH or 
HBsAg, or treated with homologous dialysable transfer factor, 
led to the following conclusions.
9.1 Antigen-specific cell-mediated immunity in actively 
sensitised rhesus monkeys (Table 37).
To determine antigen- specificity of CMI responses in immunised 
rhesus monkeys and establish the appropriateness of the tests 
(DH, LMMI, LT) used to monitor these responses in this species,
22 normal and 17 actively immunised animals were investigated.
Of the former, 2 were tested with the DH-skin test, all with 
the LMMI test and 17 with the LT-test. Of the latter, all were 
tested with the DH-skin test, 12 with the LMMI-test and 8 with 
the LT-test.
It might have been presumed that none of the tests in the normal 
control animals, but all of the tests in the immunised animals, 
would have shown antigen-reactivity. However, table 37 shows that 
none of the DH-skin tests, but some of the LMMI and LT-tests, were 
positive in normal animals. In the LMMI-test, reactivity 
(MI<0.8) was detected for all antigens (Section 4.1.3: table 17,
KLH, PPD, TB, HBsAg). This reactivity did not seem to be associated 
with the direct toxicity of the antigens upon the migrating 
Indicator cells, since migration of normal guinea pig macrophages 
alone or mixed with normal rhesus leucocytes, produced only 2 out of
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Table 37. Summary of cumulative results of delayed (DH) and 
cellular hypersensitivities (LMMI, LT) in actively 
immunised and transfer factor-treated monkeys.
Monkeys Cumulative rates of test conversions to all antigens
DHa LMMIb LTC
Active sensitisation
Normal^ 0/5 20/269 9/162
("controls") (0%) (7%) (6%)
Immunised6 60/60 64/107 50/60
(FCA t Ag) (100%) (60%) (83%)
o
P for x d vs e < 0.001 < 0.001 < 0.01
Adoptive sensitisation
Control^ 4/18 6/52 2/37
Rh-TFp (22%) (12%) (5%)
Immune^ 17/32 58/97 5/33
Rh-TFjj (53%) (60%) (15%)
P for x2 f vs g > 0.05 < 0.001 > 0.3
aDH histology results from section 3.1.3, table 13; section 3.2.3, 
table 16.
LMMI results from section 4.1.3, table 17; Section 4.2.3, table 19.
CLT results from section 5.1.3, table 21; section 5.2.3, table 24. 
dMonkeys treated with saline or nothing.
eMonkeys immunised with FCA ± KLH or HBsAg according to protocols 
(Section 2.1, figs. la-d).
fRh-7FD prepared from normal unsensitised monkeys or monkeys Immunised 
with unrelated antlgen(s) (Section 2.2.1.,table 11).
9Rh-TFn prepared from monkeys sensitised to specific antlgen(s) (Section
2.2.1 , table 1 1).
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64 (3%) positive macrophage migration tests and 20 out of 
269 (7%) positive mixed cell migration tests (Section 8.2.1: 
tables 30-31). Thus, it seems more likely that other reasons 
like cross-reactivity of these antigens with others, to which 
the monkeys may have been sensitised, must be used to explain 
these positive results. In the LT-test, reactivity (SI>2) in 
normal animals was detected only to PPD, KLH and HBsAg 
(Section 5.1.3: table 21). The reactivity to KLH seemed to be 
associated with the potential mitogenicity of this antigen 
(Section 8.3.1). Thus, in normal animals non-specific reactivity 
to antigen was either absent (Tables 37: DH) or minimal (Table 37: 
LMMI, LT).
In contrast, the table shows that, in the immunised monkeys, 
all the DH-skin tests and the majority of the LMMI and LT-tests 
showed reactivity. This reactivity was related to active 
sensitisation of the animals by immunisation with FCA, with 
or without KLH or HBsAg (Sections 8.1.1, 8.2.2, 8.3.2). Active 
sensitisation was indicated by all the three tests as follows.
Firstly, the normal saline-injected normal control animals showed 
no reactivity to any of the skin test antigens whereas all the 
immunised animals did (Section 3.1.3: table 13, KLH, PPD, HBsAg). 
Secondly, none of the immunised animals tested showed LMMI-reactivity 
to any antigen before Immunisation (Section 4.1.2: figs. KLH: 
llb-d, PPD: 12b-e, TB: 13b-d, HBsAg: 14c-d). Thirdly, only 1 out 
of 16 Immunised animals tested showed LT-reactivity before 
immunisation, and this was to the potentially mitogenic KLH 
(Section 5.1.2: fig. 31c). Hence, inrnunisation of rhesus monkeys with
i
FCA, with or without KLH or HBsAg, led to active sensitisation 
indicated in vivo by the DH-skin test reactivity to antigen, 
and in vitro by the LMMI- or LT-reactivity to antigen.
Two methods are potentially available for examining antigen- 
specificity of the active sensitisation. Firstly comparison 
of the test results in the normal with those in the immunised 
animals, and secondly comparison of the results of tests carried 
out with related and unrelated antigens in only the immunised 
animals. In this work, DH-skin tests were not carried out with 
an antigen unrelated to the sensitising antigen(s), and the 
LMMI- and LT-tests with unrelated antigens, were only carried 
out in a few animals (Sections 8.2.2: table 32; section 8.3.2: 
table 35). Thus, to determine antigen-specificity of active 
sensitisation, the test results of the normal animals were 
compared with those of the immunised ones. This demonstrated that, 
reactivity in the DH, LMMI and LT-tests was significantly greater 
in the immunised than in the normal monkeys, indicating antigen- 
specificity (Table 37: top half, P for x2 : DH<0.001, LMMI<0.001, 
LT<0.01).
In conclusion, table 37 shows, not only that active sensitisation 
of rhesus monkeys was apparently antigen-specific, but also that 
all the three tests (DH, LMMI, LT) seemed appropriate for monitoring 
CMI responsiveness 1n this species. The DH-sk1n test emerged as 
the most appropriate test. In addition further analysis of the 
results showed that 1n actively sensitised animals the antigen- 
induced LT- and LMMI- reactivities associated with each other and
with the antigen-induced DH-skin test reactivity (Section 8.4: 
table 36). Furthermore, compared with the normal animals prior to 
immunisation, in the immunised animals there was a depression of 
PHA-induced LT-reactivity, suggesting suppression of general 
cellular responsiveness in these monkeys.
9.2. Donor-specific and non-specific in vivo activities of 
rhesus dialysable transfer factor (Table 37).
To determine the specificity of in vivo activity of dialysable 
transfer factor in the rhesus monkey model, and establish the 
appropriateness of the various tests (DH, LMMI, LT) in monitoring 
CMI responses to selective antigens, 12 normal animals were treated 
with dialysable rhesus transfer factor. The cumulative number 
of control animals monitored with DH, LMMI and LT tests was 5.
Of these, 2 received normal control transfer factor, whilst 3 
others received control transfer factor not related to the test 
antigens. In contrast, 10 test monkeys received immune transfer 
factor, prepared from rhesus monkeys immunised with FCA, with 
or without KLH or HBsAg. Of these 9 were monitored with the 
DH- and LMMI-tests and 6 with the DH, LMMI and LT-tests. The 
responses in all 10, however, were followed with at least two 
of these tests.
Assuming that the in vivo specificity of transfer factor 1n this 
species was exclusively related to antigen-reactivity of the 
donor ("Donor-specific"), then none of the tests in animals
treated with the so called control transfer factor should have 
shown reactivity. In contrast, under the same conditions, 
all the tests in animals treated with immune transfer factor 
should have shown antigen reactivity.
Table 37 shows that, in DH-skin tests carried out in 
control animals 4 tests were positive. Of these one 
occurred to PPD at the first skin test, after transfer 
factor administration, and 3 to KLH and HBsAg at the second 
skin test (Section 3.2.3: table 16). The PPD-reactivity may 
have been related to pre-exposure or priming of the recipient 
with tuberculin by Mantoux tests carried out by the suppliers 
previous to transfer factor administration. In addition, this 
so called normal control transfer factor was prepared from an 
animal which had itself been previously Mantoux tested and, 
therefore, also primed with antigen (Section 8.1.2). In contrast, 
in test animals given immune transfer factor, amongst the 17 
positive DH-skin tests shown in the table, 15 occurred to KLH,
PPD and HBsAg at times when the recipients had already been 
primed with these antigens (Section 3.2.3: table 16). Comparison 
of the cumulative DH-results showed that the likelihood of 
reactivity after treatment of animals with the immune transfer 
factor was not sifnificantly different from those after the control 
transfer factor (Table 37: P>0.0.5). This meant that the rhesus 
dialysable transfer factor did not seem to adoptively transfer 
specific CMI de novo. Thus, the in vivo specificity of rhesus 
dialysable transfer factor remains equivocal, and DH-skin test 
did not seem to be an appropriate test for monitoring antigen-speclfi
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CMI-responsiveness in transfer factor-treated animals.
In LMMI-tests carried out in control animals, the table shows 
that 6 tests were positive. Out of these 4 were due to KLH 
and 2 to HBsAg (Section 4.2.3: table 19). Reasons for such 
non-specific reactivity were not known, but both these 
antigens are complex and may have been cross-reactive with 
other substances or antigens. In contrast, in test animals 
treated with immune transfer factor, the 58 positive LMMI-tests 
included reactivity to KLH, PPD, TB and HBsAg (Section 4.1.3: 
table 17). Comparison of the cumulative LMMI-results showed 
that antigen-reactivity, after treatment of monkeys with the 
immune transfer factor, was significantly greater than that 
after control transfer factor (Table 37: P<0.001). Dialysable 
rhesus transfer factor may therefore act by specific adoptive 
"sensitisation" of a cell population concerned with initiation 
and/or production of MIF/LIF lymphokines (Section 8.2.3). The 
LMMI-test therefore indicates that the specificity of rhesus 
transfer factor was related to antigen-sensitivity of the donor 
1e. "donor-specific".
In LT-tests carried out 1n control animals, table 37 shows that 
2 tests were positive. These were due to KLH (Section 5.2.3: 
table 24). In animals treated with Immune transfer factor, out 
of the 5 positive LT-tests 4 were due to KLH and 1 to PPD 
(Section 5.2.3: table 24). Thus. 1n this test, KLH was 
predominantly responsible for the LT-react1v1ty 1n the transfer 
factor-treated animals. Comparison of the cumulative LT-results
showed that the likelihood for antigen-reactivity after treatment 
of monkeys with the immune transfer factor was not significantly 
different from that after control transfer factor (Table 37: P>0.3). 
Whilst the positive results may be interpreted as non-specific 
"adjuvant-like" activity of rhesus transfer factor, it is more 
likely that the non-specific LT-reactivity in transfer factor 
recipients was related to potential mitogenicity of KLH (Section 8.3.1).
Therefore, table 37 shows that rhesus dialysable transfer factor 
can adoptively sensitise naive animals to specific antigens.
Such donor-specific in vivo activity of transfer factor could 
only be demonstrable by the LMMI-test, and apparently not by the 
DH-skin test or the LT-test. Further analysis of the results from 
animals treated with the immune transfer factor demonstrated that 
the antigen-induced in vitro LMMI-reactivity seemed to be 
dissociated from DH-skin test reactivity (Section 8.4). This 
might be indicative of different sensitivity of these tests in the 
recipients, or preferential lymphokine production. Furthermore, 
compared with the normal animals prior to administration of transfer 
factor, there was an elevation of LT-reactivity in the recipients.
This possibly reflected a non-specific "adjuvant-like" activity also 
present in the dialysable rhesus transfer factor.
9.3. Recipient-specific in vitro augmenting activity of rhesus
and human dialysable transfer factor preparations (Table 38).
The results of in vitro lymphocyte transformation studies of human 
or rhesus dialysable transfer factor (Section 6) are summarised in
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table 38. The following conclusions can be drawn, (a) The rhesus 
dialysable transfer factor could not apparently transfer antigen- 
sensitivity to naive human lymphocytes in vitro in any of the 
tests carried out. (b) The rhesus and human dialysable transfer 
factor preparations augmented antigen-stimulated lymphocyte 
transformation in vitro (Rh-TFDM: augmenting rate =92%);
H-TFdm: augmenting rate = 77%). (c) The rhesus and human
dialysable transfer factor preparations suppressed antigen- 
stimulated lymphocyte transformation in vitro (suppression rate: 
Rh-TFp^= 8%, H-TFq^= 23%). (d) The in vitro augmenting and
suppression effects of the rhesus dialysable transfer factor 
preparation crossed the species barrier, because they were 
assayed with transformation tests using human lymphocyte or 
leucocyte culutres. (e) The in vitro augmenting activities 
of rhesus and human dialysable transfer preparations, regardless 
of the antigen-specificity of donors, reflected the degree of 
antigen-sensitivity of the "recipient" cells in culture i.e. 
"recipient-specific" (Section 6.3: Rh-TFpM and KLH; n=24, r=+0.7, 
P<0.001; Rh-TFDM and PPD: n=12, r=+0.6, P<0.005; H-TFQM and PPD: 
n=l1, r=-0.7,P<0.05).
These results suggest that the in vitro assay of transfer factor 
did not show transfer of antigen-sensitivity with rhesus dialysable 
transfer factor, but that rhesus and human dialysable transfer factor 
preparations had non-specific augmenting and suppressing activities 
in vitro.
Table 38. Summary of cumulative results of in vitro activities of rhesus
and human medium-dialysed transfer factor preparations (TF^).
In vitro 
activities 
(LT-response)
Test 
antigen 
(2-100 vg)
Cumulative rates of +ve tests (0.25 - 1.0 ml TF^)
Rh-TIW  Bh-TFim“ j H‘TFmC
antigen -ve antigen +ve M antigen -ve
S
U
M
Transfer rate KLHd 0/3 0/3 j1 0/6 ND
\ m
Augmentation KLHer 10/12 14/15 jI 36/39 3/6 jI 14/18
rate ppdt NO 12/12 j} (92*) 11/12 1f (77*)
Suppression KLHe
f
2/12 1/15 j 3/39 3/6 11 4/18
rate PPDt ND 0/12 j1 («) 1/12 j1 (23*)
a Medium-dialysed rhesus transfer factor prepared from monkeys sensitised to unrelated antigen(s) (Section 2.5.6). 
b Medium-dialysed rhesus transfer factor prepared from monkeys sensitised to specific antigen(s) (Section 2.5.6). 
c Medium-dialysed human transfer factor prepared from normal Mantoux negative donors (Section 2.5.6).
^From section 6.1, fig. 47; efrom section 6.1, fig. 48, table 27; *from section 6.2, fig. 49, table 28.
F*_____
9.4 Biochemical heterogeneity of rhesus and human dialysable 
transfer factor preparations.
Preliminary biochemical analysis of transfer factor indicated 
that normal human and monkey dialysable transfer factor 
preparations can be separated on column(s) of Sephadex G-25 
into 9 to 11 fractions (Section 7.1.1: figs. 51-53). Some 
of the fractions contain materials that adsorb to the gel, 
while others contain non-adsorbing substances. A hypoxanthine- 
rich fraction, with a high absorption ratio and eluting at 1.28 V^ ., 
was indicated in preparations derived from human and monkey blood 
(Section 7.1.1; table 29: H-TFyD, fraction G, E260/E28o = 6.54; 
Rh-TFy^gi, fraction B VII, E260/E280 = 4*39) (Section 8.7).
Such a fraction was not indicated in the preparation from monkey 
lymph node and spleen cells (Section 7.1.1, table 29: Rh-TFyp^gj) 
(Section 8.7).
Without rigorous biochemical analysis in the future, it would be 
difficult to be certain of the exact chemical composition of 
dialysable transfer factor, prepared from any species or cell 
source. More biochemical studies must be carried out with both 
crude human and rhesus monkey dialysable transfer factor 
preparations, and their purified fractions, in an attempt to 
identify and characterise the various component substances. 
Therefore, as an extension of the work here, appropriate in vivo 
and in vitro experiments, and extensive biochemical studies, 
can be designed, using fractions of rhesus and/or human dialysable
ft . .
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transfer factor preparation, in an attempt to locate and 
chemically characterise the fractions with various specific 
and/or non-specific activities.
ABBREVIATIONS
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g
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hr
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H-TF
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Carbon dioxide 
Curie per milli-mole 
Cell-mediated inmunity 
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Caesium chloride 
Delayed hypersensitivity 
Deoxyribonucleic acid 
Di ni trochlorobenzene 
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Et alia (and others)
Eagle's minimum essential medium 
Extinction coefficient at 260 nm 
Extinction coefficient at 280 nm 
Freund's complete adjuvant 
Freund's incomplete adjuvant 
Figure 
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Hepatitis B surface antigen 
Hour
Trltiated methyl thymidine 
Human transfer factor 
Mitogenic factor 
Non-specific 
Old tuberculin
Level of significance (<0.05, significant) 
Phytohaemagglut1n1n
Purified protein derivative of tuberculin
PL Purified lymphocyte culture
Rh-TF Rhesus monkey transfer factor
Rh-TFp 
Rh-TFVD 
R^”TF WD
SEM
Rhesus monkey dialysable transfer factor 
Vacuum-dialysed rhesus monkey transfer factor 
Water-dialysed rhesus monkey transfer factor 
Medium-dialysed rhesus monkey transfer factor 
Standard error of the mean
SI Stimulation index
SRF Skin reactive factor
SK-SD Streptoki nase-Streptodornase
TB Particulate tubercle bacilli (killed)
TF Transfer factor
tfd
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T.U.
Dialysable transfer factor 
Non-dialysable transfer factor 
Tuberculin unit
U/ml
Ve
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Vt
X2
Units per milli-litre 
Elution volume 
Void volume 
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Chi squared test with Yate's correction.
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APPENDIX: test materials 
Acetic Acid
Type:
Code:
glacial
27013
From: BDH Co. Ltd.,
Poole,
England.
Ammonium Bicarbonate
Code: 10302
From: BDH Co. Ltd.
Ampoules
Type:
Use:
5 ml - 20 ml volumes.
to store freeze-dried dialysable leucocyte transfer
From:
factor.
Adel phi (Tubes) Ltd., 
20-21, Duncan Terrace, 
London, N.l. 
837-2959/9459
Bung
Type: 
Size: . 
From:
silicone rubber
No. E27; to fit Buchner Flask: 33 mm diameter 
ESCO (Rubber) Ltd.,
14-16 Gt. Portland Street,
London, WIN 5AB,
England.
318
Caesium chloride (CsCl)
Type: analar, 168.36 M.Wt.
From: BDH Co. Ltd.
Capillaries 
Code: 1604
Type: Micro-haematocrit centrifuge tubes (plain: 59 pi).
From: Gelman-Hawksley Ltd.,
12 Peter Road,
Lancing,
Sussex,
England.
Cover Slips
Type: round, glass
Code: No. 1
Size: 22 mm diameter
From: Chance Propper Ltd. 
Smethwick,
Waley,
England.
Crucible
Type: nickel
Code: CW-310
Size: 35 mm x 35 mm
From: Gallenkamp 
P.0. Box 290, 
Technlco House, 
Christopher Street, 
London, EC2P 2ER, 
England
Crystal Violet (counting dye)
Type: crystals
Code: 34024
From: BDH Co. Ltd.
Preparation: Stock solution (0.1% cv)
Crystal Violet (cv) ........ 0.1 gm
Acetic acid (3%) ............ 100 mis
Mixed and filtered through Whatman filter paper to remove 
c.v. sediments. Stored at room temperature. Cells were 
diluted 1/20 as follows and counted in an improved 
Neubaur haemocytomer:
Eagles MEM 0.9 mis
c.v. (0.1%) 1 .0 ml
cell suspension 0 .1 ml
Deoxyribonuclease (DNase: pure)
Type: from bovine pancreas
Code: DCLIIS; 11 mg vials
Store: +4°C
From: Cabrian Chemicals Ltd.,
Suffolk House,
George St.,
Croydon CR9 3QL,
England
Preparation: Stock solution: 1 mg/ml
DNa'se (pure) ................11 mg
Non-pyrogen1c distilled water.11 mis
Mixed and sterilised by filtration through 0.22 u mllllpore 
filter. Stored at -20°C in 1 ml aliquots.
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Deoxyribonuclease I (DNa'se I: crude)
Type: from beef pancreas
Code: DN-25; 10 mg vials
Store: +4°C
From: Sigma London Chemical Co. Ltd.,
Norbiton Station Yard,
Ki ngston-Upon-Thames,
Surrey KT2 7BH 
England.
preparation: Stock Solution: 1 mg/ml
DNa'se I .....................10 mg
Non-pyrogenic distilled water.10 mg
Mixed sterilised by filtration through 0.22 u millipore
filter. Store at -20°C in 1 ml aliquots.
Dextran
Type: Grade A powder; 200,000 - 275,000 M.W.
From: Fisons Laboratory Reagents,
Loughborough,
Leicestershire,
England.
Preparation: (a) Stock dextran: 6% solution
Dextran...................... 6 gms
Sterile Normal Saline .......  100 mis
Mixed and sterilised through 0.45 g millipore stored 
at -20°.
(b) Stock dextran: 1.5% solution
6% Dextran  ..............  1 vol.
Hank's solution.............  3 vols.
Mixed and stored at +4°C.
!Deoxyribonuclease I (DNa'se I: crude)
Type: from beef pancreas
Code: DN-25; 10 mg vials
Store: +4°C
From: Sigma London Chemical Co. Ltd.,
Norbiton Station Yard,
Ki ngston-Upon-Thames,
Surrey KT2 7BH 
England.
preparation: Stock Solution: 1 mg/ml
DNa'se I ..................... 10 mg
Non-pyrogenic distilled water.10 mg
Mixed sterilised by filtration through 0.22 y mi Hipore
filter. Store at -20°C in 1 ml aliquots.
Dextran
Type: Grade A powder; 200,000 - 275,000 M.W.
From: Fisons Laboratory Reagents,
Loughborough,
Leicestershire,
England.
Preparation: (a) Stock dextran: 6% solution
Dextran......................  6 gms
Sterile Normal Saline .......  100 mis
Mixed and sterilised through 0.45 y mi 111pore stored 
at -20°.
(b) Stock dextran: 1.5% solution
6% Dextran ...................  1 vol.
Hank's solution .............  3 vols.
Mixed and stored at +4°C.
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Dialysis tube
Type: Visking tube
Size: 8/32 mm
From: Scientific Instruments Ltd.
1 Leeke Street,
London W.C.l.,
England.
Eagle's Minimum Essential Medium (EMEM)
Type: Stock EMEM xlO with Earle's salts but without
sodium bicarbonate.
Code: 1-013M
Vols: 500 ml bottles
Store: +4°C
From: Flow Laboratories (U.K.),
P.0. Box 17,
Second Avenue Industrial Estate,
Irvine KA12 8NB,
Scotland.
Preparation: Stock EMEM (IX)
EMEM (10X) .................  50 mis
NaHC03 (7.5%) ..............  13.4 mis
L-glutam1ne (200 mM) .......  5 mis
Benzyl Penicillin
(4 x 105 Units) ............ 0.5 ml
Streptoinycln Sulphate
(4 x 105 ug/ml) ............  0.025 ml
Distilled water............  430 mis
Prepared on day of each experiment and used with uninactivated 
horse serum (10-20%) for migration tests,and used without 
serum for lymphocyte transformation tests done for normal,
actively and adoptively sensitised Rhesus monkeys.
Fibre Glass Filter
Grade: GF/A
Size: 2.5 cms
From: Whatman Lab. Sales Ltd.,
Springfield Mill, 
Maidstone,
Kent ME!4 2LE,
England.
Fi coll
Type: 400,000 M.W.; powder
Store: +4°C or room temperature
From: Pharmacia Ltd.,
Box 175,
S-75104,
Uppsala 1,
Sweden.
Preparation: Stock (6%)
Ficoll .....................  6 gms
Distilled water............  100 mis
Stirred while gradually adding powder. Stored at +4°C.
Ficoll/Triosil mixture
Preparation: Stock solution
Triosil (45.5%) ............  10 vols
Ficoll (6%).................  24 vols
Mixed and sterilised by filtration through 0.45 y millipore, 
stored at +4°C and used on same day. Used to separate 
lymphocytes from peripheral blood leucocytes. Ratio of 
Ficoll/Triosil mixture to leucocytes was 1:2 respectively.
Flask (glass)
Type : Buchner
Size: 500 mis
Code: 1170/06
From: Jobling Laboratory Division,
Stone,
Staffordshire, STT5 OBG 
England.
Formaldehyde
Type: 37%-41% concentrated
Code: 284216 N
From: BDH Chemicals Ltd.
Formal Saline
preparation: 10% Stock Solution
Formaldehyde ...............  1 vol.
Saline (0.85% NaCl) ........  9 vols
Made 1 litre stock solutions and stored at room temperature. 
Used as fixative to store rhesus monkey skin biopsies 
before despatch to Miss Rosemary Ellis for cutting and 
staining with Cole’s Haematoxylin and Eosin.
Flasks
Type: round bottom, glass
Size: 1 litre
From: Gallenkamp
I»f£-
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Freeze Dryer
(a) Model: 
From:
(b) Model: 
From:
EF03
Edwards High Vacuum Plant, 
BOC Ltd.,
Manor Royal,
Crawley,
Sussex,
England.
Virtis 10-MR-ST 
Techmation Ltd.,
58 Edgware Way,
Edgware,
Middlesex, HB88JP,
England.
Freund's Incomplete Adjuvant (FIA)
Type: 10 ml ampules
From: Difco Laboratories,
Detroit 1,
Michigan,
U.S.A.
G1 utamine (200 nfi)
Type: L-glutamine
Code: 6-134C; 50 mis volumes.
Store: -20°C
From: Flow Laboratories Ltd.,
P.0. Box 17,
Victoria Park, 
Heatherhouse Road, 
Irvine KA 128NB, 
Scotland.
m. »i »  r  *■'
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Guinea Pig (Hartley Albino)
Weight: mean = 800 grams
Sex: female
From: Tuck and Sons Ltd.,
Laboratory Animal Breeding Station,
Rayleigh,
Essex,
England.
Haemocytometer
Type: improved Neubauer,
Code: MD-210
From: Gallenkamp.
Hank's Balanced Salt Solution (HBSS)
Type: Packs A and B.
Code: BR 19.
Store: +4°C
From: Oxoid Ltd.,
London SE1 9HF,
England
Preparation: Stock Solution xl
Packs A and B were each dissolved 1n 100 mis of deionised 
water and stored at +4°C as lOx stock solutions. Before 
each set of experiments, however, the following lx solution 
was made.
Solution A (10 x ) ...........  100 mis
Solution B (10 x ) ...........  100 mis
Deionised HgO ..............  800 mis
Mixed and autoclaved at 121°C for 15 minutes. Cooled to 
room temperature and 25 mis of sterile 1.4% sodium 
bicarbonate solution were added (see sodium bicarbonate). 
Stored at 4°C in aliquots of 200 mis for pepltoneal washings 
of oil-injected guinea pigs and preparation of 1.5% dextran 
solution.
Guinea Pig (Hartley Albino)
Weight: mean = 800 grams
Sex: female
From: Tuck and Sons Ltd.,
Laboratory Animal Breeding Station, 
Rayleigh,
Essex,
England.
Haemocytometer
Type: improved Neubauer,
Code: MD-210
From: Gallenkamp.
Hank's Balanced Salt Solution (HBSS)
Type: Packs A and B.
Code: BR 19.
Store: +4°C
From: Oxold Ltd.,
London SE1 9HF,
England
Preparation: Stock Solution xl
Packs A and B were each dissolved 1n 100 mis of deionised 
water and stored at +4°C as lOx stock solutions. Before 
each set of experiments, however, the following lx solution 
was made.
Solution A (10 x) ...........  100 mis
Solution B (10 x) ...........  100 mis
Deionised HgO ..............  800 mis
Mixed and autoclaved at 121°C for 15 minutes. Cooled to 
room temperature and 25 mis of sterile 1.4% sodium 
bicarbonate solution were added (see sodium bicarbonate). 
Stored at 4°C In aliquots of 200 mis for pepltoneal washings 
of o1l-1njected guinea pigs and preparation of 1.5% dextran 
solution.
I* OE-
326
Harvesting Apparatus 
Type:
Apparatus:
From:
for lymphocyte transformation harvesting. 
Buchner Flask code: (see above).
Glass funnel, code: XX1002533 
Metal grid, code: - 
Metal Clip, code: XX1002503 
Complete set, code: XX1002530 
Millipore S.A.
46 Bis Rue Louis Blériot,
78530 Bue,
France.
Heparin (freeze-dried: mucous)
Type: preservative-free
Cone.: 20,000 U/vial
Store: +4°C
From: BDH Laboratory Reagents.
Preparation: Stock Solution; 1000 U/ml
Heparin (1 vial) ............... 20,000 Units
Non-pyrogenic saline ........... 20 mis
Mixed and sterilised by filtration through 0.22 w Millipore 
and stored at +4°C in 5 ml aliquots.
Heparin (solution: mucous)
Type: preservative-free
Cone. : 1000 Un1ts/ml
Store: +4°C
From: Weddel Pharmaceuticals Ltd
London, EC1A 9H7,
England.
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Hepatitis B Surface Antigen (HBsAg)
Stock purified HBsAg type ad was prepared by 2 methods:
a) Caesium chloride method
A modified technique of Gerin et al was used. HBsAg protein 
from serum of a healthy chronic carrier was precipitated 
with polyethylene glycol or PEG solution (5_1 V/V: final 
concentration of PEG was 5.52). This was left at +4°C 
overnight. The precipitate was collected and resuspended 
in 0.01 M Tris buffer pH 7.4 (l/12th volume or original 
mixture). 1 ml of HBsAg-rich precipitate was loaded onto 
5 ml CsCl gradient (1.1, 1.2, 1.3 gms/ml density: W/W in 
Tris buffer). Loaded gradient was imnediately spun for 18 
hours at 35,000 r.p.m. at +4°C. Aliquots of 0.1 ml were 
collected and tested with Wellcome haemagglutination test 
for HBsAg. Aliquots, with positive results at 1/512 
dilutions, were pooled and dialysed for 24-48 hours in 
3 x 5  litre changes of phosphate buffered saline at 4°C.
Protein concentration of purified HBsAg was determined by 
measurement of extinction at 280 nm in Unican Spectrophonometer 
and stored at -20°C. Hepatitis B surface antigen banded 
at 1.175 to 1.223 CsCl density.
b) Sucrose gradient method
Human serum, from a healthy chronic carrier of HBsAg, was 
spun at 25,000 r.p.m. in SW27.1 rotor for 18 hours in a 
Sorvall OTD-2 ultracentrifuge at +4°C. Supernatant was 
decanted and HBsAg-rich pellet resuspended in 1-2 mis 
of 0.01M Tris buffer (Sigma: pH 7.4). 1 ml suspension of
this pellet was loaded onto 15 ml Sucrose gradient (60%,
40%, 20% solution: W/W in Tris buffer). After 6 hours at 
+4°C one millilitre fractions were tested as above for 
HBsAg and pooled.
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In this case 2 mg/ml stock solution was made in Eagle's MEM 
and stored in 1 ml aliquots at -2U°C. Hepatitis B surface 
antigen floccule was seen in a layer between 40-60% sucrose 
solution.
Immunogen: Freund's Complete Adjuvant (FCA)
preparation: FCA; 3 mg/ml TB
F I A .................10 mis
TB (finely ground) ..30 mg
Mixed under pressure using a syringe and suspension used 
to actively immunise rhesus monkeys.
Immunogen: Hepatitis B surface antigen in Freund's complete
adjuvant
Preparation: HBsAg/FCA
HBsAg (2 mg/ml: purified ........ 1 vol.
FCA (6 mg TB/ml) ................ 1 vol.
Thoroughly mixed under pressure using a syringe and used on 
same day to Immunise rhesus monkeys. Immunogen contained 
1 mg HBsAg and 3 mg particulate TB.
Immunogen: Keyhole limpet haemocyanin in Freund's complete
adjuvant.
Preparation: KLH/FCA
KLH (2 mg/ml or 200 yg/ml) ....  1 vol.
FCA (6 mg TB/ml) ............... 1 vol.
Thoroughly mixed under pressure using a syringe and used on 
same day (or stored at +4°C) for active immunisation of rhesus 
monkeys. Immunogen contained 1 mg/ml or 100 yg/ml KLH and 
3 mg particulate TB.
"Ketalar"
Code: 
Cone.: 
Store: 
From:
(Ketamine hydrochloride)
PLR 0018/5118 
50 mg/ml; 10 ml vials 
Dark and cool place 
Parke-Davis Co., 
Pontypool,
South Wales,
U.K.
Keyhole Limpet Haemocyanin (KLH)
Type: Grade B/l gm in 65% saturated ammonium sulphate
slurry containing 46.9 mg/ml protein.
Code: 374811
From: Calbiochem Ltd.,
Thorpe House,
King Street,
Hereford HR4 9BQ,
England.
Preparation: Stock solution: 4.9 - 5.2 mg/ml
To remove ammonium sulphate, 2 mis KLH slurry (= 100 mg KLH) 
was diluted to 50 mis with non-pyrogenic saline. This was 
concentrated over an Ami con PM10 Ultrafiltration membrane 
at +4°C. The retentate was diluted to approximately 60 mis 
with saline and reconcentrated 3 times over the same 
membrane. The washed retentate was made up to 5 mis with 
saline. This stock solution now contained less than 20 pg/ml 
ammonium sulphate and 4.9 or 5.2 mg/ml protein. The actual 
protein concentration of KLH used was determined by 
measurement of extinction at 280 nm (Eggg 1 .8 = 1 mg/ml).
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Methanol
Type: analar
Code: 10158
From: BDH Co. Ltd.
Migration Plates
Type: 12 wells/plate
Code: 132
From: Steri lin,
43-45 Broad Street, 
Teddington,
Middlesex, TW11 8QZ, 
England.
Millipore Filters
Types: 22 y, 45 y
Size: 10-50 mm diameter
From: Millipore S.A.
Minimum Essential Medium - S (MEM - S)
Type:
Code:
Store
From:
Preparation:
tissue culture medium for suspension cultures 
(IX); without glutamine.
138; 500 ml bottles 
+4°C
Gibco-Biocult 
Washington Road,
Abbetslnch Industrial Estate,
Paisley, PA3 4ER 
Scotland
MEM - S/glutamine
. MEM - S (IX ) ......................  100 mis
L-glutamine (200 mM) ..........1 ml
* W
Made on same day as experiments. Used with U  glutamine in 
suspension of leucocytes or lymphocytes for in vitro tests 
with dialysable leucocyte transfer factor. However, used 
without glutamine in dialysis of rhesus monkey or human 
leucocyte lysates for preparation of medium-dialysed 
transfer factor materials.
Needles (Sterile, disposable)
Sizes and
Types: Large: 19 G 1J: 40/11
Medium: 21 G 1J: 40/8
Small: 25 G §: 16/5
From: Yale Microlance,
Becton Dickinson Co. Ltd.,
Dun Laoghaire,
County Dublin,
Ireland.
Old tuberculin
Type: 1/100 O.T. solution = 100 TU/0.1 ml
From: Evans Medical,
C/0 Vestries Ltd.,
P.0. Box 21,
Lockfield Avenue,
Enfield, Middlesex,
England.
Paraffin Oil
Type: Light liquid - specific gravity 0.865 to 0.890
Code: 29834
From: BDH Co. Ltd.
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Penicillin
Type: 
Cone. : 
From:
preparation:
Benzyl Penicillin (sodium) B.P. 
600 mg (1,000,000 Units)/vial 
Glaxo Laboratories Ltd, 
Greenford, Middlesex,
England.
Stock; 4 x 10^ Units/ml
Benzyl penicillin .........  1 vial
Distilled w ater...........  2.5 mis
Mixed on day of experiment and stored at +4°C not longer 
than 1 week for use in preparation of EMEM IX.
Phosphate Buffered Saline (PBS) 
Type: tablets
From: Oxoid Ltd.
preparation: Stock solution
Tablet ..................... 10
Distilled wa te r...........  1000 mis
Mixed and stored at 4°C.
Phytohaemagglutinin (PHA)
Type: Reagent grade: freeze dried ampules
Code: HA15
From: Mel1 come Reagents Ltd.,
Beckenham, BR3 3BS,
England.
preparation: Stock solution: 1 mg/ml
PHA ........................ 1 ampule
♦ E M E M ....................... 40 mis
Mixed and sterilised by filtration through 0.22p mill1pore. 
Stored 1n 1 ml aliquots at -20°C.
* EMEM ■ tissue culture medium without horse serum.
Planimeter
Model: Sliding bar and fixed index.
From: W.F. Stanley Co. Ltd.,
Avery Hill Road,
New El than),
London SE9,
England
POPOP (2-4-methyl-5-phenyl-oxazolyl-benzene)
Store: in dark
From: Koch-Light Laboratories Ltd.,
Colnbrook,
Bucks,
England.
PPO (2,5-diphenyloxazole)
From: Koch-Light Laboratories Ltd.
Polyethylene glycol (PEG)
Type: laboratory grade
Code: P-2263
From: Sigma Chemical Co.,
P.0. Box 14508,
St. Louis,
Mo. 63178,
U.S.A.
Purified Protein Derivative (PPD)
Type: neutralised freeze-dried powder of human
tuberculin.
Code: 292
334
From: Tuberculin Section,
Ministry of Agriculture, Fisheries and Food, 
Central Veterinary Laboratory,
New Haw, Weybridge,
Surrey, England
preparation: Stock PPD: 1 mg/ml
P P D .........................100 mg
*EMEM ........................
Mixed and placed in 37°C water-bath for a few hours. 
Sterilised by filtration through 0.22wmillipore filter. 
Stored in 1 ml aliquots at -20°C.
*EMEM = tissue culture medium without horse serum
Rhesus monkey (Macaca mulatta)
Sex: Male and Female
Weight: 3.5 - 8.0 Kg
From: Shamrock Farms (G.B.) Ltd.,
Upper Horton Farm,
Small Dole,
Nr. Henfield,
Sussex, England.
'Safety Cabinet"
Type: Laminar Flow
Size: 6 foot
From: Microflow Ltd.,
Fleet Mill,
Mlnley Road, 
Fleet, Aldershot,
Scintillation Counter (e-counter)
Type: Spectro/matic and Coruymatic 200.
From: Tracerlab Instrument Division
2 Riverdene Industrial Estate, 
Molesey Road,
Hersham, Surrey KT12 4RG 
England
Scintillation Fluid
preparation: For e-sclntillation counting
PPO ........................ 4 gins
P0P0P ...................... 0.1 gm
Toluene .................... 1 litre
Mixed and placed in 37°C waterbath overnight. Stored in 
dark at room temperature.
Scintillation Vials
a) Type: 
From:
b) Type: 
From:
Plastic
Griffiths and Nielson Plastics Ltd., 
Huffwood Trading Estate,
Brookers Road,
Blllingshurst,
Sussex, England 
Glass
Packard Instruments Ltd.,
Caversham Bridge House,
13-17 Church Road,
Caversham,
Berks R64 7AA,
England
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Sephadex G-25
Type: Medium or dry particle diameter of 50-150 p
Fractionation
Range: 1000-5000 M.W.
From: Pharmacia Fine Chemicals Ltd.
preparation: Fractionation columns
Sephadex beads were swollen overnight at room temperature 
in ammonium bicarbonate-acetic acid buffer pH 7.4 ("volatile" 
buffer). One to two chromatographic columns of 1.6 x 90 cms 
each were poured at room temperature. Columns were 
equilibrated before use by washing with 3 bed volumes of 
buffer at +4°C using a flow rate of 20 mis per hour.
Serum (horse)
Type: preservative-free, uninactivated
Code: HS38
Store: -20°C
From: Wellcome Reagents Ltd.
Sieve
Type: nickel; hemispherical
Size: to fit matching crucibles (see crucible)
From: R. Cadish and Sons,
Arcadia Ave.,
Regents Park Road,
Finchley, N3 
London, England
Sodium Biocarbonate (7.5% W/V)
Code: 7-041D
Vol: 100 ml bottles
Store: +4°C
From: Flow Laboratories Ltd.
#
Unicam SP500 series 2. 
Pye-Unicam Ltd., 
Cambridge,
England.
Spetrophotometer
Streptomyci n
Type:
Cone.:
From:
Preparation:
Streptomycin sulphate B.P. 
1 ,000,000 pg/vial 
Glaxo Laboratories Ltd.
5
Stock; 4 x 10 A^ g/ml
Streptomycin Sulphate .....  1 vial
Distilled water ...........  2.5 mis
Mixed on day of experiment for immediate use and stored at 
+4°C not longer than 1 week for subsequent use in 
preparation of EMEM IX.
Stopcock grease
50 gms tubes
to grease migration plates 
Dow Corning Ltd.,
Barry,
Glamorgan,
U.K.
Sucrose (c12H22°n)
from sugar cane, analar, 342.30 M.Wt. 
BDH Co. Ltd.
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Syringes
Types: 1-50 mis
From: Plastipak,
Becton Dickenson Co. Ltd., 
Dun Laoghaire,
Co. Dublin,
Ireland
Toluene
Type: analar; CgHgCHj = 92.14
Size: 2.5 litre bottles
From: BDH Chemicals Ltd.
Test-Tubes (glass)
Type: rimless: for in vivo experiments.
Size: 5" x J"
From: Gallenkamp
Test-Tubes (plastic)
Type: Disposable, round bottom: for in vitro experiments.
Size: 100 x 14/15 mm
From: Primax Plastic,
Weasenham Lane,
Wisbech,
Cambs.
England.
Preparation: Washing
Tubes were placed Into 2% hydrochloric acid overnight.
Rinsed twice under tap water for a few hours, and finally 
washed a few times with deionised water. They were dried, 
loosely capped and sterilised 1n the hot oven at 160°C for 
2 hours. Sterile capped tubes were used for lymphocyte 
transformation 1n the in vitro study of dialysable leucocyte 
transfer factor..
*
Test-Tube Caps (metal)
Type: plain
Code: TTA3
From: Oxoid Ltd.
Trichloroacetic Acid (TCA)
Type:
From:
CAUTION:
Preparation:
analar/CCl3 .COOH = 163.39 
BDH Chemicals Ltd.
Poison
Stock solution 5%
T C A ..........
Distilled Water 
Mixed and stored at 4°C.
5 gms 
100 mis
Triosil (or "Hypaque")
Type: 5 x 20 mis or 10 x 50 mis ampules
Store: +4°C in dark
From: Vestric Co. Ltd.,
Runcorn,
Cheshire,
U.K.
Preparation: Stock (45.5%)
Triosil .................... 20 mis
Distilled W a te r...........  24 mis
Stock solution stored in foil-wrapped dark bottle at +4°C
Tris buffer
Preparation: Stock Solution (0.01M, pH 7.4)
Trlzma (HC1) ..............  1.322 gms
Trlzma (Base) .............  0.194 gms
Distilled Water ...........  1-0 l
Made up in 1 litre volumetric flask and stored at +4°C.
Tritiated Methyl Thymidine (H-jT)
aqueous solution; 1 ml vials 
1 mCi/ml
5-19 Ci/mM
The Radiochemical Centre,
Amersham, England, 
a) Stock Solution (100 ><-Ci/ml)
H3T (ImCi/ml) .........  1 ml
Non-pyrogenic saline ... 9 mis
Mixed and stored at +4°C until before each set of experiments 
This was diluted further as follows:
Type:
Cone.: 
Specific 
Activity: 
From:
Preparation:
b) Stock solution (ItyCi/ml)
H3T (100 Ci/ml ) ....... 1 vol
*EMEM (1 x without serum).9 vols 
0.1 ml (= l/*Ci) of this concentration (10/<-Ci/ml) was used 
for pulsing lymphocyte transformation tests in experiment 
for in vivo study of dlalysable leucocyte transfer factor. 
* For in vitro study EMEM was replaced by MEM-S.
Tubercle bacilli (particulate TB)
Type: heat killed freeze dried mycobacteria
From: Tuberculin Section,
Ministry of Agriculture, Fisheries and Food, 
England.
Preparation: Stock TB: 1.5 mg/ml
TB (ground, autoclaved for
15 mins/15 lbs p.s.1) . 150 mgs
♦EMEM......................  100 mis
Thoroughly mixed and stored at +4°C 1n 1 ml aliquots.
* EMEM = tissue culture medium without horse serum.
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Tritiated Methyl Thymidine (H^T)
Type: 
Cone.: 
Specific 
Activity: 
From:
aqueous solution; 1 ml vials 
1 mCi/ml
5-19 C1/mM
The Radiochemical Centre,
Amersham, England.
Preparation: a) Stock Solution (lOO^Ci/ml)
H3T (lmCi/ml) .........  1 ml
Non-pyrogenic saline ... 9 mis
Mixed and stored at +4°C until before each set of experiments 
This was diluted further as follows:
b) Stock solution (10/tCi/ml)
H3T (100 Ci/ml ) ....... 1 voi
*EMEM (1 x without serum).9 vols 
0.1 ml (s l/*Ci) of this concentration (lO/M-Ci/ml) was used 
for pulsing lymphocyte transformation tests in experiment 
for in vivo study of dlalysable leucocyte transfer factor. 
* For in vitro study EMEM was replaced by MEM-S.
Tubercle bacilli (particulate TB)
Type: heat killed freeze-dried mycobacteria
From: Tuberculin Section,
Ministry of Agriculture, Fisheries and Food, 
England.
Preparation: Stock TB: 1.5 mg/ml
TB (ground, autoclaved for
15 mins/15 lbs p.s.1) . 150 mgs
♦ E M E M ......................  100 mis
Thoroughly mixed and stored at +4°C in 1 ml aliquots.
* EMEM - tissue culture medium without horse serum.
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Trizma (Base, HC1 )
Types : a) Base: 121.1 m.wt., No. T-1503
b) HC1 : 158.0 m.wt., No. T-3253
Grade: reagent
From: Sigma Chemical Co.
Universal (sterile)
Code: 128C, plastic
Type:
From:
plain label, 30 mis volume 
Steril in.
'Volatili' fractionation buffer (pH 7.4)
Type:
Preparation:
0.02M ammonium bicarbonate/acetic acid pH 7.4 
For fractionation purposes
Amm. Bicarb, (analar) .....  7.9 gms
Acetic Acid (2M:analar) .... 2.9 gms
Made up to 5 litres with deionised water and stored at +4°C.
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TRANSMISSION O F HEPATITIS B TO THE RHESUS MONKEY
A.J. Zuckerman. G. Scalise, M .R. Mazaheri, Jenny Kremastinou, 
C.R. Howard and K. Sorensen
ABSTRACT
The rhesus monkey does provide a suitable laboratory animal model fo r studying hepatitis 
B virus and for investigating various aspects of interaction between this infectious agent and 
the host. This species of non-human primate, however, olfers a less sensitive animal model 
for hepatitis B infection than the chimpanzee.
There have been many attempts to transmit hepatitis B virus to non-human 
primates and these studies have yielded, until recently, equivocal or negative 
results. The finding of hepatitis B surface antigen and antibody in the serum of 
a small proportion of chimpanzees, orangutans and gibbons renewed interest 
in the possibility that these primates might serve as a suitable experimental model 
for hepatitis B.
Hepatitis B surface antigen and surface antibody have been detected in 
6-12% of captive chimpanzees when tested by relatively insensitive techniques. 
Most of the animals appear to be healthy carriers of the antigen. Hepatitis B 
surface antibody was found in a significant number of captive non-human pri­
mates when sensitive techniques such as passive hemagglutination and radioimmu­
noassay had been used. Antibody was detected in the chimpanzee, orangutan, 
gibbon, baboon, Celebes ape, patas monkey, vervet, several species of macaque, 
mangabey and langur and in a number of species of New World monkey. Antibody 
was found in about 50% of chimpanzees examined but in less than 10% of most 
Old World and New World monkeys (5, 7). It appears that much of the difficulty 
which had been experienced in the past was due to the unknown susceptibility 
of these animals before experimentation and the relatively mild nature o f the 
infection.
Recent studies have shown that although hepatitis B in chimpanzees is 
consistently mild, as shown by modest serum transaminase enzyme elevations 
without jaundice or overt signs of illness, the serological responses are identical 
t<> those seen in man and further that susceptible chimpanzees are almost ts
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sensitive to infection with hepatitis B virus as man (1). However, the practical 
obstacles to the use of chimpanzees for studying infection with hepatitis B virus 
include the strictly limited availability and expense of these non-human primates.
Transmission o f  hepatitis B  to the rhesus monkey
London e t al. (1972) reported the successful serial transmission in rhesus 
monkeys (Macaco mulata) of an infectious agent, which stimulated an antibody 
response to hepatitis B surface antigen. The infection was inapparent and it 
was not associated with biochemical evidence of liver damage nor with histolo­
gical changes in the liver. Hepatitis B surface antigen was demonstrated in low 
titre and transiently in some of the sera by solid-phase radioimmunoassay. The 
antibody responses measured by radioimmunoprécipitation and passive hemagglu­
tination were similar in pattern to those observed in man following either natural 
or artificial infection with hepatitis B virus. Successful transmission was achieved 
through five serial passages in rhesus monkeys. Although the rhesus monkey 
is less susceptible to human hepatitis B virus, it does provide a more accessible 
animal species for the experimental study of this infection.
Zuckerman (1972) postulated that the high prevalence of hepatitis B antigen 
in many tropical countries may be related to changes in the immunological 
response associated with a background of repeated parasitic infection and in 
particular to the immunosuppressive effect of malaria. An extension of this 
hypothesis was the induction of chronic infection with Plasmodium inuei in the 
rhesus monkey in an attempt to enhance the susceptibility of this species of non­
human primate to hepatitis B virus.
Malaria and hepatitis B injection in the rhesus monkey
Sera from young rhesus monkeys were screened for hepatitis B surface antigen and hepa­
titis B surface antibody by solid-phase radioimmunoassay before they were admitted to the 
study. The animals were divided into small groups consisting of uninoculated controls, those 
infected chronically with Plasmodium inuei, a group inoculated intravenously with 0.23 ml of 
a well-characterized serum known to have induced clinical post-transfusion hepatitis in man 
and containing hepatitis B surface antigen subtype adw, and a small number o f animals inocu­
lated with the same hepatitis B infective serum after chronic infection with malaria was fully 
established.
Serum samples were tested for hepatitis B surface antigen and antibody by solid-phase 
radioimmunoassay. Results for antigen were considered positive only after neutralization with 
specific human antibody. Liver biopsies were examined histologically and sections were also 
stained for cytoplasmic hepatitis B surface antigen after Shikata et at. (1974). Finally, cellular 
hypersensitivity was examined by the mixed leucocyte-macrophage migration test (3) whole 
blood lymphocyte transformation and by intradcrmal tests and skin biopsy. The results of 
the studies of cell-mediated immunity will be the subject of another report.
Hepgtitit B surface antigen was detected in the serum of four out of six 
rhesus monkeys previously infected with malaria. The antigen was demonstrated 
in one animal on the day of inoculation, presumably due to the antigen present
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in the original inoculum, and the antigen was subsequently found repeatedly 
in the serum of this subject for 45 days. Surface antibody was first detected 
12 days after inoculation and it has persisted in the serum so far for 18 months. 
The presence of circulating hepatitis B antigen-antibody complexes was confirmed 
by electron microscopy. In another monkey the antigen was first detected 18 
days after inoculation and it persisted for 30 days. An antibody response followed 
54 days after inoculation. In the third animal the antigen was first found 4 days 
after inoculation and it remained in the circulation for 45 days without a detect­
able antibody response. Antigen was detected for one day only 25 days after 
inoculation in another animal, again without an antibody response (Figure 1). 
There was no detectable antigen or antibody in the remaining two monkeys 
in this group.
Fig. I. HB,Ag and anti-HB, response in rhesus monkeys infected with malaria and hepatitis B.
Hepatitis B surface antigen was not found by radioimmunoassay in any 
of four animals inoculated with hepatitis B only. An antibody response was 
elicited in only one of these rhesus monkeys, 54 days after infection, and the 
antibody has persisted for some months.
Serum containing hepatitis B antigen was collected from two of the success­
fully infected rhesus monkeys and I ml was administered intravenously to three 
animals previously infected chronically with Plasmodium inuei. Hepatitis B 
surface antigen was detected in the serum of one of these animals 49 days after 
inoculation, but an antibody response has not been observed. Further passages 
are in progress.
Infection with hepatitis B in these rhesus monkeys was subclinical, specific 
histological changes in the liver were not seen and the surface antigen was not 
detected in the liver by staining with orcein or with aldehyde fuchsin.
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SENSITISED AND TRANSFER-FACTOR TREATED RHESUS MONKEYS.
D u ra o n d e , D.C., Mazaheri, M.R., Kremastinou, J., Scalise, G., 
Anne Hamblin and Zuckerman, A.J. Kennedy Institute of 
Rheumatology, London, England; & Dept.of Microbiology,London 
School of Hygiene and Tropical Medicine.
Summary and introduction
A convenient test of cellular hypersensitivity is described 
for studying the response of rhesus monkeys to the injection 
of transfer factor. Dextran-prepared monkey leucocytes 
(>50% lymphocytes) are mixed with guinea pig peritoneal 
exudate cells (PEC) in the ratio 70% PEC to 30% leucocytes. 
The mixed cell population is packed in capillaries and 
migrated in 12-well disposable chambers using 20% horse 
serum: Eagles MEM. Monkeys actively sensitised with 
haemocyanin (KLH) and Freund's complete adjuvant (FCA) exhi­
bited strong delayed hypersensitivity reactions when skin 
tested two and four weeks later with both PPD and KLH and 
gave mixed cell migration responses and lymphocyte transfor­
mation responses to 10-100 pg/ml of KLH, PPD or particulate 
TB. However, when dialysable transfer factor, prepared 
from similarly sensitised monkeys (RH-TF) , was injected into 
unsensitised recipients, the animals acquired mixed-cell 
migration reactivity towards the three antigens at times 
when their skin tests and lymphocyte transformation responses 
remained negative. In the rhesus monkey the mixed cell 
migration system appears to provide an index of lymphocyte 
reactivity whereby adoptive sensitisation with RH-TF can be 
detected in the absence of delayed hypersensitivity or 
lymphocyte transformation responses.
During the past years, occasional laboratories have reported 
'persuasive* evidence (1) of DTF in the rhesus monkey. In 
view of the recent interest in giving DTF in chronic active 
hepatitis, and of confirmation that the rhesus monkey is 
susceptible to Hepatitls-B infection (2) , we have begun to 
study cellular immune responses and adoptive sensitisation 
“ith TF in this species. The problems of skin testing for 
low levels of delayed hypersensitivity are well recognised 
In the monkey; and the purpose of this study was therefore 
to develop in vitro test systems of cellular hypersensitivity 
uhich might be used to follow the response of rhesus monkey 
recipients to the injection of dialysable transfer factor 
(RH-TF) from actively sensitised animals.
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Methodology and design
Our experiments consist of studying the acquisition and 
specificity of delayed hypersensitivity (DH), mixed leuco­
cyte macrophage migration (LMMI) reactivity and lymphocyte 
transformation (LT) responses in rhesus monkeys actively 
immunised with haemocyanln (KLH) in Freund's complete adju­
vant (FCA) and in rhesus monkeys injected with RH-TF.
Active inxnunisation of 4-8 kg male or female animals was 
done by giving a single set of I/M and I/D injections of 
lOO ug, 250 lag or lmg KLH emulsified in FCA (containing 
3 mg heat-killed H37Rv tubercle bacilli) . . Skin tests were 
by intradermal injection of 10-30 |ig KLH or PPD in 0.1 ml 
NaCl into the anterior aspect of the chest and after clinical 
measurement of induration diameter at 24 and 48 hours, skin 
test sites were biopsied for study of lymphocyte infiltra­
tion. Lymphocyte transformation tests were done in glass 
tubes by oinituarised whole blood culture in which 0.1 ml of 
blood was added to 0.9 ml Eagle's MEM containing KLH, PPD, 
particulate tubercle bacilli (heat killed H37Rv) or reagent 
grade PHA in the concentration range 5-100 yg/ml. Cultures 
were maintained at 37° in 5% CX>2 salr for 5 days» 0.1 ml 
(1 yCi) ^H-thymidine (15-18 Ci/mM) was then added and 
cultures were harvested 18 hours later for scintillation 
counting. LT results were expressed as incremental dpm 
(^H-thymidine uptake) in the presence of antigen or PHA 
corrected for baseline dpm of control cultures maintained 
in the absence of stimulant. For the LMMI teat, 10 ml quan­
tities of heparinised (SO U/ml) blood were mixed with half 
volumes of dextran (Mwt 250,000:final concentration 0.5%). 
After sedimentation of RBC for 30-60' at 37°, leucocytes were 
centrifuged from the plasma layer, thrice washed with 20% 
horse serum (HS) ¡Eagles MEM and suspended at 1.5 x lO7 cells/ 
ml (about 50% lymphocytes) in this medium at room temperature. 
An equal volume of washed oil-induced guinea pig peritoneal 
exudate cells (at 3 x 107/ml) in 20% HS-MEM was then added 
and the cell mixtures were quickly migrated from single 
capillary tubes placed in individual wells of a 12-well 
sterile migration chamber unit. Hells were filled with 20% 
HS:MEM containing antigens (KLH, PPD, TB) at concentrations 
from 3 to 200 yg/ml. Migration ratios related to medium 
alone were evaluated after 20 hours at 37° in a 5% 002 iair 
incubator.
Dialysable transfer factor (RH-TF) was prepared from pooled 
lymph node and spleen cells obtained 4-6 weeks after sensi­
tisation of donor monkeys. Lymphoid cells were washed 
oncei cell pellets were freeze thawed lO times with lOO yg
118
20» C  1977 A lan  R. L iu , Inc ., ISO F iflh  Avcnua, N ew Y ork , NY 10011
D.C. DUMONDEafa/.
Methodology and design
Our experiments consist of studying the acquisition and 
specificity of delayed hypersensitivity (DH), mixed leuco­
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were maintained at 37° in 5% C02 :air for 5 days; 0.1 ml 
(1 uCi) 3H-thymidine (15-18 Ci'/mM) was then added and 
cultures were harvested 18 hours later for scintillation 
counting. LT results were expressed as incremental dpm 
(3H-thymidine uptake) in the presence of antigen or PHA 
corrected for baseline dpm of control cultures maintained 
in the absence of stimulant. For the LMMI test, 10 ml quan­
tities of heparinised (50 U/ml) blood were mixed with half 
volumes of dextran (Mwt 250,000>final concentration 0.5%). 
After sedimentation of RBC for 30-60' at 37°, leucocytes were 
centrifuged from the plasma layer, thrice washed wi.th 20% 
horse serum (HS)¡Eagles MEM and suspended at 1.5 x lO7 cells/ 
ml (about 50% lymphocytes) in this medium at room temperature. 
An equal volume of washed oil-induced guinea pig peritoneal 
exudate cells (at 3 x 107/ml) in 20% HS-MEM was then added 
and the cell mixtures were quickly migrated from single 
capillary tubes placed in individual wells of a 12-well 
sterile migration chamber unit. Hells were filled with 20% 
HSiMEM containing antigens (KLH, PPD, TB) at concentrations 
from 3 to 200 wg/ml. Migration ratios related to medium 
alone were evaluated after 20 hours at 37° in a 5% C02 talr 
incubator.
Dlalysable transfer factor (RH-TF) was prepared from pooled 
lymph node and spleen cells obtained 4-6 weeks after sensi­
tisation of doner idonkeys. Lymphoid cells were washed 
once; cell pellets were freeze thawed lO times with lOO ug
ACQUISITION OF MIXED CELL MIGRATION REACTIViTY
DNase/lO® lymphocytes;__ __ _____ and RH-TF was obtained by vacuum
dialysis at 4° and subsequent freeze-drying of the dialysate. 
Recipient naive monkeys were first examined several times by 
LMMI and LT to ensure absence of cellular hypersensitivity 
towards KLH, PPD and TB; and to ensure that LT responses to 
PIIA were normal. For injection, RH-TF from 3-9 x lO9 donor 
mononuclear cells were dissolved in 20-30 ml volumes of 
NaCl and the material was distributed subcutaneously over the 
back and intramuscularly in all four upper limbs of individ­
ual recipient monkeys.
Results; (a) Acquisition of cellular immune responses 
following active immunisation (Tables 1-3)______________
TABLE 1 DELAYED HYPERSENSITIVITY* FOLLOWING ACTIVE 
IMMUNISATION OF RHESUS MONKEYS
Skin test* 
diameter at 2w
Skin test* 
diameter at 4w
KLH PPD KLH PPD
30ug lOpg 30 w g 10ug 30ug lOug 30ug lOpg
Monkey 
No. 16
27 25 31 26 31 24 21 16
Monkey 
No. 17
20 23 36 33 11 <3 21 <3
*(average diameter of 24 hr-induration in mm when skin tested 
2w and 4w after sensitisation with lOOyg KLH in FCA)
Monkeys actively immunised with KLH in FCA developed delayed 
hypersensitivity (DH; Table 1), lymphocyte transformation 
(LTtTable 2) and mixed cell migration reactivity (LMMI:Table 
3) towards KLH, PPD and particulate TB. DH responses were 
all well marked by 2 weeks and were still present 6 weeks 
after sensitisation; LT and LMMI responses varied widely 
from animal to animal but were generally not present until 
the second week of sensitisation. The histology of positive 
(>3mra induration) DH responses showed widespread infiltration 
°t all dermal layers with lymphocytes, macrophages and poly­
morphs , the latter being prominent in the more intense reac­
tions. The pattern of acquisition and duration of lin vitro 
(LT/LMMI) reactivity could not be predicted from a knowledge 
°f the skin reactions, and in individual animals, LT and LMMI 
responses did not run parallel with each other. LT responses 
to pha fell sharply after immunisation (Table 2).
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DNase/lO® lymphocytes; and RH-TF was obtained by vacuum 
dialysis at 4° and subsequent freeze-drying of the dialysate. 
Recipient naive monkeys were first examined several times by 
LMMI and LT to ensure absence of cellular hypersensitivity 
towards KLH, PPD and TB; and to ensure that LT responses to 
PHA were normal. For injection, RH-TF from 3-9 x lO9 donor 
mononuclear cells were dissolved in 20-30 ml volumes of 
NaCl and the material was distributed subcutaneously over the 
back and intramuscularly in all four upper limbs of individ­
ual recipient monkeys.
Results; (a) Acquisition of cellular immune responses 
following active immunisation (Tables 1-3)______________
TABLE 1 DELAYED HYPERSENSITIVITY* FOLLOWING ACTIVE 
IMMUNISATION OF RHESUS MONKEYS
Skin test* 
diameter at 2w
Skin test* 
diameter at 4w
KLH PPD KLH PPD
30ug lOyg 30yg long 30nq long 30ng long
Monkey 
No. 16
27 25 31 26 31 24 21 16
Monkey 
No. 17
20 23 36 33 11 <3 21 <3
‘(average diameter of 24 hr-induration in mm when skin tested 
2w and 4w after sensitisation with lOOng KLH in FCA)
Monkeys actively immunised with KLH in FCA developed delayed 
hypersensitivity (DH: Table 1), lymphocyte transformation 
(LTiTable 2) and mixed cell migration reactivity (LMMI ¡Table 
3) towards KLH, PPD and particulate TB. DH responses were 
all well marked by 2 weeks and ware still present 6 weeks 
after sensitisation; LT and LMMI responses varied widely 
from animal to animal but were generally not present until 
the second week of sensitisation. The histology of positive 
(>3mra induration) DH responses showed widespread infiltration 
°f all dermal layers with lymphocytes, macrophages and poly- 
r°rphs, the latter being prominent in the more intense reac- 
tlons. The pattern of acquisition and duration of iin vitro 
(LT/LMMI) reactivity could not be predicted from a knowledge 
°f the skin reactions, and in individual animals, LT and LMMI 
responses didnot run parallel with each other. LT responses 
to pha fell sharply after Immunisation (Table 2).
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TABLE 2 LYMPHOCYTE TRANSFORMATION RESPONSES FOLLOWING 
ACTIVE IMMUNISATION OF RHESUS MONKEYS
Test , 
and
cone.
AG
(wg/m:
-thvaidine incorporation (mean Adpm/culture)
L)
before
sensn.
after sensitisation
lw 2w 3w 4w 5w
Monkey No. 16
KLH SO 129 300 225 681 3284 728
io loo 170 820 626 1885 284
PPD 50 -24 61 122 105 84 129
IO -16 35 157 117 74 239
TB 50 -77 -30 78 99 448 40
lo 77 -52 68 67 -24 334
PHA 25 8182 3904 793 247 394 402
Monkey No. 17
KLH 50 30 -51 972 174 262 -19
IO 15 164 191 60 750 341
PPD 50 -34 -45 379 490 62 72
IO 4 -116 280 233 86 193
TB 50 -15 -84 111 180 94 69
IO -IO -77 -29 182 140 70
PHA 25 5013 loo 964 229 342 301
TABLE 3 MIXED CELL MIGRATION REACTIVITY (LMMI)
FOLLOWING ACTIVE IMMUNISATION OF RHESUS MONKEYS
Test AG 
and
cone, (uq/ml)
Migration index (medium control - 1.00)
before
•ensile
after sensitisation
lw 2w 3w 4w 5w
Monkey N o. 16
KLH loo 1 .0 5 , .87 .94 .9 7 .67 .97 .94
33 1 .1 2 , .87 .8 0 .8 9 .71 .88 .9 3
PPD loo l . U ,  .87 .89 1 .0 0 .83 .77 .9 0
33 1 .0 3 , .95 .96 1 .1 4 .87 .84 .92
TB lOO .8 9 ,1 .1 9 .8 0 1 .0 0 .52 .79 .82
33 1 .0 4 ,1 .2 7 .8 7 1 .0 2 .8 0 1 .1 5 1 .0 0
Monkey No. 17
KLH loo 1 .0 6 , .92 1 .1 0 .7 4 .53 .8 0 1 .1 9
33 1 .0 6 ,1 .0 0 .9 8 .7 1 .58 .78 1 .0 8
PPD loo .9 8 ,1 .0 4 1 .0 4 .9 7 .65 .67 .9 0
33 l . U ,  .99 .9 6 .9 8 .63 .62 1 .1 3
TB loo .9 1 ,  .82 .89 .7 6 .38 .71 1 .0 2
33 .8 9 , .86 .81 .9 0 .54 .7 3 1 .1 0
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Results: (b) Acquisition of cellular immune responses
following injection of RH-TF (Tables 4-7)_______________
TABLE 4 RESULTS OF REPEATED SKIN TESTS FOR DELAYED
HYPERSENSITIVITY IN CONTROL AND TF-INJECTED MONKEYS
Skin test 
AG and 
dose
Diameter 24- 
dlfferent times
-hr induration (mm) at 
after first TF injection
13 days 27 days 34 days
Monkey No. 35 ('normal' TF)s-
KLH(50ug) <3 <3 <3
PPD(50pg) <3 <3 <3
NaCl(0.1 ml) <3 <3 <3
Monkey No. 36 (KLH + FCA TF) X-
KLH(50pg) <3 7 9.5
PPD(SOug) <3 11.5 13
NaCl(0.1 ml) <3 <3 <3
TABLE S LYMPHOCYTE TRANSFORMATION RESPONSES FOLLOWING 
INJECTION OF RH-TF INTO RHESUS MONKEYS
Test AG 
and
cone, (uq/ml)
thymidine Incorporation (mean Adpm/culture)
before
TF
days after TF
6 13 20 34
Monkey NO. 35 ('normal' TF):-
KLH 50 80 -3 O 12 45
lo 64 -4 21 16 109
PPD 50 60 -20 -23 16 33
lO 37 -24 -2 lo 66
TB 50 7 -13 -15 3 22
io 42 3 15 io 40
PHA 25 2524 19,670 11,256 7,373 14,649
Monkey No. 36 ( KLH+FCA TF) 1-
KLH 50 74 -9 12 -11 24
lo 62 —6 29 -37 30
PPD 50 5 -36 -32 -22 16
io 22 -23 -21 -13 -7
TB 50 11 11 36 -15 -1
io 50 -2 22 -12 4
PHA 25 2024 905 1275 1301 2514
1 >
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Tables 4-6 show an illustrative experiment with two monkeys 
(No. 35, No, 36). 'Control' monkey 35 received RH-TF from 
2.4 x lO3 non-immune lymph node and spleen cells on day O; 
a repeat injection on day 3 ; and 20 ml NaCl on day 20.
Monkey 36 received 4.5 x 10 'immune* (KLH + FCA) spleen and 
lymph node cell RH-TF on days O, 3 and 20. Both monkeys 
were skin-tested on days 13, 27 and 34 (see Table 4). The 
data shows that the control monkey failed to react in all 
tests with the exception of LMMI to the highest concentration 
of KliH on day 6. In contrast, the 'test* monkey acquired 
LMMI reactivity (Table 6) on day 6 which was lost by day 13 
and later, despite repeated skin tests and a further injec­
tion of RH-TF. Even on day 13, DH responses in this monkey 
were negative. However, positive DH responses were obtained 
on days 27 and 34 (Table 4)> these raise the question of 
whether RH-TF was acting to facilitate the selective develop­
ment of DH by repeated skin testing. LT responses following 
RH-TF were uniformly negative to the antigens; PHA responses 
behaved differently in the two animals.
TABLE 6 MIXED CELL MIGRATION REACTIVITY (LMMI) FOLLOWING 
RH-TF INJECTION INTO RHESUS MONKEYS*
Test AG 
and
Migration index (medium control ” 1.00)
before days after TFcone. Uig/mi) TF 6 13 20 27 34
Monkey No. 35 ('normal' TF) «-
KLH loo .90,1.03 .75 1.24 1.21 1.48 .86
33 .96,1.25 .80 1.29 1.45 1.36 .90
PPD loo .96,1.OS .81 1.14 1.10 1.06 .83
33 .96,1.15 1.07 1.04 1.28 .81 .91
TB loo 1.11, .99 .86 1.14 ND ND .90
33 .96, .96 .94 1.07 ND ND .92
Monkey No. 36 (KLH+FCA TF) 1-
KLH loo .94,1.04 .74 1.08 1.17 .89 1.00
33 .85,1.01 .88 1.07 .96 .74 .90
PPD 100 .90, .96 .65 1.05 .86 .89 .99
33 1.00,1.04 .58 .99 .82 .81 .92
TB loo .88, .82 .60 .85 .78 .79 .96
33 .96,1.04 .79 .89 .74 .77 .91
* ( for TF schedule see text)
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Table 7 shows that different patterns of LMMI reactivity 
were acquired by two different recipient animals (no. 19,
No. 27) receiving a single injection of RH-TF (KLH + FCA) 
from another pool at two different doses (8 and 4 x 109 cell- 
equivalents) . Neither of these monkeys had acquired DH 
responses when skin tested on days 7 and 14. The circum­
stances which govern the early (2-3 day! or later <7-14 day) 
acquisition of LMMI reactivity in RH-TF recipients are not 
yet defined.
TABLE 7 DIFFERENT PATTERNS OF ACQUISITION OF LMMI 
REACTIVITY AFTER RH-TF INJECTION*
Monkey and 
test AG
Migration index (medium ■* 1,,00)
before
TF
days after TF
___2-3___ 7 12-14 43 70
Control N O . 18 (NaCl only):-
KLH loo 1.16 .78 .97 .83 • 1.20
PPD loo 1.00 1.02 .83 .73 - 1.02
TB loo 1.13 .90 1.2S .99 - 1.07
KLH+FCA TF (No.19)i 8 X IO9 ;-
KLH loo 1.07 .77 .46 .48 - 0.73
PPD loo .87 .66 .47 .59 - 1.17
TB loo .88 .80 .55 .59 - 0.77
KLH+FCA TF (No.27)t 4 x IO9 «-
KU1 loo .99 1.30 - .51 1.11 .
33 .94 1.07 - .61 .99 -
TB loo .87 1.19 - .85 1.16 -
33 .80 1.26 - .90 1.04 -
* (for TF and skin test schedule see text)
Discussion and conclusions
Our limited experience of RH-TF and of the active induction 
of CMI in the rhesus monkey leads us to the following interim 
conclusionsi (1) that DH is easy to demonstrate following 
active immunisation but that it seems inappropriate for 
following the response to RH-TF; (2) that LT responses 
develop after active immunisation but not after RH-TF; and 
(3) that the LMMI test, probably indicative of lymphokine 
Production, emergea as the most useful of the three tests for 
studying the CMI-response of recipients of RH-TF. This
to the suggestion that if RH-TF acta without further
D.C. DUMONDE*»*/.
antigen upon naive animals, it may do so by preferentially 
'sensitising' a cell population concerned with initiating or 
producing MIF-lymphokine rather than with the production of 
skin-reactive or mitogenic lymphokines. We know that these 
three lymphokines differ in parallel bioassay in the guinea 
pig (3) and it is reasonable to suppose that they differ also 
in the rhesus monkey. The results support the view that 
DTF may initiate or promote adoptive sensitisation for 
selective lymphokine production (4) and indicate that the 
LMMI test is worthy of further exploitation in this context 
in the rhesus monkey.
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It has been reported that dialysable leucocyte extract preparations, thought to con­
tain transfer factor, may be used therapeutically for the treatment of a variety of 
immunodeficiency syndromes. Clinical and laboratory studies have suggested that 
such preparations, in addition to transferring specific cellular immunity may also 
contain non-specific adjuvant activities. Attempts at immunotherapy of viral in­
fections are described against a background of current research on the biological 
and biochemical properties o f leucocyte dialysates.
Key words: dialysable leucocyte extract, viral immunotherapy
INTRODUCTION
Landsteiner and Chase (1942) reported that delayed hypersensitivity skin reactions 
to simple chemical compounds could be transferred from sensitized to unsensitized 
guinea pigs with live peritoneal exudate cells, but not with heated cells or serum, thereby 
distinguishing cell-mediated from humoral antibody-mediated responses. Extending this 
work to man, Lawrence (1949, 1952) described the passive or adoptive cellular transfer 
of both local and systemic cutaneous delayed hypersensitivity to microbial antigens, using 
viable blood leucocytes. In contrast to the guinea pig, where skin reactions could only be 
demonstrated for up to 5 days posttransfer, it was reported that in man transferred skin
Address reprint requests to M. R. Mazaheri, Department of Medical Microbiology, London School 
of Hygiene and Tropical Medicine. Keppcl Street, London WCIE 7HT, England.
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reactivity persisted from 3 months to as long as 2 years. This observation was inconsistent 
with the view that transferred delayed hypersensitivity lasted only as long as the donor 
cells remained viable. Furthermore, similar transfers could be achieved when peripheral 
blood leucocytes were disrupted either with distilled water, or freeze-thawing in the 
presence or absence of ribonucléase and deoxyribonuclease (Lawrence 1954, 1955). Such 
methods o f disruption did not apparently cause loss o f transfer activity. Since DNase and 
RNase did not seem to affect the transfer of delayed hypersensitivity, the mechanism of 
transfer did not appear to depend on the presence o f  highly polymerized DNA or RNA.
In addition, only small amounts of intact or disrupted cells (0.1—0.4 ml of packed white 
cells) relative to a large recipient mass were required to transfer cutaneous sensitivity. It 
was, therefore, concluded that the transfer component might be a self-replicating molecule.
Further studies (Lawrence and Pappenheimer, 1956) implied that the transfer 
extract was not immunogenic and that transferred cutaneous delayed hypersensitivity was 
not a function of humoral immunity. The term transfer factor was therefore introduced 
to describe the material in the leucocyte extracts responsible for the adoptive transfer of 
cell-mediated immunity. It was subsequently shown that transfer factor could be extracted 
without loss of activity from the bulk of the disrupted leucocytes by exhaustive dialysis 
into distilled water and lyophilisation (Lawrence e t al., 1963). The term dialysable transfer 
factor was therefore reserved for the unidentified factor or factors contained in the crude 
dialysate which were capable of transferring delayed cutaneous hypersensitivity (Lawrence, 
1969; Lawrence and Al-Askari, 1971). It has subsequently been suggested that the term 
dialysable leucocyte extract (Valdimarsson, 1975; Arala-Chaves et al., 1976) should be 
used to describe the total crude extract of leucocytes, which has been used to treat diseases 
where there is a defect in cellular immunity. It is believed that the transfer factor com­
ponent of dialysable leucocyte extract may reconstitute specific cellular immunity and, 
therefore, be responsible for the therapeutic efficacy of leucocyte dialysates. However, 
there is now evidence that such material may also possess nonspecific adjuvant activities 
which may play an important role In immunotherapy.
Specificity
Clinical observations. Clinical and immunological observations on the acquisition 
of delayed type hypersensitivity following the administration of transfer factor have led 
to the concept that transfer factor converts nonimmune to Immune lymphocytes in vivo. 
Thus, it has been repeatedly reported that previously unresponsive recipients acquire 
delayed type skin reactions to antigens to which the donor was positive (Rapaport et al., 
1960; Kirkpairick and Smith, 1976). However, there are reports that recipients may 
acquire skin test reactivities which were not demonstrable in the donor (Levin et al., 1971 ; 
Spitler et al., 1972; Griscelli, 1975). It has also been shown that not all positive skin 
reactions demonstrable in the donor may be transferred to the recipients (Kirkpatrick and 
Smith, 1976). Other alterations in cellular-immune responsiveness, which do not apparently 
relate to donor specificity, have been reported in recipients. These include altered mixed 
lymphocyte culture responsiveness (Dupont et al., 1974), increased responsiveness to 
phytohaemagglutinin in vitro (Arala-Chaves et al., 1974; Valdimarsson et al., 1974) and 
increases in the numbers of circulating T-cells as shown by increased sheep red blood cell 
rosetting (Wybran et al., 1973). These observations in man have led to the concept that 
dialysable leucocyte extract, in addition to conferring antigen responsiveness, may also 
possess nonspecific adjuvant properties. Further support for this hypothesis has been
• i
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gained from laboratory studies designed to test dialysable leucocyte extract activity in 
vivo in animals and in vitro.
In vivo and in vitro test system for transfer factor. Much of the scepticism which 
surrounded the early work on transfer factor resulted from the inability to demonstrate 
the transfer phenomenon in animals. Recently, however, studies in nonhuman primates, 
guinea pigs, and other animals have demonstrated that some of the properties of leucocyte 
extracts described in man may be reproduced in animals.
In nonhuman primates successful transfer of delayed hypersensitivity using viable 
leucocytes and leucocyte extracts has been reported from monkey to monkey (Zanelli 
and Adler, 1975) and from man to monkey (Steele et al., 1976a). Immunological specifici­
ty was implied by the observation that recipients never converted to antigens to which 
the donor did not react in vivo.
In guinea pigs transfer of delayed hypersensitivity has proved extremely difficult 
(Bloom and Chase, 1967). However, recent studies have shown that guinea pigs primed 
with antigen gave delayed skin reaction following injection of dialysable leucocyte extract 
(Welch et al., 1976). Whilst exposure to antigen is a prerequisite for the demonstration of 
subsequent delayed hypersensitivity skin reacitons, the role of donor specificity in 
eliciting such responses has yet to be fully determined.
In vitro tests for transfer factor have also provided evidence for both specific and 
nonspecific activities in dialysable leucocyte extract preparations (Hamblin, 1977). It has 
been reported that human and monkey dialysable leucocyte extracts nonspecifically 
augment antigen and mitogen induced lymphocyte transformation (Hamblin et al., 1976a, 
b; Mazaheri, unpublished). However, evidence has also been presented that such trans­
formation test systems may also be used to detect the specific conversion of nonimmune 
to immune lymphocytes (Arala-Chaves et al., 1976).
Thus in vivo and in vitro test systems for transfer factor lend support to the clinical 
observations that dialysable leucocyte extract contains both specific and nonspecific 
activities. However, the relative importance of the specific and nonspecific activities of 
dialysable leucocyte extract for the treatment of disease have yet to be delineated. The 
biochemical properties of dialysable leucocyte extract have therefore been investigated in 
an attempt to determine which components of the extract are responsible for the altera­
tions in cellular immune function in vivo and in vitro.
Biochemical Properties of Dialysable Leucocyte Extract
Using the transfer of delayed hypersensitivity as the criteria for assessing potency, 
the following properties of transfer factor were described by Lawrence (1974). The 
material is present in dialysable or ultrafiltrable extracts of disrupted leucocytes and there­
fore has a molecular weight of less than 10,000. It is not immunogenic, it is not an 
immunoglobulin, and it is separable from histocompatability antigens. The activity is not 
destroyed by repeated freeze-thawing, and it is not inactivated by DNase, RNase, and 
trypain. It is stable for months to several years at -20°C or freeze-dried at 4°C.
Fractionation of dialysable leucocyte extract has been attempted in order to locate 
its specific and nonspecific components. Sephadex column chromatography has shown 
that the material is of heterogenous composition and can be separated into a number of 
fractions (Baram et al., 1966; Arala-Chaves et al., 1967; Gottlieb et al.,I973; Zuckerman 
et al., 1974; Burger et al., 1976a). Several publications report that one o f the fractions.
«
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rich in hypoxanthine, is associated with the ability to transfer delayed skin reactions 
(O’Dorisio et al., 1976; Tomar et al., 1976; Kirkpatrick et al., 1976). Others have pro­
duced evidence for fractions which nonspecifically stimulate weak immune reactivity in 
vivo (Krohn et al., 1976), and nonspecifically augment lymphocyte transformation in 
vitro (Burger et al., 1976b, Littman et al., 1977). More biochemical studies are required 
to relate these activities to each other and to the therapeutic efficacy of dialysable leuco­
cyte extract.
Im m unotherapy  o f  Viral Infections
The concept that transfer factor could restore defective cell-mediated immunity as 
expressed by the acquisition of delayed-type skin reactions resulted in its therapeutic use 
in the treatment of a wide variety of acquired and congenital immunodeficiency diseases 
(Lawrence, 1974; Fundenberg et al. 1974). Therapeutic benefit from treatment with 
dialysable leucocyte extract has been reported for many disseminated intracellular infec­
tions, including viral infections (Zuckerman, 1975; Heim et al., 1976).
The initial attempts at immunotherapy of viral infections employed viable leuco­
cytes, presumed to contain transfer factor. Thus Kempe (1960) treated a young boy 
suffering from progressive vaccinia infection with peripheral blood or lymph node 
leucocytes, and by transplantation of sensitized lymph nodes form vaccinated immune 
donors. The progression of the lesions was arrested and delayed hypersensitivity to in­
activated vaccinia virus was conferred. Similarly O’Connell et al. (1964) treated an elderly 
patient suffering from severe progressive vaccinia. Intramuscular and subcutaneous in­
jections of specific immune leucocytes were given on 2 occasions about 2 months apart. 
Acquisition of cutaneous delayed hypersensitivity to vaccinia antigen and termination of 
the infection were reported.
These initial studies were extended to the use of dialysable leucocyte extract 
thought to contain transfer factor. Drew et al. (1973) treated a patient with disseminated 
herpes zoster with dialysable leucocyte extract prepared from a pool of 27 healthy donors 
who demonstrated immunity to varicella-zoster in vitro. The patient, a 44-year-old man 
with stage IV B Hodgkin’s disease and defective cell-mediated immunity was not treated 
with immunosuppressive drugs or corticosteroids in the 3 months preceding therapy. 
Following 2 subcutaneous injections of dialysable leucocyte extract the vesicular lesions 
completely healed. Moulias et al. (1973)treated 2 children with “giant-cell” measles 
pneumonia with dialysable leucocyte extract from immune donors. The patients responded 
with improvement and regression of the pulmonary lesions. Positive in vitro leucocyte 
migration inhibition responses to measles virus were reported after transfer, indicating 
improved cell-mediated immunity to the virus. Moulias et al. (1973) also treated 7 children 
with sub-acute sclerosing panencephalitis (SSPE), a degenerative disease associated with 
measles virus infection. Clinical improvement was seen in 2 out of the 7 children although 
5 out of 7 sliowed conversion of the leucocyte migration inhibition test to measles antigen 
in vitro. Vandvik et al. (1973) treated a 16-year-old boy with SSPE with dialysable leuco­
cyte extract from donors with measles immunity. The patient improved clinically and 
developed delayed hypersensitivity to various antigens and a selective reduction in measles 
antibody titre in the cerebrospinal fluid and serum. Rytel et al. (1975) treated a renal 
transplant patient with cytomegalovirus retinitis with dialysable leucocyte extract. Inacti­
vation of the natural inflammatory lesions was seen. The patient also acquired delayed 
skin reaction and in vitro inhibition of leucocyte migration.
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Attempts have been made to treat patients with chronic active hepatitis with transfer 
factor. There was no clinical improvement in a 29-year-old patient with chronic active 
hepatitis who received, over a period of 8 weeks, 17 injections of dialysable leucocyte 
extract twice weekly (Tong et al., 1976). Each injection was derived from 5 X 10s leuco­
cytes from a donor who previously had acute hepatitis B, and showed lymphocyte reactiv­
ity to hepatitis B surface antigen in vitro. Clinical and biochemical improvement was not 
observed. However, the transfer of cell-mediated immunity was demonstrated by the 
appearance of delayed hypersensitivity to mumps and streptokinase-streptodornase and 
by in vitro lymphocyte responses to hepatitis B surface antigen. It was suggested that 
clinical improvement might have been seen with increased quantity, frequency, and dura­
tion of treatment. Kohler et al. (1974) treated a healthy persistent carrier of hepatitis B 
surface antigen with lymphocytes from an individual who had recovered from hepatitis 
B 8 months previously. Within 24 hours of the administration of lymphocytes, there was 
an increase in the titre of the surface antigen and of serum aspartate transaminase levels, 
suggesting liver cell damage. It was presumed that the development of cell-mediated 
immunity to hepatitis B was reflected in the injury of the virus-laden liver cells.
Another patient, a 4-month-old infant, who acquired hepatitis B from her mother 
at birth was given dialysable leucocyte extract prepared from the mother’s leucocytes on 
2 occasions. The recipient promptly developed an increase in the titre of hepatitis B sur­
face antigen and elevation of serum transaminase activity. Subsequently, however, the 
liver function tests returned to normal and the titre of hepatitis B surface antigen decreased 
by 95%.
Jain et al. (1975) treated 3 patients with dialysates prepared from healthy donors 
and donors who had recovered from hepatitis B infection. One patient with hepatitis B 
surface antigen-positive chronic active hepatitis and cirrhosis did not respond to “normal" 
dialysable leucocyte extract, but injection of “specific” dialysable leucocyte extract 
resulted in a 2-fold increase in T lymphocytes, as measured by sheep red blood cell reset­
ting. The second patient, also did not respond to “normal” dialysable leucocyte extract, 
but showed a transient increase in transaminase activity. This suggested stimulation of 
cell-mediated immunity with a resulting hepatic damage. The third patient suffered from 
antigen-positive active chronic hepatitis complicated by primary liver cancer. This patient 
was being treated with corticosteroids and did not respond to either “normal" or “specific” 
dialysable leucocyte extract. There was no change in the serum titre of hepatitis B surface 
antigen in any of the patients.
The above accounts of the therapeutic use of transfer factor reflect the anecdotal 
future of the work. A major criticism of transfer factor therapy has been the lack of 
properly controlled clinical trials. Since many diseases go through natural cycles of relapse 
and remission, and patients may be treated with other therapeutic agents, it is often dif­
ficult to assess the clinical benefit of treatment with transfer factor. Schulman et al. (1976) 
initiated a small, double-blind controlled trial with dialysable leucocyte extract. Four 
patients with chronic active hepatitis received dialysable leucocyte extract from pools of 
donors who had recovered from hepatitis B and A, while 4 others received normal saline. 
The results indicate that all 4 patients receiving dialysable leucocyte extract showed bio­
chemical evidence of improvement, with a fall in serum transaminase activity. In 3 of the 
patients it was considered that there was also histological improvement, but hepatitis B 
surface antigen remained in the serum. The patients responding to dialysable leucocyte 
extract have remained in remission for periods of 9 months to 1V4 years. None of the 4
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recipients of normal saline improved. Based on these observations it was considered that 
dialysable leucocyte extract may be useful for the management of chronic hepatitis B in­
fection (Schulman, 1977; personal communication).
It has been reported that transfer factor is a safe therapeutic agent. However, reacti­
vation associated with reconstitution of cellular immunity may in itself produce deleterious 
side-effects.
Moulias et al. (1973) reported that regression of the pulmonary lesions in the child­
ren with measles pneumonia was associated with an initial inflammatory response. In 
addition, Drew et al. (1973) reported that their patient with Hodgkin’s disease and dis­
seminated herpes zoster developed fever and intense erythema around the vesicles follow­
ing injections of dialysable leucocyte extract. Finally, it has been suggested that the in­
creases in serum transaminase levels in chronic active hepatitis after the administration of 
dialysable leucocyte extract may reflect liver damage due to cellular immune reactions 
against the virus-laden liver cells (Kohler et al., 1974). Therefore, therapy with dialysable 
leucocyte extract should be used with caution for the treatment of disseminated intracellu­
lar infections.
Many of the problems relating to the treatment of infectious diseases could be clari­
fied with an animal model. Several reports exist which suggest that transfer factor may be 
used to protect animals from infection. Thus Steele et al. (1976b) demonstrated that 
marmosets could be protected from fatal herpes simplex virus type 1 infection using 
dialysable leucocyte extract prepared from a human donor with marked cellular immunity 
to this virus. The protection was reported as being specific since it was ineffective against 
another membe' of the herpes group of viruses, herpes virus saimuri. Trepo and Prince 
(1976) treated hepatitis B virus carrier chimpanzees with leucocyte from donors sensitive 
to hepatitis B surface antigen and/or PPD. Systemic and local transfer of donor specific 
skin reactivity and leucocyte migration inhibition to both antigens were demonstrable in 
recipient monkeys. The development of delayed hypersensitivity to hepatitis B surface 
antigen in the chimpanzees was not accompanied by serious liver damage.
This review has summarized the immunotherapy of viral disease with transfer factor, 
a term which refers to “specific” transfer of delayed hypersensitivity, mainly in man. 
However, a more appropriate term, dialysable leucocyte extract, has been used here since 
this term embraces all the emerging specific and non-specific activities of leucocyte extracts 
observed clinically in man, experimentally in animals and in vitro studies. The treatment 
of a variety of viral infections with dialysable leucocyte extract has strongly suggested that 
an improvement in cellular immunity is often clinically beneficial. Controlled clinical trials 
are required to determine the role of dialysable leucocyte extract in the management of 
viral infections. Such trials, together with continued laboratory studies, will in due course 
relate the biological and biochemical activities of dialysable leucocyte extract to its use­
fulness as a therapeutic agent.
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